{"id": "civic.eid:238", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.292Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.292Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:167", "type": "Document", "label": "Denis et al., 2015, Clin. Chim. Acta", "xrefs": ["pmid:25668228"], "title": "EGFR T790M resistance mutation in non small-cell lung carcinoma."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:DBx_D7JPPPE0dTTK1bfQDhyUMNPebSvz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:1409", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-27T15:12:01.726Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:469", "type": "Agent", "name": "\u9648\u7965"}, "date": "2017-05-31T08:25:32.570Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:39:43.821Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:954", "type": "Document", "label": "Chapman et al., 2011, N. Engl. J. Med.", "xrefs": ["pmc:PMC3549296", "pmid:21639808"], "title": "Improved survival with vemurafenib in melanoma with BRAF V600E mutation."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:xS7w5SBa9KU-CnD4-ZYg7e4eWMg_QRqs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1592", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-08T07:15:29.028Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-08-17T16:58:18.364Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1053", "type": "Document", "label": "Greig, 2016, Drugs", "xrefs": ["pmid:26729184"], "title": "Osimertinib: First Global Approval."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:1867", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-12-16T21:20:38.487Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-01-01T00:31:00.329Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-01-19T19:59:33.268Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-01-01T00:30:29.190Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1286", "type": "Document", "label": "Mok et al., 2016, N. Engl. J. Med.", "xrefs": ["pmid:27959700"], "title": "Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:2994", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-05-10T13:02:15.905Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T20:28:13.558Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-09-02T01:01:38.682Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T20:18:55.930Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1724", "type": "Document", "label": "Khozin et al., 2014, Oncologist", "xrefs": ["pmc:PMC4077454", "pmid:24868098"], "title": "U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:teH1xxIK6r4jpsaY8NccNewpkJ0YcjYX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:2997", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-05-10T13:09:08.566Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T20:22:52.896Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1725", "type": "Document", "label": "Dungo et al., 2013, Drugs", "xrefs": ["pmid:23982599"], "title": "Afatinib: first global approval."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:AEC2fbyX0a0Y3wtOYoALtu06a2AJbVtm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:9851", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The open-label phase 3 BEACON CRC trial included 665 patients with BRAF V600E-mutated metastatic CRC. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators\u2019 choice of either cetuximab and irinotecan or cetuximab and FOLFIRI. The median overall survival was 8.4 months (95% CI, 7.5 to 11.0) in the doublet-therapy group and 5.4 months (95% CI, 4.8 to 6.6) in the control group, with a significantly lower risk of death compared to the control group (hazard ratio for death doublet-group vs. control, 0.60; 95% CI, 0.45 to 0.79; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group, 20% in the doublet-therapy group (95% CI 13 to 29) and 2% (95% CI, 0 to 7) in the control group (doublet group vs. control P<0.001). Median PFS was 4.2 months (95% CI, 3.7 to 5.4) in the doublet-therapy group, and 1.5 months (95% CI, 1.5 to 1.7) in the control group (hazard ratio for disease progression doublet-group vs control, 0.40; 95% CI, 0.31 to 0.52, P<0.001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-09T20:40:42.744Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-09T20:42:29.151Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2022-02-11T23:51:32.656Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3025", "type": "Document", "label": "Kopetz et al., 2019, N. Engl. J. Med.", "xrefs": ["pmid:31566309"], "title": "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:c2PfzLMShNKjM4iuJgjpJLGb8vKJYFNl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049106", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:P1PY89shAjemg7jquQ0V9pg1VnYnkPeK", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049106", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:483", "type": "TherapeuticDescriptor", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "xrefs": ["ncit:C98283"], "alternate_labels": ["Braftovi", "LGX 818", "LGX-818", "LGX818"], "therapeutic": "rxcui:2049106"}, {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}]}}
{"id": "civic.eid:3017", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6). At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:14", "type": "Agent", "name": "Katie Campbell"}, "date": "2017-05-18T15:56:13.383Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-06-29T14:32:01.444Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-09-05T18:46:09.318Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-06-24T06:04:59.298Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-06-24T06:00:00.982Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1296", "type": "Document", "label": "Planchard et al., 2016, Lancet Oncol.", "xrefs": ["pmc:PMC4993103", "pmid:27283860"], "title": "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:fgXM1I7Z7ZVCgcL1lRHMDrX5UhaxO_ua", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:7315", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisib\u2013fulvestrant across prespecified subgroups, including E542K (N=60, HR 0.60, 95% CI 0.29-1.23), E545X, and H1047X.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-05-20T12:28:53.619Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-08T02:46:54.369Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-08-08T02:49:18.815Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-08T02:42:17.438Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2888", "type": "Document", "label": "Andr\u00e9 et al., 2019, N. Engl. J. Med.", "xrefs": ["pmid:31091374"], "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer."}], "evidence_level": {"id": "vicc:e00001", "type": "Coding", "label": "authoritative evidence"}, "target_proposition": {"id": "proposition:H4nEeT-z7KsUdUOSbrexqLg_R8VjJRF_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2169285", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:QoPu2SO9N_zsHY4X6TMs5q3CLWJMHAQa", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2169285", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:570", "type": "TherapeuticDescriptor", "label": "Alpelisib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C94214"], "alternate_labels": ["BYL719", "Phosphoinositide 3-kinase Inhibitor BYL719", "Piqray"], "therapeutic": "rxcui:2169285"}, {"id": "civic.tid:54", "type": "TherapeuticDescriptor", "label": "Fulvestrant", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1379"], "alternate_labels": ["7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol", "Faslodex", "Faslodex(ICI 182,780)", "ICI 182,780", "ICI 182780", "ZD9238"], "therapeutic": "rxcui:282357"}]}}
{"id": "civic.eid:2258", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:19.791Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:50:33.456Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2019-12-19T23:27:01.598Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:50:20.193Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1417", "type": "Document", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "xrefs": ["pmc:PMC2663546", "pmid:19284554"], "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2274", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:21.077Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T01:58:19.721Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T01:57:41.879Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1417", "type": "Document", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "xrefs": ["pmc:PMC2663546", "pmid:19284554"], "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2505", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patients having BRAF mutations were associated with reduced overall survival (11.1 mo vs. 46.1 mo for wild-type, P=0.006). BRAF mutations were more frequent in tumors with superficially spreading histological sub-type (43%  vs. 19% , P<0.001) compared to BRAF wild-type tumors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:04:54.722Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:18:19.338Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:17:59.727Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1488", "type": "Document", "label": "Long et al., 2011, J. Clin. Oncol.", "xrefs": ["pmid:21343559"], "title": "Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:ycO7LBDP---yYBV52L6tjm0tQJ7ggCRp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1424911", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}}
{"id": "civic.eid:3693", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:00.126Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T15:52:58.857Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T15:51:07.346Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1920", "type": "Document", "label": "Kaczirek et al., 2015, Clin Colorectal Cancer", "xrefs": ["pmid:25666295"], "title": "FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:6qY8-4NR1mnWEhFHeATXrfoNLxo3J0hE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Om0yyht6SnNmdAVYgTuYIXptr3aYzSx5", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:878", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:3882", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:37:01.543Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T16:08:11.086Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T16:08:13.149Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1920", "type": "Document", "label": "Kaczirek et al., 2015, Clin Colorectal Cancer", "xrefs": ["pmid:25666295"], "title": "FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:94", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.686Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.686Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:104", "type": "Document", "label": "Ponti et al., 2013, J. Clin. Pathol.", "xrefs": ["pmid:23463675"], "title": "The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:h4dMKm5e90UKLwdT4QwGBRqE2wPpT4zG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nstQWjDNJb8qwT0ZtyIGNK9El0LZGMn5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1424911", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:11", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}}
{"id": "civic.eid:95", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.727Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-18T21:13:53.271Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-18T21:13:57.592Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.727Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:105", "type": "Document", "label": "Menzies et al., 2014, Clin. Cancer Res.", "xrefs": ["pmid:24583796"], "title": "Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:pszxvq2klgdS8gFUDix0DGw5akTv4gTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:1398", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-24T16:18:21.729Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:42:21.422Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:947", "type": "Document", "label": "McArthur et al., 2014, Lancet Oncol.", "xrefs": ["pmc:PMC4382632", "pmid:24508103"], "title": "Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:b3f7MP6XtAP-IiLVqnnnlrIk2qsy_Zs_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4860", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:402", "type": "Agent", "name": "Mario Lamping"}, "date": "2017-06-08T14:54:26.305Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:44:23.062Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2018-05-23T12:46:45.422Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:43:40.748Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2158", "type": "Document", "label": "Ramalingam et al., 2016, Ann. Oncol.", "xrefs": ["pmid:26768165"], "title": "Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:p7sVbOSDxfEcJfJzPqC8Kxl7rO37GPxZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2058848", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:44", "type": "TherapeuticDescriptor", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C53398"], "alternate_labels": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"], "therapeutic": "rxcui:2058848"}}
{"id": "civic.eid:6178", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 792 (91%) patients had V600E, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 150/397 patients (38%) in the treatment group and 229/395 patients (58%) in the placebo group for a 95% CI Hazard Ratio of 0.48 (0.39-0.58).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-05-23T16:09:47.748Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-05-23T17:55:59.145Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2475", "type": "Document", "label": "Long et al., 2017, N. Engl. J. Med.", "xrefs": ["pmid:28891408"], "title": "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:pszxvq2klgdS8gFUDix0DGw5akTv4gTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:6938", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival and secondary endpoints including disease response. The hazard ratio for progression or death in the V600E group was 0.81 for dabrafenib-trametinib vs dabrafenib-alone. Of 179 V600E patients in the dabrafenib-trametinib group, 68% of patients had a response, which was 15 percentage points higher than in the dabrafenib-alone group (95% CI, 4 to 24; P=0.006).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-10-02T06:22:31.389Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-11-08T17:53:08.339Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-11-08T17:53:46.541Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-11-08T17:54:34.540Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2671", "type": "Document", "label": "Long et al., 2014, N. Engl. J. Med.", "xrefs": ["pmid:25265492"], "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:pszxvq2klgdS8gFUDix0DGw5akTv4gTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:7612", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "665 patients with BRAF V600E-mutated metastatic CRC were enrolled In this open-label, phase 3 trial. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators\u2019 choice of either cetuximab and irinotecan or cetuximab and FOLFIRI. The median overall survival was 9.0 months in the triplet-therapy group and 5.4 months in the control group (hazard ratio for death, 0.52; 95% confidence interval [CI], 0.39 to 0.70; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group and 2% (95% CI, 0 to 7) in the control group (triplet group vs. control P<0.001). The median progression-free survival in the triplet-therapy group was 4.3 months (95% CI, 4.1 to 5.2) and 1.5 months (95% CI, 1.5 to 1.7) in the control group (hazard ratio for disease progression or death, 0.38; 95% CI, 0.29 to 0.49; P<0.001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-10-02T13:26:21.367Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2022-02-11T23:34:29.885Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-02-11T23:46:25.787Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-19T00:48:57.058Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3025", "type": "Document", "label": "Kopetz et al., 2019, N. Engl. J. Med.", "xrefs": ["pmid:31566309"], "title": "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:MnBrZIOoshPdIMhm64nfK2rwV9lSYiK_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049106", "type": "Therapeutic"}, {"id": "rxcui:2049122", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7g5X81wE2go4GE_fB45SjFamVMgpnwsA", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049106", "type": "Therapeutic"}, {"id": "rxcui:2049122", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:483", "type": "TherapeuticDescriptor", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "xrefs": ["ncit:C98283"], "alternate_labels": ["Braftovi", "LGX 818", "LGX-818", "LGX818"], "therapeutic": "rxcui:2049106"}, {"id": "civic.tid:485", "type": "TherapeuticDescriptor", "label": "Binimetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "xrefs": ["ncit:C84865"], "alternate_labels": ["ARRY-162", "ARRY-438162", "MEK162", "Mektovi"], "therapeutic": "rxcui:2049122"}, {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}]}}
{"id": "civic.eid:15", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "GIST cancer with D842V mutation is resistant to imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.416Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.416Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:61", "type": "Document", "label": "Corless et al., 2005, J. Clin. Oncol.", "xrefs": ["pmid:15928335"], "title": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:16", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.457Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-30T00:05:58.650Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-12-01T15:26:38.712Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.457Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:19", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.597Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-19T00:09:28.109Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-09-05T19:40:44.924Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.597Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:64", "type": "Document", "label": "Kiladjian et al., 2006, Blood", "xrefs": ["pmid:16709929"], "title": "High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:-LCqcbYJnkkWqLsFp92BcM5WxYM39U_F", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.V6Z7o5Im9ksiY2MojjqjLb86Xe4jjhlg", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:253453", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3336", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:64", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:9", "type": "DiseaseDescriptor", "label": "Polycythemia Vera", "xrefs": ["DOID:8997"], "disease": "ncit:C3336"}, "object_descriptor": {"id": "civic.tid:24385", "type": "TherapeuticDescriptor", "label": "Peginterferon Alfa-2b", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "mesh:D019698", "type": "DiseaseDescriptor", "label": "Hepatitis C, Chronic", "disease": "mondo:0005354"}]}}], "xrefs": ["ncit:C1845"], "alternate_labels": ["PEG Interferon Alpha-2b", "PEG Intron", "PEG-IFN Alfa-2b", "PEG-IFN-a 2b", "PEG-Interferon Alfa-2b", "PEG-Intron", "Pegylated Interferon Alpha-2b", "Polyethylene Glycol IFN-A2b", "Polyethylene Glycol Interferon Alfa-2b", "SCH 54031", "Sylatron"], "therapeutic": "rxcui:253453"}}
{"id": "civic.eid:240", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.388Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.388Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:169", "type": "Document", "label": "Sequist et al., 2011, Sci Transl Med", "xrefs": ["pmc:PMC3132801", "pmid:21430269"], "title": "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:hqKqOwifiGbqT9f1RkM254mj9y9i0n8k", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2058848", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:44", "type": "TherapeuticDescriptor", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C53398"], "alternate_labels": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"], "therapeutic": "rxcui:2058848"}}
{"id": "civic.eid:275", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.735Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-18T18:35:08.112Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-18T18:39:43.553Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.735Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:182", "type": "Document", "label": "Fukihara et al., 2014, Oncology", "xrefs": ["pmid:24457318"], "title": "Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:4VWDXHDzyWUOdByvvGK0iqDkCHwRS_TC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:306", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.888Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-14T10:51:56.847Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-05-02T09:21:08.701Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.888Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:123", "type": "Document", "label": "De Roock et al., 2010, JAMA", "xrefs": ["pmid:20978259"], "title": "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:jGbiXvIkc-azo7u4bW6UTarjSaC2lAkw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:436", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-07-02T04:11:50.928Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-18T16:49:32.392Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-18T17:15:52.280Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-07-02T04:11:50.820Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:259", "type": "Document", "label": "Woyach et al., 2014, N. Engl. J. Med.", "xrefs": ["pmc:PMC4144824", "pmid:24869598"], "title": "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:GPAQHGiWQ8y6XdICe033kijlKRPP8Awk", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.N7eoPAzmgrcdHMkpaz2z4H1RW4LpBFfY", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1442981", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:168", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:227", "type": "TherapeuticDescriptor", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015451", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphocytic, Chronic, B-Cell", "disease": "ncit:C3163"}, {"id": "mesh:D020522", "type": "DiseaseDescriptor", "label": "Lymphoma, Mantle-Cell", "disease": "ncit:C4337"}, {"id": "mesh:D008258", "type": "DiseaseDescriptor", "label": "Waldenstrom Macroglobulinemia", "disease": "ncit:C80307"}]}}], "xrefs": ["ncit:C81934"], "alternate_labels": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"], "therapeutic": "rxcui:1442981"}}
{"id": "civic.eid:646", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:14", "type": "Agent", "name": "Katie Campbell"}, "date": "2015-11-09T20:28:42.533Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2015-11-09T20:34:36.178Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:408", "type": "Document", "label": "Sequist et al., 2015, N. Engl. J. Med.", "xrefs": ["pmid:25923550"], "title": "Rociletinib in EGFR-mutated non-small-cell lung cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:UDP5UTYpeIjYWI3Cf3W4EflMGFKZ3L9J", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C99905", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:91", "type": "TherapeuticDescriptor", "label": "Rociletinib", "xrefs": ["ncit:C99905"], "alternate_labels": ["CO-1686", "N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide"], "therapeutic": "ncit:C99905"}}
{"id": "civic.eid:659", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-02T04:31:36.903Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-22T00:55:50.988Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-22T15:27:10.621Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-12-02T04:33:01.739Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:416", "type": "Document", "label": "Sun et al., 2009, Lung Cancer", "xrefs": ["pmid:19157633"], "title": "Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:iPlTIfA8rRVqo0826HioWDtuBk4W2nUv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UnXTqUCwUNH3EAbokMdUZPj0ggS81Khs", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:39541", "type": "Therapeutic"}, {"id": "rxcui:1299922", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:249", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:TgPtIuv9V-lbf4OQZ9w7ag3sI2QRhkFz", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:39541", "type": "Therapeutic"}, {"id": "rxcui:1299922", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:85", "type": "TherapeuticDescriptor", "label": "Gemcitabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C66876"], "alternate_labels": ["1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose", "2'Deoxy-2',2'-Difluorocytidine", "DFdC", "DFdCyd", "Difluorodeoxycytidine"], "therapeutic": "rxcui:12574"}, {"id": "civic.tid:96", "type": "TherapeuticDescriptor", "label": "Vinorelbine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1275"], "alternate_labels": ["3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine", "5'-Nor-Anhydrovinblastine", "Dihydroxydeoxynorvinkaleukoblastine", "Nor-5'-Anhydrovinblastine"], "therapeutic": "rxcui:39541"}, {"id": "civic.tid:73", "type": "TherapeuticDescriptor", "label": "Docetaxel", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:608", "type": "DiseaseDescriptor", "label": "Head and neck cancer", "disease": "ncit:C4013"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:658", "type": "DiseaseDescriptor", "label": "Prostate cancer", "disease": "ncit:C7378"}]}}], "xrefs": ["ncit:C1526"], "alternate_labels": ["Docecad", "N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol", "RP56976", "Taxotere", "Taxotere Injection Concentrate", "[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"], "therapeutic": "rxcui:1299922"}]}}
{"id": "civic.eid:673", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-04T00:40:03.449Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T20:35:01.376Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-05-31T15:35:21.580Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-05-10T18:22:29.248Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-12-09T21:24:56.905Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:907", "type": "Document", "label": "Chung et al., 2006, Gynecol. Oncol.", "xrefs": ["pmid:16875718"], "title": "XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:PlWky7xgyDVndIsUsKNDJ_6N9Kdd2wGD", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rUPB3ij0_aTjphjV2yUUyR1wcR8JR_4T", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9311", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:261", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:159", "type": "DiseaseDescriptor", "label": "Cervical Cancer", "xrefs": ["DOID:4362"], "disease": "ncit:C9311"}, "object_descriptor": {"id": "civic.tcd:xFFut3eEUjgeT2G4uNtiphTfxMQw9B4X", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:93", "type": "TherapeuticDescriptor", "label": "Carboplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C1282"], "alternate_labels": ["(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum", "1,1-cyclobutanedicarboxylic Acid Platinum Complex", "Blastocarb", "CBDCA", "Carboplat", "Carboplatin Hexal", "Carboplatino", "Carboplatinum", "Carbosin", "Carbosol", "Carbotec", "Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum", "Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)", "Cis-diammine(cyclobutanedicarboxylato)platinum II", "Displata", "Ercar", "JM-8", "Nealorin", "Novoplatinum", "Paraplat", "Paraplatin", "Paraplatin AQ", "Paraplatine", "Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)", "Platinwas", "Ribocarbo"], "therapeutic": "rxcui:40048"}, {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}]}}
{"id": "civic.eid:676", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-04T04:24:31.933Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:214", "type": "Agent", "name": "Jake Lever"}, "date": "2016-09-30T23:00:35.758Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-02T15:11:45.090Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-12-11T21:16:46.464Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:430", "type": "Document", "label": "Caronia et al., 2009, Pharmacogenomics J.", "xrefs": ["pmid:19434073"], "title": "Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:WfAs-Y6VHjREHF0LGziJ3ZdQhbfmBsdu", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.fzUnu0PBAjqQ3qMW1KgvUQae4U3pSAjM", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2555", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9145", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:264", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:134", "type": "DiseaseDescriptor", "label": "Osteosarcoma", "xrefs": ["DOID:3347"], "disease": "ncit:C9145"}, "object_descriptor": {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}}
{"id": "civic.eid:738", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-22T13:52:47.298Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-24T21:36:00.796Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-27T21:28:40.691Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-24T21:31:03.255Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:486", "type": "Document", "label": "Yoo et al., 2016, Cancer Res Treat", "xrefs": ["pmc:PMC4843750", "pmid:26130666"], "title": "Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:816", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-12T10:25:26.787Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-18T19:55:57.565Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-18T19:56:58.994Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-01-28T04:23:37.049Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:548", "type": "Document", "label": "Rowland et al., 2015, Br. J. Cancer", "xrefs": ["pmc:PMC4580381", "pmid:25989278"], "title": "Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:R6kd1VbbX_M-9Bs9WkrHDmTG-EmunICY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:879", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-14T20:16:44.813Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-09T00:22:49.252Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-13T03:54:15.763Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-22T17:18:50.452Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-09T00:15:24.113Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:592", "type": "Document", "label": "Sequist et al., 2013, J. Clin. Oncol.", "xrefs": ["pmid:23816960"], "title": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:qGwQR6KRs2XOfhjFQ8saILaI5RO0DQUX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:965", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-26T19:37:06.770Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-06-15T19:51:19.769Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T15:35:43.588Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-08T07:16:18.205Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-03T22:54:31.387Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:667", "type": "Document", "label": "J\u00e4nne et al., 2015, N. Engl. J. Med.", "xrefs": ["pmid:25923549"], "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:982", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-02-07T14:36:26.220Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-09T01:13:02.721Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-13T05:52:41.374Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-09T01:12:20.349Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:679", "type": "Document", "label": "Wu et al., 2014, Lancet Oncol.", "xrefs": ["pmid:24439929"], "title": "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:qGwQR6KRs2XOfhjFQ8saILaI5RO0DQUX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:1088", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:130", "type": "Agent", "name": "Robert Lesurf"}, "date": "2016-02-23T15:49:55.311Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2021-12-29T21:38:21.380Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-17T19:28:12.150Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-03-25T22:46:26.821Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:52:25.527Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:747", "type": "Document", "label": "Norton et al., 2014, Cancer Immunol Res", "xrefs": ["pmc:PMC4215796", "pmid:24989892"], "title": "Association studies of Fc\u03b3 receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:l-jl9Szk5j5fp7hz7b096rd9un3kmgjp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.FYgu5NU0Xid2r6l5KYCGANi5gmuoUYh1", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2103478", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:456", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}}
{"id": "civic.eid:1181", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-03-21T14:48:27.137Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-05-17T17:10:27.354Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:814", "type": "Document", "label": "Rowland et al., 2016, Eur. J. Cancer", "xrefs": ["pmid:26812186"], "title": "Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:1399", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-24T16:19:16.499Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:48:54.600Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T23:40:52.807Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:48:31.455Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:947", "type": "Document", "label": "McArthur et al., 2014, Lancet Oncol.", "xrefs": ["pmc:PMC4382632", "pmid:24508103"], "title": "Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:_tSPfOSkFMlxltmnB_NLVOxWjoMnqv0D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1405", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-27T00:46:41.253Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:43:23.692Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T23:41:26.324Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:42:50.988Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:953", "type": "Document", "label": "Kopetz et al., 2015, J. Clin. Oncol.", "xrefs": ["pmc:PMC4669589", "pmid:26460303"], "title": "Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:GyTl-Ef5EFPmxguxr6_ZwPSdAx4bKvgg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1421", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 344 had V600E mutation. 174 patients were treated with vemurafenib and placebo, and 170 were treated with vemurafenib and cobimetinib and tested for progression free survival. 88 of 174 monotherapy group patients had an event with median progression free survival of 6.5 months. In the combination group 58 of 174 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.57 (0.41-0.80).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:112", "type": "Agent", "name": "Connor Liu"}, "date": "2016-06-28T20:46:18.081Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-08T16:13:48.806Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-11-08T16:29:15.554Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-05T19:41:03.096Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:963", "type": "Document", "label": "Larkin et al., 2014, N. Engl. J. Med.", "xrefs": ["pmid:25265494"], "title": "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:8S_GJT2rwb8YwHK9I-vyyagIPGqJJeay", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1722365", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:sUZF6fX-tmv7MQt76twjivm3eJ5Znrzm", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1722365", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:342", "type": "TherapeuticDescriptor", "label": "Cobimetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C68923"], "alternate_labels": ["Cotellic", "GDC-0973", "MEK Inhibitor GDC-0973", "XL518"], "therapeutic": "rxcui:1722365"}, {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}]}}
{"id": "civic.eid:1725", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:228", "type": "Agent", "name": "Yang-Yang Feng"}, "date": "2016-10-27T02:19:45.259Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-05-02T20:43:21.762Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-04T23:12:14.024Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1170", "type": "Document", "label": "Gotlib et al., 2016, N. Engl. J. Med.", "xrefs": ["pmid:27355533"], "title": "Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:gD2ZSt2lwde1lONvKUFF5BcG_ppYpjpO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nMt7siwiRwJd_T_l46fg_fFaPZ7-H4sN", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1919083", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9235", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:65", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2150", "type": "DiseaseDescriptor", "label": "Systemic Mastocytosis", "xrefs": ["DOID:349"], "disease": "ncit:C9235"}, "object_descriptor": {"id": "civic.tid:323", "type": "TherapeuticDescriptor", "label": "Midostaurin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C1872"], "alternate_labels": ["CGP 41251", "CGP41251", "N-Benzoyl-Staurosporine", "N-Benzoylstaurosporine", "PKC-412", "PKC412", "Rydapt"], "therapeutic": "rxcui:1919083"}}
{"id": "civic.eid:1749", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients (N=37/48). Patients without the V600E mutation had evidence of tumor regression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:175", "type": "Agent", "name": "Lee Trani"}, "date": "2016-11-18T01:46:39.944Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-17T23:02:57.395Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-12T05:48:37.310Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:175", "type": "Agent", "name": "Lee Trani"}, "date": "2016-12-04T11:24:43.361Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-01-05T19:08:17.281Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:352", "type": "Document", "label": "Flaherty et al., 2010, N. Engl. J. Med.", "xrefs": ["pmc:PMC3724529", "pmid:20818844"], "title": "Inhibition of mutated, activated BRAF in metastatic melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:b3f7MP6XtAP-IiLVqnnnlrIk2qsy_Zs_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1757", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T/T).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:175", "type": "Agent", "name": "Lee Trani"}, "date": "2016-12-01T09:38:45.415Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-14T14:39:29.050Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T16:19:17.672Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-12-02T22:14:35.668Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1221", "type": "Document", "label": "Nikas et al., 2015, Am J Cancer Res", "xrefs": ["pmc:PMC4656744", "pmid:26693073"], "title": "A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:StpBzAlTTFPQCtzy5cCKtw5v3lVkUwgS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.9kMMd5idDGHaZZx48pl82b5Qcpc1m87C", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:4492", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7418", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:258", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:579", "type": "DiseaseDescriptor", "label": "Rectum Cancer", "xrefs": ["DOID:1993"], "disease": "ncit:C7418"}, "object_descriptor": {"id": "civic.tid:420", "type": "TherapeuticDescriptor", "label": "Fluorouracil", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C505"], "alternate_labels": ["2,4-Dioxo-5-fluoropyrimidine", "5 FU", "5 Fluorouracil", "5 Fluorouracilum", "5-FU", "5-Fluoro-2,4(1H, 3H)-pyrimidinedione", "5-Fluoro-2,4(1H,3H)-pyrimidinedione", "5-Fluorouracil", "5-Fluracil", "5FU", "AccuSite", "Adrucil", "Carac", "Fluoro Uracil", "Fluouracil", "Flurablastin", "Fluracedyl", "Fluracil", "Fluril", "Fluroblastin", "Ribofluor", "Ro 2-9757", "Ro-2-9757"], "therapeutic": "rxcui:4492"}}
{"id": "civic.eid:1770", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richter\u2019s transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-12-02T09:31:27.325Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-01-23T14:42:11.225Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1237", "type": "Document", "label": "Maddocks et al., 2015, JAMA Oncol", "xrefs": ["pmc:PMC4520535", "pmid:26182309"], "title": "Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:GPAQHGiWQ8y6XdICe033kijlKRPP8Awk", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.N7eoPAzmgrcdHMkpaz2z4H1RW4LpBFfY", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1442981", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:168", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:227", "type": "TherapeuticDescriptor", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015451", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphocytic, Chronic, B-Cell", "disease": "ncit:C3163"}, {"id": "mesh:D020522", "type": "DiseaseDescriptor", "label": "Lymphoma, Mantle-Cell", "disease": "ncit:C4337"}, {"id": "mesh:D008258", "type": "DiseaseDescriptor", "label": "Waldenstrom Macroglobulinemia", "disease": "ncit:C80307"}]}}], "xrefs": ["ncit:C81934"], "alternate_labels": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"], "therapeutic": "rxcui:1442981"}}
{"id": "civic.eid:1863", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-12-13T18:49:46.498Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-01-01T21:00:15.143Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1282", "type": "Document", "label": "Sun et al., 2013, Lung Cancer", "xrefs": ["pmid:24035188"], "title": "Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:Cjf96A9wqWIQMgUTz28OTg6JDrFqFPnQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:1902", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-02-13T12:48:47.025Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-02-14T21:10:27.103Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1336", "type": "Document", "label": "Hong et al., 2016, Cancer Discov", "xrefs": ["pmid:27729313"], "title": "Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:CnbyyaBQJE0R0f3Llv7kLotEZkLkOxnl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:rF1JcnGq_-VTc0yiCsNIORfNqXQCC3yM", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2135", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:03.868Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-25T01:03:32.111Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-29T23:56:12.985Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:21:59.780Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1210", "type": "Document", "label": "Flaherty et al., 2012, N. Engl. J. Med.", "xrefs": ["pmid:22663011"], "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:8_L3X6Ige9-6uWgvdVvBkQiLIvOK6dZV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:2621", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:30.482Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T15:16:47.532Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-10-21T23:33:22.755Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T15:16:55.478Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1501", "type": "Document", "label": "Douillard et al., 2010, J. Clin. Oncol.", "xrefs": ["pmid:20038723"], "title": "Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:c4WdqL5-kPyKfrnmThAqr8vTcxjz5Bal", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:3039", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363. 58 patients with advanced solid tumors were treated. In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations. Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response. Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:402", "type": "Agent", "name": "Mario Lamping"}, "date": "2017-05-25T10:35:39.555Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-09T18:44:09.074Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-02-10T23:45:50.232Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-09T18:44:10.647Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1745", "type": "Document", "label": "Hyman et al., 2017, J. Clin. Oncol.", "xrefs": ["pmid:28489509"], "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:vA_ykuw4k3e0gMe6NhvNuE_SVmZEq1vc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._veAF5iFKxk_oSX9jnfNc4AHp8MvUCKO", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C102564", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:4", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:112", "type": "TherapeuticDescriptor", "label": "Capivasertib", "xrefs": ["ncit:C102564"], "alternate_labels": ["AZD5363"], "therapeutic": "ncit:C102564"}}
{"id": "civic.eid:3750", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:52.214Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-25T00:33:21.687Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-29T23:45:43.642Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-15T14:25:06.855Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:60", "type": "Document", "label": "Trunzer et al., 2013, J. Clin. Oncol.", "xrefs": ["pmid:23569304"], "title": "Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:b3f7MP6XtAP-IiLVqnnnlrIk2qsy_Zs_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3758", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 51% response rate, as compared to a 64% response rate (p<0.001) in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=312). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:57.704Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-11-08T18:02:01.973Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-11-08T18:02:40.648Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:517", "type": "Agent", "name": "Susanna Kiwala"}, "date": "2019-01-17T21:03:15.150Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-15T14:37:34.134Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:353", "type": "Document", "label": "Robert et al., 2015, N. Engl. J. Med.", "xrefs": ["pmid:25399551"], "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:hpod_CG36DGOcw3hSorKprPGgcRWMdxL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:5958", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\nWithin the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:24:33.558Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-15T21:50:44.217Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:PX2KF06FDLt2fBuKmp2SdmjhWlge3i-Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:6123", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-04-16T15:25:31.220Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-05-23T18:47:26.667Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2468", "type": "Document", "label": "Corcoran et al., 2018, Cancer Discov", "xrefs": ["pmc:PMC5882509", "pmid:29431699"], "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:qc821cMPyk08jcAGfHBplIGSR1x4Ms0h", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:TC0qf-K34RiO4MPOvi-7wmgAjjt7va7T", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}, {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}]}}
{"id": "civic.eid:6179", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 78 (9%) patients had V600K, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 16/41 patients (39%) in the treatment group and 19/37 patients (51%) in the placebo group for a 95% CI Hazard Ratio of 0.54 (0.27-1.06).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-05-23T16:14:00.413Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-05-23T17:49:06.963Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:05:02.864Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-05-23T17:46:03.974Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2475", "type": "Document", "label": "Long et al., 2017, N. Engl. J. Med.", "xrefs": ["pmid:28891408"], "title": "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:0547u-q83RGm0HNMzIZxoFbu51yDHgyx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:6940", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy. From V600E patients, 45 received monotherapy and 92 received combination therapy. Hazard ratio for progression or death was 0.43 (95% CI, 0.27-0.71). Both patients with the BRAF V600E and V600K mutation showed significant improvement in progression-free survival.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-10-04T17:51:16.648Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-11-08T17:16:02.466Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-08T17:18:57.301Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-11-08T17:16:04.526Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:103", "type": "Document", "label": "Flaherty et al., 2012, N. Engl. J. Med.", "xrefs": ["pmc:PMC3549295", "pmid:23020132"], "title": "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:pszxvq2klgdS8gFUDix0DGw5akTv4gTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:6965", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 56 had V600K mutation. 32 patients were treated with vemurafenib and placebo, and 24 were treated with vemurafenib and cobimetinib and tested for progression free survival. 17 of 32 monotherapy group patients had an event with median progression free survival of 5.3 months. In the combination group 4 of 24 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.27 (0.09-0.81).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-01T18:33:31.884Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-11-08T16:57:06.335Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-08T16:57:23.712Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-11-08T16:57:28.960Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:963", "type": "Document", "label": "Larkin et al., 2014, N. Engl. J. Med.", "xrefs": ["pmid:25265494"], "title": "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:0547u-q83RGm0HNMzIZxoFbu51yDHgyx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:6975", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anaplastic thyroid carcinoma responded to treatment (overall response rate 69%; 95% CI, 41% to 89%). Seven patients had ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached after 120 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-11-13T23:10:06.032Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-10T18:03:25.994Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-12-11T07:18:39.590Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-04-28T11:56:06.263Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-09T22:12:19.305Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2686", "type": "Document", "label": "Subbiah et al., 2018, J. Clin. Oncol.", "xrefs": ["pmc:PMC5791845", "pmid:29072975"], "title": "Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:CxGnLmIsKIrJQKmi9UAfYMGHxsjTZfH1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3878", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3040", "type": "DiseaseDescriptor", "label": "Thyroid Gland Anaplastic Carcinoma", "xrefs": ["DOID:80522"], "disease": "ncit:C3878"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:7583", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Off-label use of vemurafenib to treat BRAF V600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated.\nFifty-four patients from 12 countries were treated with vemurafenib 20 mg/kg/day.\nBecause LCH is a heterogeneous systemic disease, the quantitative Disease Activity Score (DAS), which reflects overall LCH extension, was used as an evaluation criterion.\nAt 8 weeks, 38 patients had CRs (non-active disease) and 16 PRs (active disease better).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-09-21T13:14:27.406Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-19T20:20:14.783Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-19T20:15:14.532Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3012", "type": "Document", "label": "Donadieu et al., 2019, J. Clin. Oncol.", "xrefs": ["pmc:PMC6823889", "pmid:31513482"], "title": "Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:mbNCVCcoHWvkEM_0eZQxdk6x1lb4Wwqb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C6921", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1762", "type": "DiseaseDescriptor", "label": "Langerhans Cell Sarcoma", "xrefs": ["DOID:7146"], "disease": "ncit:C6921"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:7601", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 trial, patients with H3 K27M mutant glioma have been treated with DRD2 antagonist ONC201. Among 29 patients, 1 patient experienced complete clinical regression lasting >14 months, and 3 patients experienced durable partial response by RANO. 10 patients had a best response of stable disease by RANO, with a few of these patients showing substantial tumor regression in some lesions. Author concluded that ONC201 is well tolerated and has clinical activity against K27M-mutated glioma.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-09-26T09:34:39.841Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-10T18:41:06.527Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-12-10T20:21:06.638Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-03-02T23:32:48.990Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-03-17T20:10:04.671Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3021", "type": "Document", "label": "Isabel Arrillaga, 2019, ASCO Annual Meeting, Abstract 3005", "xrefs": ["asco.abstract:3005"], "title": "Single agent ONC201 in adult recurrent H3 K27M-mutant glioma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:24JvQnoSOaBlWOjQKWMAxoDv8-wl6ZnT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yrd-TcXk6dkOJoK5ER1PQVWY5e5vHqtS", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C113792", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3059", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2416", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2596", "type": "DiseaseDescriptor", "label": "Glioma", "disease": "ncit:C3059"}, "object_descriptor": {"id": "civic.tid:696", "type": "TherapeuticDescriptor", "label": "Akt/ERK Inhibitor ONC201", "xrefs": ["ncit:C113792"], "alternate_labels": ["ONC-201", "ONC201", "TIC10"], "therapeutic": "ncit:C113792"}}
{"id": "civic.eid:7710", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P\u2009<\u2009.0001). \nPatients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53).\nThe RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-10-25T16:28:58.181Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-01-13T01:49:16.184Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-01-13T01:28:58.005Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-04T16:41:48.447Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3061", "type": "Document", "label": "Sherman et al., 2016, Cancer", "xrefs": ["pmid:27525386"], "title": "Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:8ymvHHl0n1sX4dpR-jqkPzX07_pwijfU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ld4IL6kursGxjcAXopnYRTKKS-06pP8-", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1363267", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3879", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:113", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:15", "type": "DiseaseDescriptor", "label": "Thyroid Gland Medullary Carcinoma", "xrefs": ["DOID:3973"], "disease": "ncit:C3879"}, "object_descriptor": {"id": "civic.tid:144", "type": "TherapeuticDescriptor", "label": "Cabozantinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:68942", "type": "DiseaseDescriptor", "label": "Thyroid cancer medullary", "disease": null}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}, {"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}]}}], "xrefs": ["ncit:C52200"], "alternate_labels": ["1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-", "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"], "therapeutic": "rxcui:1363267"}}
{"id": "civic.eid:9018", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positive papillary thyroid cancer that have become resistant to radioactive iodine (the standard treatment). There were 116 patients identified for this trial, 51 of which met the conditions to be included. These 51 patients were split into two cohorts: 1) patients that had never been treated with a multikinase inhibitor targeting VEGFR and 2) patients that have previously been treated with a VEGFR multikinase inhibitor. In cohort 1, ten of 26 patients had best overall response. Best overall response was defined as the proportion of patients with a complete or partial response, however these ten patients were all partial response. In the same cohort 1, nine had achieved stable disease control for at least six months; therefore, 19 patients achieved disease control (73% of total cohort 1, 95% CI 52-88). In cohort 2, of 23 eligible patients, six had a partial response as best overall response and six had stable disease control for at least six months; therefore, 12 patients achieved disease control. (55% of total cohort 2, 95% CI 32-76). The authors conclude that vemurafenib is a potential treatment option for late-stage BRAF V600E-positive papillary thyroid cancer for treatment in patients na\u00efve to a multikinase inhibitor (Cohort 1) and to patients that have been previously treated with a multikinase inhibitor (Cohort 2).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:950", "type": "Agent", "name": "Sydney R. Anderson"}, "date": "2021-01-26T23:01:07.575Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:950", "type": "Agent", "name": "Sydney R. Anderson"}, "date": "2021-01-26T23:26:50.257Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-26T23:27:09.523Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-26T23:27:12.743Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1052", "type": "Document", "label": "Brose et al., 2016, Lancet Oncol.", "xrefs": ["pmid:27460442"], "title": "Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:zI37LGiUHpkQrnA_oPVPwZeLf700PlwO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4035", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:156", "type": "DiseaseDescriptor", "label": "Thyroid Gland Papillary Carcinoma", "xrefs": ["DOID:3969"], "disease": "ncit:C4035"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:83", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective analysis of genetic markers in 503 metastatic colorectal cancer patients who participated in the CORRECT phase III trial of regorafenib. PIK3CA mutations were identified in the tumors of 84 patients, including 27 with PIK3CA E542K. Authors found a clinical benefit of regorafenib across PIK3CA mutated and wildtype subgroups (progression free survival with regorafenib vs placebo: mutant HR: 0.54, wildtype HR: 0.50, P=0.85). Authors do not provide direct comparison between patients with wildtype and PIK3CA E542K patients. Note that it's unclear how many PIK3CA wildtype patients harbor KRAS mutations, though authors' suggest that regorafenib induces clinical benefit regardless of KRAS or PIK3CA mutation status.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.307Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-07-22T22:21:45.733Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2021-07-26T20:05:02.596Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.307Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:4081", "type": "Document", "label": "Tabernero et al., 2015, Lancet Oncol", "xrefs": ["pmc:PMC7513622", "pmid:26184520"], "title": "Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:jN12JixBjoBNeeqiD0URb-S9W9vM1byW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:126", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, and had individual response data. One patient (who harbored BRAF V600E in low copy number) responded, 11 had stable disease, and 18 progressed. Treatments included cetuximab + irinotecan (n=20), cetuximab monotherapy (n=5), cetuximab + FOLFIRI (n=4), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 8 weeks (2-32 weeks), median OS was 25 weeks (4-237 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 61 years old (42-78) and there were 16 males and 14 females. Authors concluded that BRAF mutation (23/24 of mutants were BRAF V600E) was strongly associated with poor response to cetuximab and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:43.915Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-13T22:18:05.690Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-13T22:27:02.649Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-12T23:36:16.735Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:43.915Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:8gj1z2Oih-yf5hY6eLNk8fzdRkUTHc8M", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:229", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:47.921Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-24T00:09:57.412Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-02-24T00:12:24.938Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:47.921Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:162", "type": "Document", "label": "Lim et al., 2014, J Thorac Oncol", "xrefs": ["pmid:24736073"], "title": "Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:4VWDXHDzyWUOdByvvGK0iqDkCHwRS_TC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:239", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.356Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.356Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:168", "type": "Document", "label": "Kobayashi et al., 2005, N. Engl. J. Med.", "xrefs": ["pmid:15728811"], "title": "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:ubBKghiT5mGCQMsup4qNdWzTBY-OMFzG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:251", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) were significantly shorter in mutated patients.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.841Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-31T01:54:46.280Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-07-18T15:21:33.180Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.841Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:175", "type": "Document", "label": "Marchetti et al., 2009, Neoplasia", "xrefs": ["pmc:PMC2745674", "pmid:19794967"], "title": "Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:M4Qvd5g5y-oNes0l98EbAMyAsOPgSngP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:304", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.809Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.809Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:192", "type": "Document", "label": "Prenen et al., 2006, Clin. Cancer Res.", "xrefs": ["pmid:16638875"], "title": "Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:XOC3psUflO_k0P7NI7IYLM7Plz_e7NmP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CW1xXH97SiVFOHQp0rQ7-T5yYdwCE3ta", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:73", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:669", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-03T22:35:02.129Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2022-02-24T20:40:57.154Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-02-24T21:31:43.124Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-12-11T21:18:05.985Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:424", "type": "Document", "label": "Huang et al., 2009, Cancer Chemother. Pharmacol.", "xrefs": ["pmid:18704422"], "title": "The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:nvUDtq04WtQV70JY4My4DfMCZ81a1s1E", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.9kMMd5idDGHaZZx48pl82b5Qcpc1m87C", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:4492", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9331", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:258", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:21", "type": "DiseaseDescriptor", "label": "Stomach Cancer", "xrefs": ["DOID:10534"], "disease": "ncit:C9331"}, "object_descriptor": {"id": "civic.tid:420", "type": "TherapeuticDescriptor", "label": "Fluorouracil", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C505"], "alternate_labels": ["2,4-Dioxo-5-fluoropyrimidine", "5 FU", "5 Fluorouracil", "5 Fluorouracilum", "5-FU", "5-Fluoro-2,4(1H, 3H)-pyrimidinedione", "5-Fluoro-2,4(1H,3H)-pyrimidinedione", "5-Fluorouracil", "5-Fluracil", "5FU", "AccuSite", "Adrucil", "Carac", "Fluoro Uracil", "Fluouracil", "Flurablastin", "Fluracedyl", "Fluracil", "Fluril", "Fluroblastin", "Ribofluor", "Ro 2-9757", "Ro-2-9757"], "therapeutic": "rxcui:4492"}}
{"id": "civic.eid:674", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-04T01:13:35.596Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-04T04:27:12.123Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-22T15:22:20.145Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-12-11T21:17:41.957Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:428", "type": "Document", "label": "Gr\u00e9en et al., 2006, Clin. Cancer Res.", "xrefs": ["pmid:16467099"], "title": "mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:9jpGMGFsDmefMZ2LTS1_2_LOvUUpNtDw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.aamhpjWh7Ux4YOQxQRVGH-tJYZfvAAWl", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:56946", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:262", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:81", "type": "TherapeuticDescriptor", "label": "Paclitaxel", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:54036", "type": "DiseaseDescriptor", "label": "Kaposi sarcoma", "disease": "ncit:C9087"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C1411"], "alternate_labels": ["5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine", "Anzatax", "Asotax", "Bristaxol", "Praxel", "Taxol", "Taxol Konzentrat", "[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"], "therapeutic": "rxcui:56946"}}
{"id": "civic.eid:677", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-04T05:06:18.933Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-12-11T21:16:42.041Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:431", "type": "Document", "label": "Gandara et al., 2009, J. Clin. Oncol.", "xrefs": ["pmc:PMC2717760", "pmid:19470925"], "title": "Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:oM_UmP8Z0yPre9zipJTm9mFdbNet5jyn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.fzUnu0PBAjqQ3qMW1KgvUQae4U3pSAjM", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:56946", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:264", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:AxHYAnCZAUw1ShJYYZKndWIE3M53hjHd", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:56946", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:93", "type": "TherapeuticDescriptor", "label": "Carboplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C1282"], "alternate_labels": ["(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum", "1,1-cyclobutanedicarboxylic Acid Platinum Complex", "Blastocarb", "CBDCA", "Carboplat", "Carboplatin Hexal", "Carboplatino", "Carboplatinum", "Carbosin", "Carbosol", "Carbotec", "Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum", "Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)", "Cis-diammine(cyclobutanedicarboxylato)platinum II", "Displata", "Ercar", "JM-8", "Nealorin", "Novoplatinum", "Paraplat", "Paraplatin", "Paraplatin AQ", "Paraplatine", "Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)", "Platinwas", "Ribocarbo"], "therapeutic": "rxcui:40048"}, {"id": "civic.tid:81", "type": "TherapeuticDescriptor", "label": "Paclitaxel", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:54036", "type": "DiseaseDescriptor", "label": "Kaposi sarcoma", "disease": "ncit:C9087"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C1411"], "alternate_labels": ["5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine", "Anzatax", "Asotax", "Bristaxol", "Praxel", "Taxol", "Taxol Konzentrat", "[2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"], "therapeutic": "rxcui:56946"}]}}
{"id": "civic.eid:883", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-14T21:20:59.651Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-02-03T23:36:04.917Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:594", "type": "Document", "label": "Yang et al., 2012, Lancet Oncol.", "xrefs": ["pmid:22452895"], "title": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:qGwQR6KRs2XOfhjFQ8saILaI5RO0DQUX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:885", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-14T22:30:27.621Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-11T16:44:50.552Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-18T18:40:33.268Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-11T16:43:20.605Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:595", "type": "Document", "label": "Rosell et al., 2012, Lancet Oncol.", "xrefs": ["pmid:22285168"], "title": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:teH1xxIK6r4jpsaY8NccNewpkJ0YcjYX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:964", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-26T19:25:34.209Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-11T21:34:35.205Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-13T05:06:33.185Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-11T21:30:18.405Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:666", "type": "Document", "label": "Thress et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4771182", "pmid:25939061"], "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:7ju0gPvZ0teo6gPF5K4KpcTAgv68UqdM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.xBOuXRHMA9-vqyYsZPx1_E6lOIoZZbs0", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:415", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:966", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-26T19:51:58.427Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-11T21:39:47.552Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:668", "type": "Document", "label": "Sequist et al., 2016, JAMA Oncol", "xrefs": ["pmid:26720284"], "title": "Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:1180", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7\u20133.8) and 7.2 months (95% CI 5.7\u20139.7).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-03-21T14:41:38.819Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-03-23T03:27:43.735Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-03-23T22:01:26.973Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-03-23T03:21:21.761Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:813", "type": "Document", "label": "Schirripa et al., 2015, Ann. Oncol.", "xrefs": ["pmid:26371285"], "title": "Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:1216", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 448 metastatic colorectal cancer patients treated with EGFR-TKIs and tested for EGFR and KRAS mutations, 69 tested positive for KRAS mutations. In 38 EGFR wildtype patients treated with erlotinib or gefitinib, those with KRAS G12C mutations (n=24) had shorter progression free survival rates compared to patients with non-G12C KRAS mutations (n=14; 4.3 vs 9 weeks; P = 0.009; HR=2.7). This was true when restricted to patients with an adenocarcinoma subtype only (n=18 vs 12; 4.1 vs 9 weeks; P = 0.007; HR=3.1). Overall survival was not different between groups.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:112", "type": "Agent", "name": "Connor Liu"}, "date": "2016-04-05T12:31:59.648Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-02T20:43:25.785Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-10-10T22:52:55.080Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-02T20:43:28.279Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:839", "type": "Document", "label": "Fiala et al., Cancer Genet", "xrefs": ["pmid:23313110"], "title": "The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:G_S8Ov9fG9uuzX6_6QCFpvuVmEVQ72z8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:1365", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:112", "type": "Agent", "name": "Connor Liu"}, "date": "2016-06-01T15:46:15.532Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-17T05:50:00.838Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-28T00:12:40.740Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-17T05:46:37.480Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:928", "type": "Document", "label": "Lam et al., 2010, J. Clin. Oncol.", "xrefs": ["pmc:PMC2881718", "pmid:20368568"], "title": "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:O0o5M08l0R7KVbRHOXuufPILafCp_lzZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ld4IL6kursGxjcAXopnYRTKKS-06pP8-", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3879", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:113", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:15", "type": "DiseaseDescriptor", "label": "Thyroid Gland Medullary Carcinoma", "xrefs": ["DOID:3973"], "disease": "ncit:C3879"}, "object_descriptor": {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}}
{"id": "civic.eid:1391", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-24T09:44:42.398Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:49:26.384Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:943", "type": "Document", "label": "Yu et al., 2013, Clin. Cancer Res.", "xrefs": ["pmc:PMC3630270", "pmid:23470965"], "title": "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:rD2bQvD9KVZUcNEXOqHHQAm50t0We0BW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:1406", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-27T04:50:30.244Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:26:31.478Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T23:30:33.021Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:26:33.141Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:345", "type": "Document", "label": "Falchook et al., 2012, Lancet", "xrefs": ["pmc:PMC4109288", "pmid:22608338"], "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:9yk2UmqmKkbHZP316l709nPB-_yHudSP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1424911", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}}
{"id": "civic.eid:1410", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation. \nConfirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-27T15:14:40.878Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:13:09.254Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:354", "type": "Document", "label": "Sosman et al., 2012, N. Engl. J. Med.", "xrefs": ["pmc:PMC3724515", "pmid:22356324"], "title": "Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:xS7w5SBa9KU-CnD4-ZYg7e4eWMg_QRqs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1413", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-28T02:17:50.156Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-28T15:02:02.741Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-28T20:20:59.513Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-28T15:01:25.556Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:957", "type": "Document", "label": "Yaeger et al., 2015, Clin. Cancer Res.", "xrefs": ["pmid:25589621"], "title": "Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:-6aazcN9vGcoY3Yf_zkR0rlwLEljfYQH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:aqQX-Uu5M67jU4vqRwbOB7diuYQozPtZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:1591", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors.\n51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months.\nIn cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-05T07:14:49.255Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-08-15T19:24:48.017Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-16T07:40:06.652Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-08-15T19:24:50.052Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1052", "type": "Document", "label": "Brose et al., 2016, Lancet Oncol.", "xrefs": ["pmid:27460442"], "title": "Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:zI37LGiUHpkQrnA_oPVPwZeLf700PlwO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4035", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:156", "type": "DiseaseDescriptor", "label": "Thyroid Gland Papillary Carcinoma", "xrefs": ["DOID:3969"], "disease": "ncit:C4035"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1665", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR (median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for time to treatment failure (HR = 0.1030; P = .0004).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2016-09-14T14:09:54.116Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-04-02T17:34:49.523Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-04-02T17:35:35.112Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-09-15T16:46:44.536Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1127", "type": "Document", "label": "Yang et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:18509184"], "title": "Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:c4WdqL5-kPyKfrnmThAqr8vTcxjz5Bal", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:1667", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition by gefitinib (n=1) or erlotinib (n=40) underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients, had the T790M EGFR mutation present, indicating its importance in the development of resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2016-09-16T01:26:05.747Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-07T21:30:58.331Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-11T18:10:24.035Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-09-16T08:01:18.758Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1128", "type": "Document", "label": "Belchis et al., 2016, Oncotarget", "xrefs": ["pmc:PMC5216719", "pmid:27304188"], "title": "Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:d8L8hph685R200FfxflNmSMJEZPsO0gv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:1669", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2016-09-16T01:48:28.629Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-09-23T20:24:28.159Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1130", "type": "Document", "label": "Hoogstraat et al., 2015, Pigment Cell Melanoma Res", "xrefs": ["pmid:25515853"], "title": "Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:a2WBx7VottAegcHIRlfFZAWx8QZjtcgb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.X09E2r2MjKn-w1Ggsuy0XMWJ5_-lr-gd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:658", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1736", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib. In this study 44 of 56 patients were treated with either gefitinib or erlotinib. 35 patients had a G719 mutation but the majority of these were G719S (20 with G719S, 9 with G719A, 3 with G719C).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:238", "type": "Agent", "name": "Shuba Krishna"}, "date": "2016-11-04T16:55:52.811Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-01-30T17:19:19.931Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2018-01-30T17:20:46.558Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-04T17:06:40.993Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1180", "type": "Document", "label": "Otsuka et al., 2015, Anticancer Res.", "xrefs": ["pmid:26124334"], "title": "Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:auJs41GwQLK0Hx8P2nxGIBsRgnEQROpi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3PO39DSennfsuKhGmlGEImSRA0C1WDjN", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:134", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:1746", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2016-11-17T20:46:03.264Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-17T23:07:32.788Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-27T22:43:12.446Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-27T17:34:36.020Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1208", "type": "Document", "label": "Choudhury et al., 2016, J. Clin. Oncol.", "xrefs": ["pmid:27044931"], "title": "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:oEN-PzUuh3gDk8xhNJ0tuKgZG3-YHqZj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1anE7melz3tEAD_6EUcISIp6vgmGu3yI", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2930", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:701", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:642", "type": "DiseaseDescriptor", "label": "Transitional Cell Carcinoma", "xrefs": ["DOID:2671"], "disease": "ncit:C2930"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:1747", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2016-11-17T20:46:54.219Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-17T23:11:26.288Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-12-01T15:27:14.187Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-17T23:15:01.922Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-27T17:31:44.759Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1208", "type": "Document", "label": "Choudhury et al., 2016, J. Clin. Oncol.", "xrefs": ["pmid:27044931"], "title": "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:WfE9DdKnOE_ge88Ojw4mIAKuMKtPQ36D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JC6own7wEZPGsYstR4hKlmXcnwKn2wpE", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2930", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:702", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:642", "type": "DiseaseDescriptor", "label": "Transitional Cell Carcinoma", "xrefs": ["DOID:2671"], "disease": "ncit:C2930"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:1748", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2016-11-17T20:47:54.079Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-17T23:13:19.961Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-27T22:40:53.917Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-27T17:36:06.306Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1208", "type": "Document", "label": "Choudhury et al., 2016, J. Clin. Oncol.", "xrefs": ["pmid:27044931"], "title": "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:1UDUYyZZ7Y31QtwncdsRRLYwQBo-jykI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.z7ARybY3rznTxs4CxVMdAHYC-yEsUKxD", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2930", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:703", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:642", "type": "DiseaseDescriptor", "label": "Transitional Cell Carcinoma", "xrefs": ["DOID:2671"], "disease": "ncit:C2930"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:2115", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029). Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively). Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:57.220Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-04-02T01:25:29.712Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-12T03:37:33.409Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-04-02T01:25:38.421Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:100", "type": "Document", "label": "Di Nicolantonio et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:19001320"], "title": "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:R6kd1VbbX_M-9Bs9WkrHDmTG-EmunICY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:2117", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:58.340Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T23:00:01.336Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T23:02:10.044Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T23:02:19.137Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1479", "type": "Document", "label": "Souglakos et al., 2009, Br. J. Cancer", "xrefs": ["pmc:PMC2720232", "pmid:19603024"], "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:pTlGntSf9CNnSxqN-KDNOwSbw5SBwFer", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:32592", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:237", "type": "TherapeuticDescriptor", "label": "Oxaliplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}, {"id": "hemonc:585", "type": "DiseaseDescriptor", "label": "Colon cancer", "disease": "ncit:C9242"}]}}], "xrefs": ["ncit:C1181"], "alternate_labels": ["1-OHP", "Ai Heng", "Aiheng", "DACPLAT", "Dacotin", "Diaminocyclohexane Oxalatoplatinum", "ELOXATIN", "Eloxatine", "JM-83", "Oxalato (1R,2R-cyclohexanediamine)platinum(II)", "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)", "Oxalatoplatin", "Oxalatoplatinum", "RP 54780", "RP-54780", "SR-96669", "Trans-l DACH Oxalatoplatinum", "Trans-l Diaminocyclohexane Oxalatoplatinum", "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum", "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"], "therapeutic": "rxcui:32592"}}
{"id": "civic.eid:2118", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:58.450Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T22:53:05.648Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T22:53:19.000Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:23:08.548Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1479", "type": "Document", "label": "Souglakos et al., 2009, Br. J. Cancer", "xrefs": ["pmc:PMC2720232", "pmid:19603024"], "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:nPdmybPCZyKW4yNXRp7f6s80BEM2XZhf", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:153329", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}}
{"id": "civic.eid:2121", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=0.003) and reduced overall survival (15.0mo vs. 24.6mo, P=0.002) compared to those with wildtype BRAF.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:58.671Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-06T19:52:38.383Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-29T23:48:39.259Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:22:09.982Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1481", "type": "Document", "label": "Tol et al., 2009, N. Engl. J. Med.", "xrefs": ["pmid:19571295"], "title": "BRAF mutation in metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:n5f_VByo02ipCCgkCz1PXtLxskpfBjQe", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2046138", "type": "Therapeutic"}, {"id": "rxcui:194000", "type": "Therapeutic"}, {"id": "rxcui:32592", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:Ak6hp_rMbp-qqpqM6XULZHux5GbB8qFG", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2046138", "type": "Therapeutic"}, {"id": "rxcui:194000", "type": "Therapeutic"}, {"id": "rxcui:32592", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:33", "type": "TherapeuticDescriptor", "label": "Bevacizumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D003110", "type": "DiseaseDescriptor", "label": "Colonic Neoplasms", "disease": "ncit:C2953"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D002289", "type": "DiseaseDescriptor", "label": "Carcinoma, Non-Small-Cell Lung", "disease": "ncit:C2926"}, {"id": "mesh:D005909", "type": "DiseaseDescriptor", "label": "Glioblastoma", "disease": "ncit:C3058"}, {"id": "mesh:D002292", "type": "DiseaseDescriptor", "label": "Carcinoma, Renal Cell", "disease": "mondo:0005086"}, {"id": "mesh:D002583", "type": "DiseaseDescriptor", "label": "Uterine Cervical Neoplasms", "disease": "ncit:C9311"}]}}], "xrefs": ["ncit:C2039"], "alternate_labels": ["ABP 215", "Anti-VEGF", "Anti-VEGF Humanized Monoclonal Antibody", "Anti-VEGF RhuMAb", "Avastin", "BP102", "BP102 Biosimilar", "Bevacizumab Awwb", "Bevacizumab Biosimilar ABP 215", "Bevacizumab Biosimilar BEVZ92", "Bevacizumab Biosimilar BI 695502", "Bevacizumab Biosimilar CBT 124", "Bevacizumab Biosimilar CT-P16", "Bevacizumab Biosimilar FKB238", "Bevacizumab Biosimilar GB-222", "Bevacizumab Biosimilar HD204", "Bevacizumab Biosimilar HLX04", "Bevacizumab Biosimilar IBI305", "Bevacizumab Biosimilar LY01008", "Bevacizumab Biosimilar MIL60", "Bevacizumab Biosimilar MYL-1402O", "Bevacizumab Biosimilar Mvasi", "Bevacizumab Biosimilar QL 1101", "Bevacizumab Biosimilar RPH-001", "Bevacizumab Biosimilar SCT501", "Bevacizumab Biosimilar Zirabev", "Bevacizumab-awwb", "Bevacizumab-bvzr", "HD204", "Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer", "MYL-1402O", "Mvasi", "Recombinant Humanized Anti-VEGF Monoclonal Antibody", "RhuMab-VEGF", "SCT501", "Zirabev"], "therapeutic": "rxcui:2046138"}, {"id": "civic.tid:32", "type": "TherapeuticDescriptor", "label": "Capecitabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}, {"id": "hemonc:585", "type": "DiseaseDescriptor", "label": "Colon cancer", "disease": "ncit:C9242"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1794"], "alternate_labels": ["5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine", "Ro 09-1978/000", "Xeloda"], "therapeutic": "rxcui:194000"}, {"id": "civic.tid:237", "type": "TherapeuticDescriptor", "label": "Oxaliplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}, {"id": "hemonc:585", "type": "DiseaseDescriptor", "label": "Colon cancer", "disease": "ncit:C9242"}]}}], "xrefs": ["ncit:C1181"], "alternate_labels": ["1-OHP", "Ai Heng", "Aiheng", "DACPLAT", "Dacotin", "Diaminocyclohexane Oxalatoplatinum", "ELOXATIN", "Eloxatine", "JM-83", "Oxalato (1R,2R-cyclohexanediamine)platinum(II)", "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)", "Oxalatoplatin", "Oxalatoplatinum", "RP 54780", "RP-54780", "SR-96669", "Trans-l DACH Oxalatoplatinum", "Trans-l Diaminocyclohexane Oxalatoplatinum", "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum", "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"], "therapeutic": "rxcui:32592"}]}}
{"id": "civic.eid:2207", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 76 patients harbored KRAS G12D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Five patients had partial response, 34 had stable disease, and 37 progressed. Treatments included cetuximab + irinotecan (n=61), cetuximab + FOLFIRI (n=6), cetuximab monotherapy (n=5), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (3-169 weeks), median OS was 31 weeks (6-232 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (32-86), and there were 43 males and 33 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:55.534Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T00:50:25.444Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-07T01:36:02.499Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T00:40:25.219Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-07T01:35:37.024Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:TlVywyQ5mWBwUhE0EKa8yL3QHFB9EZJE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:2219", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 39 patients harbored KRAS G12V, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 16 had stable disease, and 20 progressed. Treatments included cetuximab + irinotecan (n=30), cetuximab + FOLFIRI (n=2), cetuximab monotherapy (n=2), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + irinotecan + oxaliplatin + 5FU + bevacizumab (n=1), and cetuximab+irinotecan+oxaliplatin+5FU (n=1). Median PFS was 12 weeks (1-37 weeks), median OS was 32 weeks (4-77 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 63 years old (34-76), and there were 21 males and 18 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:01.075Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T01:08:04.860Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T01:08:18.189Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T01:06:10.872Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T01:07:36.705Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:Mbn5sm4UhaBWJ4Btlb5mp7j_hP_fjlsP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:2634", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:44.197Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-05-18T21:31:31.742Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-06-15T18:57:23.917Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-05-18T21:31:36.867Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1513", "type": "Document", "label": "Han et al., 2012, J. Clin. Oncol.", "xrefs": ["pmid:22370314"], "title": "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:oFB8FgJ0_PfyHhfsmd_FIJAT8Ya8BtjH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:3755", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a clinical study (NCT01307397) of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), median overall survival was 61.9% (95% CI: 50.1-73.6) and median progression free survival was 7.4 months (95% CI: 5.5-9.2). Median duration of response was 7.4 months (95% CI: 5.7-9.2), with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:55.670Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-24T22:26:02.910Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-29T23:51:37.526Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-15T14:26:43.144Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1955", "type": "Document", "label": "Rutkowski et al., 2015, Contemp Oncol (Pozn)", "xrefs": ["pmc:PMC4631301", "pmid:26557775"], "title": "The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:b3f7MP6XtAP-IiLVqnnnlrIk2qsy_Zs_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3757", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases, while 15% (25/167) of patients harboring BRAF V600E experienced progressive disease.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:56.993Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-24T21:56:12.646Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-29T23:46:37.928Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-15T14:33:52.604Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1957", "type": "Document", "label": "Ugurel et al., 2015, Ann. Oncol.", "xrefs": ["pmid:25524477"], "title": "A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:b3f7MP6XtAP-IiLVqnnnlrIk2qsy_Zs_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3881", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had partial response, 19 had stable disease, and 22 progressed. Treatments included cetuximab + irinotecan (n=38), cetuximab + FOLFIRI (n=5), cetuximab monotherapy (n=4), cetuximab + oxaliplatin + 5FU (n=2), and cetuximab + irinotecan + oxaliplatin + 5FU (n=1). Median PFS was 16 weeks (3-101 weeks), median OS was 33 weeks (3-161 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 65 years old (34-78), and there were 29 males and 20 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:37:00.861Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T01:11:05.326Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T01:11:19.842Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T01:13:12.893Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T01:12:38.605Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4006", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12S, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had stable disease and seven progressed. Treatments included cetuximab + irinotecan (n=13), cetuximab + FOLFIRI (n=1), cetuximab+5FU (n=1), cetuximab + irinotecan + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (2-50 weeks), median OS was 25 weeks (10-135 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 59 years old (31-69), and there were 9 males and 7 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:45.692Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T01:02:25.174Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T01:02:37.778Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-13T01:24:27.458Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T01:01:35.113Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:n5yAWUbB1phBm0bV3_URu8KuM2Eu_Tw4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4180", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600K mutation (n=18) were associated with a 5.6% (1/18) complete response, a 22.2% (4/18) partial response and stable disease in 44.4% (8/18) of cases; however, 27.8% (5/18) of patients harboring BRAF V600K experienced progressive disease and patients with BRAF V600E mutation achieved a more impressive clinical benefit, as compared to patients with BRAF V600K mutation (P=0.016).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:41:29.945Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:20:22.949Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-24T21:23:51.765Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:19:22.545Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1957", "type": "Document", "label": "Ugurel et al., 2015, Ann. Oncol.", "xrefs": ["pmid:25524477"], "title": "A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:_tSPfOSkFMlxltmnB_NLVOxWjoMnqv0D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4181", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600K mutation and treated with vemurafenib (n=34) were associated with a 44% response rate, as compared to a 65% response rate in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=34).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:41:30.686Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-15T18:21:51.575Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:05:18.817Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-02-15T16:24:02.614Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:353", "type": "Document", "label": "Robert et al., 2015, N. Engl. J. Med.", "xrefs": ["pmid:25399551"], "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:jQRhunzdUxIneAgSVN6i763I3Bi4QseW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:4429", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 22 patients harbored KRAS G12A, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 12 had stable disease, and seven progressed. Treatments included cetuximab + irinotecan (n=18), cetuximab monotherapy (n=1), cetuximab + FOLFIRI (n=2), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 18 weeks (1-34 weeks), median OS was 35 weeks (1-143 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (22-77) and there were 11 males and 11 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:50:39.900Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T00:51:40.563Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T00:51:56.782Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T00:52:10.854Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T00:21:35.877Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:BT_V6YJrOawOoh3NYM52rlSdoheOx1hr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4603", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This study (NCT01459757) is a retrospective analysis of sunitinib efficacy on imatinib resistant or intolerant gastrointestinal stromal tumor (GIST) patients who were treated in an open-label clinical trial (NCT00094029). Tumor tissue for mutational status assessment was obtained from 230 patients on one or more occassions (pre-imatinib, post-imatinib/pre-sunitinib, post-sunitinib). Tissue was assessed for mutations in KIT exons 9, 11, 13, and 17 and in PDGFRA exons 12 and 18.  With sunitinib treatment, patients with a primary (pre-imatinib) KIT exon 9 mutation (n=42) displayed significantly better PFS compared with those with a primary KIT exon 11 mutation (n=143; p = .011),  significantly longer OS (p =.002), and significantly higher ORR (p=.012). The authors conclude that sunitinib displays higher activity in KIT exon 9 vs KIT 11 mutant GIST patients.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:08.380Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-07-21T22:36:18.010Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-21T22:36:33.812Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-21T22:39:53.255Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2043", "type": "Document", "label": "Reichardt et al., 2016, BMC Cancer", "xrefs": ["pmc:PMC4714485", "pmid:26772734"], "title": "Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:eFTlepqoyCkSMJfUHP4VJ5epX8i4mFhn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RrrRa6y26sh-_t1dj7fNj4jv0aPCpofl", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1551", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:5959", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\nAmong 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:26:38.387Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-15T21:52:07.664Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:6mCK6UNqk8zLS0s5A-MscEIrmafTUyf6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:6045", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 \u201cbasket\u201d study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response rate of 29%.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-03-19T15:37:06.558Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-10T18:02:36.541Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-12-11T07:19:07.879Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:21:06.334Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1040", "type": "Document", "label": "Hyman et al., 2015, N. Engl. J. Med.", "xrefs": ["pmc:PMC4971773", "pmid:26287849"], "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:B7XBrHz1-RXwT435aRF-YvBHa6ujxq4j", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3878", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3040", "type": "DiseaseDescriptor", "label": "Thyroid Gland Anaplastic Carcinoma", "xrefs": ["DOID:80522"], "disease": "ncit:C3878"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:6124", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-04-16T15:26:48.248Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-05-23T18:47:37.233Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2468", "type": "Document", "label": "Corcoran et al., 2018, Cancer Discov", "xrefs": ["pmc:PMC5882509", "pmid:29431699"], "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:OYI_Ram1sz54YOHJQ7AublViEyDBevrk", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:57", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["DOID:50861"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "civic.tcd:TJUHf9p152aDhRuAJ6lB5jfabJYZcqE_", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:6402", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T22:55:04.863Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T22:55:12.424Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1479", "type": "Document", "label": "Souglakos et al., 2009, Br. J. Cancer", "xrefs": ["pmc:PMC2720232", "pmid:19603024"], "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:dXc2_1ToYTAOWxuuzopACZUzTLyTjVBD", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Sx0r938r9xS6vFaqkhckqW4t9q11m69b", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:153329", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2398", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}}
{"id": "civic.eid:6403", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T23:01:12.592Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T23:01:48.958Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1479", "type": "Document", "label": "Souglakos et al., 2009, Br. J. Cancer", "xrefs": ["pmc:PMC2720232", "pmid:19603024"], "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:gYa_LRk4mCgVU4O90nSQoNlrpu8YiIy2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Sx0r938r9xS6vFaqkhckqW4t9q11m69b", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:32592", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2398", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:237", "type": "TherapeuticDescriptor", "label": "Oxaliplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}, {"id": "hemonc:585", "type": "DiseaseDescriptor", "label": "Colon cancer", "disease": "ncit:C9242"}]}}], "xrefs": ["ncit:C1181"], "alternate_labels": ["1-OHP", "Ai Heng", "Aiheng", "DACPLAT", "Dacotin", "Diaminocyclohexane Oxalatoplatinum", "ELOXATIN", "Eloxatine", "JM-83", "Oxalato (1R,2R-cyclohexanediamine)platinum(II)", "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)", "Oxalatoplatin", "Oxalatoplatinum", "RP 54780", "RP-54780", "SR-96669", "Trans-l DACH Oxalatoplatinum", "Trans-l Diaminocyclohexane Oxalatoplatinum", "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum", "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"], "therapeutic": "rxcui:32592"}}
{"id": "civic.eid:7260", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase III trial, patients with BRAF V600E mutated metastatic colorectal cancer received triplet combination with encorafenib + binimetinib + cetuximab in a second or third-line setting. In the safety-lead in part of this trial, 30 patients were given triplet therapy, of which 29 with V600E mutation were included in the efficacy analysis. The objective response rate was 48% [95%CI: 29.4 - 67.5], median PFS was 8.0 mo [95%CI: 5.6 - 9.3], and median OS was 15.3 mo [95%CI: 9.6 - not reached]. The author concluded that triplet therapy was well tolerated and PFS and OS were substantially improved over historical standard of care.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-04-27T00:10:18.322Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-03-04T21:13:06.020Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-03-10T23:25:46.970Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-19T19:00:49.605Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2858", "type": "Document", "label": "Scott Kopetz, 2019, Gastrointestinal Cancers Symposium, Abstract 688", "xrefs": ["asco.abstract:688"], "title": "Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC)."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:MnBrZIOoshPdIMhm64nfK2rwV9lSYiK_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049106", "type": "Therapeutic"}, {"id": "rxcui:2049122", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7g5X81wE2go4GE_fB45SjFamVMgpnwsA", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2049106", "type": "Therapeutic"}, {"id": "rxcui:2049122", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:483", "type": "TherapeuticDescriptor", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "xrefs": ["ncit:C98283"], "alternate_labels": ["Braftovi", "LGX 818", "LGX-818", "LGX818"], "therapeutic": "rxcui:2049106"}, {"id": "civic.tid:485", "type": "TherapeuticDescriptor", "label": "Binimetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "xrefs": ["ncit:C84865"], "alternate_labels": ["ARRY-162", "ARRY-438162", "MEK162", "Mektovi"], "therapeutic": "rxcui:2049122"}, {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}]}}
{"id": "civic.eid:7264", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase II trial, 33 patients with advanced or metastatic biliary tract cancer (BTC) received dabrafenib (D) and trametinib (T) in a second or higher line therapeutic context. Of the 33 patients, 30 had BRAF V600E mutated tumors, and 32 were evaluable. Objective response rate was 41% (13/32; 95% CI, 24 - 59%). Median PFS was 7.2 months (95% CI, 4.6 - 10.1 months), and median OS was 11.3 months (95% CI, 7.3 - 17.6 months). The author concluded that D+T therapy should be considered for patients with BRAF V600E mutated BTC.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-04-27T11:11:51.231Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-19T19:36:19.752Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-19T20:28:57.586Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-19T20:29:00.964Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2860", "type": "Document", "label": "Zev A. Wainberg, 2019, Gastrointestinal Cancers Symposium, Abstract 187", "xrefs": ["asco.abstract:187"], "title": "Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600E&#x2013;mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:rY4LadrnitsHkSwH2VcJfZ-TQGZkjYn-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "mondo:0003060", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1065", "type": "DiseaseDescriptor", "label": "Biliary Tract Cancer", "xrefs": ["DOID:4607"], "disease": "mondo:0003060"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:258", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumor (located in rectum) of one patient who experienced partial response (patient 38; Supplemental Table 1), following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.118Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T20:53:40.658Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T21:51:42.974Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.118Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:2APhLRtWXrKHa0DqG9-yiH-RSlulALWw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:675", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2015-12-04T02:59:42.761Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-03-22T01:39:32.860Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-04-25T19:01:13.680Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-12-11T21:17:33.517Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:429", "type": "Document", "label": "Yan et al., 2011, Asian Pac. J. Cancer Prev.", "xrefs": ["pmid:22296372"], "title": "Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:3f3bdIsuCk5z4KFp1e8xrkJsO4OkCPf-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.LNpp8uLB2raTfBUKOXRPm9omT28jpHOH", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:263", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:xFFut3eEUjgeT2G4uNtiphTfxMQw9B4X", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:93", "type": "TherapeuticDescriptor", "label": "Carboplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C1282"], "alternate_labels": ["(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum", "1,1-cyclobutanedicarboxylic Acid Platinum Complex", "Blastocarb", "CBDCA", "Carboplat", "Carboplatin Hexal", "Carboplatino", "Carboplatinum", "Carbosin", "Carbosol", "Carbotec", "Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum", "Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)", "Cis-diammine(cyclobutanedicarboxylato)platinum II", "Displata", "Ercar", "JM-8", "Nealorin", "Novoplatinum", "Paraplat", "Paraplatin", "Paraplatin AQ", "Paraplatine", "Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)", "Platinwas", "Ribocarbo"], "therapeutic": "rxcui:40048"}, {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}]}}
{"id": "civic.eid:806", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-12T08:23:29.181Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-07T05:21:27.857Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-07T05:36:11.761Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-07T05:20:26.600Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:540", "type": "Document", "label": "Osumi et al., 2015, Mol Clin Oncol", "xrefs": ["pmc:PMC4534836", "pmid:26623049"], "title": "Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:994", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable disease lasting longer than 16 weeks, and 8 experienced disease progression (including 2 with prior vemurafenib treatment). One of the partial responders had a concomitant EGFR mutation, and two of the stable disease patients had other concomitant mutations (in RET or MET). The median days on treatment was 113 (18-366) for BRAF V600E melanoma patients and 107 (17-323) for BRAF V600 wildtype patients (n=23). Patients with BRAF V600E mutant melanoma experienced similar response rates (24% vs 20%) and rates of metabolic response measured by decrease in FDG uptake assessed by FDG-PET (86% vs 75%) compared to non-BRAF mutant patients. Patients with melanoma, either BRAF wt or V600E, experienced significant decreases in Ki67 expression by day 15 of MEK inhibitor treatment (P<0.02). The authors conclude that RO4987655 has clinical activity in BRAF V600E and BRAF wt melanoma.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-10T08:44:45.036Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T23:52:57.843Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-24T23:54:10.934Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-25T00:04:27.453Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-12T22:29:42.053Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:688", "type": "Document", "label": "Zimmer et al., 2014, Clin. Cancer Res.", "xrefs": ["pmid:24947927"], "title": "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:djOJ2oYcLngj6KQyDSAlkEvE_xndUSAl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C82696", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:243", "type": "TherapeuticDescriptor", "label": "MEK Inhibitor RO4987655", "xrefs": ["ncit:C82696"], "alternate_labels": ["RO-4987655", "RO4987655"], "therapeutic": "ncit:C82696"}}
{"id": "civic.eid:1142", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving selumetinib and docetaxel combined treatment had a trend towards longer OS, PFS and ORR compared to other KRAS mutations, but the differences did not reach statistical significance. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-29T12:39:14.558Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-01-29T23:09:24.740Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-03-10T23:47:13.527Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-03-01T14:51:03.325Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:791", "type": "Document", "label": "J\u00e4nne et al., 2015, Br. J. Cancer", "xrefs": ["pmc:PMC4506393", "pmid:26125448"], "title": "Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:z5mW-sadgXvev0o3Q9PD_Ifenr1kRDbQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1299922", "type": "Therapeutic"}, {"id": "rxcui:2289380", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:XLPSZcKSHPHqVNFvaTkpEccouN1BleTZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1299922", "type": "Therapeutic"}, {"id": "rxcui:2289380", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:73", "type": "TherapeuticDescriptor", "label": "Docetaxel", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:608", "type": "DiseaseDescriptor", "label": "Head and neck cancer", "disease": "ncit:C4013"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:658", "type": "DiseaseDescriptor", "label": "Prostate cancer", "disease": "ncit:C7378"}]}}], "xrefs": ["ncit:C1526"], "alternate_labels": ["Docecad", "N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol", "RP56976", "Taxotere", "Taxotere Injection Concentrate", "[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"], "therapeutic": "rxcui:1299922"}, {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}]}}
{"id": "civic.eid:1579", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-07-27T18:33:17.944Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-08-15T19:25:01.669Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1043", "type": "Document", "label": "Tiacci et al., 2015, N. Engl. J. Med.", "xrefs": ["pmc:PMC4811324", "pmid:26352686"], "title": "Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:4iS2t_6p1rrCBK8qq2s6gSTqI4IBn9Ar", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7402", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:665", "type": "DiseaseDescriptor", "label": "Hairy Cell Leukemia", "xrefs": ["DOID:285"], "disease": "ncit:C7402"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:2008", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:27.499Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T20:14:00.128Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T19:51:04.125Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T01:42:44.249Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1416", "type": "Document", "label": "Endoh et al., 2006, J Thorac Oncol", "xrefs": ["pmid:17409929"], "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:lhywRIjI5US6eddI5ChJBdGiVcQ5dX0g", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7377", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:23", "type": "DiseaseDescriptor", "label": "Lung Cancer", "xrefs": ["DOID:1324"], "disease": "ncit:C7377"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2009", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:27.573Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:52:07.547Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-07-18T15:21:47.755Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:51:57.065Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1417", "type": "Document", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "xrefs": ["pmc:PMC2663546", "pmid:19284554"], "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2240", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:17.869Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T20:11:29.062Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T19:52:02.132Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:45:30.331Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1416", "type": "Document", "label": "Endoh et al., 2006, J Thorac Oncol", "xrefs": ["pmid:17409929"], "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:ySRFiqA_9snwkXUfRXG0-xvoctIHF4px", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7377", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:23", "type": "DiseaseDescriptor", "label": "Lung Cancer", "xrefs": ["DOID:1324"], "disease": "ncit:C7377"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2247", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:18.726Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:51:27.815Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2019-08-12T21:55:17.810Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2019-12-19T23:40:37.748Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:50:42.490Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1417", "type": "Document", "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.", "xrefs": ["pmc:PMC2663546", "pmid:19284554"], "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2257", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:19.726Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T20:13:28.743Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T19:49:13.587Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:44:24.221Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1416", "type": "Document", "label": "Endoh et al., 2006, J Thorac Oncol", "xrefs": ["pmid:17409929"], "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:wd9JALmQuWP0_xgJwMPOMvYt3VsKvheY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7377", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:23", "type": "DiseaseDescriptor", "label": "Lung Cancer", "xrefs": ["DOID:1324"], "disease": "ncit:C7377"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2273", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:21.013Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T20:14:47.148Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T18:55:55.274Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T01:49:23.531Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1416", "type": "Document", "label": "Endoh et al., 2006, J Thorac Oncol", "xrefs": ["pmid:17409929"], "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:JlKdIPCecc4X3EEzPaLwETdeH3oYHmw-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7377", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:23", "type": "DiseaseDescriptor", "label": "Lung Cancer", "xrefs": ["DOID:1324"], "disease": "ncit:C7377"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2327", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:40.123Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T03:23:12.424Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-25T19:50:31.859Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T03:27:58.536Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1425", "type": "Document", "label": "Houillier et al., 2010, Neurology", "xrefs": ["pmid:20975057"], "title": "IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:BTB1V6RlacKo8o8Oz_Rbb_wJGqe_sRX6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:37776", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "mondo:0005499", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:59", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:98", "type": "DiseaseDescriptor", "label": "Brain Glioma", "xrefs": ["DOID:60108"], "disease": "mondo:0005499"}, "object_descriptor": {"id": "civic.tid:11", "type": "TherapeuticDescriptor", "label": "Temozolomide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:604", "type": "DiseaseDescriptor", "label": "Glioblastoma", "disease": "ncit:C3058"}, {"id": "hemonc:559", "type": "DiseaseDescriptor", "label": "Anaplastic glioma", "disease": "ncit:C127816"}]}}], "xrefs": ["ncit:C1244"], "alternate_labels": ["3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide", "8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one", "CCRG-81045", "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-", "M & B 39831", "M And B 39831", "Methazolastone", "RP-46161", "SCH 52365", "TMZ", "Temcad", "Temodal", "Temodar", "Temomedac"], "therapeutic": "rxcui:37776"}}
{"id": "civic.eid:2331", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:43.351Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T03:30:24.678Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-25T19:50:14.045Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T03:28:45.228Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1434", "type": "Document", "label": "2015, Cancer Discov", "xrefs": ["pmid:25583779"], "title": "IDH1 inhibitor shows promising early results."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:XzhdxvwlwRCnwF5SATQDFHseoCCFLXYL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:59", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:454", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C114383"], "alternate_labels": ["AG-120", "Tibsovo"], "therapeutic": "rxcui:2049873"}}
{"id": "civic.eid:2506", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population, however, sub-group analysis for patients with V600K did not show significant improvement in PFS (HR: 0.50, 95% CI:0.18-1.35).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:04:54.903Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2021-01-05T22:03:08.154Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2021-02-02T01:49:03.867Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:18:34.395Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1210", "type": "Document", "label": "Flaherty et al., 2012, N. Engl. J. Med.", "xrefs": ["pmid:22663011"], "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:5flWULM16OL3R6iAz07Z5pRlSjjKHrU0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:4290", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:39.381Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-11T00:38:14.043Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-11T01:12:52.590Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-16T05:19:47.909Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2067", "type": "Document", "label": "De Gr\u00e8ve et al., 2016, PLoS ONE", "xrefs": ["pmc:PMC4816447", "pmid:27032107"], "title": "Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:64rhaTRjJsCQ8ITpsF__1TSOOypqTk-P", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4814", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 16 patients with metastatic breast cancer (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16), including ESR1 D538G (n=2), detected at any time or at initial blood draw, were associated with reduced progression free survival (HR=0.31, 95% CI: 0.05-0.95, P=0.047), as compared with patients with wildtype ESR1 (n=11). There was no significant difference in overall survival (median; 14.1 versus\n12.8 months, HR=0.40; 95% CI: 0.06-2.0, P-value=0.24).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:56:17.686Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-25T21:43:29.084Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-25T22:25:41.000Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-20T18:36:31.862Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2136", "type": "Document", "label": "Gyanchandani et al., 2016, Oncotarget", "xrefs": ["pmid:27556863"], "title": "Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:gkBAB5CeNVPFHDQjL0TFpHo0qTxMmcr7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VUrBmnIanxIELmkweHMA-oSus-zpdjyL", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:72965", "type": "Therapeutic"}, {"id": "rxcui:1601374", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:47", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:8e8qOIfzxekUHTOw_hUntYTTmid3PG3R", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:72965", "type": "Therapeutic"}, {"id": "rxcui:1601374", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:375", "type": "TherapeuticDescriptor", "label": "Letrozole", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1527"], "alternate_labels": ["4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile", "CGS 20267", "Femara"], "therapeutic": "rxcui:72965"}, {"id": "civic.tid:429", "type": "TherapeuticDescriptor", "label": "Palbociclib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C49176"], "alternate_labels": ["6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one", "Ibrance", "PD 0332991", "PD 332991", "PD 991", "PD-0332991", "Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-"], "therapeutic": "rxcui:1601374"}]}}
{"id": "civic.eid:6183", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-05-31T23:03:27.916Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-06-13T21:48:24.631Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-02-26T23:53:00.132Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-06-04T15:38:44.894Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2478", "type": "Document", "label": "Urata et al., 2016, J. Clin. Oncol.", "xrefs": ["pmid:27022112"], "title": "Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:oFB8FgJ0_PfyHhfsmd_FIJAT8Ya8BtjH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:1143", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving combination selumetinib and docetaxel had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-29T12:40:22.485Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-31T00:07:55.251Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-02-24T00:58:44.966Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-04T06:12:59.751Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:791", "type": "Document", "label": "J\u00e4nne et al., 2015, Br. J. Cancer", "xrefs": ["pmc:PMC4506393", "pmid:26125448"], "title": "Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer."}], "evidence_level": {"id": "vicc:e00005", "type": "Coding", "label": "clinical cohort evidence"}, "target_proposition": {"id": "proposition:Z_feM78TtvTOihwJrcnPH-i0fao6PM9X", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1299922", "type": "Therapeutic"}, {"id": "rxcui:2289380", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:XLPSZcKSHPHqVNFvaTkpEccouN1BleTZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1299922", "type": "Therapeutic"}, {"id": "rxcui:2289380", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:73", "type": "TherapeuticDescriptor", "label": "Docetaxel", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:608", "type": "DiseaseDescriptor", "label": "Head and neck cancer", "disease": "ncit:C4013"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:658", "type": "DiseaseDescriptor", "label": "Prostate cancer", "disease": "ncit:C7378"}]}}], "xrefs": ["ncit:C1526"], "alternate_labels": ["Docecad", "N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol", "RP56976", "Taxotere", "Taxotere Injection Concentrate", "[2aR-[2a Alphaa,4beta,4a Beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester"], "therapeutic": "rxcui:1299922"}, {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}]}}
{"id": "civic.eid:2159", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:28.033Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-07T01:17:07.456Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T08:56:04.408Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1524", "type": "Document", "label": "Kosaka et al., 2006, Clin. Cancer Res.", "xrefs": ["pmid:17020982"], "title": "Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ubBKghiT5mGCQMsup4qNdWzTBY-OMFzG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2232", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:17.260Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:21:13.209Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:21:03.087Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1412", "type": "Document", "label": "Amado et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:18316791"], "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:xTALYouVRGlRIOMLO_Z-_53DLegLgV5C", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:2236", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:17.575Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:22:05.522Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:21:39.354Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1412", "type": "Document", "label": "Amado et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:18316791"], "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:I3aHgqvm6GcTQHLdR2Z2inCkSEooTm-C", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:2253", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:19.411Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:22:58.680Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:22:37.006Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1412", "type": "Document", "label": "Amado et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:18316791"], "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:VucLsGxegHDayF4LgNO1NkdtSAxP4rAF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:2264", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:20.317Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:24:01.357Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:23:28.676Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1412", "type": "Document", "label": "Amado et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:18316791"], "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:3oWMCbd4O3Y7pcH-ZokoRgQd47iXgLbX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._AIonI6Sp_E7tTUN81jJbNG3tERDCkVk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:530", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:2269", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:20.727Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:20:32.131Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T01:51:15.745Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1412", "type": "Document", "label": "Amado et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:18316791"], "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:iQA8YjyfGY0-bu-OCXWl6xouT0UO19rK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:2286", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:26.053Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-08T13:13:32.327Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-08T13:10:57.994Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1423", "type": "Document", "label": "Reles et al., 2001, Clin. Cancer Res.", "xrefs": ["pmid:11595686"], "title": "Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:mS61ACjXDNSyTyNGOMxl7Tn231eqYEhS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wSr96dRXIuv1ILWNBWS-cu97XgQWde0R", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:918", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tcd:xFFut3eEUjgeT2G4uNtiphTfxMQw9B4X", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:93", "type": "TherapeuticDescriptor", "label": "Carboplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C1282"], "alternate_labels": ["(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum", "1,1-cyclobutanedicarboxylic Acid Platinum Complex", "Blastocarb", "CBDCA", "Carboplat", "Carboplatin Hexal", "Carboplatino", "Carboplatinum", "Carbosin", "Carbosol", "Carbotec", "Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum", "Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)", "Cis-diammine(cyclobutanedicarboxylato)platinum II", "Displata", "Ercar", "JM-8", "Nealorin", "Novoplatinum", "Paraplat", "Paraplatin", "Paraplatin AQ", "Paraplatine", "Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)", "Platinwas", "Ribocarbo"], "therapeutic": "rxcui:40048"}, {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}]}}
{"id": "civic.eid:2508", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had  EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations treated with gefitinib were associated with improved response rates (42.1% vs. 6.6%, P=0.04) compared to wildtype EGFR patients.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:05:16.400Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T15:21:33.163Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T15:21:38.004Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1501", "type": "Document", "label": "Douillard et al., 2010, J. Clin. Oncol.", "xrefs": ["pmid:20038723"], "title": "Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:M2ezlYZeZmA6UYQllaV1_fHYIZ1gRer7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.OrAPQnKf0Wz2BZoLDoTj3GSeiBeZvtGk", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:999", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2745", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:09.277Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-08T13:17:13.711Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-08T13:06:09.071Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1423", "type": "Document", "label": "Reles et al., 2001, Clin. Cancer Res.", "xrefs": ["pmid:11595686"], "title": "Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:zV51lhYSKlkXLLOjG6pJtMr5oxXWmP5Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.khvmSzP9uXl-D3_-BCZ-UOo_k75HfzLt", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1068", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tcd:xFFut3eEUjgeT2G4uNtiphTfxMQw9B4X", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:40048", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:93", "type": "TherapeuticDescriptor", "label": "Carboplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C1282"], "alternate_labels": ["(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum", "1,1-cyclobutanedicarboxylic Acid Platinum Complex", "Blastocarb", "CBDCA", "Carboplat", "Carboplatin Hexal", "Carboplatino", "Carboplatinum", "Carbosin", "Carbosol", "Carbotec", "Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum", "Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II)", "Cis-diammine(cyclobutanedicarboxylato)platinum II", "Displata", "Ercar", "JM-8", "Nealorin", "Novoplatinum", "Paraplat", "Paraplatin", "Paraplatin AQ", "Paraplatine", "Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)", "Platinwas", "Ribocarbo"], "therapeutic": "rxcui:40048"}, {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}]}}
{"id": "civic.eid:2878", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:27.661Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:39:43.891Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:39:37.824Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1328", "type": "Document", "label": "Swisher et al., 2017, Lancet Oncol.", "xrefs": ["pmid:27908594"], "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:dObO4kqZnDRdBKtVEvOoo553CucYvUpy", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.benC4UUNxcP6CreZ5gLcez-rDmdjXvtB", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1862579", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1246", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:431", "type": "TherapeuticDescriptor", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C137800"], "alternate_labels": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"], "therapeutic": "rxcui:1862579"}}
{"id": "civic.eid:2880", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:27.844Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:59:04.849Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:58:59.121Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1328", "type": "Document", "label": "Swisher et al., 2017, Lancet Oncol.", "xrefs": ["pmid:27908594"], "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:9BhCrlDGJhCwrYOeAV-JN4Yc-q47Zqyi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Cyu7CgDWXT2g3b7cKZibvf53fQXzuuRU", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1862579", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1248", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:431", "type": "TherapeuticDescriptor", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C137800"], "alternate_labels": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"], "therapeutic": "rxcui:1862579"}}
{"id": "civic.eid:2881", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:27.925Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:00:56.708Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:00:48.148Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1328", "type": "Document", "label": "Swisher et al., 2017, Lancet Oncol.", "xrefs": ["pmid:27908594"], "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:WGaXM9GxqkhNAK24AvTFTnJ6ZscjGw4Y", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.-U0JWJQGHvk6eyDACbDVRbEjgGC8MdzX", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1862579", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1249", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:431", "type": "TherapeuticDescriptor", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C137800"], "alternate_labels": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"], "therapeutic": "rxcui:1862579"}}
{"id": "civic.eid:2882", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:28.005Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:01:12.303Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:01:06.484Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1328", "type": "Document", "label": "Swisher et al., 2017, Lancet Oncol.", "xrefs": ["pmid:27908594"], "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:LCDoPKKvZ0AjCysOK_3PDEuBHerCORVp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mzn-rSpggKuhyIQz5dlS5jyhFbNvNQf8", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1862579", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1250", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:431", "type": "TherapeuticDescriptor", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C137800"], "alternate_labels": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"], "therapeutic": "rxcui:1862579"}}
{"id": "civic.eid:2883", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:28.093Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:02:24.285Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:01:28.512Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1328", "type": "Document", "label": "Swisher et al., 2017, Lancet Oncol.", "xrefs": ["pmid:27908594"], "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:jK5C6iYPwy35UZoR6wrZWNdenEBHj3Hx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G5-TIZ5vc4j9k9PeQhGPWtpvhfVG5FiC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1862579", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1251", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:431", "type": "TherapeuticDescriptor", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C137800"], "alternate_labels": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"], "therapeutic": "rxcui:1862579"}}
{"id": "civic.eid:2884", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:28.187Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:03:52.163Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T15:03:43.834Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1328", "type": "Document", "label": "Swisher et al., 2017, Lancet Oncol.", "xrefs": ["pmid:27908594"], "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:YbyOavvRF3CYHes9Kvb6YXprvN3JLzDV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JKn3gyPVc8bhehD04Loc3LX03xvVqB7u", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1862579", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1252", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:431", "type": "TherapeuticDescriptor", "label": "Rucaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C137800"], "alternate_labels": ["6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-", "8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one"], "therapeutic": "rxcui:1862579"}}
{"id": "civic.eid:3851", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:27.200Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-10T13:12:46.037Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-10T13:12:52.016Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1924", "type": "Document", "label": "Su et al., 2012, N. Engl. J. Med.", "xrefs": ["pmc:PMC3724537", "pmid:22256804"], "title": "RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:zAqZlmlqHmJZ6cu6GP2gFIjwi_N7eU64", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Z1VxpmB2Ui54Nd4GCsBXMjb2WDaCU7Ja", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4819", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:274", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:130", "type": "DiseaseDescriptor", "label": "Skin Squamous Cell Carcinoma", "xrefs": ["DOID:3151"], "disease": "ncit:C4819"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3862", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:36.231Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T16:41:45.898Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T16:34:30.331Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2008", "type": "Document", "label": "Misale et al., 2012, Nature", "xrefs": ["pmc:PMC3927413", "pmid:22722830"], "title": "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:1yWKPSBahwElWmJvwd0pVW6T6ROCFha4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tLDWoYXQHs6bKtABt0_xJU86pLjjCdgX", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:907", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4022", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 wild-type patients. The FLT3 D835 mutation positive patients were treated with sunitinib after failure of standard chemotherapy. After 4wk of sunitinib therapy, one patient showed morphological response and the other patient showed partial response to sunitinib therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:58.380Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-15T20:37:27.033Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-15T20:25:09.835Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2030", "type": "Document", "label": "Fiedler et al., 2005, Blood", "xrefs": ["pmid:15459012"], "title": "A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:cNXnum0iMP9Mfx2sV-QCaVDJRb08KwAU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4147", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a subungual melanoma patient harboring the KIT K642E mutation was reported to have a partial response to dasatinib monotherapy of 24 weeks with a 56% tumor reduction.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:50.374Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T11:37:46.919Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T11:37:57.199Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2056", "type": "Document", "label": "Kluger et al., 2011, Cancer", "xrefs": ["pmc:PMC3116034", "pmid:21523734"], "title": "A phase 2 trial of dasatinib in advanced melanoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:cVwD_KBVzjjmlM8s1pHtuKfeeY1nK8w_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qqyXsR4-bT1oCgmCJM4qHholRwDQ602L", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:978", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:4273", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:47:35.821Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-08-17T16:19:12.089Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-08-17T16:14:17.352Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2079", "type": "Document", "label": "Lund-Iversen et al., 2012, J Thorac Oncol", "xrefs": ["pmid:22895145"], "title": "Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:2dL3r0uETV52mLhqtEoUb1OnIv78WZvH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2TmSETRJQzrU-OXco267vKiGgGY4qCLK", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:562", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4643", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:38.432Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T07:15:07.575Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T07:14:35.127Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2116", "type": "Document", "label": "Arcila et al., 2013, Mol. Cancer Ther.", "xrefs": ["pmc:PMC3714231", "pmid:23371856"], "title": "EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Cn2JdNHiv-Zi07qYy4rdKm6rPwhJ-wBU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.p8Y2dQ5nBfPI0l2GzPViuwrBnVv7jPO1", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1566", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4654", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy. Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:46.155Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-20T15:22:42.362Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-20T15:22:44.870Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2117", "type": "Document", "label": "Khamaysi et al., 2016, Br. J. Dermatol.", "xrefs": ["pmid:26822128"], "title": "Segmental basal cell naevus syndrome caused by an activating mutation in smoothened."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:h9ZSDTDg9jNJDXIzMlKZUPlbeN0EIxaG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.8f8ZfbLyMJvGCXConL8k3JWsKG430vJp", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1242987", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2921", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1570", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:314", "type": "DiseaseDescriptor", "label": "Basal Cell Carcinoma", "xrefs": ["DOID:2513"], "disease": "ncit:C2921"}, "object_descriptor": {"id": "civic.tid:190", "type": "TherapeuticDescriptor", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "DiseaseDescriptor", "label": "Cutaneous basal cell carcinoma", "disease": null}]}}], "xrefs": ["ncit:C74038"], "alternate_labels": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"], "therapeutic": "rxcui:1242987"}}
{"id": "civic.eid:4776", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in any patients who did not experience a durable clinical benefit.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:42.223Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-04-16T14:09:47.951Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-04-16T14:09:51.126Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2123", "type": "Document", "label": "Rizvi et al., 2015, Science", "xrefs": ["pmc:PMC4993154", "pmid:25765070"], "title": "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:-Q4i6ElpQbTZsh9qRG1h4AJ-wQn53VD8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.z1MGBq0wa5r2nUuM8ol-2UpqoqFZcgnq", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1547545", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1647", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:138", "type": "TherapeuticDescriptor", "label": "Pembrolizumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C106432"], "alternate_labels": ["Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide", "Keytruda", "Lambrolizumab", "MK-3475", "SCH 900475"], "therapeutic": "rxcui:1547545"}}
{"id": "civic.eid:4777", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous mutation burden, treated with pembrolizumab monotherapy, was associated with a durable clinical benefit; POLD1 deleterious mutation was not identified in patients who did not experience a durable clinical benefit.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:42.867Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-04-16T14:12:37.098Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-04-16T14:12:40.147Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2123", "type": "Document", "label": "Rizvi et al., 2015, Science", "xrefs": ["pmc:PMC4993154", "pmid:25765070"], "title": "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:kvKuo6n1r74vavhl4q6CzP4zpF1zl7p8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cjbZK4U-m_qmxPJmFL59CBaz_eBUW5VH", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1547545", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1648", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:138", "type": "TherapeuticDescriptor", "label": "Pembrolizumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C106432"], "alternate_labels": ["Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide", "Keytruda", "Lambrolizumab", "MK-3475", "SCH 900475"], "therapeutic": "rxcui:1547545"}}
{"id": "civic.eid:486", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2015-08-05T18:46:53.541Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-08-26T18:50:42.414Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-08-05T18:46:53.541Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:296", "type": "Document", "label": "Str\u00f6bel et al., 2004, N. Engl. J. Med.", "xrefs": ["pmid:15201427"], "title": "Thymic carcinoma with overexpression of mutated KIT and the response to imatinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ZWsnLdz0fGdNCHWu74XEiYV2sMX8NtAv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.kq8UicVBL8c9jhJNWV8wFYpsoeuc6B8I", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7569", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:202", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:239", "type": "DiseaseDescriptor", "label": "Thymic Carcinoma", "xrefs": ["DOID:3284"], "disease": "ncit:C7569"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:1108", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:130", "type": "Agent", "name": "Robert Lesurf"}, "date": "2016-02-24T23:23:09.191Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:17:13.874Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:372", "type": "Document", "label": "Wagle et al., 2014, N. Engl. J. Med.", "xrefs": ["pmc:PMC4564868", "pmid:25295501"], "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:2weVvoiSoQI7EWngKgCKkcjZxxCELAvi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.BdPOqjS2rmbWzoZcfxIJRSbihI82COzm", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:141704", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4815", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:469", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:155", "type": "DiseaseDescriptor", "label": "Thyroid Gland Carcinoma", "xrefs": ["DOID:3963"], "disease": "ncit:C4815"}, "object_descriptor": {"id": "civic.tid:41", "type": "TherapeuticDescriptor", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:45070", "type": "DiseaseDescriptor", "label": "Subependymal giant cell astrocytoma", "disease": "ncit:C3696"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:641", "type": "DiseaseDescriptor", "label": "Neuroendocrine tumor", "disease": "ncit:C3809"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C48387"], "alternate_labels": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"], "therapeutic": "rxcui:141704"}}
{"id": "civic.eid:1110", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:130", "type": "Agent", "name": "Robert Lesurf"}, "date": "2016-02-24T23:26:52.295Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:25:04.013Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:372", "type": "Document", "label": "Wagle et al., 2014, N. Engl. J. Med.", "xrefs": ["pmc:PMC4564868", "pmid:25295501"], "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Wibt9Z1e2xJfokJ7b5d1U9XPhMeDwYcm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mWN-AFixmkqHVuKjA0fLe3k2r13MWdhF", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:141704", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4815", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:470", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:155", "type": "DiseaseDescriptor", "label": "Thyroid Gland Carcinoma", "xrefs": ["DOID:3963"], "disease": "ncit:C4815"}, "object_descriptor": {"id": "civic.tid:41", "type": "TherapeuticDescriptor", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:45070", "type": "DiseaseDescriptor", "label": "Subependymal giant cell astrocytoma", "disease": "ncit:C3696"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:641", "type": "DiseaseDescriptor", "label": "Neuroendocrine tumor", "disease": "ncit:C3809"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C48387"], "alternate_labels": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"], "therapeutic": "rxcui:141704"}}
{"id": "civic.eid:717", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-18T10:35:56.843Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-10T21:24:01.882Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-08-15T20:02:53.128Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-23T08:39:55.377Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-23T22:56:41.557Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:472", "type": "Document", "label": "Montagut et al., 2012, Nat. Med.", "xrefs": ["pmid:22270724"], "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:If7Ryn_0-J-IXHcI7vcuv1sEnZ21XDOv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VDg4To7ePAbIjjPfop3VmeFbcUpvgsf5", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:453", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:728", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-21T09:17:56.671Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-01-27T21:35:47.855Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-13T05:34:28.526Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-23T23:59:33.313Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:477", "type": "Document", "label": "Bahadoran et al., 2013, J. Clin. Oncol.", "xrefs": ["pmid:23715574"], "title": "Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:7m-NOBmQct_IOpgDWumuFAWxkSjDdTqG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2UeGMRTqHbmtgmiJbqa7vyXvVAv0ZW_m", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:288", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:791", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-07T13:30:28.609Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-03T22:23:13.338Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-13T05:30:52.089Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-03T22:16:40.075Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:525", "type": "Document", "label": "Van Allen et al., 2015, JAMA Oncol", "xrefs": ["pmc:PMC4557203", "pmid:26181029"], "title": "Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:7VAZDJhBQ8v-ALVRFzrFs4RJxwmG74w1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.401wL6hOe-0nralm6dqE6-jiulch3DcC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C34447", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:320", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:37", "type": "DiseaseDescriptor", "label": "Head And Neck Squamous Cell Carcinoma", "xrefs": ["DOID:5520"], "disease": "ncit:C34447"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:1057", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 (Futuximab/Modotuximab mixture) treatment. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-22T09:36:05.863Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-21T22:42:36.401Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-04-27T04:01:17.899Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-03-30T12:39:01.354Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-23T21:27:48.497Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:746", "type": "Document", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26888827"], "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Jl_Bj5Ob8s83rvxIKtAyVlyO9L0Yaa9G", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.YKWplwPvmiyxVogUgeZ-igxbo1vZbr2H", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C91381", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:443", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:273", "type": "TherapeuticDescriptor", "label": "Futuximab/Modotuximab Mixture", "xrefs": ["ncit:C91381"], "alternate_labels": ["Anti-EGFR Monoclonal Antibody Mixture Sym004", "Futuximab/Modotuximab", "Futuximab/Zatuximab", "Sym004"], "therapeutic": "ncit:C91381"}}
{"id": "civic.eid:1058", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. Sym004 is a 1:1 mixture\nof two non-overlapping anti-EGFR monoclonal antibodies. In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines.\nG465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-22T09:39:23.630Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-24T11:13:13.745Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-02-24T17:44:07.853Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:83", "type": "Agent", "name": "Lynzey Kujan"}, "date": "2016-02-22T21:24:04.324Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-23T21:16:52.770Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:746", "type": "Document", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26888827"], "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:yIy24iBNfTRzXrykcOtXInggZoGEqN03", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.YKWplwPvmiyxVogUgeZ-igxbo1vZbr2H", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:443", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:1414", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-28T05:12:42.011Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-28T15:17:40.056Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-28T19:21:56.130Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-28T15:17:41.981Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:958", "type": "Document", "label": "Ali et al., 2014, Case Rep Oncol", "xrefs": ["pmc:PMC4067722", "pmid:24987354"], "title": "Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:zI37LGiUHpkQrnA_oPVPwZeLf700PlwO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4035", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:156", "type": "DiseaseDescriptor", "label": "Thyroid Gland Papillary Carcinoma", "xrefs": ["DOID:3969"], "disease": "ncit:C4035"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1567", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1).\nA JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-25T07:42:19.052Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-26T22:12:57.918Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-08T03:31:32.544Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T21:27:04.497Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1036", "type": "Document", "label": "Zaretsky et al., 2016, N. Engl. J. Med.", "xrefs": ["pmid:27433843"], "title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:sIdoMs5TCwEAskNfJbQb8x3JZ9J6MaG9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gD8UzOyMtXmMKb7c5EEWhUeh73s4bS-3", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1547545", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:614", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:138", "type": "TherapeuticDescriptor", "label": "Pembrolizumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C106432"], "alternate_labels": ["Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide", "Keytruda", "Lambrolizumab", "MK-3475", "SCH 900475"], "therapeutic": "rxcui:1547545"}}
{"id": "civic.eid:1602", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:14", "type": "Agent", "name": "Katie Campbell"}, "date": "2016-08-16T05:59:34.705Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-16T07:45:22.080Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-08-19T18:25:06.132Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-16T07:43:11.406Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1062", "type": "Document", "label": "Wagle et al., 2011, J. Clin. Oncol.", "xrefs": ["pmc:PMC3157968", "pmid:21383288"], "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:a0Te09vtxFhjZyPzoNvzjxKgOzajrZa2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UzMvDxAVEEQbq31meAbiBkIvleY7w-ke", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:627", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1608", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-08-17T20:27:38.895Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:725", "type": "Agent", "name": "Andreea Chiorean"}, "date": "2018-07-05T14:22:55.274Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-12T18:27:08.302Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-18T11:22:22.045Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1065", "type": "Document", "label": "Zhou et al., 2016, N. Engl. J. Med.", "xrefs": ["pmid:27518686"], "title": "Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:7tmVqJnpOhDYxfINH8kSxfzSXomqcag5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.GkIYk_TJFbD44Jcy2WpfAu-0XyXkOQJh", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1193326", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "mondo:0009892", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:631", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:2137", "type": "DiseaseDescriptor", "label": "Chuvash Polycythemia", "xrefs": ["DOID:60474"], "disease": "mondo:0009892"}, "object_descriptor": {"id": "civic.tid:386", "type": "TherapeuticDescriptor", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "DiseaseDescriptor", "label": "Graft versus host disease", "disease": "ncit:C3063"}, {"id": "hemonc:655", "type": "DiseaseDescriptor", "label": "Polycythemia vera", "disease": "ncit:C3336"}, {"id": "hemonc:635", "type": "DiseaseDescriptor", "label": "Myelofibrosis", "disease": "ncit:C3248"}]}}], "xrefs": ["ncit:C77888"], "alternate_labels": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"], "therapeutic": "rxcui:1193326"}}
{"id": "civic.eid:1661", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline). In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild-type MEK1 as well as increased colony formation and tumor growth in-vivo. Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-09-13T08:35:06.559Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T21:38:05.790Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1124", "type": "Document", "label": "Grisham et al., 2015, J. Clin. Oncol.", "xrefs": ["pmc:PMC4669594", "pmid:26324360"], "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:xpXFqZ1koZ-YhIknIoYpi57tIFdZhzto", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.baTN4Iph6e9emEOfjrJhRUBDQczcyEIt", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7550", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:655", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:87", "type": "DiseaseDescriptor", "label": "Ovarian Serous Carcinoma", "xrefs": ["DOID:50933"], "disease": "ncit:C7550"}, "object_descriptor": {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}}
{"id": "civic.eid:1856", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in 2/3 Ewing Sarcoma patients with germline PTPRD mutations (V253I and W775*, R995C). The third patient had stable disease (T781A mutant). Four wildtype patients had stable or progressive disease.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:258", "type": "Agent", "name": "Rodrigo Dienstmann"}, "date": "2016-12-02T14:42:23.132Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T06:10:38.241Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2017-02-23T19:40:03.561Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-16T19:15:26.633Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1276", "type": "Document", "label": "Jiang et al., 2013, Oncotarget", "xrefs": ["pmc:PMC3757245", "pmid:23800680"], "title": "Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:DiK1ok7gXBMb0jQ-CTz8U9d1ZW8JLpnE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NMASsOy4-x4ydnqk49QvsArnAQf1GneH", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C79828", "type": "Therapeutic"}, {"id": "ncit:C95797", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4835", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:792", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:135", "type": "DiseaseDescriptor", "label": "Ewing Sarcoma Of Bone", "xrefs": ["DOID:3368"], "disease": "ncit:C4835"}, "object_descriptor": {"id": "civic.tcd:SunT6HNOnWd9x4jZqzCZjdlnGffyGYUE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C79828", "type": "Therapeutic"}, {"id": "ncit:C95797", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:423", "type": "TherapeuticDescriptor", "label": "Cixutumumab", "xrefs": ["ncit:C79828"], "alternate_labels": ["Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12", "IMC-A12"], "therapeutic": "ncit:C79828"}, {"id": "civic.tid:246", "type": "TherapeuticDescriptor", "label": "Teprotumumab", "xrefs": ["ncit:C95797"], "alternate_labels": ["Anti-IGF-1R Monoclonal Antibody R1507", "Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I Receptor)(Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer", "R1507", "RG1507", "RO4858696-000", "RV001 Monoclonal"], "therapeutic": "ncit:C95797"}]}}
{"id": "civic.eid:1864", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-12-15T21:56:33.707Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-07T21:12:39.193Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-02-13T13:27:44.418Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-07T21:12:43.238Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1283", "type": "Document", "label": "Bahcall et al., 2016, Cancer Discov", "xrefs": ["pmc:PMC5140694", "pmid:27694386"], "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:B5Fym_6gHom2DzWIHN97S2gvpKYATdzJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lqT_dLf_cLMUusUMgp51UIRu2qJSkolF", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1363267", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:798", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:144", "type": "TherapeuticDescriptor", "label": "Cabozantinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:68942", "type": "DiseaseDescriptor", "label": "Thyroid cancer medullary", "disease": null}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}, {"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}]}}], "xrefs": ["ncit:C52200"], "alternate_labels": ["1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-", "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"], "therapeutic": "rxcui:1363267"}}
{"id": "civic.eid:1865", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-12-15T21:57:27.115Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-07T21:13:54.250Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-02-13T13:27:18.626Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-07T21:13:58.773Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1283", "type": "Document", "label": "Bahcall et al., 2016, Cancer Discov", "xrefs": ["pmc:PMC5140694", "pmid:27694386"], "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:L7uGOs_conFCEd6Q432NsWTr2eYB4PR5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lqT_dLf_cLMUusUMgp51UIRu2qJSkolF", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C104732", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:798", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:425", "type": "TherapeuticDescriptor", "label": "Savolitinib", "xrefs": ["ncit:C104732"], "alternate_labels": ["AZD 6094", "AZD6094", "HMPL-504", "Volitinib"], "therapeutic": "ncit:C104732"}}
{"id": "civic.eid:1985", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%). Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding. Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-03-24T08:14:42.650Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T14:38:24.738Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1395", "type": "Document", "label": "Sharma et al., 2016, Oncotarget", "xrefs": ["pmid:27626698"], "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Z3lh2cro4iOxW_zB3G2e5EVH0SWGYmWX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Kzx-ci9KIT2zSj9-X9wYEtbbyxmjyfdb", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1442981", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:870", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:227", "type": "TherapeuticDescriptor", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015451", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphocytic, Chronic, B-Cell", "disease": "ncit:C3163"}, {"id": "mesh:D020522", "type": "DiseaseDescriptor", "label": "Lymphoma, Mantle-Cell", "disease": "ncit:C4337"}, {"id": "mesh:D008258", "type": "DiseaseDescriptor", "label": "Waldenstrom Macroglobulinemia", "disease": "ncit:C80307"}]}}], "xrefs": ["ncit:C81934"], "alternate_labels": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"], "therapeutic": "rxcui:1442981"}}
{"id": "civic.eid:2158", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy, comparison of DNA sequences from the original diagnostic biopsy specimen and a post-treatment biopsy specimen demonstrated that 3 patients acquired a new EGFR-T790M mutation. Analysis of EGFR sequence from 155 NSCLC samples prior to treatment with an EGFR inhibitor showed no T790M mutations, suggesting that T790M is associated with progression on gefitinib or erlotinib. In vitro experiments showed that the addition of T790M drastically reduced sensitivity to gefitinib or erlotinib in cells containing the sensitizing EGFR mutation L858R.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:24.705Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-06T23:14:51.150Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-16T20:31:40.333Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-16T20:38:24.912Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T08:55:40.155Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1520", "type": "Document", "label": "Pao et al., 2005, PLoS Med.", "xrefs": ["pmc:PMC549606", "pmid:15737014"], "title": "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:d8L8hph685R200FfxflNmSMJEZPsO0gv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:4198", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 4 were del E746-A750. 3 had adenocarcinoma with bronchioloalveolar carcinoma (BAC) features, with response duration and overall survival of 8 and 15 months, 5+ and 5+ months (treatment ongoing at study end) and 28 and 30+ months (alive at study end), and one former smoker with adenocarcinoma with BAC features, who had response duration of 5+ months with treatment ongoing at study end.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:42:27.594Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-21T03:54:58.361Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-29T21:34:44.584Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-04-17T23:04:18.729Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1509", "type": "Document", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC516528", "pmid:15329413"], "title": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:TkqfFX9HbLhBIipEifDTfhLgd3GyueqQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4_z-sPp1Hb0OeQhs_-VlATlyJ_lQbDjT", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1002", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4494", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib.\n\nA 45 year old male never smoker had progressive disease as best response with +24% change to target lesions, progression free survival of 3.8 months, and still alive at study end after 39.3 months. \n\nA 79 year old female never smoker had progressive disease as best response with +13% change to target lesions, progression free survival of 6 months and overall survival of 14 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:30.259Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-10T18:09:46.152Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-18T01:50:42.042Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-08T23:47:47.047Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:5POxMtlqwrFz_3hrTR7oVYoJxKFHPmIR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Daydg17safvIKs_ENTrvKpfoSooKgImP", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1514", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4801", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progressive disease. Both patients were white females, had adenocarcinoma, and were treated with erlotinib as first line therapy. One was 76 years old with 6 former pack years, 38.1% increase in target lesion, 1 month PFS and 12 month OS. The other was 67 years old with 2 former pack years, 6.0% increase in target lesion, 1 month PFS and 1.5 month OS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:56:05.399Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-10T18:14:09.250Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-10T18:13:22.701Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-18T02:13:13.673Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-08T23:47:00.431Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:dMuMhA4dc9z7Qk2ouWLAi6ANkBahfIj5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.HwbhKSEjn4cE_4hdFVIyX4CZSCorC0Wb", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2214", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:5829", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinotecan (a topoisomerase I inhibitor). Whole genome sequencing of the tumor revealed a somatic RAD50 (L1237F) mutation, which was identified as a potential sensitizing lesion contributing to the profound response. Six rad50-mutant yeast strains and genetically engineered mouse embryonic fibroblasts were established and demonstrated severe sensitivity to camptothecin (Chk1 inhibitor).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:544", "type": "Agent", "name": "Sebastian Wagner"}, "date": "2017-09-20T20:06:41.265Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-09-21T18:58:38.123Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-04-27T18:49:06.892Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-09-21T18:58:43.846Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2356", "type": "Document", "label": "Al-Ahmadie et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4155059", "pmid:24934408"], "title": "Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:wcGznln0Km9s8Rj0iMaGMq7u2vG_jMQz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.iMuLpN8FuG9vnmT1LzCuhKSsedpyjGTj", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C66961", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C6176", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2168", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1693", "type": "DiseaseDescriptor", "label": "Ureter Small Cell Carcinoma", "xrefs": ["DOID:6886"], "disease": "ncit:C6176"}, "object_descriptor": {"id": "civic.tcd:MS46Knve6PfTIRC46pX9lhYnFP_VBKim", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C66961", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:543", "type": "TherapeuticDescriptor", "label": "Checkpoint Kinase Inhibitor AZD7762", "xrefs": ["ncit:C66961"], "alternate_labels": ["AZD-7762", "AZD7762"], "therapeutic": "ncit:C66961"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:6260", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600K\u2014no other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-27T19:57:59.650Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T20:03:51.158Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:04:25.786Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:04:31.807Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:rAg1gtlW24oGh-BElsHefLVPFzkuv0dp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gI0FOE6Esplrs92wp0CJWOeriC8srpYN", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1424911", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:169", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}}
{"id": "civic.eid:6268", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-27T21:21:24.864Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T20:38:17.949Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:38:56.814Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:43:06.419Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:vAAn80PZ7PFi5-5VnMLIHAiAlvzUo0sl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AkAaSQnClitRy1XGwEM4IeqbjC9uZIKq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2364", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:6381", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2018-07-13T08:00:53.879Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-13T13:56:22.238Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2522", "type": "Document", "label": "Dao et al., 2014, Leuk Res Rep", "xrefs": ["pmc:PMC4145163", "pmid:25180155"], "title": "Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:hNvXcmrcKYYSb_ZlIBQZIbSb1hXUrc91", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.febEL6t9p7599KYWol9A4wPFuh1cGDyd", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1193326", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3179", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2387", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2127", "type": "DiseaseDescriptor", "label": "Chronic Neutrophilic Leukemia", "xrefs": ["DOID:80187"], "disease": "ncit:C3179"}, "object_descriptor": {"id": "civic.tid:386", "type": "TherapeuticDescriptor", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "DiseaseDescriptor", "label": "Graft versus host disease", "disease": "ncit:C3063"}, {"id": "hemonc:655", "type": "DiseaseDescriptor", "label": "Polycythemia vera", "disease": "ncit:C3336"}, {"id": "hemonc:635", "type": "DiseaseDescriptor", "label": "Myelofibrosis", "disease": "ncit:C3248"}]}}], "xrefs": ["ncit:C77888"], "alternate_labels": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"], "therapeutic": "rxcui:1193326"}}
{"id": "civic.eid:8063", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased in frequency during treatment. PolyPhen-2 and SIFT functional predict folding changes to activation-loop domain. DiFi cells transfected with PIK3CA V955I plasmid assayed with western blot for pAKT (phosphorylated AKT) and pERK showed increased phosphorylation, which was not affected by the addition of cetuximab. PIK3CA V955I transfected cells also promoted cell viability in the presence of cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1120", "type": "Agent", "name": "Robert Fullem"}, "date": "2020-03-27T07:44:57.869Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-03-27T15:59:08.426Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-06T19:13:42.109Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-03-27T15:42:58.721Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2196", "type": "Document", "label": "Xu et al., 2017, Clin. Cancer Res.", "xrefs": ["pmc:PMC5559326", "pmid:28424201"], "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:4zzn6nhDPTY4ICjVhkr8PaM6dmYSw1tb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.LPyMFKyhP-q86-yaOeAAhUwuux-Lhjr2", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3001", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:9404", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This case reports a 16-mo-old boy with metastatic neuroblastoma (stage M). Genomic analysis of a diagnostic biopsy of the tumor and matched normal identified two germline mutations in FANCA and somatic ALK-I1171T mutation. Functional investigation of this mutation including PC12 cell neurite outgrowth, NIH3T3 transformation and phosophoproteomics showing increased ALK signaling all suggested that it was a gain function. The patient was treated with Ceritinib as a monotherapy for 7.5 months. The residual primary decreased in size (44% volume reduction at 6 months of treatment) and was surgically removed. At 21 months of followup a complete remission was observed (including all metastatic sites).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2021-06-15T21:05:16.468Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2021-06-16T12:14:09.615Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:4032", "type": "Document", "label": "Guan et al., 2018, Cold Spring Harb Mol Case Stud", "xrefs": ["pmc:PMC6071567", "pmid:29907598"], "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:9UGlr5KxP3lHxdK_rCJierxEyOCnYOJW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.j3QgmmWdoxPLYlEl3A2ChIGlm2qLAnXo", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1535457", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3371", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:159", "type": "TherapeuticDescriptor", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C115112"], "alternate_labels": ["2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-", "LDK 378", "LDK378", "Zykadia"], "therapeutic": "rxcui:1535457"}}
{"id": "civic.eid:10031", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. Three patients had the PIK3CA p.K944N mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-05T20:02:27.722Z", "activity": {"type": "Coding", "label": "submitted"}}], "is_reported_in": [{"id": "civic.source:2196", "type": "Document", "label": "Xu et al., 2017, Clin. Cancer Res.", "xrefs": ["pmc:PMC5559326", "pmid:28424201"], "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Z9yil0tW5SjZ-pTZIEyBjTaacaOJk3wV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4Q-bwKEnaKVDJpNy-l10AjtCY_h-qI4R", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3666", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:10032", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA F930S mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-05T20:04:27.212Z", "activity": {"type": "Coding", "label": "submitted"}}], "is_reported_in": [{"id": "civic.source:2196", "type": "Document", "label": "Xu et al., 2017, Clin. Cancer Res.", "xrefs": ["pmc:PMC5559326", "pmid:28424201"], "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:o5dcEBANq0FrxXFYnYC25-K7fc2TnUPh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JxkEmK0vRwDDZ76leuqKeqRO1j9ixgkj", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3667", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:10033", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.V955G mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-05T20:06:06.525Z", "activity": {"type": "Coding", "label": "submitted"}}], "is_reported_in": [{"id": "civic.source:2196", "type": "Document", "label": "Xu et al., 2017, Clin. Cancer Res.", "xrefs": ["pmc:PMC5559326", "pmid:28424201"], "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:dpFtjq3qEt5cGafeaqvolEvYD8UH5kSh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.S2W-KxLNmACCpYyeh4UOUdwN_bysLlEs", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3668", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:10034", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.K966E mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-05T20:07:46.374Z", "activity": {"type": "Coding", "label": "submitted"}}], "is_reported_in": [{"id": "civic.source:2196", "type": "Document", "label": "Xu et al., 2017, Clin. Cancer Res.", "xrefs": ["pmc:PMC5559326", "pmid:28424201"], "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:JF4Ccbia4N46J3F0KPnvt-NEdIL4l8p1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gKmU-nQnXJ7DYihjcPCkYoHsgK_gv--z", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3669", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:272", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.583Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-30T21:40:38.068Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-31T00:13:21.939Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.583Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:179", "type": "Document", "label": "Hammerman et al., 2011, Cancer Discov", "xrefs": ["pmc:PMC3274752", "pmid:22328973"], "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:thapnbv3SlIzCdya_gxwW5yD--cFK3Es", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.0COWxyRirygNWrsbEk8Y486RHdM4-x8W", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1546019", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:145", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:jmoytbxOWt7JafXnPYxjtvnXiTGnD2uf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1546019", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:277", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.801Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-30T21:38:36.304Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-31T02:19:22.956Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-30T21:38:49.932Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.801Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:183", "type": "Document", "label": "Li et al., 2014, Lung Cancer", "xrefs": ["pmid:24636847"], "title": "Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:n_55IfRmXFdyHRVrp0TXP4fMvb0vtsMM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:337525", "type": "Therapeutic"}, {"id": "rxcui:282443", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:gLfpmiZeKZhOgi_mvPUVi0MB2VBYSsjd", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:337525", "type": "Therapeutic"}, {"id": "rxcui:282443", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}, {"id": "civic.tid:156", "type": "TherapeuticDescriptor", "label": "Pemetrexed", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:25309", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer nonsquamous", "disease": null}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C61614"], "alternate_labels": ["L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)", "MTA", "Multitargeted Antifolate", "Pemfexy"], "therapeutic": "rxcui:282443"}]}}
{"id": "civic.eid:387", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation, and 1 patient (patient 95, see supplemental table 1) had PIK3CA E545K in the primary tumor without co-occurring mutations in the other tested genes. This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, there was one patient (Patient 55, Table S1) who had E545K as the only noted variant, but experienced partial response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:53.584Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-10-23T22:27:49.873Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-10-23T22:28:12.663Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:53.584Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:rYiPQYMxXR7y5aYm1jcsKB3t0R5eeAO2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:647", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2015-11-11T08:05:16.115Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-03-22T16:26:59.108Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-04-08T15:13:01.877Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-11-11T21:04:34.629Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:409", "type": "Document", "label": "Mateo et al., 2015, N. Engl. J. Med.", "xrefs": ["pmid:26510020"], "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:tPagN2I6GwrVNz9-pvIsci46QExmtPP0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.pHOpPahXStgEfK2waemo8pW-KDW5zNnK", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1597582", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7378", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:243", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:46", "type": "DiseaseDescriptor", "label": "Prostate Cancer", "xrefs": ["DOID:10283"], "disease": "ncit:C7378"}, "object_descriptor": {"id": "civic.tid:42", "type": "TherapeuticDescriptor", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D010051", "type": "DiseaseDescriptor", "label": "Ovarian Neoplasms", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C71721"], "alternate_labels": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"], "therapeutic": "rxcui:1597582"}}
{"id": "civic.eid:648", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2015-11-11T08:08:46.907Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-03-22T16:20:33.436Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-04-08T15:17:02.753Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-11-11T21:04:14.524Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:409", "type": "Document", "label": "Mateo et al., 2015, N. Engl. J. Med.", "xrefs": ["pmid:26510020"], "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:BkbaL1pKsiNhOk-y0R9ni68ye4DeEMR3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.LHE7rF-ocGT5Mfp69j9W3RZ4Fn6c9cW_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1597582", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7378", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:244", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:46", "type": "DiseaseDescriptor", "label": "Prostate Cancer", "xrefs": ["DOID:10283"], "disease": "ncit:C7378"}, "object_descriptor": {"id": "civic.tid:42", "type": "TherapeuticDescriptor", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D010051", "type": "DiseaseDescriptor", "label": "Ovarian Neoplasms", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C71721"], "alternate_labels": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"], "therapeutic": "rxcui:1597582"}}
{"id": "civic.eid:699", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-15T13:25:33.125Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-18T03:27:49.217Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-26T21:44:12.779Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-18T03:24:26.522Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:457", "type": "Document", "label": "Boidot et al., 2016, Int J Colorectal Dis", "xrefs": ["pmid:26561417"], "title": "HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:AuHEXBQgFAO6g47meIkb0Q2hZESBp3ru", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Z1VxpmB2Ui54Nd4GCsBXMjb2WDaCU7Ja", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C2167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:274", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:145", "type": "TherapeuticDescriptor", "label": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor", "xrefs": ["ncit:C2167"], "therapeutic": "ncit:C2167"}}
{"id": "civic.eid:709", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-17T12:04:37.514Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-29T05:22:16.900Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-29T17:26:26.189Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-23T19:56:43.255Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:466", "type": "Document", "label": "Davies et al., 2015, Mol. Cancer Ther.", "xrefs": ["pmid:26351323"], "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ha-Lcq4bU7cwPjQpiyPho2FN0NzLKD2O", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._veAF5iFKxk_oSX9jnfNc4AHp8MvUCKO", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C102564", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:4", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:112", "type": "TherapeuticDescriptor", "label": "Capivasertib", "xrefs": ["ncit:C102564"], "alternate_labels": ["AZD5363"], "therapeutic": "ncit:C102564"}}
{"id": "civic.eid:739", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-22T14:07:40.435Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-22T21:13:08.743Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-22T21:13:12.609Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-22T21:26:11.245Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-22T19:47:58.071Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:487", "type": "Document", "label": "Shiver et al., 2015, N. Engl. J. Med.", "xrefs": ["pmc:PMC4652581", "pmid:26466009"], "title": "Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:MMZkpqi94oFczNJeosLZGXtvbPf0wJDb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ZJHpOtx1gjh5SzQpe3jPcyVy-Vaz9ssb", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1544460", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4068", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:294", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:311", "type": "DiseaseDescriptor", "label": "Merkel Cell Carcinoma", "xrefs": ["DOID:3965"], "disease": "ncit:C4068"}, "object_descriptor": {"id": "civic.tid:120", "type": "TherapeuticDescriptor", "label": "Idelalisib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:581", "type": "DiseaseDescriptor", "label": "Chronic lymphocytic leukemia", "disease": "ncit:C3163"}, {"id": "hemonc:599", "type": "DiseaseDescriptor", "label": "Follicular lymphoma", "disease": "ncit:C3209"}]}}], "xrefs": ["ncit:C78825"], "alternate_labels": ["5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- Quinazolin-4-one", "CAL-101", "GS 1101", "GS-1101", "Phosphoinositide-3 Kinase Delta Inhibitor CAL-101", "Zydelig"], "therapeutic": "rxcui:1544460"}}
{"id": "civic.eid:745", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-28T09:48:59.363Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-29T00:12:13.287Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-29T06:21:00.918Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-29T00:10:42.900Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:492", "type": "Document", "label": "Yauch et al., 2009, Science", "xrefs": ["pmid:19726788"], "title": "Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Ysdl5vPKj6I2wZBPjaA27R9iRrKjUM9m", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hyt2pj4IH9Y-SEnEF-jNElPBrIIxBwwy", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1242987", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3222", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:299", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:361", "type": "DiseaseDescriptor", "label": "Medulloblastoma", "xrefs": ["DOID:50902"], "disease": "ncit:C3222"}, "object_descriptor": {"id": "civic.tid:190", "type": "TherapeuticDescriptor", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "DiseaseDescriptor", "label": "Cutaneous basal cell carcinoma", "disease": null}]}}], "xrefs": ["ncit:C74038"], "alternate_labels": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"], "therapeutic": "rxcui:1242987"}}
{"id": "civic.eid:1089", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy with cetuximab and sirolimus and continued for 9 months. Disease burden was not measurable by Response Evaluation Criteria in Solid Tumors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:8", "type": "Agent", "name": "Zachary Skidmore"}, "date": "2016-02-23T16:40:51.360Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:51:55.154Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-24T00:19:48.517Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:52:03.359Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:748", "type": "Document", "label": "Ganesan et al., 2016, J. Clin. Oncol.", "xrefs": ["pmid:24934779"], "title": "Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:gsXX10Z_A8wiQs3-pAPVPwqF7CoIi4gF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.d5fSYowd-IInSaxWmXoCT5LRh92Ej82-", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:35302", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4819", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:460", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:130", "type": "DiseaseDescriptor", "label": "Skin Squamous Cell Carcinoma", "xrefs": ["DOID:3151"], "disease": "ncit:C4819"}, "object_descriptor": {"id": "civic.tcd:nk5jSUmDAbqS51d-Wm-vj2BlH0T_HAyq", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:35302", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}]}}
{"id": "civic.eid:1271", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mutation. Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib. In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-04-18T11:50:00.618Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-10-19T15:57:01.955Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-10-19T15:57:43.664Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-23T16:12:20.061Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:859", "type": "Document", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "xrefs": ["pmc:PMC3730818", "pmid:23598171"], "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:RGryKRVVQcQD1m8cez8kilRKvNfCyV3-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:1333", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-05-24T08:08:47.747Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:55:10.005Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T20:27:46.348Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T20:25:12.798Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T20:25:46.986Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:859", "type": "Document", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "xrefs": ["pmc:PMC3730818", "pmid:23598171"], "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:xseKpkbROqvfzfA6Pah46F_CMCHcq6rn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.vCqbachGaFmgPnncXcegGSNZIU9BaO8E", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:549", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:1394", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-24T10:04:57.031Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-07T15:16:40.138Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-10T21:22:42.850Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-07T15:16:41.874Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:944", "type": "Document", "label": "Hellmann et al., 2014, J Thorac Oncol", "xrefs": ["pmc:PMC4655969", "pmid:25521405"], "title": "Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:VVbxD_auXWdIN3dmWieugyMOEwUOJ3an", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2TmSETRJQzrU-OXco267vKiGgGY4qCLK", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:562", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:1400", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 53 year old male presented with a scalp lesion which was incompletely excised. Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed. After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy. 12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-24T16:19:37.777Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:33:19.757Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T23:29:52.198Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:33:21.440Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:948", "type": "Document", "label": "Sahadudheen et al., 2016, Case Rep Oncol Med", "xrefs": ["pmc:PMC4775779", "pmid:26989536"], "title": "Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:_tSPfOSkFMlxltmnB_NLVOxWjoMnqv0D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cxfjgf47lCYesVEe7nvEMqHLxqh2eliW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:563", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1430", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-29T08:11:49.070Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-30T04:03:38.218Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-01T16:10:32.873Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-01T16:10:09.915Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-29T15:28:13.214Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:969", "type": "Document", "label": "Klempner et al., 2016, Cancer Discov", "xrefs": ["pmid:27048246"], "title": "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:uR37fBPMCnHiF09psE66kK9xV23Kwo3U", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C95404", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:53", "type": "DiseaseDescriptor", "label": "Gastrointestinal Neuroendocrine Tumor", "xrefs": ["DOID:50626"], "disease": "ncit:C95404"}, "object_descriptor": {"id": "civic.tcd:1u3GKJEPeqRgZXTAhLQ3qlT5HZt4jdzH", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1424911", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}, {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}]}}
{"id": "civic.eid:1460", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks. Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:44:29.419Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:320", "type": "Agent", "name": "Daniel Gaston"}, "date": "2017-02-14T18:12:07.776Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-02-14T21:47:48.229Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-18T15:24:45.418Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:338", "type": "Document", "label": "Dahlman et al., 2012, Cancer Discov", "xrefs": ["pmc:PMC3449158", "pmid:22798288"], "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:0VVcTToc3JoIvjgjG6jM2wyJO_Ex6jcP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.aSpuln9wE4lEOFN7gLZVnfLkjD77G9CK", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C84858", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:582", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:350", "type": "TherapeuticDescriptor", "label": "MEK Inhibitor TAK-733", "xrefs": ["ncit:C84858"], "alternate_labels": ["TAK-733"], "therapeutic": "ncit:C84858"}}
{"id": "civic.eid:1463", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:51:20.816Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-19T19:34:04.415Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:850", "type": "Document", "label": "Falchook et al., 2012, Lancet Oncol.", "xrefs": ["pmc:PMC4109286", "pmid:22805292"], "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:aI12ef-4KCpotup2BqtHeObckC4CsNqT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UWxPidYtS3knxlRYq3cYDlrgNultPLWV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:585", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:1556", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-07-18T16:50:05.356Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-20T11:56:20.709Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-08-28T04:50:34.766Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-20T11:52:22.795Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1028", "type": "Document", "label": "Baker et al., 2013, Clin. Cancer Res.", "xrefs": ["pmc:PMC3878304", "pmid:23969938"], "title": "Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:RafMy31EgQle50CWDXXFTz1hVoyjjrnU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MswFBbwawqmZ-OcumYQ5lb69AVzAq2GV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:612", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}}
{"id": "civic.eid:1698", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-09-20T15:06:53.976Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T22:24:29.343Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1147", "type": "Document", "label": "Sharman et al., 2014, Clin Lymphoma Myeloma Leuk", "xrefs": ["pmid:24997557"], "title": "Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:XFgKYOBexcFD5ibB82vAGKtFYSNlpLZx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1763", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a single patient with lung cancer and specifically in a metastatic brain lesion following gefitinib treatment. Functional validation of its role in drug sensitivity was examined in cell lines (293T and Ba/F3 cells).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:304", "type": "Agent", "name": "Steven Van Vooren"}, "date": "2016-12-01T16:43:54.950Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-04T21:55:29.503Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-02-06T22:44:51.914Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-01-31T22:47:32.639Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1331", "type": "Document", "label": "Balak et al., 2006, Clin. Cancer Res.", "xrefs": ["pmid:17085664"], "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ishui0D1zgK9fVc10aZppc3trHaXjQd7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.r7fvKXSJgCFuurk2GjVwMyy0oBlYh_Qp", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:712", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:1786", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (435 days) survival suggested sensitivity in this patient. Literature analysis did not identify additional reports of patients harboring this mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:258", "type": "Agent", "name": "Rodrigo Dienstmann"}, "date": "2016-12-02T10:32:15.146Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-21T16:23:37.070Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T22:10:11.896Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T22:14:13.389Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1244", "type": "Document", "label": "Klughammer et al., 2016, J Thorac Oncol", "xrefs": ["pmid:26773740"], "title": "Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:_EDLCI80fldETbpdoupwVx_c0dFIRs4x", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NRGjJ6RZpkKGkuIl-F635o1C_flkwAbC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:723", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:1799", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it was concluded that although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:258", "type": "Agent", "name": "Rodrigo Dienstmann"}, "date": "2016-12-02T11:00:55.921Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-21T16:29:06.874Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-11T02:55:11.669Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-21T16:29:09.903Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1244", "type": "Document", "label": "Klughammer et al., 2016, J Thorac Oncol", "xrefs": ["pmid:26773740"], "title": "Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:FPaatdkHljDDr7l4Hu-W-zysnk1-8ZRp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.X-TA45UAONMe_dWRFbxZtV2GaUsejPS6", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:736", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:1889", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day). The time to progression of this single agent was four months. The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-01-10T20:38:30.796Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-06T23:48:22.870Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-02-07T18:07:26.733Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-02-06T22:30:53.189Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:661", "type": "Document", "label": "De Gr\u00e8ve et al., 2012, Lung Cancer", "xrefs": ["pmid:22325357"], "title": "Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:M2n3dqUarMmu5KUdtp5hkb7aQF6qgKnc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ZODmqQEoby3uGC5ug-eQB9D6K5XLbIe1", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:816", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:1894", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-01-10T21:01:31.401Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-06T23:45:37.980Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-02-07T18:08:40.484Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-06T23:44:21.670Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:729", "type": "Document", "label": "Kris et al., 2015, Ann. Oncol.", "xrefs": ["pmid:25899785"], "title": "Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:cLArCOritWW65kdvZIEnn2J6w2oudM5a", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.o7MsvWmauzgq0zloyZX_nCTKGAIlJPrD", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2058848", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:818", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:44", "type": "TherapeuticDescriptor", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C53398"], "alternate_labels": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"], "therapeutic": "rxcui:2058848"}}
{"id": "civic.eid:1898", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D. All 7 metastatic lung lesions regressed 40 days after therapy, and the patient had a 9-month partial response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:14", "type": "Agent", "name": "Katie Campbell"}, "date": "2017-01-31T16:51:03.312Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-23T00:05:06.327Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-23T02:35:08.113Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-01-31T17:24:06.335Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1330", "type": "Document", "label": "Tran et al., 2016, N. Engl. J. Med.", "xrefs": ["pmc:PMC5178827", "pmid:27959684"], "title": "T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:vXwETiDFo5uHk18WE4BlpsBzilGAaZsR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C28699", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:685", "type": "TherapeuticDescriptor", "label": "Therapeutic Tumor Infiltrating Lymphocytes", "xrefs": ["ncit:C28699"], "alternate_labels": ["Tumor Infiltrating Lymphocyte Therapy", "Tumor Infiltrating Lymphocytes"], "therapeutic": "ncit:C28699"}}
{"id": "civic.eid:1999", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and NRAS. This patient was was a 60 year old female treated with cetuximab monotherapy as 5th line therapy who experienced partial response and had PFS of 31 weeks and OS of 59 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:23.651Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:33:36.646Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:33:52.650Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:29:35.671Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:33:55.918Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:DxRN1dtNb6rSRRYLvHfmU4_kZ9uYgQnH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:931", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:2002", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and BRAF. This patient was a 64 year old male treated with cetuximab and irinotecan as 5th line therapy who experienced stable disease and had PFS of 64 weeks and OS of 84 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:25.384Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-02-25T02:45:14.907Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T22:24:07.933Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-02-25T02:45:42.430Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T22:24:15.869Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:8FPc3mdVXCSowZplTGkjkFldl2igcQ-L", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Om0yyht6SnNmdAVYgTuYIXptr3aYzSx5", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:878", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2178", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. All three patients were males treated with panitumumab monotherapy. Their characteristics are as follows: 51 year old who experienced progressive disease (PFS: 8 weeks; OS: 24 weeks) and had three prior lines of chemotherapy; 54 year old who experienced progressive disease (PFS: 8 weeks; OS: 17 weeks) and had two prior lines of chemotherapy; 52 year old who experienced stable disease (PFS: 12 weeks; OS: 46 weeks) and had two prior lines of chemotherapy. Per the authors criteria, the clinical benefit rate is 1/3 and the response rate is 0/3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:49.427Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-01T23:59:26.922Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:00:35.649Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-01T23:55:23.594Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:00:38.267Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:TJ5-PSDc8zeTAKDG-tlAZNEaEEk0dbBs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:2181", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PIK3CA. Both patients experienced stable disease, which the authors classified as non-response. The two patients whose tumors harbored NRAS Q61L included a 53 year old female treated with cetuximab and irinotecan as a 6th line treatment who had PFS of 12 weeks and OS of 25 weeks; and a 64 year old female treated with cetuximab and ironotecan as a 3rd line therapy who had PFS of 12 weeks and OS of 46 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:49.794Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-10T21:53:48.818Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T21:54:02.761Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-02-25T01:28:23.041Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T21:52:45.715Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:2rXLGFaXKO7we7PgNS5sRI_sQ7u7Z6nA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CVBMOLB83i86owaBt636xVhdQ7aeTfyf", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:95", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2193", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12D, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 55 year old female treated with panitumumab monotherapy as 3rd line therapy who experienced progressive disease (PFS: 8 weeks; OS: 9 weeks).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:52.822Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-01T23:46:06.236Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-01T23:47:54.598Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-01T23:47:15.753Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-01T23:49:05.122Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:I3aHgqvm6GcTQHLdR2Z2inCkSEooTm-C", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:2201", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored BRAF D594G and was wildtype for KRAS, NRAS and PIK3CA. This patient was a 63 year old female treated with cetuximab and irinotecan (3rd line) who was one of two patients harboring a BRAF mutant tumor to experience a partial response. Progression free survival was 36 weeks and overall survival was 42 weeks from time of cetuximab administration. Authors note that cetuximab response is in accordance with cell line data suggesting that D594G cannot directly activate MAPK signaling, and that D594G mutants have low levels of p-MEK and are resistant to MEK inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:54.756Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-13T22:40:31.007Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-13T22:41:18.055Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-13T22:38:47.076Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-13T22:41:34.965Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:EqIYHn652Fue3ECysb2bC9CC83vkfFOi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:611", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2213", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E545Q (exon 10), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab and irinotecan and experienced partial responses. One patient was a 44 year old female, on 5th line therapy, with a PFS of 67 weeks and an OS of 209 weeks. The other patient was a 46 year old male, on 2nd line therapy, with a PFS of 22 weeks and an OS of 105 weeks. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:59.138Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:24:21.525Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:27:46.024Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:19:41.804Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:21:16.542Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:MW47t3gWIHZrOEIU_cIxk-3xQD3iUmLh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4BYZppCvYIbPaKyAkn4KA9fjgfdPnd7Z", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:881", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2217", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored PIK3CA E545K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Five patients had partial response, six had stable disease, and five progressed, resulting in a response rate of 5/16 and a clinical benefit rate of 11/16 according to author criteria. Treatments included cetuximab + irinotecan (n=13), cetuximab monotherapy (n=1), cetuximab + bevacizumab (n=1), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 24 weeks (2-60 weeks), median OS was 43 weeks (9-107 weeks), and median number of previous chemotherapy lines was 2 (1-5). Median age was 58 years old (43-79), and there were 10 males and 6 females. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:00.717Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:27:04.593Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:28:20.659Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:16:24.330Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:15:55.746Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:DisSodA1O6oYQj07rHVUrYng93QMjPR5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:2225", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 68 irinotecan-refractory metastatic colorectal cancer patients, one patient's tumor harbored a KRAS codon 146 mutation but was wildtype for BRAF, and KRAS codons 12, 13, and 61. This patient did not respond to irinotecan and cetuximab combination therapy and experienced progression free survival (PFS) lasting less than 10 months and overall survival (OS) lasting less than 30 months. Median PFS for patients with BRAF, KRAS G12/G13 wildtype tumors harboring mutations in either KRAS codon 146 (n=1) or KRAS codon 61 (n=7) was lower than patients whose tumors were additionally wildtype for KRAS A146 and Q61 (PFS: 3.8 vs 5.3mo, p= 0.023), though there wasn't a significant difference in overall survival (OS: 9.7 vs 14.8 mo, p=0.320).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:09.141Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-18T20:29:06.689Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-02-01T23:24:27.649Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2021-02-02T02:31:57.490Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-09-06T20:22:37.206Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1480", "type": "Document", "label": "Loupakis et al., 2009, Br. J. Cancer", "xrefs": ["pmc:PMC2736831", "pmid:19603018"], "title": "KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:aHWDLaV7W52vteXHk1xkgzaDCfPOF2cc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.pQddIJpJK1Hh6j5RpxcCcpSRJchDrBZn", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:905", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2292", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 0. Resection was performed on patients with greater than 50% size reduction of the lesion. This patient did not undergo resection, and had on overall survival of 7.4 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:26.514Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-18T02:17:42.472Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-12-18T22:59:28.525Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-15T07:21:12.539Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1557", "type": "Document", "label": "Bataille et al., 2003, MP, Mol. Pathol.", "xrefs": ["pmc:PMC1187340", "pmid:14514923"], "title": "Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:SkCYuJDFXD2i5T0M106hnzSQ6m_P1Yqg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AXS1g9tgzIx75-Vv9T9DjEt4On7db0_k", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2555", "type": "Therapeutic"}, {"id": "rxcui:4179", "type": "Therapeutic"}, {"id": "rxcui:632", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4911", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:121", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1322", "type": "DiseaseDescriptor", "label": "Stomach Carcinoma", "xrefs": ["DOID:5517"], "disease": "ncit:C4911"}, "object_descriptor": {"id": "civic.tcd:iX4s_CHRa8HCapUK6uTigtUxYo5IMhyU", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2555", "type": "Therapeutic"}, {"id": "rxcui:4179", "type": "Therapeutic"}, {"id": "rxcui:632", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}, {"id": "civic.tid:500", "type": "TherapeuticDescriptor", "label": "Etoposide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}]}}], "xrefs": ["ncit:C491"], "alternate_labels": ["4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]", "9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one", "Demethyl Epipodophyllotoxin Ethylidine Glucoside", "EPEG", "Lastet", "Toposar", "VP 16", "VP 16-213", "VP-16", "VP-16-213", "VP16", "Vepesid"], "therapeutic": "rxcui:4179"}, {"id": "civic.tid:325", "type": "TherapeuticDescriptor", "label": "Mitomycin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C1820"], "alternate_labels": ["(1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione", "Ametycine", "Jelmyto", "MITO", "MITO-C", "MITOMYCIN C", "Mito-Medac", "Mitocin", "Mitocin-C", "Mitolem", "Mitomycin-C", "Mitomycin-X", "Mitomycine C", "Mitosol", "Mitozytrex", "Mutamycin", "Mutamycine", "NCI-C04706", "[1aS-(1a Alpha,8beta,8a Alpha,8b Alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"], "therapeutic": "rxcui:632"}]}}
{"id": "civic.eid:2306", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 2. Resection was performed on patients with >50% size reduction of the lesion. Consistent with response to preoperative chemotherapy, this patient did undergo resection, and had an overall survival of 12.6 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:28.288Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-18T02:17:05.211Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-18T02:16:32.659Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-15T07:33:14.484Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1557", "type": "Document", "label": "Bataille et al., 2003, MP, Mol. Pathol.", "xrefs": ["pmc:PMC1187340", "pmid:14514923"], "title": "Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ERvIbjFfjtGlQw6-Blifw9QX5VaLIFhV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.uI4nm8TgYWMXJIEl6R66zPRs7uJgguRF", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2555", "type": "Therapeutic"}, {"id": "rxcui:4179", "type": "Therapeutic"}, {"id": "rxcui:632", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4911", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:922", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1322", "type": "DiseaseDescriptor", "label": "Stomach Carcinoma", "xrefs": ["DOID:5517"], "disease": "ncit:C4911"}, "object_descriptor": {"id": "civic.tcd:iX4s_CHRa8HCapUK6uTigtUxYo5IMhyU", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2555", "type": "Therapeutic"}, {"id": "rxcui:4179", "type": "Therapeutic"}, {"id": "rxcui:632", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}, {"id": "civic.tid:500", "type": "TherapeuticDescriptor", "label": "Etoposide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}]}}], "xrefs": ["ncit:C491"], "alternate_labels": ["4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]", "9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one", "Demethyl Epipodophyllotoxin Ethylidine Glucoside", "EPEG", "Lastet", "Toposar", "VP 16", "VP 16-213", "VP-16", "VP-16-213", "VP16", "Vepesid"], "therapeutic": "rxcui:4179"}, {"id": "civic.tid:325", "type": "TherapeuticDescriptor", "label": "Mitomycin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C1820"], "alternate_labels": ["(1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione", "Ametycine", "Jelmyto", "MITO", "MITO-C", "MITOMYCIN C", "Mito-Medac", "Mitocin", "Mitocin-C", "Mitolem", "Mitomycin-C", "Mitomycin-X", "Mitomycine C", "Mitosol", "Mitozytrex", "Mutamycin", "Mutamycine", "NCI-C04706", "[1aS-(1a Alpha,8beta,8a Alpha,8b Alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"], "therapeutic": "rxcui:632"}]}}
{"id": "civic.eid:2513", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E2) had the E746_A750del mutation. The patient was a male never smoker, and demonstrated response for 8.5 months. Overall survival was 21+ months as the patient was alive at study end.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:05:21.731Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-04-15T19:51:33.549Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-04-19T20:12:11.618Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-04-17T23:04:27.439Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1509", "type": "Document", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC516528", "pmid:15329413"], "title": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:id1Ql5OIHdaRP9WaxWdQ9xwBRE-8hr8D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4_z-sPp1Hb0OeQhs_-VlATlyJ_lQbDjT", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2923", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1002", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1163", "type": "DiseaseDescriptor", "label": "Bronchiolo-alveolar Adenocarcinoma", "xrefs": ["DOID:4926"], "disease": "ncit:C2923"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:2886", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation. None of the patients had mutations in BRAF, NRAS, or GNAQ. Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks. One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylate\u2013resistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:122", "type": "Agent", "name": "Deb Irene"}, "date": "2017-03-30T23:11:39.077Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-11T14:58:31.579Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-11T15:03:21.184Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:122", "type": "Agent", "name": "Deb Irene"}, "date": "2018-01-17T07:49:32.397Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-11T14:41:02.034Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1593", "type": "Document", "label": "Carvajal et al., 2011, JAMA", "xrefs": ["pmc:PMC3986039", "pmid:21642685"], "title": "KIT as a therapeutic target in metastatic melanoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:r3XYgl8t7o71XRLz8naYNzrtncFK0XgS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.k2xXiu-T1lSzrMEKj4oJo8vrUM0mG7A4", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:986", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2918", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance. The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-05T13:26:28.366Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T20:15:11.980Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:49:15.643Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T19:57:54.587Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:55:41.183Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:_yAwjBoY6zpFg6I7nBWC1bWYBOfd-f0-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2919", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed \"extreme\" imatinib resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-05T13:27:49.585Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T21:02:34.590Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:47:47.285Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:47:51.075Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:y8dg5O6sg3JDkIJejEb8AmxQExHs8CmW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lKdmdWowkrPgjRq61xYdyrqn1cEO-9v5", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:989", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2920", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-05T13:32:10.721Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T21:22:25.365Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:44:28.338Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:44:38.841Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:cXfRrQPvj5EL4d6myGAct1uaSUdUYUb_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Ngswf8Gwjbd8yulTDd9v5u5oAYy95ffd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1264", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2921", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-05T13:33:10.635Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T21:41:48.992Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:38:21.726Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:39:17.043Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ne0wPuerJDe_Oy2KnuiahJ_osyosqBAd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.N2jbfonrm2l9DY5w196I8E3q8GqLDt54", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1265", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2922", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D820G showed \"extreme\" imatinib resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-05T13:34:13.092Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T22:00:21.538Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:46:43.686Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:46:46.492Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:86V_SWpUj65nFzrCvW_8nnslYd1bTZ5r", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.xTOqcm23tQTngix3Db7HBb2KnlBuezej", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1266", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2923", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D816H showed \"extreme\" imatinib resistance. It was also highly resistant in isolation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-05T13:35:01.406Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T22:07:59.440Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:45:56.181Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:45:59.903Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:yj5C5eKEKkDRQAwZUVupFKQHm-s4-6S2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RQAhdmX7Am7xNvM-DGvM4gPqYrq1ZD25", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:983", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2924", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro T670I showed \"extreme\" imatinib resistance. It also showed resistance in isolation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-05T13:48:13.404Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-07-06T22:14:02.249Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:34:07.289Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-27T15:34:52.425Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:JDcfHBvflIH4S_Pj1ZEfO1ViJiZTLwol", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2987", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. The patient remained on study treatment for more than 3.5 years because of clinical benefit.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-25T16:53:09.532Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2019-11-05T23:55:05.695Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1689", "type": "Document", "label": "Drilon et al., 2017, Cancer Discov", "xrefs": ["pmc:PMC5380583", "pmid:28183697"], "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:M_8XNOEBkXRko3hyPtnmqhnxzeh-D8GL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2Nwe9jilIDgzEuvgyj3V5EsOFjGC905G", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2197862", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1295", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:426", "type": "TherapeuticDescriptor", "label": "Entrectinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C114984"], "alternate_labels": ["N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide", "RXDX 101", "RXDX-101", "RXDX101", "Rozlytrek"], "therapeutic": "rxcui:2197862"}}
{"id": "civic.eid:3028", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A patient with an uncontrolled relapse of c-kit-positive mesenchymal tumor in descending part of the duodenum had received 400mg Imatinib daily for more than 10 years at the time of publication. He responded well to therapy (Karnofsky index 90%). KIT V559D (Exon 11) was identified in the diagnostic biopsy and indicated as a positive predictor of imatinib response with long term usage.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:436", "type": "Agent", "name": "Alihan Durace"}, "date": "2017-05-21T13:27:36.305Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-28T01:09:25.434Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-21T20:55:19.802Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-06T18:58:19.153Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-06T18:34:00.954Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1734", "type": "Document", "label": "Cameron et al., 2011, Case Rep Oncol", "xrefs": ["pmc:PMC3220906", "pmid:22114577"], "title": "Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ZDh1dpwElXev5sVZoB1GRU4iez9PNswO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wkbbLzMJDVWkn-GLG_Q3IhYQ261bvMFN", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:968", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:3777", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years later. This mass progressed under treatment at which point PCR amplification of BRAF exon 15 and subsequent Sanger sequencing the initial biopsy revealed the tumor harbored a BRAF V600E mutation. Based on these results, vemurafenib monotherapy was started and radiological and clinical response was noted after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:35:15.687Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1189", "type": "Agent", "name": "Laveniya Satgunaseelan"}, "date": "2022-03-02T14:29:16.231Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-10-30T16:40:15.933Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-19T20:36:15.281Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1974", "type": "Document", "label": "del Bufalo et al., 2014, J Transl Med", "xrefs": ["pmc:PMC4279809", "pmid:25524464"], "title": "Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:F-rakWCPUiLZ7WlHOTJ1Ezv1cyuZQ9DF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4048", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1673", "type": "DiseaseDescriptor", "label": "Childhood Pilocytic Astrocytoma", "xrefs": ["DOID:6812"], "disease": "ncit:C4048"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3787", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:35:22.395Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T20:28:44.414Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-29T23:47:51.642Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T20:28:23.182Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1984", "type": "Document", "label": "Combe et al., 2015, Invest New Drugs", "xrefs": ["pmid:26490654"], "title": "Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:1nsplQuU3-ianCwvfqBaKo0YcW7XQz7S", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7550", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:87", "type": "DiseaseDescriptor", "label": "Ovarian Serous Carcinoma", "xrefs": ["DOID:50933"], "disease": "ncit:C7550"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3802", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st generation TKI gefitinib. 4 patients had partial response with progression free survival (PFS) of 4.3, 19.3, 10.0, 8.7 months; overall survival (OS) of 4.3, 34.9, 15.7, 15.7 months; and all 4 were alive at study end. One patient had stable disease, PFS 6.5 months, OS 15.2 months, and was not alive at study end. One patient had progressive disease as response, with PFS of 2.8 months, OS of 10.7 months, and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:35:38.195Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T19:07:25.624Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T21:26:16.079Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T21:49:12.862Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T21:31:36.199Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:0qdR0Q-HXOSrJBVv05YW2M-l44zFK38t", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U5KCINj8e9QhYAbBlFUiQWa5oWvL1uXs", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1020", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:3824", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 78 year old female treated with panitumumab monotherapy as 2nd line therapy who experienced progressive disease (PFS: 5 weeks).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:02.740Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-01T23:49:24.952Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-01T23:52:19.180Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-01T23:51:20.203Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-01T23:53:15.306Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:xTALYouVRGlRIOMLO_Z-_53DLegLgV5C", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:3827", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, and had individual response data. This patient was was a male treated with panitumumab monotherapy as 1st line therapy who experienced progressive disease (PFS: 7 weeks; OS: 10 weeks).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:05.371Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-02T00:02:48.536Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:04:57.370Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-02T00:05:01.059Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:05:58.708Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:m9yuxxn52Rx8DMOMGQB7KMd2rtdsRMEB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:3832", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R88Q, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old female treated with cetuximab and irinotecan as 2nd line therapy who experienced a partial response (PFS: 32 weeks, OS: 32 weeks).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:08.819Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:17:29.031Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:17:52.681Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:17:48.362Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:18:29.544Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:wFwS07DmahdzaIBbliULu8crC6kSUMY5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eN83zAbXzj42T7obe8mp6hxZxDJr146I", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:929", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:3841", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047R (exon 21), were wildtype for KRAS, BRAF and NRAS, and had individual response data. All patients were treated with cetuximab and irinotecan, four as 3rd line therapy, one as 4th line. Patient characteristics are as follows: a 65 year old female who experienced stable disease (PFS: 33 weeks, OS: 37 weeks); a 56 year old female who experienced stable disease (PFS: 28 weeks, OS: 43 weeks); a 69 year old female who experienced progressive disease (PFS: 10 weeks, OS: 28 weeks); a 63 year old male who experienced progressive disease (PFS:11 weeks, OS: 18 weeks); a 60 year old female who experienced progressive disease (PFS: 12 weeks, OS: 34 weeks). Based off this information and clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:19.650Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:42:40.117Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:43:19.558Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:43:07.378Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:45:19.187Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:tjEALvww_SMs6SxXFhmTtf8XHZDgz3a0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:3847", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 69 year old male treated with cetuximab + FOLFIRI as 3rd line therapy who experienced progressive disease and had PFS of 13 weeks and OS of 36 weeks. Using this information and data from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:24.153Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:36:41.194Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:39:17.784Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:37:18.655Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:40:05.861Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:mrankJpi2MPmuhdG1Cr-3pIoQlbvao4x", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.vxWenCx5Zh7thv9vYTHJsjn12LIMFve1", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:940", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:3870", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61R and were wild type for PIK3CA, BRAF, and NRAS. Both were treated with cetuximab and irinotecan as 3rd line treatments. One patient was a 72 year old female who experienced progressive disease 12 weeks following treatment; OS was 20 weeks. The other patient was a 43 year old female who experienced stable disease for the duration of the study and did not progress.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:44.281Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-01-29T02:50:42.294Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-13T15:40:10.902Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-01-29T02:51:38.447Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-13T15:40:42.532Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:qyri4in5RutOyPPLTK2MYpvJkJZt7Cfk", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TSexofDgsT4bZdNCzT42l2tqurCkFhFP", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:909", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:4082", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients 11, 69, and 73 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT W557_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patient 11 started on 25 mg sunitinib daily, for a two week on/two week off schedule. Patients 69 and 73 were on a 50 mg sunitib per day for four weeks on/ two weeks off. All three patients experienced stable disease for less than 6 months. Time to progression for patients 11, 69, and 73: 8, 22, and 10 weeks. Overall survival for patients 11, 69, and 73: 10, 38, and 19 weeks (Table A1).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:51.973Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:26:57.030Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:27:33.339Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:27:35.949Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:42ngEl1uFcVFPYb3HrPHjg84zoNQY7dE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2gBgJAKNHo14J6N0g8ZYsewGjZK1O2tQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:961", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4122", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient 72 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V560D mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced progressive disease. Time to progression and overall survival were 9 and 33 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:26.879Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:56:57.863Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:57:14.029Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:55:40.816Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:6HrehLUH3Bo3-nBpp-zOuRp5xQa1xNsU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wkbbLzMJDVWkn-GLG_Q3IhYQ261bvMFN", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:971", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4210", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 81, smoker) was treated with gefitinib and had a partial response, progression free survival (PFS) of 21.7 months, overall survival (OS) of 22.5 months and was alive at study end. The second patient (M, 76, smoker) was treated with erlotinib and had stable disease as response, PFS of 2.6 months, OS of 2.6 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:42:45.673Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T19:05:30.164Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T21:45:25.608Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T21:45:42.457Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:YPq1ITRn5xRmhdWNOU5jMeoug9SBcl0o", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.aPbfWsOSRTYhHz9hDO6g8Ax7taHsCDAk", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1420", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:4226", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 51, nonsmoker) had a partial response, progression free survival (PFS) of 6.9 months, overall survival (OS) of 29.7 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:43:28.627Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T16:14:43.658Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:40:44.694Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:10:13.961Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:40:50.870Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:uaM_0iNfDe9uCls6pK8pnlJk7cjFS0qy", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.44GT_hMXYwgln7n19qP7aatPEyNWWpKD", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1892", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4248", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 79, nonsmoker) had a partial response, progression free survival (PFS) of 5.0 months, overall survival (OS) of 15.0 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:44:51.695Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T19:02:33.546Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:45:30.295Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:21:13.611Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:45:46.293Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:dYaUiMQBPhqh7EaQEE_1ufSPxpTzBfpQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._ArpGDJIQd2Kw9sqLHRmUZa_Xu5GD2B-", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1897", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4252", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 66, nonsmoker) had a partial response, progression free survival (PFS) of 15.2 months, overall survival (OS) of 29.3 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:45:30.194Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T19:10:14.528Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:31:50.975Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:23:22.154Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:31:55.219Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:DjDyV1wlWuZ14YJikzHJGsPT72tDGGit", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KxWljJVfUhT5CuYiJzDuChVjz53DnUmg", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1457", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4288", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following crizotinib progression and once pre-treatment. This patient was a 27 year old female with one pack year who experienced partial response on crizotinib as 4th line therapy. The patient's pre-crizotinib biopsy was ALK+ and lacked the EGFR mutation. A biopsy taken after 63 days on crizotinib showed EGFR L858R mutation and lacked ALK gene rearrangement by FISH (ALK Loss). Of note, a second post-treatment biopsy (after 113 on crizotinib) showed ALK rearrangement but lacked EGFR mutation. The authors interpreted the emergence of an ALK negative tumor (first post-critozitinib biopsy) as evidence of a separate oncogenic driver (EGFR L858R).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:37.175Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-02-04T23:27:47.836Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-02-04T23:25:48.666Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-10-06T21:43:22.909Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:30.561Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:507", "type": "Document", "label": "Doebele et al., 2012, Clin. Cancer Res.", "xrefs": ["pmc:PMC3311875", "pmid:22235099"], "title": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:L6YKV_Vwsky2D9Mm2R2NJrQahYJQcc7D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:4424", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 7 patients harbored PIK3CA E542K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Two patients had partial response, three had stable disease, and two progressed, resulting in a response rate of 2/7 and a clinical benefit rate of 5/7 according to author criteria. Treatments included cetuximab + irinotecan (n=5), cetuximab + FOLFIRI (n=1), and cetuximab monotherapy (n=1). Median PFS was 34 weeks (17-48 weeks), median OS was 46 weeks (27-91 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 59 years old (53-74), and there were 6 females and one male. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:50:32.803Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:25:50.644Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:28:05.465Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T21:58:16.774Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:06:21.571Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:tvn8MjblI8tiqgqbvKy7Sz0E7ZZZ14eb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4432", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047L (exon 21), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were males treated with cetuximab + irinotecan as 3rd line therapy and experienced progressive disease. One patient was 73 years old with a PFS of 11 weeks and an OS of 31 weeks. The other patient was 61 years old with a PFS and OS of 4 weeks. Authors concluded from this information and data from larger cohort that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:50:42.373Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:59:18.518Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:59:31.534Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:59:49.258Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:01:27.298Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ghX7tI550DB4Uri77Q3lb1x3cFAm47Ud", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mCpnGyjIgv27feD0L-LFc95zm7d6RmDt", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1151", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:4463", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA S158L, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 53 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 1 week; OS: 3 weeks).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:03.289Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:14:31.385Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:14:44.023Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:14:49.375Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:15:18.793Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:WkIr4C90w9D841GLTbpVvD2y9fIYxm8B", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ucb5X_48VDayD9-_X2ZUB42qpx8o-3kb", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1499", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:4472", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to be non-responders to cetuximab in combination with irinotecan, (BRAF mutation positive: responders vs. non-responders = 0 vs. 6; BRAF wild-type: responders vs. non-responders 30 vs. 17; P=0.004), as compared to patients with wild-type BRAF.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:10.123Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T12:48:20.747Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-30T15:24:58.796Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T12:48:22.477Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1946", "type": "Document", "label": "Hsu et al., 2016, Oncotarget", "xrefs": ["pmc:PMC5008360", "pmid:26989027"], "title": "Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:EqIYHn652Fue3ECysb2bC9CC83vkfFOi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:611", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:4493", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1.6 months, and overall survival of 4.4 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:29.552Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-10T18:56:13.169Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-18T01:46:31.019Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-08T23:49:28.535Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:-4Sl8WTmDjamvXDEGrnKM3745KA3ru1w", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.M8PexLRl72ptK5F806FDVtZ061KiX5HQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1513", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4597", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:03.083Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:37:23.199Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:38:34.259Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:38:37.115Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:SZjWnrjmNxW_4rBawkxP-gtOZe0bOTT2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4667", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E1) had the del L747-S752 insQ mutation. The patient was a male never smoker and demonstrated response for 8 months. He continued to show response and remain on the drug when the manuscript was written.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:55.485Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-04-17T23:18:39.145Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-04-17T23:21:33.069Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-04-17T23:18:19.738Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1509", "type": "Document", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC516528", "pmid:15329413"], "title": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:qBxmACRVgr1cKX9p-TFw8MuaA02ghKTv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.8h-Bq_UDQEFEFWzAaF2ZZGLFNPz9yGXA", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1580", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4669", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 83, nonsmoker) had a partial response, progression free survival (PFS) of 37.5 months, overall survival (OS) of 53.3 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:57.708Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T18:41:51.818Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:33:45.668Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:46:23.233Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:34:10.914Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:4ALkipiXpGKmIqXdFE7IdVgLi9RUjm40", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._EkfbCP1sA-P9ODq7tlvh-IWb3FhnOtc", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1477", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4802", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best response with +2.3% change to target lesions, progression free survival of 2.1 months and overall survival of 16.5 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:56:06.657Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-10T19:00:32.668Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-10T18:59:53.961Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-08T23:45:43.333Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:KnyilFF7X7efVgJFQbkdZP_wAlmuLhh4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.T8W7v7wFSIueQhXivzirzxnG5lZemOzY", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1667", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4803", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 57 year old male 10 packyear former smoker with lung adenocarcinoma with EGFR P772_V774insPHV mutation was given erlotinib as first line treatment, and had progressive disease as best response with progression free survival of 2 months and overall survival of 16 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:56:07.734Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-05-27T22:32:19.374Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-27T22:59:40.763Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-08T23:46:02.219Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:NEaBMdK-7FObQFbdvoSHzsMw0LF4aOMh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2Ym0TXI4KAfjjWJKJ6a5t4ifbrl3bV_g", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1668", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4905", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response and showed maximum tumor shrinkage of 33% with trametinib as the first-line treatment and had a partial response for 6.2 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-06-21T19:26:44.710Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-03-20T15:48:06.455Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2178", "type": "Document", "label": "Bowyer et al., 2014, Melanoma Res.", "xrefs": ["pmid:24933606"], "title": "Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:qruyZSRg2zHTsFtc5nd3yQs7Nep2H2ZI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bTQroAvfd2NBts79PH2faeuM74FJxj6F", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:583", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:4955", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRAF. He was then treated with trastuzumab combined with infusional 5-Fu and leucovorin but exhibited no response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:8", "type": "Agent", "name": "Zachary Skidmore"}, "date": "2017-06-22T22:33:40.563Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-10-11T18:55:50.597Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1164", "type": "Document", "label": "Aung et al., 2016, Cold Spring Harb Mol Case Stud", "xrefs": ["pmc:PMC5002925", "pmid:27626067"], "title": "Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Bm5B4RTNJB_82fD3RExz_jfL491NPDXn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Gb-3idkBuAo7OTK9h1VU76Re2uWRfCnk", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2103478", "type": "Therapeutic"}, {"id": "rxcui:225852", "type": "Therapeutic"}, {"id": "rxcui:4492", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:39", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:57", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["DOID:50861"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "civic.tcd:7VqT9zshKTBhH6t4et38ItzQoh3_XLuc", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2103478", "type": "Therapeutic"}, {"id": "rxcui:225852", "type": "Therapeutic"}, {"id": "rxcui:4492", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}, {"id": "civic.tid:531", "type": "TherapeuticDescriptor", "label": "Leucovorin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C71631"], "alternate_labels": ["5-Formyltetrahydrofolate", "Folinic Acid"], "therapeutic": "rxcui:225852"}, {"id": "civic.tid:420", "type": "TherapeuticDescriptor", "label": "Fluorouracil", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C505"], "alternate_labels": ["2,4-Dioxo-5-fluoropyrimidine", "5 FU", "5 Fluorouracil", "5 Fluorouracilum", "5-FU", "5-Fluoro-2,4(1H, 3H)-pyrimidinedione", "5-Fluoro-2,4(1H,3H)-pyrimidinedione", "5-Fluorouracil", "5-Fluracil", "5FU", "AccuSite", "Adrucil", "Carac", "Fluoro Uracil", "Fluouracil", "Flurablastin", "Fluracedyl", "Fluracil", "Fluril", "Fluroblastin", "Ribofluor", "Ro 2-9757", "Ro-2-9757"], "therapeutic": "rxcui:4492"}]}}
{"id": "civic.eid:5902", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologic regression at 12 weeks. At 6 months the patient was still on treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2017-12-30T22:40:51.673Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-11T03:32:12.794Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-11T03:22:41.511Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-01-04T16:22:33.021Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2381", "type": "Document", "label": "Kocsis et al., 2017, J Gastrointest Oncol", "xrefs": ["pmc:PMC5401859", "pmid:28480077"], "title": "Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:2FD1gHJSCIDguj8cO8FDzmvMy40Ttfy-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4436", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:29", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "xrefs": ["DOID:4947"], "disease": "ncit:C4436"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:5903", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two cases of patients with BRAF V600E positive, refractory intrahepatic cholangiocarcinoma showed excellent clinical and radiographic response to combination dabrafenib and trametinib treatment. One patient achieved complete remission at 6 months with progression at 9 months and the other partial remission at 2 months and no progression as of 5 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2017-12-30T22:42:55.372Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-01-04T16:20:58.823Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-12T17:53:12.986Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-01-04T16:16:25.389Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2380", "type": "Document", "label": "Lavingia et al., 2016, J Gastrointest Oncol", "xrefs": ["pmc:PMC5177579", "pmid:28078132"], "title": "Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:eMAxLQtCL8sz4sFvTALlYx8xauUsVeKp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C35417", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1165", "type": "DiseaseDescriptor", "label": "Intrahepatic Cholangiocarcinoma", "xrefs": ["DOID:4928"], "disease": "ncit:C35417"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:5904", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Dabrafenib and trametinib combination showed durable response for a patient with standard chemotherapy and radiation refractory, poorly differentiated, intrahepatic cholangiocarcinoma harboring BRAF V600E. At time of publication, 8.5 months, the patient was still on treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2017-12-30T22:44:59.232Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-13T16:33:25.099Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-13T16:22:59.484Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-01-04T16:31:33.561Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2379", "type": "Document", "label": "Loaiza-Bonilla et al., 2014, Ecancermedicalscience", "xrefs": ["pmc:PMC4239128", "pmid:25435907"], "title": "Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:eMAxLQtCL8sz4sFvTALlYx8xauUsVeKp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C35417", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1165", "type": "DiseaseDescriptor", "label": "Intrahepatic Cholangiocarcinoma", "xrefs": ["DOID:4928"], "disease": "ncit:C35417"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:5906", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 31 year old patient with metastatic cholangiocarcinoma with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. By 2 months, 50% reduction of tumor volume was noted, including multiple lung metastases, complete clinical response was noted by CT 6 months post therapy and this treatment was continued.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-01-02T21:58:01.210Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-02-15T15:54:50.834Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-14T19:05:37.281Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-02-15T20:49:46.561Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-02-15T15:54:52.118Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2382", "type": "Document", "label": "Silkin et al., 2016, J Gastrointest Cancer", "xrefs": ["pmid:26687137"], "title": "Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:u9isdON6YKcZALY2A4t9GvQ6s2AOZaiH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4436", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:29", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "xrefs": ["DOID:4947"], "disease": "ncit:C4436"}, "object_descriptor": {"id": "civic.tcd:keEkpEukYHqb30iQi2psXXZ3Lz1wK7-2", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:5938", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 43 year old female neversmoker lung adenocarcinoma patient with EGFR M766_A767insASV mutation was given erlotinib as first line treatment, and had progressive disease as best response with -3.9% change to target lesions, progression free survival of 1 month.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T01:50:16.272Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-05-28T18:53:48.633Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-18T02:30:39.784Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:dDUAoE4MWgJbYTTGFcPPNYvL0XZbS_2z", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.X-TA45UAONMe_dWRFbxZtV2GaUsejPS6", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2213", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:5961", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:29:32.613Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-10T18:01:25.062Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-12-10T19:35:35.237Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-10-24T16:08:47.560Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:rN4WKVGAY3q_wz4BoTNIHmAFCGdBWjIX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1298944", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3878", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3040", "type": "DiseaseDescriptor", "label": "Thyroid Gland Anaplastic Carcinoma", "xrefs": ["DOID:80522"], "disease": "ncit:C3878"}, "object_descriptor": {"id": "civic.tcd:QjxndwLs8w8D3pJIekSdxyQ8LOHQSIF_", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1298944", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:247", "type": "TherapeuticDescriptor", "label": "Pertuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C38692"], "alternate_labels": ["2C4", "2C4 Antibody", "HS627", "Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer", "MoAb 2C4", "Monoclonal Antibody 2C4", "Omnitarg", "Perjeta", "Pertuzumab Biosimilar HS627", "RO4368451", "RhuMAb2C4"], "therapeutic": "rxcui:1298944"}]}}
{"id": "civic.eid:5962", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:30:45.823Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-15T23:22:39.489Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:26:42.311Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:25:20.515Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:rcEJH8lF-QEIiR-dfJAXvJzeTbsF60IU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4044", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:124", "type": "DiseaseDescriptor", "label": "Laryngeal Squamous Cell Carcinoma", "xrefs": ["DOID:2876"], "disease": "ncit:C4044"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:6005", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analyzed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-02-23T19:55:29.260Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-20T22:26:26.571Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-20T22:23:23.503Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2359", "type": "Document", "label": "Cecchini et al., 2017, J Natl Compr Canc Netw", "xrefs": ["pmid:28874593"], "title": "EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:sC1f7944u0aPUAkOHkKrVIvjnp9N5F32", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jIytcqDhenXpXhAKfPqA6tsDvS5i6SEU", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C8294", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1012", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:158", "type": "DiseaseDescriptor", "label": "Pancreatic Adenocarcinoma", "xrefs": ["DOID:4074"], "disease": "ncit:C8294"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:7463", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A melanoma patient harboring the KIT S628N activating mutation underwent second-line imatinib therapy following lung metastatic progression that appeared after an eighth cycle of chemotherapy. The S628N mutation was not present in the blood, which confirmed that it was a somatic mutation. After 3 months of imatinib treatment (300 mg/d for first three weeks, then 400 mg/d), the patient exhibited disease progression and increased tumor size, and after an additional three months of imatinib treatment (400 mg/d), the patient developed multiple supratentorial brain metastases in addition to increased lung metastases and died 5 days later. The authors reported preclinical data which indicated variant sensitivity to imatinib. although this outcome did not coroberate the preclinical result, the authors still concluded the variant may be sensitive.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-08-05T23:07:14.805Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-05T23:10:55.180Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2054", "type": "Document", "label": "Vita et al., 2014, JAMA Dermatol", "xrefs": ["pmid:25317746"], "title": "Characterization of S628N: a novel KIT mutation found in a metastatic melanoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:gtEMujk3NIYQvwoTKrLuczOYGy3eT5OB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nk4PdRd1ft2MmNl1CPXEHh47vBckdGBG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1659", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:7498", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A patient with platinum-refractory oral cavity head and neck squamous carcinoma underwent comprehensive genomic profiling that identified an activating MET R1004G mutation. The patient showed a rapid response to the treatment of crizotinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-08-17T13:38:14.906Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-10-10T14:07:08.323Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2980", "type": "Document", "label": "Chu et al., 2019, Oncologist", "xrefs": ["pmc:PMC6795166", "pmid:31391294"], "title": "MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:j7xucpMhcqM4Jjtq-kM-qyRc4Evdnp65", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.E6Coa9FNrfrV8mKxZ2y5f7fIw7UPFtvF", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4013", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2774", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:453", "type": "DiseaseDescriptor", "label": "Head And Neck Cancer", "xrefs": ["DOID:11934"], "disease": "ncit:C4013"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:7616", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated.\nTreated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/9) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT\nTreated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E.\nTreated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-10-05T01:47:13.103Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-12-13T09:45:13.593Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-09T05:31:36.667Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-12-13T09:45:17.461Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3026", "type": "Document", "label": "Menzer et al., 2019, J. Clin. Oncol.", "xrefs": ["pmid:31580757"], "title": "Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:xkd-QsLq7tAejPAw3cI9kD5bZtXKuyHF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nstQWjDNJb8qwT0ZtyIGNK9El0LZGMn5", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C155322", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:11", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:699", "type": "TherapeuticDescriptor", "label": "BRAF Inhibitor", "xrefs": ["ncit:C155322"], "alternate_labels": ["B-RAF Inhibitor"], "therapeutic": "ncit:C155322"}}
{"id": "civic.eid:7629", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated.\nTreated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT\nTreated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E.\nTreated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-10-05T02:02:07.903Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-12-13T09:44:17.365Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-09T05:33:00.928Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-12-13T09:44:20.614Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3026", "type": "Document", "label": "Menzer et al., 2019, J. Clin. Oncol.", "xrefs": ["pmid:31580757"], "title": "Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:LzgEdVVflqQGqeqSDRUy65967bXDQZ-v", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nstQWjDNJb8qwT0ZtyIGNK9El0LZGMn5", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C155322", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:11", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:DL-rzLeUUdAwgqhOo4lMSKVLq4CR4E9_", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C155322", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:699", "type": "TherapeuticDescriptor", "label": "BRAF Inhibitor", "xrefs": ["ncit:C155322"], "alternate_labels": ["B-RAF Inhibitor"], "therapeutic": "ncit:C155322"}, {"id": "civic.tid:110", "type": "TherapeuticDescriptor", "label": "Mitogen-Activated Protein Kinase Kinase Inhibitor", "xrefs": ["ncit:C69145"], "therapeutic": "ncit:C69145"}]}}
{"id": "civic.eid:7635", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated.\nTreated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT\nTreated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E.\nTreated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-10-05T02:09:14.775Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T11:44:09.804Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3026", "type": "Document", "label": "Menzer et al., 2019, J. Clin. Oncol.", "xrefs": ["pmid:31580757"], "title": "Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:NXRQe_PPruc08XrfTOg7M7cXMbO_cDYh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4ujc2ZO2CAhxbhEBJTgHvpRJcwilL461", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C155322", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2826", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:DL-rzLeUUdAwgqhOo4lMSKVLq4CR4E9_", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C155322", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:699", "type": "TherapeuticDescriptor", "label": "BRAF Inhibitor", "xrefs": ["ncit:C155322"], "alternate_labels": ["B-RAF Inhibitor"], "therapeutic": "ncit:C155322"}, {"id": "civic.tid:110", "type": "TherapeuticDescriptor", "label": "Mitogen-Activated Protein Kinase Kinase Inhibitor", "xrefs": ["ncit:C69145"], "therapeutic": "ncit:C69145"}]}}
{"id": "civic.eid:7724", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a case report, a 3\u2010year\u2010old girl with glioblastoma harboring a probable germline heterozygous BRCA2 Lys3326Ter (K3326*) nonsense variant. After debulking surgery, the patient received standard\u2010of\u2010care treatment with radiation and temozolomide. Nine months later the PARP inhibitor olaparib was administered in combination with temozolomide for 16 cycles. This regimen was well tolerated by the patient and serial imaging showed a reduction in tumor size.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-10-26T22:03:30.900Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-12T00:40:38.904Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-12T00:45:26.280Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-04-29T17:21:39.882Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-04-29T17:02:33.820Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3071", "type": "Document", "label": "Valiakhmetova et al., 2019, Oncologist", "xrefs": ["pmid:32043779"], "title": "Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:0NJAZeDrNqsF5OI_ONI7DM0-QPhAw_K7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.N_6pOdOBjcnXQdHScTI4jDtQH6LEUSSg", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1597582", "type": "Therapeutic"}, {"id": "rxcui:37776", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3058", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2871", "neoplasm_type_descriptor": {"id": "civic.did:19", "type": "DiseaseDescriptor", "label": "Glioblastoma", "xrefs": ["DOID:3068"], "disease": "ncit:C3058"}, "object_descriptor": {"id": "civic.tcd:mnqlxI5kTjJ6WninClclCU94-Xy_RBfY", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1597582", "type": "Therapeutic"}, {"id": "rxcui:37776", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:42", "type": "TherapeuticDescriptor", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D010051", "type": "DiseaseDescriptor", "label": "Ovarian Neoplasms", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C71721"], "alternate_labels": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"], "therapeutic": "rxcui:1597582"}, {"id": "civic.tid:11", "type": "TherapeuticDescriptor", "label": "Temozolomide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:604", "type": "DiseaseDescriptor", "label": "Glioblastoma", "disease": "ncit:C3058"}, {"id": "hemonc:559", "type": "DiseaseDescriptor", "label": "Anaplastic glioma", "disease": "ncit:C127816"}]}}], "xrefs": ["ncit:C1244"], "alternate_labels": ["3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide", "8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one", "CCRG-81045", "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-", "M & B 39831", "M And B 39831", "Methazolastone", "RP-46161", "SCH 52365", "TMZ", "Temcad", "Temodal", "Temodar", "Temomedac"], "therapeutic": "rxcui:37776"}]}}
{"id": "civic.eid:7730", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib.\nWithin 4 weeks of initiating therapy, her serum\nCA19-9 had fallen from 36,000 to 8,100 U/mL, and the radiographic partial response was revealed by CT at 8 weeks after initiation of trametinib. cfDNA measurements for BRAF and TP53 alleles revealed a dramatic decline in response to trametinib. \nAfter 6 months of therapy, radiographic progression was identified.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-11-09T15:00:30.002Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-14T10:41:26.820Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3083", "type": "Document", "label": "Aguirre et al., 2018, Cancer Discov", "xrefs": ["pmc:PMC6192263", "pmid:29903880"], "title": "Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:FOcjMRO4YtRtdgMFOq7Q6SpSrQUWLEft", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.oknK-cjBz-mlqtbVlkuQw_OFNuw35o10", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9005", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2794", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:556", "type": "DiseaseDescriptor", "label": "Pancreatic Cancer", "xrefs": ["DOID:1793"], "disease": "ncit:C9005"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:7833", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "FGFR2 p.P253R mutation detected in patient with head and neck SCC.  Mutation initially detected by RNA-Seq and confirmed by Sanger sequencing.  Patient is 52 y/o male with initial diagnosis of SCC of right tongue in 2008.  Recurrences treated with surgery, radiotherapy and chemotherapy including carboplatin, paclitaxel, cisplatin, and cetuximab.  In 2012, progression was detected in right neck and left axilla.  Patient was treated with 800 mg of pazopanib daily.  At 12 day follow up patient had marked reduction in tumor size.  Patient continued treatment for 2 months until he presented with right carotid hemorrhage.  Last follow up shows patient is alive 11 months after beginning pazopanib treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:787", "type": "Agent", "name": "Geoff Lyle"}, "date": "2020-01-14T19:58:29.167Z", "activity": {"type": "Coding", "label": "submitted"}}], "is_reported_in": [{"id": "civic.source:3136", "type": "Document", "label": "Liao et al., 2013, Cancer Res.", "xrefs": ["pmc:PMC3749739", "pmid:23786770"], "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:3CtKJRiHCcEIk4nmVY0jaypcIVY_jrAl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mU-P67n2iFDHVlLDSEBYTbiOMJlPYGf5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:714438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C34447", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2905", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:37", "type": "DiseaseDescriptor", "label": "Head And Neck Squamous Cell Carcinoma", "xrefs": ["DOID:5520"], "disease": "ncit:C34447"}, "object_descriptor": {"id": "civic.tid:56", "type": "TherapeuticDescriptor", "label": "Pazopanib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C74547"], "alternate_labels": ["Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-", "GW786034"], "therapeutic": "rxcui:714438"}}
{"id": "civic.eid:10035", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed. 1 patient had the PIK3CA p.L938* mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant did not exhibit resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-05T20:17:10.157Z", "activity": {"type": "Coding", "label": "submitted"}}], "is_reported_in": [{"id": "civic.source:2196", "type": "Document", "label": "Xu et al., 2017, Clin. Cancer Res.", "xrefs": ["pmc:PMC5559326", "pmid:28424201"], "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:mxD0UM6JTShy5_X_aWEtJkKP5VZNdvmt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.6qUj0X0feKveHQmxs3MEu81dnZXKpuqz", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:3670", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:10325", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a 32-year old male patient with pilocytic astrocytoma. Genomic profiling (FoundationOne) revealed a FGFR1 N546K mutation. The patient was enrolled in a phase I/II trial of pemigatinib and achieved a partial response lasting 18 months.", "specified_by": "metakb.method:1", "is_reported_in": [{"id": "civic.source:4291", "type": "Document", "label": "Capone et al., 2022, JCO Precis Oncol", "xrefs": ["pmid:35507888"], "title": "Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:NYpp7mxVNk8CrPl77bb6GHTuIvHleNF6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4OW2WDKXQ4JxiQz6RWz5YQM3XQyxcLeb", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2359268", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4047", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:515", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:166", "type": "DiseaseDescriptor", "label": "Pilocytic Astrocytoma", "xrefs": ["DOID:4851"], "disease": "ncit:C4047"}, "object_descriptor": {"id": "civic.tid:1975", "type": "TherapeuticDescriptor", "label": "Pemigatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}]}}], "xrefs": ["ncit:C121553"], "alternate_labels": ["2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-", "INCB054828", "Pemazyre"], "therapeutic": "rxcui:2359268"}}
{"id": "civic.eid:17", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.498Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-08-01T16:06:55.930Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.498Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:6", "type": "Document", "label": "Imielinski et al., 2014, J. Clin. Invest.", "xrefs": ["pmc:PMC3973082", "pmid:24569458"], "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:3nZcSFZbxUrlPTshTQLLElZk0HUwESV2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NcfHbQ_k1M8S4zdJ9JAhe1qFBaBXQIil", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:10", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}}
{"id": "civic.eid:21", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.722Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.722Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:66", "type": "Document", "label": "Banerji et al., 2008, Mol. Cancer Ther.", "xrefs": ["pmid:18375819"], "title": "BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:nERiyDdJPb0Mpz7N-zWQHI2gs9iHtqpo", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.r4_0KPC2QwJjEZRfWUZFgbp0LvvM9IYY", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C37899", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:93", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:10", "type": "TherapeuticDescriptor", "label": "Tanespimycin", "xrefs": ["ncit:C37899"], "alternate_labels": ["17-(Allylamino)-17-demethoxygeldanamycin", "17-AAG", "17-Allylamino-17-demethoxygeldanamycin", "17-Demethoxy-17-(2-propenylamino)geldanamycin", "17-N-allylamino-17-demethoxy Geldanamycin", "17-N-allylamino-17-demethoxygeldanamycin", "Geldanamycin, 17-allylamino-17-demethoxy-", "KOS-953"], "therapeutic": "ncit:C37899"}}
{"id": "civic.eid:22", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.781Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.781Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:67", "type": "Document", "label": "Soon et al., 2011, Arch Dermatol", "xrefs": ["pmid:21576590"], "title": "NRAS-mutant melanoma: response to chemotherapy."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:C7Odc5DV_QowIEbcyPceuu2Xw9wrIrny", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CVBMOLB83i86owaBt636xVhdQ7aeTfyf", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:37776", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:95", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:11", "type": "TherapeuticDescriptor", "label": "Temozolomide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:604", "type": "DiseaseDescriptor", "label": "Glioblastoma", "disease": "ncit:C3058"}, {"id": "hemonc:559", "type": "DiseaseDescriptor", "label": "Anaplastic glioma", "disease": "ncit:C127816"}]}}], "xrefs": ["ncit:C1244"], "alternate_labels": ["3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide", "8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one", "CCRG-81045", "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-", "M & B 39831", "M And B 39831", "Methazolastone", "RP-46161", "SCH 52365", "TMZ", "Temcad", "Temodal", "Temodar", "Temomedac"], "therapeutic": "rxcui:37776"}}
{"id": "civic.eid:23", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.827Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.827Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:67", "type": "Document", "label": "Soon et al., 2011, Arch Dermatol", "xrefs": ["pmid:21576590"], "title": "NRAS-mutant melanoma: response to chemotherapy."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:s1BLAwRkAN8IPQAGndy_2W9Zm7e03xF1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RI834ljUlgAn9ez2JG32bVVchgx-t7Pp", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:37776", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:96", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:11", "type": "TherapeuticDescriptor", "label": "Temozolomide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:604", "type": "DiseaseDescriptor", "label": "Glioblastoma", "disease": "ncit:C3058"}, {"id": "hemonc:559", "type": "DiseaseDescriptor", "label": "Anaplastic glioma", "disease": "ncit:C127816"}]}}], "xrefs": ["ncit:C1244"], "alternate_labels": ["3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide", "8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one", "CCRG-81045", "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-", "M & B 39831", "M And B 39831", "Methazolastone", "RP-46161", "SCH 52365", "TMZ", "Temcad", "Temodal", "Temodar", "Temomedac"], "therapeutic": "rxcui:37776"}}
{"id": "civic.eid:91", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.585Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.585Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:101", "type": "Document", "label": "Rudin et al., 2013, J Thorac Oncol", "xrefs": ["pmc:PMC3634121", "pmid:23524406"], "title": "Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:li7U3CZvtp7Uv2IaeT8h_eArR3ypuXG9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1424911", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}}
{"id": "civic.eid:388", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumors of four patients (Patient Ids: 7, 42, 52, 64; Table S1) and the metastatic tumor of one patient (11; Table S1), who experienced disease progression following treatment. It was also noted in the primary tumors of 3 patients (25, 48, 88; Table S1) who experienced stable disease following treatment.This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, one patient (38, Table S1) had PIK3CA H1047R as the only noted variant, but experienced partial response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:53.614Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T20:51:30.235Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T21:41:52.834Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-10-09T21:56:43.856Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:53.614Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:2APhLRtWXrKHa0DqG9-yiH-RSlulALWw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:757", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-30T15:03:53.888Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-18T19:46:22.819Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-18T21:12:55.913Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-02-03T23:13:29.080Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:500", "type": "Document", "label": "Sarker et al., 2015, Clin. Cancer Res.", "xrefs": ["pmc:PMC4287394", "pmid:25370471"], "title": "First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:sKnG2Emmgwm3tWO0uJugRgLYtDFOA-EL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:794", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-08T12:17:40.331Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-21T16:21:18.604Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-02-22T20:30:50.631Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-08T20:51:04.577Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:528", "type": "Document", "label": "Van Allen et al., 2014, Nat. Med.", "xrefs": ["pmc:PMC4048335", "pmid:24836576"], "title": "Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:qxTUstigU4hLo4A_jd7fs1U15INKpHWZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G-Fn2qLS-0ud98S5NNSSWeuiZ15OaYQo", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1946825", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:322", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:148", "type": "TherapeuticDescriptor", "label": "Abemaciclib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C97660"], "alternate_labels": ["2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)", "LY-2835219", "LY2835219", "Verzenio"], "therapeutic": "rxcui:1946825"}}
{"id": "civic.eid:937", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-19T09:39:58.109Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-08T22:54:31.475Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-20T23:19:29.689Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-03-10T15:36:32.544Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-08T22:53:49.538Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:641", "type": "Document", "label": "Yap et al., 2011, J. Clin. Oncol.", "xrefs": ["pmid:22025163"], "title": "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:6Mo-nuQclP1wYq6N25VT6o4eGVDX-KUH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C90581", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3850", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:169", "type": "DiseaseDescriptor", "label": "Pancreatic Carcinoma", "xrefs": ["DOID:4905"], "disease": "ncit:C3850"}, "object_descriptor": {"id": "civic.tid:43", "type": "TherapeuticDescriptor", "label": "Akt Inhibitor MK2206", "xrefs": ["ncit:C90581"], "alternate_labels": ["1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-", "MK 2206", "MK-2206", "MK-2206 FREE BASE", "MK2206"], "therapeutic": "ncit:C90581"}}
{"id": "civic.eid:1078", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-23T08:37:39.480Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:32:30.744Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:32:36.523Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:38:18.807Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:472", "type": "Document", "label": "Montagut et al., 2012, Nat. Med.", "xrefs": ["pmid:22270724"], "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Hsf90jhJ5QlfbRQuGOJMi6fBOK1zmZMG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VDg4To7ePAbIjjPfop3VmeFbcUpvgsf5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:453", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:1131", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:130", "type": "Agent", "name": "Robert Lesurf"}, "date": "2016-02-26T21:28:18.660Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-03-08T17:48:40.440Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:782", "type": "Document", "label": "Palmirotta et al., 2009, Anticancer Res.", "xrefs": ["pmid:19661358"], "title": "A novel K-ras mutation in colorectal cancer. A case report and literature review."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:bxDZ2bvbSuGTxTiBtsKID5lEX12z0Hbq", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Nep4la-HCabJwJ4g_Ur7HQrTpT4TeHUQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7966", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:479", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:691", "type": "DiseaseDescriptor", "label": "Colon Mucinous Adenocarcinoma", "xrefs": ["DOID:3029"], "disease": "ncit:C7966"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:1269", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and two of these were germline mutations.  Of these 2 germline patients, 1 showed stable disease (SD) and 1 complete response (CR). In contrast, in the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The authors conclude this finding is promising and merits further study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-04-17T10:15:40.081Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-13T16:49:37.472Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-28T00:35:18.435Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-13T16:49:40.358Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:859", "type": "Document", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "xrefs": ["pmc:PMC3730818", "pmid:23598171"], "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:aZUVgjr8yzKbU9mjzD9sAwRLJ4rNMXco", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eDIGsnE6r2Z4xJ1HLKHFZhShBjcUGpgJ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:9", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:1270", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.  11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation. Two of these R1275Q mutations were germline and two were somatic. Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD). In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The stable disease patient had an R1275L mutation in ALK. In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-04-17T10:28:41.838Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-13T16:53:04.178Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-28T00:30:02.945Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-13T16:51:45.994Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:859", "type": "Document", "label": "Moss\u00e9 et al., 2013, Lancet Oncol.", "xrefs": ["pmc:PMC3730818", "pmid:23598171"], "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:aZUVgjr8yzKbU9mjzD9sAwRLJ4rNMXco", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eDIGsnE6r2Z4xJ1HLKHFZhShBjcUGpgJ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:9", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:1395", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-24T10:09:00.967Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-07T23:51:43.733Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:945", "type": "Document", "label": "Masago et al., 2010, Jpn. J. Clin. Oncol.", "xrefs": ["pmid:20522446"], "title": "Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I)."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:cQDDC6LPqg42JnUU_Gn4mTmtRElzsT8b", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2TmSETRJQzrU-OXco267vKiGgGY4qCLK", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:562", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:1423", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:112", "type": "Agent", "name": "Connor Liu"}, "date": "2016-06-28T21:14:43.309Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-08T17:47:50.024Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:964", "type": "Document", "label": "Iurlo et al., 2014, Oncotarget", "xrefs": ["pmc:PMC4148089", "pmid:25015329"], "title": "Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:52SjHYWUzxbSrGbQxeHqH7ohiMAUO6lx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._7X7oCH1wcicJ3YAIWH8xgI1GawA24e7", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3483", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:201", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:251", "type": "DiseaseDescriptor", "label": "Chronic Leukemia", "xrefs": ["DOID:1036"], "disease": "ncit:C3483"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:1533", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-07-11T18:49:45.576Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-12T17:41:55.412Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-20T18:36:33.985Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-12T16:03:10.190Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1021", "type": "Document", "label": "Turajlic et al., 2014, Ann. Oncol.", "xrefs": ["pmc:PMC3999800", "pmid:24504448"], "title": "Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:lhaf-VxwRcFEIpRj8iAvQPUn33sytU37", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QYkNQvhUn7ivhb5plpyq7Hb9EpKTXT91", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:604", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1549", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses. One of the partial responses harbored a PIK3CA E542K mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T14:05:56.590Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-08-04T21:19:44.657Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-05T06:54:49.550Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-21T17:20:26.485Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1026", "type": "Document", "label": "Dolly et al., 2016, Clin. Cancer Res.", "xrefs": ["pmc:PMC4876928", "pmid:26787751"], "title": "Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:VBvZeZKPDnfoY0ne7VNp95beNFHSVkdl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C91731", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C34447", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:37", "type": "DiseaseDescriptor", "label": "Head And Neck Squamous Cell Carcinoma", "xrefs": ["DOID:5520"], "disease": "ncit:C34447"}, "object_descriptor": {"id": "civic.tid:377", "type": "TherapeuticDescriptor", "label": "Apitolisib", "xrefs": ["ncit:C91731"], "alternate_labels": ["GDC 0980", "GDC-0980", "GNE 390", "RG 7422"], "therapeutic": "ncit:C91731"}}
{"id": "civic.eid:1580", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patient\u2019s genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-07-27T18:48:29.631Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-04T21:50:39.205Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-09-04T22:34:24.648Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-04T21:48:56.018Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1043", "type": "Document", "label": "Tiacci et al., 2015, N. Engl. J. Med.", "xrefs": ["pmc:PMC4811324", "pmid:26352686"], "title": "Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:IOLIOANuVbafVrWrPiUYF1w61-U2ernz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7402", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:665", "type": "DiseaseDescriptor", "label": "Hairy Cell Leukemia", "xrefs": ["DOID:285"], "disease": "ncit:C7402"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1589", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-04T07:56:37.087Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-08-04T14:55:55.220Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1050", "type": "Document", "label": "Pietrantonio et al., 2016, Cancer Discov", "xrefs": ["pmid:27325282"], "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:-6aazcN9vGcoY3Yf_zkR0rlwLEljfYQH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:aqQX-Uu5M67jU4vqRwbOB7diuYQozPtZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:1603", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-16T09:25:27.561Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T22:45:18.808Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-11-07T20:32:22.532Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T22:45:22.232Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1063", "type": "Document", "label": "Palma et al., 2015, Eur. Urol.", "xrefs": ["pmid:25766722"], "title": "Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:sv58QXYW5_RzXC8Dje1pFcSe8mK8wOsv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.FNHAUxkAFnYKIjkp3qxbDsoN31F2i-wp", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:714438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2930", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:628", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:642", "type": "DiseaseDescriptor", "label": "Transitional Cell Carcinoma", "xrefs": ["DOID:2671"], "disease": "ncit:C2930"}, "object_descriptor": {"id": "civic.tid:56", "type": "TherapeuticDescriptor", "label": "Pazopanib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C74547"], "alternate_labels": ["Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-", "GW786034"], "therapeutic": "rxcui:714438"}}
{"id": "civic.eid:1617", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation. Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-29T09:14:32.485Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-06T00:48:13.723Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1069", "type": "Document", "label": "Kl\u00fcmpen et al., 2011, J. Clin. Oncol.", "xrefs": ["pmc:PMC4856022", "pmid:21189378"], "title": "mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:I3O1OSKspLHJjJ2AQdTuz6a0-GV0oVK6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1EVCGMpJzbtg8gql2VrApTPz5McvT_gg", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:141704", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9005", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:634", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:556", "type": "DiseaseDescriptor", "label": "Pancreatic Cancer", "xrefs": ["DOID:1793"], "disease": "ncit:C9005"}, "object_descriptor": {"id": "civic.tid:41", "type": "TherapeuticDescriptor", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:45070", "type": "DiseaseDescriptor", "label": "Subependymal giant cell astrocytoma", "disease": "ncit:C3696"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:641", "type": "DiseaseDescriptor", "label": "Neuroendocrine tumor", "disease": "ncit:C3809"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C48387"], "alternate_labels": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"], "therapeutic": "rxcui:141704"}}
{"id": "civic.eid:1623", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-31T08:34:34.960Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T23:21:05.312Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1075", "type": "Document", "label": "Sun et al., 2016, Onco Targets Ther", "xrefs": ["pmc:PMC4936809", "pmid:27445490"], "title": "Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:wDKKBfuacOmFTEbQhA2EB8S8ged7Bz3S", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:141704", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tcd:hAKRvUsYco9D9KhfWrgO7JE2mcctWJ0Y", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:141704", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:41", "type": "TherapeuticDescriptor", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:45070", "type": "DiseaseDescriptor", "label": "Subependymal giant cell astrocytoma", "disease": "ncit:C3696"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:641", "type": "DiseaseDescriptor", "label": "Neuroendocrine tumor", "disease": "ncit:C3809"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C48387"], "alternate_labels": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"], "therapeutic": "rxcui:141704"}, {"id": "civic.tid:54", "type": "TherapeuticDescriptor", "label": "Fulvestrant", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1379"], "alternate_labels": ["7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol", "Faslodex", "Faslodex(ICI 182,780)", "ICI 182,780", "ICI 182780", "ZD9238"], "therapeutic": "rxcui:282357"}]}}
{"id": "civic.eid:1652", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-09-12T07:40:49.650Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T23:27:02.787Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1116", "type": "Document", "label": "Heist et al., 2016, J Thorac Oncol", "xrefs": ["pmid:27343442"], "title": "Acquired Resistance to Crizotinib in NSCLC with MET\u00a0Exon 14 Skipping."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:28STe92mypTQ6Hc3eGEZwMwdSdbTIDrp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wlreUeNuU4y1nx3PP5s4polEIruvosqO", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:649", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:1670", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2016-09-17T16:14:43.607Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-07T21:28:23.221Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-11T17:41:41.694Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-09-19T07:17:35.374Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1128", "type": "Document", "label": "Belchis et al., 2016, Oncotarget", "xrefs": ["pmc:PMC5216719", "pmid:27304188"], "title": "Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:C3FP0jX5K3UbkFdPUXJ71Nex5rGfl5vp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:1699", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-09-20T15:09:05.653Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T22:24:12.743Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1147", "type": "Document", "label": "Sharman et al., 2014, Clin Lymphoma Myeloma Leuk", "xrefs": ["pmid:24997557"], "title": "Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:XFgKYOBexcFD5ibB82vAGKtFYSNlpLZx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1715", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-10-11T08:06:38.499Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T22:20:27.069Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-11-07T20:32:51.837Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T22:20:48.394Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1158", "type": "Document", "label": "Palma et al., 2014, Case Rep Oncol", "xrefs": ["pmc:PMC4164090", "pmid:25232318"], "title": "Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:FyoQ1mmJYBU7dNqx-juMjfERBPABDVvc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:1724", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-10-25T17:54:40.532Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-01-18T16:19:16.924Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-01-18T16:23:00.825Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T23:29:20.124Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:186", "type": "Document", "label": "Borad et al., 2014, PLoS Genet.", "xrefs": ["pmc:PMC3923676", "pmid:24550739"], "title": "Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:nbsvz_VlZa_aCuk17ti7Vs4llMQpomcW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yI-Frf1V6gEML12FtvK6iHuTF1EX6seG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4436", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:691", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:29", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "xrefs": ["DOID:4947"], "disease": "ncit:C4436"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:2037", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PIK3CA E545K was the only variant noted in the primary tumor (found in the sigma-rectum junction) of one patient who experienced partial response following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. See Patient 55 from Supplemental Table 1 for more information on this patient.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:58:15.910Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-10-23T21:46:32.887Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-10-23T21:47:44.937Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T16:42:19.498Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:rYiPQYMxXR7y5aYm1jcsKB3t0R5eeAO2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:2157", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:22.328Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T08:54:59.861Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T15:36:01.221Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T08:54:39.366Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1516", "type": "Document", "label": "Planchard et al., 2015, Ann. Oncol.", "xrefs": ["pmid:26269204"], "title": "EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:hyS_zXBas4tpONalpRnKiSbRf7S8X4eS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:2184", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and PIK3CA. Overall, one patient experienced stable disease, and the other four experienced progressive disease.The five patients whose tumors harbored NRAS Q61R included a 65 year old male treated with cetuximab monotherapy as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 41 weeks; a 47 year old female treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 4 weeks and OS of 10 weeks; a 60 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced stable disease and had PFS of 24 weeks and OS of 38 weeks; a 47 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced progressive disease and had PFS of 14 weeks and OS of 18 weeks; and a 77 year old male treated with cetuximab monotherapy as a 1st line therapy who experienced progressive disease and had PFS of 7 weeks and OS of 67 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:50.826Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-10T22:03:11.899Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T22:03:25.873Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-02-25T02:33:26.780Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T22:03:32.496Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:e6ctjf6Fon57nawx9EmeoJi44AZDEjK0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RI834ljUlgAn9ez2JG32bVVchgx-t7Pp", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:96", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:2198", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 75 year old female treated with cetuximab and irinotecan as 2nd line therapy (discontinued for toxic/biochemical reasons) who experienced a partial response (PFS: 43 weeks, OS: 57 weeks). Using clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in the source) mutations predict weak or no resistance to cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:54.352Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:50:43.229Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:50:55.516Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:48:26.396Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:49:40.898Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Z-Fsr_Okof7ADodlavSAYP-xWq0l3-iT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nyuWYXXVPT_eO8mWhz_HvPXsS5rPrazX", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:885", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2268", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:20.607Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-04-11T20:09:54.022Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-05-11T15:28:14.060Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:43:39.586Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1416", "type": "Document", "label": "Endoh et al., 2006, J Thorac Oncol", "xrefs": ["pmid:17409929"], "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:z-9bakdouJQGd7vpwnPFCSMX1OLTxfHE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7377", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:23", "type": "DiseaseDescriptor", "label": "Lung Cancer", "xrefs": ["DOID:1324"], "disease": "ncit:C7377"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2417", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. This patient's GIST had a KIT exon 8 deletion/insertion TYD417-419Y. This patient represents the first reported sporadic GIST with a KIT exon 8 mutation as germline DNA from surrounding normal tissue was was KIT wildtype. The patient had an unconfirmed partial response to 400mg daily imatinib (TTP 8.1 months) and a censored OS of 59.3 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:02:51.351Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-08T17:40:08.906Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-08T17:40:23.400Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-08T17:40:25.627Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1586", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651078", "pmid:18955451"], "title": "Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:C3EMj2k9wUSzlwVNkXOiEl6Qb9RZBbPS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JwDFXrh_Ycdb1NopvaVaOO7zoAlKgAV8", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2620", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2478", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:49.029Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-26T18:16:47.681Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-26T18:18:03.643Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-26T18:22:33.941Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2632", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:43.581Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-21T03:43:29.306Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-08T20:54:29.334Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-08T20:54:33.330Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1509", "type": "Document", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC516528", "pmid:15329413"], "title": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:teH1xxIK6r4jpsaY8NccNewpkJ0YcjYX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:2889", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 69 y.o. woman presented with metastatic mucosal melanoma of the anus. KIT was amplified in the tumor and harbored the K642E mutation. Post surgery with extensive margins, she was given a dose of anti-CTLA-4 antibody and adjuvant radiation therapy for 2.5 weeks.  Two weeks post radiation she developed nodules in the same region and testing indicated they were malignant melanoma with high KIT expression. She enrolled in a clinical trial with a dose of 400mg imatinib per day (Nov 2006). Less than 4 weeks later, all nodules had disappeared. Upon a lowered dosage to 200mg of imatinib, the nodules returned and subsequently the dosage was increased to 600mg/day. The patient remained melanoma-free on 600mg imatinib until a follow up in Jan 2008. The authors do not provide further details on patient outcome.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:122", "type": "Agent", "name": "Deb Irene"}, "date": "2017-03-31T04:18:38.988Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-11T15:13:19.966Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T11:31:41.715Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-10-17T09:44:40.214Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-11T15:13:22.715Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1649", "type": "Document", "label": "Lutzky et al., 2008, Pigment Cell Melanoma Res", "xrefs": ["pmid:18510589"], "title": "Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:M_YzDNypfNat2-lfMWCkCGOiUfQXUtyT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qqyXsR4-bT1oCgmCJM4qHholRwDQ602L", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C114828", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:978", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:83", "type": "DiseaseDescriptor", "label": "Mucosal Melanoma", "xrefs": ["DOID:50929"], "disease": "ncit:C114828"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2906", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-04-04T11:42:33.437Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-23T13:43:52.292Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-23T13:43:12.116Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T16:49:25.837Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1669", "type": "Document", "label": "Leventakos et al., 2016, J Thorac Oncol", "xrefs": ["pmc:PMC5035584", "pmid:27211795"], "title": "S768I Mutation in EGFR in Patients with Lung Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:an5Wriq6-qPlOGipi59idAEymLsiqz2u", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2TmSETRJQzrU-OXco267vKiGgGY4qCLK", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:562", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:3690", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA. This patient was was a 73 year old male treated with cetuximab and irinotecan as 4th line therapy who experienced progressive disease and had PFS of 10 weeks and OS of 36 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:33:57.984Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-10T22:12:50.558Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T22:13:12.467Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-17T20:57:54.592Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-10T22:13:24.125Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:2iI0YKWKmE0Hg2HsQImu4JQzN_16QUvn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CMcJNS2hl5LwQd2mDCHwPZowQ8JhCuE3", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:893", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:4062", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient 3 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/two weeks off. This patient experienced stable disease less than 6 months; time to progresssion of 14 weeks and overall survival of 17 weeks (Table A1).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:32.694Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:17:03.146Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:20:40.203Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:20:44.194Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:n2DLJiuz9cSK8fWyy2pD2UAlt08A-vxB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Mpx_awhBN5_SId6bGlNVakmB2V2i1cNe", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:949", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4095", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient 47 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K558_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/one week off.  The patient experienced progressive disease. Time to progression was censored at 5 weeks, and overall survival was 60 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:03.852Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:50:21.022Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:51:38.862Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:51:41.213Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:GgHLc3HQwRhvGVmRyipo1dgeIppZHx9q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.pE9Bl5DqO_qy0NWTGv1zfMullzdE6tT3", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:964", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4136", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient 29 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT L576P mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/two weeks off.  The patient experienced stable disease for less than 6 months. Time to progression and overall survival were 31 and 29 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:39.466Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:30:09.708Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:30:41.612Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:30:44.714Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:P4mSroiD2YiIvTxDmoQNboXdHRz08Cwo", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1i40nlLTUTxkw3VAG3tTQSuNjTWnMdy5", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:72", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4142", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient 74 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT D579 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced stable disease for less than six months. Time to progression was censored at 10 weeks and overall survival was 85 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:46.414Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:58:57.226Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:59:23.199Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:59:25.776Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:AQto6_krKeJbZRuGttKdQKE2iR7t-u47", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.oToThcBUs1VzesQkoIWDju4gFbvODfyg", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:977", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4220", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21.  Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 62, nonsmoker) was treated with gefitinib and had progressive disease, progression free survival (PFS) of 1.0 months, overall survival (OS) of 7.7 months and was not alive at study end. The second patient (M, 39, nonsmoker) was treated with erlotinib and had progressive disease as response, PFS of 2.3 months, OS of 7.2 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:43:14.860Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:55:25.028Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-11T04:00:57.586Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:08:08.982Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:55:33.765Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:2yAJO0u4JZ55HSwJiHVR2BPNaI7BcJTF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.osNBozkZp1wAKFFpS1vaF6CntV6rCX8i", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1891", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:4231", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:43:40.490Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T16:19:56.400Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:41:32.909Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:12:34.492Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:41:56.098Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Aoc_2FreWqQsnMyQqBw38_hkU6DwPMox", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3wQZ7tYnsEHm_QPcW3sw1iKzpTmqzYZx", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1894", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4239", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, nonsmoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 28.1 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:44:15.485Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T16:33:57.960Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T18:07:40.580Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:16:40.919Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T18:09:03.185Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:xcGJTWVs6-cDSD7zo2KWxydH-595FxIH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JL1wie_tcoV3HHX-Mq3nBAGeE1cR6g00", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1895", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4244", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 46, nonsmoker) had progressive disease as response, progression free survival (PFS) of 3.3 months, overall survival (OS) of 13.9 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:44:35.424Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T23:00:14.313Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-11T03:58:43.678Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:18:45.519Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:37:31.017Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ErRPDUfVIIilGddfxemf0Yoz7eDWnGNs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.I453sG0qG-lB27rglyIi1QluV4hlyamW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1896", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4256", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 73, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.9 months, overall survival (OS) of 9.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:46:04.504Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T18:28:14.111Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:36:40.514Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:36:02.895Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:36:46.822Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Hk3JPqUIXNqwzO8hiHytJi86nDozSjjM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ecuZjHuEfWdQwEgFqMYgyk5nLODMfJvy", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1899", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4260", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, smoker) progressive disease as response, progression free survival (PFS) of 1.1 months, overall survival (OS) of 1.1 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:46:23.969Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T18:34:46.743Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:38:34.948Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:38:01.378Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:38:38.904Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:5GbKnHfsL7wNPnvknwj4ZSvIDlffwZc-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U52FXKrgePglVnHJDADMZkNAUBMfSZ3k", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1463", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4264", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 69, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.7 months, overall survival (OS) of 1.6 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common mutations (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:46:54.262Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-19T18:21:09.890Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2020-08-19T18:37:43.686Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-06T22:41:31.250Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-06T22:39:41.921Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1503", "type": "Document", "label": "Wu et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21531810"], "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:MV91XchfXTu3P_0g1HQxW9-9aadSNhTn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.dd-rTFby6KoOjD7Rj53riN6rt9S8bG-M", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1466", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:4464", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E81K, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy and experienced stable disease, resulting in a response rate of 0/2 and a clinical benefit rate of 2/2 according to author criteria. One patient was a 57 year old female with a PFS of 24 weeks and an OS of 100 weeks. The other patient was a 60 year old male with a PFS of 23 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:04.052Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:57:30.121Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T22:57:47.968Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T22:52:55.407Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-02T02:41:36.205Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:-iRGTjPGGiuuoEzl5WCAPcUZHqo1IQD-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qAvQOEpH-g59SN2fUhCQo8EUb03WQlfQ", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:32592", "type": "Therapeutic"}, {"id": "rxcui:4492", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1500", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:-TUOzS0ClpVaUo5oisn2Bt0H0ZHPi1cJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:32592", "type": "Therapeutic"}, {"id": "rxcui:4492", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:237", "type": "TherapeuticDescriptor", "label": "Oxaliplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}, {"id": "hemonc:585", "type": "DiseaseDescriptor", "label": "Colon cancer", "disease": "ncit:C9242"}]}}], "xrefs": ["ncit:C1181"], "alternate_labels": ["1-OHP", "Ai Heng", "Aiheng", "DACPLAT", "Dacotin", "Diaminocyclohexane Oxalatoplatinum", "ELOXATIN", "Eloxatine", "JM-83", "Oxalato (1R,2R-cyclohexanediamine)platinum(II)", "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)", "Oxalatoplatin", "Oxalatoplatinum", "RP 54780", "RP-54780", "SR-96669", "Trans-l DACH Oxalatoplatinum", "Trans-l Diaminocyclohexane Oxalatoplatinum", "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum", "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"], "therapeutic": "rxcui:32592"}, {"id": "civic.tid:420", "type": "TherapeuticDescriptor", "label": "Fluorouracil", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C505"], "alternate_labels": ["2,4-Dioxo-5-fluoropyrimidine", "5 FU", "5 Fluorouracil", "5 Fluorouracilum", "5-FU", "5-Fluoro-2,4(1H, 3H)-pyrimidinedione", "5-Fluoro-2,4(1H,3H)-pyrimidinedione", "5-Fluorouracil", "5-Fluracil", "5FU", "AccuSite", "Adrucil", "Carac", "Fluoro Uracil", "Fluouracil", "Flurablastin", "Fluracedyl", "Fluracil", "Fluril", "Fluroblastin", "Ribofluor", "Ro 2-9757", "Ro-2-9757"], "therapeutic": "rxcui:4492"}]}}
{"id": "civic.eid:4467", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R93W, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old male treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy who experienced progressive disease (PFS: 8 weeks).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:06.344Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:10:56.265Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:11:18.376Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:11:21.248Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:11:49.951Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:LnRmSmrq8zCXz1fM0MBXhPUJ8g3m93mi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7cYvH4ptwO0n4cf9aWSSniyZ1skEg86F", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:32592", "type": "Therapeutic"}, {"id": "rxcui:4492", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1178", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:-TUOzS0ClpVaUo5oisn2Bt0H0ZHPi1cJ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:32592", "type": "Therapeutic"}, {"id": "rxcui:4492", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:237", "type": "TherapeuticDescriptor", "label": "Oxaliplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}, {"id": "hemonc:585", "type": "DiseaseDescriptor", "label": "Colon cancer", "disease": "ncit:C9242"}]}}], "xrefs": ["ncit:C1181"], "alternate_labels": ["1-OHP", "Ai Heng", "Aiheng", "DACPLAT", "Dacotin", "Diaminocyclohexane Oxalatoplatinum", "ELOXATIN", "Eloxatine", "JM-83", "Oxalato (1R,2R-cyclohexanediamine)platinum(II)", "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)", "Oxalatoplatin", "Oxalatoplatinum", "RP 54780", "RP-54780", "SR-96669", "Trans-l DACH Oxalatoplatinum", "Trans-l Diaminocyclohexane Oxalatoplatinum", "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum", "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"], "therapeutic": "rxcui:32592"}, {"id": "civic.tid:420", "type": "TherapeuticDescriptor", "label": "Fluorouracil", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C505"], "alternate_labels": ["2,4-Dioxo-5-fluoropyrimidine", "5 FU", "5 Fluorouracil", "5 Fluorouracilum", "5-FU", "5-Fluoro-2,4(1H, 3H)-pyrimidinedione", "5-Fluoro-2,4(1H,3H)-pyrimidinedione", "5-Fluorouracil", "5-Fluracil", "5FU", "AccuSite", "Adrucil", "Carac", "Fluoro Uracil", "Fluouracil", "Flurablastin", "Fluracedyl", "Fluracil", "Fluril", "Fluroblastin", "Ribofluor", "Ro 2-9757", "Ro-2-9757"], "therapeutic": "rxcui:4492"}]}}
{"id": "civic.eid:4589", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. Three patients whose GIST harbored KIT D820Y experienced clinical benefit (defined as complete response, partial response, stable disease >16 weeks) in response to regorafenib. One patient remained on study without disease progression for >11 months, one patient developed disease progression at 5.7 months, and the other patient underwent surgical removal of all residual disease after 7 months, but continued on regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from these patients demonstrated decreased levels of KIT phosphorylation in response to regorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:52:57.107Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-03-21T20:39:45.702Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-03-21T20:40:03.129Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-03-21T20:39:58.350Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2045", "type": "Document", "label": "George et al., 2012, J. Clin. Oncol.", "xrefs": ["pmc:PMC3675695", "pmid:22614970"], "title": "Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:LWCFUFgoGhMN-X8zhTvSSZgEtjBBPUvy", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.k2xXiu-T1lSzrMEKj4oJo8vrUM0mG7A4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:986", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:4595", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. One patient whose GIST harbored KIT N882K did not experienced disease progression for >7 months following treatment by regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from this patient demonstrated decreased levels of KIT phosphorylation in response to regorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:01.648Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-03-21T20:40:57.558Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-03-21T20:41:06.231Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-03-21T20:41:08.879Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2045", "type": "Document", "label": "George et al., 2012, J. Clin. Oncol.", "xrefs": ["pmc:PMC3675695", "pmid:22614970"], "title": "Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ZWgwD8Pbp26N_4CSRrlG8gKKI2I-wnd8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:5960", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:28:09.865Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:16:51.275Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:12:26.540Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:16:21.948Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:GyTl-Ef5EFPmxguxr6_ZwPSdAx4bKvgg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5964", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:35:59.901Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:14:51.775Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:13:00.062Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:14:27.695Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:S9dp0q4ycCFKfitfIAD3vejeldmNvkRL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Aot_NMjWMtFBGF7qphX8PRPhHbQy7lt7", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1106", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5965", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:36:58.351Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:10:06.966Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:20:34.105Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:09:51.894Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:oxiQkExYa0EpC4PCHAP_xiRfc3mN4Puw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.B9uTMfw3IDLuBkIUoj_ZAhRmnV_gqSj8", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:992", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5966", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:37:53.993Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:08:14.393Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:20:52.540Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:08:00.140Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:pvvy-k2s04pWCi8V7_RrlpKku1NaVRb2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SN41fJllnfQ_DhYtSYy_8aMGWpanvtH2", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2221", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5967", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:38:55.655Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:06:19.630Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:21:16.812Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T01:05:54.876Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:OGLwg7FSEXIU-QqVbz9j0u1Z7A1LSWe3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x5vRUc7DTFSfx5pt-br8CokXP4nGCKHW", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1186", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5968", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:39:42.568Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:29:37.031Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:21:53.015Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:29:25.314Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:wIMUjdBZx911VyM-5CXCOiUa7wwp0sj_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7eSQ_SJENIh9RJqKFIC_MtjExNqzuQdL", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2222", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5969", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:40:21.374Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:28:34.325Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:22:07.187Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:28:17.551Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ZWx7r2pfzwESK2cFK4EP7XJOuI8YHEBb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.83yWphFc1Hfr3VygXn2NWL6Rr2CzlkP3", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1627", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5970", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:41:09.767Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:27:12.698Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:22:21.646Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:26:59.706Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:J9ADN2GC5n3cWUOBHnOKAk58W1hYLRRK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nbhOgbpC-K2Blf-92OOjpkTF_5srfzPS", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2223", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5971", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:41:49.075Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:24:46.714Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:22:45.346Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:24:08.194Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:q0DddUV0kWI_owL9jeXEjBSzh0OpunUQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bTQroAvfd2NBts79PH2faeuM74FJxj6F", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:583", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5972", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-14T12:42:35.506Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:15:10.176Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T11:24:30.637Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2018-02-16T00:14:38.238Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2414", "type": "Document", "label": "Hainsworth et al., 2018, J. Clin. Oncol.", "xrefs": ["pmid:29320312"], "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:VxIBfvZEw5eZq_oceJrmaBCA8MmUC6j8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yYHDlGjad8ynXBXtWWvjxjk6mh80TUme", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2224", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:5987", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed molecular profiling was performed on a biopsy from a liver lesion that demonstrated an IDH1 mutation, R132H. The patient subsequently received a mutant IDH1 inhibitor (AG-120), but with no response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-02-14T20:05:44.282Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-05-01T22:32:29.835Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-15T14:20:27.246Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1360", "type": "Document", "label": "Brody et al., 2016, Cancer Biol. Ther.", "xrefs": ["pmid:27466707"], "title": "Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:-cuzVc4Iwlje9kbpivD1C97mGbQsZKsT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cXxt95ehS1vnyR-ZKhMNpx2eKUX136uo", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2049873", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9120", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:420", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:141", "type": "DiseaseDescriptor", "label": "Pancreatic Ductal Adenocarcinoma", "xrefs": ["DOID:3498"], "disease": "ncit:C9120"}, "object_descriptor": {"id": "civic.tid:454", "type": "TherapeuticDescriptor", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "DiseaseDescriptor", "label": "Cholangiocarcinoma", "disease": "ncit:C4436"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C114383"], "alternate_labels": ["AG-120", "Tibsovo"], "therapeutic": "rxcui:2049873"}}
{"id": "civic.eid:6006", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analysed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging  revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-02-23T19:57:20.738Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-20T22:30:58.473Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-20T22:31:28.654Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2359", "type": "Document", "label": "Cecchini et al., 2017, J Natl Compr Canc Netw", "xrefs": ["pmid:28874593"], "title": "EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ZcwYkNcgUEjc6_mbrU5wzfrOJ8T0TlSO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C8294", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:158", "type": "DiseaseDescriptor", "label": "Pancreatic Adenocarcinoma", "xrefs": ["DOID:4074"], "disease": "ncit:C8294"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:6049", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Of the 33 patients with desmoid fibromatosis treated with meloxicam, a COX-2 selective inhibitor, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD). The following 3 point mutations were identified in 21 of the 33 cases (64%): T41A (16 cases), S45F (4 cases) and S45P (one case). All four cases with S45F mutation exhibited strong nuclear expression of \u03b2-catenin. S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017)", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2018-03-21T13:24:04.597Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-10-08T17:54:19.533Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-10T18:28:05.981Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2444", "type": "Document", "label": "Hamada et al., 2014, PLoS ONE", "xrefs": ["pmc:PMC4006838", "pmid:24788118"], "title": "CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:0hoIa4py30Lc2plUqbSma_N0yeoxuCf0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RingEmHe_hOcfl7_z9yGuNisZTk6hX7t", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:41493", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9182", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1286", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2967", "type": "DiseaseDescriptor", "label": "Desmoid Tumor", "xrefs": ["DOID:80366"], "disease": "ncit:C9182"}, "object_descriptor": {"id": "civic.tid:572", "type": "TherapeuticDescriptor", "label": "Meloxicam", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C61439"], "alternate_labels": ["4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide", "Mobec", "Mobic", "Mobicox", "Movalis", "Movatec"], "therapeutic": "rxcui:41493"}}
{"id": "civic.eid:6181", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a G719A mutation, was administered a TKI, and an NSCLC progression was observed.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-05-31T18:53:48.219Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-05-31T19:52:03.498Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2473", "type": "Document", "label": "Locatelli-Sanchez et al., 2013, Lung", "xrefs": ["pmid:23749122"], "title": "Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:8BWVUx6L7AIpNzAzNwVUSFL87_5dQ0UJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.OrAPQnKf0Wz2BZoLDoTj3GSeiBeZvtGk", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:999", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:6182", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a R705K mutation, was administered a TKI, and an NSCLC progression was observed.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-05-31T19:00:45.048Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-05-31T19:48:07.683Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-05-31T19:57:26.087Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-05-31T19:59:11.597Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2473", "type": "Document", "label": "Locatelli-Sanchez et al., 2013, Lung", "xrefs": ["pmid:23749122"], "title": "Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:yQte4Wx8Z0bwt25UAmDalbuwQ3I5DlC_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1b-pmOjjn15NgYLUbE4Ns0I9F9x2U3gp", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2333", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:6312", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G13V was the only variant noted in the primary colon tumor of one patient who experienced disease progression (Patient 4; Supplemental Table 1) following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-02T20:41:24.700Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T21:58:13.432Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:00:22.096Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T19:50:54.086Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:00:24.954Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:eXKele_DCvlA2IX2tDVLrQCqLrEoogPO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.DHw8aeHVE1Bw1q7LpDgWpjVHH-T1Q81I", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1517", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:6314", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G12S was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment (colon tumor of patient 20; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-02T20:48:14.569Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T22:39:14.897Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:02:19.020Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T19:56:51.243Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T18:27:03.415Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:xMRkgWcF9MQ4btfF4IKjFT3NopdJrVrV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:6316", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12D was the only variant noted in the primary tumor of two patients who experienced stable disease  following treatment (Patients 22 and 36; colon and rectum tumors; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-02T20:55:09.393Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T22:08:05.717Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:11:10.387Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T19:57:43.588Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T18:27:56.775Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:BVsvGZk2a6c4OswSVRq5fHqz0Y0-0kJl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:6319", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12A was the only variant noted in the both the primary and metastatic colon tumors of one patient (Patient 29; Supplemental table 1) , and the primary colon tumor of another patient (104; Table S1),  who both experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T16:10:48.273Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T22:23:21.205Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:23:42.566Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T20:03:45.655Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T18:28:19.872Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:F1C5iDSiikDB82KtwXnKVpVjTbt8e-vO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:6320", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G13D was the only variant noted in the primary colon tumors of two patients who experienced partial response following treatment (Patients 37, 47; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T16:12:06.366Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T22:24:54.019Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:26:41.015Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T20:05:13.989Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T18:29:10.394Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:QAyQaIJFZFplXiWxLTYdGb7leu4LzLG9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:6322", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary rectal tumor of one patient who experienced disease progression following treatment (Patient 45; Supplemental Table 1). This is response is consistent with observations made of the larger cohort, where patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant. However, two other patients (37 and 47; Table S1) had G13D as their only noted variant, but experienced partial response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T16:14:22.656Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T22:31:54.468Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:33:05.864Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T20:04:44.254Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T18:29:27.374Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:QAyQaIJFZFplXiWxLTYdGb7leu4LzLG9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:6323", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12V was the only variant noted in the primary rectal tumor of one patient who experienced disease progression (patient 56; Supplemental Table 1), and the primary colon tumors of two patients (9, 13; Supplemental Table 1) who experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T16:15:29.484Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-11-02T22:10:58.015Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-02T22:14:59.678Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-03T19:52:22.212Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T18:29:35.397Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:176", "type": "Document", "label": "Sartore-Bianchi et al., 2009, Cancer Res.", "xrefs": ["pmid:19223544"], "title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:B2s4HFfio6NU41COFS-lZ4CgI4Nm7GvO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:7021", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 17-year-old Native American female with B-ALL had persistent MRD at the end of induction. In addition to a complex karyotype, sequencing revealed a novel F694L mutation in JAK2, a p.Cys119_Ile121delinsTrpGlyLeu in IKZF1, and a IGH-CRLF2 translocation, all consistent with BCR-ABL1 like B-ALL. In addition to conventional cytotoxic therapy, the patient was started on 40 mg/m2/day ruxolitinib TKI BID for 2 weeks on, 2 weeks off, and MRD diminished to <0.01% prior to allogeneic transplant. The patient was in remission with 100% engraftment from a full match sibling at day 100 post-transplant.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:766", "type": "Agent", "name": "Kristen Lipscomb Sund"}, "date": "2018-12-28T13:49:04.502Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-12-28T16:18:06.705Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2719", "type": "Document", "label": "Mayfield et al., 2017, Pediatr Blood Cancer", "xrefs": ["pmc:PMC5366086", "pmid:27860260"], "title": "Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:WDDD_CNR1WnHu7WQlqL90DTNtt07MWZd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QkL8LBuj8GTxSebrariDQEzGvFMWIMy_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1193326", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2587", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tid:386", "type": "TherapeuticDescriptor", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "DiseaseDescriptor", "label": "Graft versus host disease", "disease": "ncit:C3063"}, {"id": "hemonc:655", "type": "DiseaseDescriptor", "label": "Polycythemia vera", "disease": "ncit:C3336"}, {"id": "hemonc:635", "type": "DiseaseDescriptor", "label": "Myelofibrosis", "disease": "ncit:C3248"}]}}], "xrefs": ["ncit:C77888"], "alternate_labels": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"], "therapeutic": "rxcui:1193326"}}
{"id": "civic.eid:7288", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient 36 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V555_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off.  The patient experienced progressive disease. Time to progression and overall survival were 10 and 108 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-05-03T23:45:15.818Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-05-03T23:45:39.299Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:beL5xPqP7Yb8E-bx3SL-sZtMNsaJ2RuC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ATm0fufjEXHMpM_23Zg4F9-VBD5Ci_8d", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2695", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:7465", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, COS-7 cells expressing KIT D816V activating mutation demonstrated resistance to 1uM dasatinib treatment. In a separate in vitro study, TF-1 cells expressing KIT D816V activating mutation demonstrated resistance to 1 and 10 uM imatinib treatment. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation with addition of inhibitors. No reduction in D816V autophosphorylation was observed with inhibitor treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-08-05T23:08:31.903Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-05T23:11:19.861Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2054", "type": "Document", "label": "Vita et al., 2014, JAMA Dermatol", "xrefs": ["pmid:25317746"], "title": "Characterization of S628N: a novel KIT mutation found in a metastatic melanoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:rwQpLDPvEPU63MO_kA6Hns58HGOtAavu", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nMt7siwiRwJd_T_l46fg_fFaPZ7-H4sN", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1546019", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:65", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tcd:jKuLlWRt_pXwz9R2lQrLzMdihFWFZMMK", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SEQUENTIAL"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1546019", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}]}}
{"id": "civic.eid:7812", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 R367Q enriched to a variant allele frequency (VAF) of 25% at relapse and only a VAF of .02% at diagnosis. R367Q could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-10T14:06:51.171Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-23T23:38:48.480Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-01-23T23:39:55.941Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-23T23:23:36.475Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2020-01-14T17:54:02.517Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3131", "type": "Document", "label": "Meyer et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3681285", "pmid:23377183"], "title": "Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:Fnx09GkLk4-ccE9aEZZ-vlue-qXnODtg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3QL816E82t5euatEr_7eLqoMQzCfNrCC", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3168", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:238", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2991", "type": "DiseaseDescriptor", "label": "Childhood Acute Lymphocytic Leukemia", "xrefs": ["DOID:80144"], "disease": "ncit:C3168"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:8185", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before and after progression on venetoclax. The previously described BCL2 G101V mutation was observed in 1 patient at progression", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1002", "type": "Agent", "name": "Rashmi Kanagal-Shamanna, MD"}, "date": "2020-05-01T19:52:17.909Z", "activity": {"type": "Coding", "label": "submitted"}}], "is_reported_in": [{"id": "civic.source:3376", "type": "Document", "label": "Lucas et al., 2020, Blood", "xrefs": ["pmid:32232486"], "title": "Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:1908XknC4RFiIq__2oShugEQ7Cy6H-_b", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.W2DykRCbXOXmqZLLiZeELFbtnqJvuqOW", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1747556", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C27911", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2960", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:191", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma", "xrefs": ["DOID:6354"], "disease": "ncit:C27911"}, "object_descriptor": {"id": "civic.tid:574", "type": "TherapeuticDescriptor", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:581", "type": "DiseaseDescriptor", "label": "Chronic lymphocytic leukemia", "disease": "ncit:C3163"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C103147"], "alternate_labels": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"], "therapeutic": "rxcui:1747556"}}
{"id": "civic.eid:8375", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-26T18:54:11.450Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-02T23:38:03.509Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-02T23:38:09.282Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3502", "type": "Document", "label": "Blombery et al., 2019, Br. J. Haematol.", "xrefs": ["pmid:31234236"], "title": "Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:b-ICx3_0XquQYSfb0KiMLHPo_W7H6wlC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._ZzqdXiiqCOs9iTFtw5ac6N6_lT9vbfe", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1747556", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3209", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3082", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:51", "type": "DiseaseDescriptor", "label": "Follicular Lymphoma", "xrefs": ["DOID:50873"], "disease": "ncit:C3209"}, "object_descriptor": {"id": "civic.tid:574", "type": "TherapeuticDescriptor", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:581", "type": "DiseaseDescriptor", "label": "Chronic lymphocytic leukemia", "disease": "ncit:C3163"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C103147"], "alternate_labels": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"], "therapeutic": "rxcui:1747556"}}
{"id": "civic.eid:8933", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One 56 year old female with advanced recurrent low grade serous ovarian cancer with NRAS Q61K mutation had a partial response to trametinib, with short follow-up.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:143", "type": "Agent", "name": "Klaus Metzeler"}, "date": "2020-11-28T09:26:01.788Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-28T17:12:39.393Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-28T17:09:05.034Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3765", "type": "Document", "label": "Champer et al., 2019, Gynecol Oncol Rep", "xrefs": ["pmc:PMC6374783", "pmid:30809568"], "title": "Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:ao2T-HOaCkF9jdy9eshLotx13HaUOkwn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NHUtQ1IbZA9ZlH8wKbaMNF0W7esiwPKj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7550", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:427", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1432", "type": "DiseaseDescriptor", "label": "Ovary Serous Adenocarcinoma", "xrefs": ["DOID:5744"], "disease": "ncit:C7550"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:9377", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A phase I safety and dose-escalation study (NCT01897571) was completed for tazemetostat in relapsed or refractory B-cell non-Hodgkin lymphoma or advanced solid tumors. Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. EZH2 mutation status was assessed retrospectively. Two DLBCL patients had mutations. One of these (with a Y646H mutation) had a durable partial response before disease progression after 16 months on study. The variant in the second patient was not reported and the duration of therapy for this patient that did not respond was among the shortest in the trial.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2021-06-11T16:32:57.985Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2021-06-11T17:02:23.933Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2021-06-11T17:11:59.859Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2021-06-11T17:00:53.924Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2517", "type": "Document", "label": "Italiano et al., 2018, Lancet Oncol.", "xrefs": ["pmid:29650362"], "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:0puGnLIQlml4SibZlcrsDtU-_OJjJDeD", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4FXzRDEsDlQTLRAMaSVhLEuX-rZdv01X", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2274378", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C8851", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3364", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:45", "type": "DiseaseDescriptor", "label": "Diffuse Large B-cell Lymphoma", "xrefs": ["DOID:50745"], "disease": "ncit:C8851"}, "object_descriptor": {"id": "civic.tid:411", "type": "TherapeuticDescriptor", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "xrefs": ["ncit:C107506"], "alternate_labels": ["E7438", "EPZ-6438", "EPZ6438", "N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide", "N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide"], "therapeutic": "rxcui:2274378"}}
{"id": "civic.eid:1191", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab.\nNGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%). Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response. The patient remained almost asymptomatic and without disease progression after 39 weeks.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-03-30T12:27:54.429Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-03-31T07:08:38.841Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-04-08T02:05:50.497Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-03-31T07:08:13.758Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-04-08T02:05:17.647Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:822", "type": "Document", "label": "Loaiza-Bonilla et al., 2016, Cureus", "xrefs": ["pmc:PMC4780686", "pmid:27004155"], "title": "KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:iJT5LfU8R1zg2Iv36stjPCMrLpbs4i59", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.c-Zrgkno33ozKUU94B2xyEN-8dFd4CXn", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C5105", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:502", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:57", "type": "DiseaseDescriptor", "label": "Colorectal Adenocarcinoma", "xrefs": ["DOID:50861"], "disease": "ncit:C5105"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:1396", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with stage IV lung adenocarcinoma and a 15\u2013base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-24T10:15:48.847Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-07T23:57:16.335Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:946", "type": "Document", "label": "Yu et al., 2015, JAMA Oncol", "xrefs": ["pmc:PMC4665629", "pmid:26181354"], "title": "Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:3wMlYtsfA0N3xrZv3C5yjv6DPAD2Psnb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.xBOuXRHMA9-vqyYsZPx1_E6lOIoZZbs0", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:415", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:1397", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report of a patient with stage IV lung adenocarcinoma and a 15\u2013base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-24T10:16:43.175Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-09-11T19:53:59.808Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-08T00:00:13.360Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:946", "type": "Document", "label": "Yu et al., 2015, JAMA Oncol", "xrefs": ["pmc:PMC4665629", "pmid:26181354"], "title": "Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:hyS_zXBas4tpONalpRnKiSbRf7S8X4eS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:1550", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T14:08:20.021Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-08T05:08:54.447Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-09T20:09:44.731Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-08T05:08:59.260Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1026", "type": "Document", "label": "Dolly et al., 2016, Clin. Cancer Res.", "xrefs": ["pmc:PMC4876928", "pmid:26787751"], "title": "Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:P07KNaw0Z5jV_4icmVn3tthVbC7NS_3D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C91731", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:377", "type": "TherapeuticDescriptor", "label": "Apitolisib", "xrefs": ["ncit:C91731"], "alternate_labels": ["GDC 0980", "GDC-0980", "GNE 390", "RG 7422"], "therapeutic": "ncit:C91731"}}
{"id": "civic.eid:1554", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and panitumumab). The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months. No response was observed after cetuximab was given as a third line therapy. The second patient received panitumumab with FOLFOX and showed no signs of progression for 8 months with reduction of the size of metastases.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2016-07-15T16:14:08.316Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T16:29:19.934Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-16T21:26:46.526Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-16T21:26:48.968Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1027", "type": "Document", "label": "Amaki-Takao et al., 2016, Oncology", "xrefs": ["pmid:27404270"], "title": "Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:qG7jyYemxLZief25JK1hfUcDBjH9Zky_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:611", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:1787", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:258", "type": "Agent", "name": "Rodrigo Dienstmann"}, "date": "2016-12-02T10:33:22.251Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-05-13T00:53:09.322Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-05-18T17:22:22.029Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-05-18T17:22:01.900Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1244", "type": "Document", "label": "Klughammer et al., 2016, J Thorac Oncol", "xrefs": ["pmid:26773740"], "title": "Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:j6Nc53AM9y8K_4rwGxqHXdVEZv3AJNt8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KPoLdDgwIyBvW9JyoGxYdwor1UEAhanp", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:724", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:1905", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-02-13T12:58:01.343Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-08-31T19:47:16.103Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1336", "type": "Document", "label": "Hong et al., 2016, Cancer Discov", "xrefs": ["pmid:27729313"], "title": "Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:HBc2KPUmat7dVZ-_ahqQ-wa7Mz9BgEYd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wr2xPRTIoPPfVsO621LkxXquZuv1H_7C", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:825", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:rF1JcnGq_-VTc0yiCsNIORfNqXQCC3yM", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2204", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 68 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 18 weeks; OS: 34 weeks). Authors considered stable disease as both clinical benefit and non response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:55.134Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-02T00:10:06.080Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:10:21.476Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-17T21:18:52.548Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:10:45.346Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:GiP8Vs6A8vC091Xus7zNKHgxFApjmtsG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.6ZS84FXRs9aO5v0z-XrD3UPSBr3DivZf", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:896", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:E39_bNJqxD2YlQvEbnaYPTYj7A6sKF3V", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:2465", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This patient was from a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in the study were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored a homozygous deletion of KIT codons 484 to 487 (KHNG; K484_G487del).  The patient's response to imatinib was not assessed, and the TTP was 46.9 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:32.735Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-08T17:50:40.046Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-08T17:50:48.328Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-08T17:50:50.103Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1586", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651078", "pmid:18955451"], "title": "Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:v2lQhN7Q1GiJY_5h_6i_OJVFdV7M3Nkd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.meF24rocahMNLkWZ-p_ZDry4oAb0HBjH", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2622", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2474", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This case study examines one patient from a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in this cohort were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored PDGFRA exon 12 V561D. The patient was treated with 800mg of imatinib per day, and had not progressed or died as of 31 months of follow up (vs median TTP of 12.8 months for WT).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:47.268Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-08T18:32:07.390Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-08T18:32:27.370Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-08T18:32:29.249Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1586", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651078", "pmid:18955451"], "title": "Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:5iZl5ZGPxlSB1E0FmhiBUc8Wxb5dKp_m", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PmR2KGO2d96zDOFtI79sijmIhGO2v-a0", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:941", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2624", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:31.521Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-07-21T03:52:04.354Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-08T20:52:25.158Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-08T20:52:28.542Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1509", "type": "Document", "label": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC516528", "pmid:15329413"], "title": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:oFB8FgJ0_PfyHhfsmd_FIJAT8Ya8BtjH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2934", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-04-11T09:15:37.576Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T20:12:15.704Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-04-19T09:09:33.185Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T20:12:20.028Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:381", "type": "Document", "label": "Awad et al., 2013, N. Engl. J. Med.", "xrefs": ["pmc:PMC3878821", "pmid:23724914"], "title": "Acquired resistance to crizotinib from a mutation in CD74-ROS1."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:1CEPHzEDc_HEY_V69jdLm_0j452OoEGz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5CsNnz26PLs2l1QXVplEHgNRPXpEX9oz", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1271", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:3842", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 50 year old male treated with panitumumab monotherapy as 3rd line therapy (discontinued for toxic/biochemical reasons) who experienced stable disease (PFS: 22 weeks; OS: 74 weeks). Authors considered stable disease as both clinical benefit and non-response", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:20.406Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-02T00:14:35.359Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:15:20.580Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-17T21:41:08.280Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-12-02T00:15:31.974Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:J_mkvnkTX-U3wggh8vsxUw11FCl2Fqc0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.6ZS84FXRs9aO5v0z-XrD3UPSBr3DivZf", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:263034", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:896", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}}
{"id": "civic.eid:4047", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and NRAS, and had individual response data. Patient characteristics are as follows: a 48 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 72 weeks, OS: 105 weeks); a 46 year old male treated with cetuximab monotherapy as 5th line therapy who experienced stable disease (PFS: 24 weeks, OS: 57 weeks); a 61 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 12 weeks, OS: 45 weeks). The response rate was 0/3 and the clinical benefit rate was 2/3 according to author criteria.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:20.596Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:06:19.633Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:06:34.575Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-25T23:07:16.519Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-11-25T23:07:52.661Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:76", "type": "Document", "label": "De Roock et al., 2010, Lancet Oncol.", "xrefs": ["pmid:20619739"], "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:rVF9idZgAaQMyRCt9jxUhPlu9AbDEvIv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.HH5UAG0bBYrpvHa1oxXJ1rvff1bkgh3N", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:930", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4475", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L298V evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:12.289Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-07-19T20:49:46.590Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T21:09:44.010Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T21:10:17.376Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1996", "type": "Document", "label": "Cortes et al., 2011, Blood", "xrefs": ["pmc:PMC4916618", "pmid:21865346"], "title": "Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:7LWMkzreOqsxfBBc2J2pkyzIQE8mSinH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hn3DNg2NmqN3kJG0GMqDgwHf7ikewT6n", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1506", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:4", "type": "DiseaseDescriptor", "label": "Chronic Myeloid Leukemia", "xrefs": ["DOID:8552"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "civic.tid:520", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C60809"], "alternate_labels": ["4-Anilino-3-quinolinecarbonitrile", "4-Anilinobenzo(g)quinoline-3-carbonitrile", "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile", "Bosulif", "SKI 606", "SKI-606"], "therapeutic": "rxcui:1307619"}}
{"id": "civic.eid:4768", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with C475V, 1/1 had a CHR and 1/1 had a MCyR. 9 patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:35.501Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-11-16T21:28:39.230Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-16T21:33:42.144Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-16T21:33:44.706Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1997", "type": "Document", "label": "Khoury et al., 2012, Blood", "xrefs": ["pmc:PMC4916559", "pmid:22371878"], "title": "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:uAUFd3G713OgSifeqn-1SFpQMkgksdl8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AHjZBfY5TFrI_jqv4JDA9cYRcszQgGEs", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1307619", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1639", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:4", "type": "DiseaseDescriptor", "label": "Chronic Myeloid Leukemia", "xrefs": ["DOID:8552"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "civic.tid:520", "type": "TherapeuticDescriptor", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "DiseaseDescriptor", "label": "chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C60809"], "alternate_labels": ["4-Anilino-3-quinolinecarbonitrile", "4-Anilinobenzo(g)quinoline-3-carbonitrile", "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile", "Bosulif", "SKI 606", "SKI-606"], "therapeutic": "rxcui:1307619"}}
{"id": "civic.eid:6977", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in a single imatinib resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-11-16T21:32:18.704Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-11-16T21:43:57.431Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-16T21:44:24.421Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-16T21:44:26.141Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1997", "type": "Document", "label": "Khoury et al., 2012, Blood", "xrefs": ["pmc:PMC4916559", "pmid:22371878"], "title": "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure."}], "evidence_level": {"id": "vicc:e00008", "type": "Coding", "label": "case study evidence"}, "target_proposition": {"id": "proposition:OkCSaam8k4VEyisfYEPWWicwq7a91GE7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AHjZBfY5TFrI_jqv4JDA9cYRcszQgGEs", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3174", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1639", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:4", "type": "DiseaseDescriptor", "label": "Chronic Myeloid Leukemia", "xrefs": ["DOID:8552"], "disease": "ncit:C3174"}, "object_descriptor": {"id": "civic.tid:537", "type": "TherapeuticDescriptor", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C1687"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:1738", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2016-11-08T13:10:43.995Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-25T22:29:53.450Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-08T21:37:37.714Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-08T21:37:58.847Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1184", "type": "Document", "label": "Noeparast et al., 2016, Oncotarget", "xrefs": ["pmid:27577079"], "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7wO8tipEVHK4eCP4wYBtdiMbOFLlUToY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rKg5FjSjGdNSsJt-49egT_8M0jwyr3SK", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:694", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:oBrlcO23adoVXv51xh-5Wigy0QyDWtfr", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:2251", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:19.064Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:28:16.903Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:28:05.057Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1421", "type": "Document", "label": "Rowley et al., 2002, Oncogene", "xrefs": ["pmid:12483530"], "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2262", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:20.141Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:27:34.395Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:27:25.682Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1421", "type": "Document", "label": "Rowley et al., 2002, Oncogene", "xrefs": ["pmid:12483530"], "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:3852", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:27.926Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-10T00:25:28.510Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-10T00:20:06.638Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:457", "type": "Document", "label": "Boidot et al., 2016, Int J Colorectal Dis", "xrefs": ["pmid:26561417"], "title": "HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:rl15SJVWBcTSoLV9ekPoImS2oHUvoDKe", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Z1VxpmB2Ui54Nd4GCsBXMjb2WDaCU7Ja", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:274", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:3878", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:36:58.711Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T17:06:51.090Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T17:03:59.865Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2008", "type": "Document", "label": "Misale et al., 2012, Nature", "xrefs": ["pmc:PMC3927413", "pmid:22722830"], "title": "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4190", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:42:04.361Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:45:34.285Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:44:01.342Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hiW8cTHi4T9g6Chhtzppeft3lT_JhDYh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3PO39DSennfsuKhGmlGEImSRA0C1WDjN", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:134", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4197", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:42:21.766Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:40:11.950Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:38:33.252Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:QJpfIZ3IVS7NlbC0WTgBMS9zk3XtM0Po", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.pof-6-XZQl9IFVDWdMN-wQUYSH60sK-B", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1001", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4266", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L747_P753>S and EGFR L858R expressing cells were 5 nmol/L and 6 nmol/L, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:46:58.816Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:36:45.006Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:34:48.449Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:BIhjzWPzRKqaVmy2NWOEtBoo8hJJ2bsJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jIytcqDhenXpXhAKfPqA6tsDvS5i6SEU", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1012", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4275", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:47:38.334Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T10:48:20.007Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T10:47:15.731Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:I-O-rFrpcn2PWnlSGceqgDqpvugLi8gY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7mGWSx_S9atbu6nmmozfM0lGdON1_B1M", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1445", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4276", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:47:40.237Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T11:15:10.591Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T11:11:05.814Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:tAUDE3IbJ1kw4s__ICwhWSnVDc2zf5hr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.42kjfaZSad5lp3V-01dETLJd1nsBcU0k", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1446", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4279", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a COS-7 cell line expressing EGFR R831H demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:47:50.539Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-19T00:37:06.223Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-18T23:34:24.533Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2081", "type": "Document", "label": "Foster et al., 2010, World J Surg Oncol", "xrefs": ["pmc:PMC2970593", "pmid:20942962"], "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Opk3fp9I-aCS4TQ_RXnZ4AIwXTR9OlY7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.zyQIL9ViKjvmBzThXMzh3O-IoxJsBZQ8", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4456", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1017", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:112", "type": "DiseaseDescriptor", "label": "Malignant Mesothelioma", "xrefs": ["DOID:1790"], "disease": "ncit:C4456"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4287", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:21.657Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-17T21:37:42.058Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:04.861Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2070", "type": "Document", "label": "Ray et al., 2016, Oncotarget", "xrefs": ["pmc:PMC5356576", "pmid:27612423"], "title": "Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:teH1xxIK6r4jpsaY8NccNewpkJ0YcjYX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4301", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a COS-7 cell line expressing EGFR E868G demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:58.442Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-19T00:36:04.336Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-18T23:34:00.866Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2081", "type": "Document", "label": "Foster et al., 2010, World J Surg Oncol", "xrefs": ["pmc:PMC2970593", "pmid:20942962"], "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9gTBU6aOWWKge6cXMJ1SikisKJaZy_a9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TlRrtAAlXs-0LggDQNQC65LqqQyAt24C", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4456", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1482", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:112", "type": "DiseaseDescriptor", "label": "Malignant Mesothelioma", "xrefs": ["DOID:1790"], "disease": "ncit:C4456"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4468", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:07.198Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:00:35.978Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T10:56:35.530Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:2XwuEh9gm8s37cGlijxK6ydl6-gNKHHT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MsTpDu-QSsQpjdcpMYx9u-qXM3l5ueqM", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1181", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4487", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a HCT116 cell line expressing ARID1A Q456* mutation demonstrated increased sensitivity to dasatinib treatment, compared to HCT116 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:20.838Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T20:36:57.224Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T20:39:53.966Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1706", "type": "Document", "label": "Miller et al., 2016, Mol. Cancer Ther.", "xrefs": ["pmid:27364904"], "title": "Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hubibB1GZzkf4vYfbZd87Zj8xHOpHTNV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ruYFoQ7uE8C1lpUOdwQFiIFh4sTzQMcX", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C40077", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1510", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:88", "type": "DiseaseDescriptor", "label": "Ovarian Clear Cell Carcinoma", "xrefs": ["DOID:50934"], "disease": "ncit:C40077"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:4495", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:30.992Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-15T00:35:31.754Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-15T00:32:16.205Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:bn-bXmaLW0rSmvDJYcrH5_5l71V1MlJj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.uqLzgiFp4z1SrCDTfu3f_Z8QWuSD8ZC7", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1187", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4496", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:31.829Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-14T22:58:15.847Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-14T22:50:58.970Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:zXyPJBZeTDeQ1UbaBeoiQ8bRIXH6Bf6s", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.n1UECm1S3T-cN7jwEzR_mNZASK1itHDz", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1188", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4497", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Ba/F3 and BID007 cell lines expressing EGFR A763_Y764insFQEA demonstrated increased sensitivity to erlotinib treatment (IC50=0.048\ufffdM and 0.082\ufffdM, respectively), comparable to Ba/F3 and NCI-H3255 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=0.006\ufffdM and 0.068\ufffdM, respectively). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:32.655Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T11:32:18.322Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T11:29:18.823Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8_0VbCdPN7MyeRhc8FZ-w3MSfFWH4e7R", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.WF4OU3_AFjbZd5cwZJ7QB-MIoZncHxV_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1515", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4653", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild-type SMO. Resistance was determined by assessing GLI1 mRNA expression levels.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:45.550Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-20T16:00:55.498Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-20T16:00:58.066Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:493", "type": "Document", "label": "Atwood et al., 2015, Cancer Cell", "xrefs": ["pmc:PMC4357167", "pmid:25759020"], "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:h9ZSDTDg9jNJDXIzMlKZUPlbeN0EIxaG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.8f8ZfbLyMJvGCXConL8k3JWsKG430vJp", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1242987", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2921", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1570", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:314", "type": "DiseaseDescriptor", "label": "Basal Cell Carcinoma", "xrefs": ["DOID:2513"], "disease": "ncit:C2921"}, "object_descriptor": {"id": "civic.tid:190", "type": "TherapeuticDescriptor", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "DiseaseDescriptor", "label": "Cutaneous basal cell carcinoma", "disease": null}]}}], "xrefs": ["ncit:C74038"], "alternate_labels": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"], "therapeutic": "rxcui:1242987"}}
{"id": "civic.eid:4656", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a COS-7 cell line expressing EGFR E734Q demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:47.647Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-19T00:34:04.938Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-18T23:32:47.508Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2081", "type": "Document", "label": "Foster et al., 2010, World J Surg Oncol", "xrefs": ["pmc:PMC2970593", "pmid:20942962"], "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qSUDAPRgLkw7fFalFZrHePAxcqnH1V3s", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.LtmIc7A-UZ4aT62DbTrajMOqOoeM4WB8", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4456", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1572", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:112", "type": "DiseaseDescriptor", "label": "Malignant Mesothelioma", "xrefs": ["DOID:1790"], "disease": "ncit:C4456"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4657", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a COS-7 cell line expressing EGFR T785A demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:48.364Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-19T00:33:03.315Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-18T23:32:25.329Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2081", "type": "Document", "label": "Foster et al., 2010, World J Surg Oncol", "xrefs": ["pmc:PMC2970593", "pmid:20942962"], "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:RW1KvTd5Hbt-OSOiXYcjvlsORsL2coTz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.B0L282OI99NcF9d1wqf1YZzX04mebGuc", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4456", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1573", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:112", "type": "DiseaseDescriptor", "label": "Malignant Mesothelioma", "xrefs": ["DOID:1790"], "disease": "ncit:C4456"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4658", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a COS-7 cell line expressing EGFR C797Y demonstrated increased sensitivity to erlotinib treatment, compared to COS-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:49.183Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-19T00:32:11.283Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-18T23:32:06.882Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2081", "type": "Document", "label": "Foster et al., 2010, World J Surg Oncol", "xrefs": ["pmc:PMC2970593", "pmid:20942962"], "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:LNiSw5UbGR7-sbae7SEZ0oAoa4-sUrg6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eVxGJxa_W_CdChZJofMdLKeb9mZfiAGh", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4456", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1574", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:112", "type": "DiseaseDescriptor", "label": "Malignant Mesothelioma", "xrefs": ["DOID:1790"], "disease": "ncit:C4456"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4799", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:56:03.440Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T10:45:06.373Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T10:43:49.847Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8YIPHaXac1NC90KdW9FyuSSlJ_4l93VJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.fh5YuhsxAYO5fM2TAnC_B64fecZt_Hpg", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1664", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4800", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:56:04.116Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T10:41:54.010Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T10:35:51.805Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:vyph_wdBk5fhsiaoiyETTCiJFW-u7pd3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.uCosmcfK9BBelNIYMnmfyt99VCrN-evo", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1665", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:241", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.433Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.433Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7moptChVfqiycrzl50WUxBJWXk6UIkOO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Gb-3idkBuAo7OTK9h1VU76Re2uWRfCnk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:480167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:39", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}}
{"id": "civic.eid:281", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.961Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2021-12-31T21:33:36.151Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-31T22:22:10.194Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.961Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:dPj7tkxP9flu70sdDlZLYNwhsftqGV9N", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gb8REjJatcpIgb1B3LKiIDI4DhJd70Bk", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:37", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:282", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.993Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-09-13T07:15:09.423Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.993Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hfH1o3OTqF41k4Txn7vK8qlQTCLx5c2-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3P7YFnWviseBjIu47efiz9U5fIZu9lLh", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:38", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:283", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.035Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.035Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lA98S9COajq1aiyS82mIFvKsLeN0la7U", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Gb-3idkBuAo7OTK9h1VU76Re2uWRfCnk", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:39", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:284", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.066Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.066Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Ly4MPu-_AESVtB3C5sy1fg4KPPsCN0cY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.kRHG_C2MeeeJSYOB0uOfSzf-z-L2XxCK", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:40", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:286", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.129Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T22:41:31.202Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-05-31T15:40:02.271Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.129Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:KTZKVJ3KEvdu72EHv4mKxz6xFi6cCvSP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wvgGKsvEghsBXGSOXRrcBnon5YeWKoQq", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:42", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:bf_BuyNMwaqXScLEAS5F0_LZZf1t1H2f", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}]}}
{"id": "civic.eid:287", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.162Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.162Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:L-SOQ9eK9fbI3oS9meDjw8YrF_lqkJM9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2h6g2RkbhEbyCbzwBscKijV6CsLw2XZA", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:43", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:288", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.200Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-09-13T07:05:13.806Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.200Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:S6XSsZMud_7JZrzrSJL3ls7XP0woxT3E", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4XK29Fat7-Qy7WpPdFMMCK15FaEC-O5O", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:44", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:289", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.241Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.241Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Ypuz2E97dAvHomf9LKUyuh7aQUVigoQO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UODigU-kVH-oc3cGpEfL8RBPYzZuxbRJ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:45", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:290", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the L536Q ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.277Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T22:57:59.060Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-31T01:23:57.973Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.277Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:30", "type": "Document", "label": "Robinson et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC4009946", "pmid:24185510"], "title": "Activating ESR1 mutations in hormone-resistant metastatic breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ItNejPNkgDcGDld-TTo8skzSaxu_oHK-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5ZOkJ_z4WY-prWoX_bz-OKTLxQAAhME0", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:46", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:Dsj0jsyr-fQXgAxQL6jcaLTVy4zoAdvF", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:53", "type": "TherapeuticDescriptor", "label": "Tamoxifen", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62078"], "alternate_labels": ["1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene"], "therapeutic": "rxcui:10324"}, {"id": "civic.tid:54", "type": "TherapeuticDescriptor", "label": "Fulvestrant", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1379"], "alternate_labels": ["7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol", "Faslodex", "Faslodex(ICI 182,780)", "ICI 182,780", "ICI 182780", "ZD9238"], "therapeutic": "rxcui:282357"}]}}
{"id": "civic.eid:291", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the N538G ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.315Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T23:03:48.727Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-31T01:24:19.313Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.315Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:30", "type": "Document", "label": "Robinson et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC4009946", "pmid:24185510"], "title": "Activating ESR1 mutations in hormone-resistant metastatic breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:cOjwyrHKYzwLlsgGnWCHnLxCGSL3BMJI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VUrBmnIanxIELmkweHMA-oSus-zpdjyL", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:47", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:Dsj0jsyr-fQXgAxQL6jcaLTVy4zoAdvF", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:53", "type": "TherapeuticDescriptor", "label": "Tamoxifen", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62078"], "alternate_labels": ["1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene"], "therapeutic": "rxcui:10324"}, {"id": "civic.tid:54", "type": "TherapeuticDescriptor", "label": "Fulvestrant", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1379"], "alternate_labels": ["7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol", "Faslodex", "Faslodex(ICI 182,780)", "ICI 182,780", "ICI 182780", "ZD9238"], "therapeutic": "rxcui:282357"}]}}
{"id": "civic.eid:292", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537C ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.353Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T23:04:29.770Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-31T01:24:51.226Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.353Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:30", "type": "Document", "label": "Robinson et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC4009946", "pmid:24185510"], "title": "Activating ESR1 mutations in hormone-resistant metastatic breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7bQvS2jojvUv93hWriUsvRM2j6rH9OeP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.FApHkwk1OD_nXJmrzBf7xUP9z0NtWl2q", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:48", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:Dsj0jsyr-fQXgAxQL6jcaLTVy4zoAdvF", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:53", "type": "TherapeuticDescriptor", "label": "Tamoxifen", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62078"], "alternate_labels": ["1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene"], "therapeutic": "rxcui:10324"}, {"id": "civic.tid:54", "type": "TherapeuticDescriptor", "label": "Fulvestrant", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1379"], "alternate_labels": ["7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol", "Faslodex", "Faslodex(ICI 182,780)", "ICI 182,780", "ICI 182780", "ZD9238"], "therapeutic": "rxcui:282357"}]}}
{"id": "civic.eid:293", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537N ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.393Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T23:05:29.346Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-31T01:25:14.467Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.393Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:30", "type": "Document", "label": "Robinson et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC4009946", "pmid:24185510"], "title": "Activating ESR1 mutations in hormone-resistant metastatic breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:PL8ceCYCa41HSkUx3w69lVJPd0GWjOQt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.P0nisTOh1cxoPjsVBzFL8qpbkMitw2Qf", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:49", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:Dsj0jsyr-fQXgAxQL6jcaLTVy4zoAdvF", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:53", "type": "TherapeuticDescriptor", "label": "Tamoxifen", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62078"], "alternate_labels": ["1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene"], "therapeutic": "rxcui:10324"}, {"id": "civic.tid:54", "type": "TherapeuticDescriptor", "label": "Fulvestrant", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1379"], "alternate_labels": ["7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol", "Faslodex", "Faslodex(ICI 182,780)", "ICI 182,780", "ICI 182780", "ZD9238"], "therapeutic": "rxcui:282357"}]}}
{"id": "civic.eid:294", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537S ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.435Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T23:06:27.172Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-31T01:18:54.128Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.435Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:30", "type": "Document", "label": "Robinson et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC4009946", "pmid:24185510"], "title": "Activating ESR1 mutations in hormone-resistant metastatic breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ZlFiOQ3VvscShssp4U38gLKdgyjvu92V", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PnJlRfBCZ6YxYPGMNHJQkxYTWrmTr0M4", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:50", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:Dsj0jsyr-fQXgAxQL6jcaLTVy4zoAdvF", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10324", "type": "Therapeutic"}, {"id": "rxcui:282357", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:53", "type": "TherapeuticDescriptor", "label": "Tamoxifen", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62078"], "alternate_labels": ["1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene"], "therapeutic": "rxcui:10324"}, {"id": "civic.tid:54", "type": "TherapeuticDescriptor", "label": "Fulvestrant", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1379"], "alternate_labels": ["7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol", "Faslodex", "Faslodex(ICI 182,780)", "ICI 182,780", "ICI 182780", "ZD9238"], "therapeutic": "rxcui:282357"}]}}
{"id": "civic.eid:642", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:85", "type": "Agent", "name": "Maira Pires"}, "date": "2015-10-27T18:39:47.030Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2015-10-27T23:44:38.619Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:405", "type": "Document", "label": "Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC2538882", "pmid:18227510"], "title": "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lwhcNcjj--RjLfSQS4HtQdJ3nBPc4Crv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "ncit:C48369", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C7377", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:23", "type": "DiseaseDescriptor", "label": "Lung Cancer", "xrefs": ["DOID:1324"], "disease": "ncit:C7377"}, "object_descriptor": {"id": "civic.tcd:52k4gMOXAfLSe2V5I5XjawdIEXJV5QRW", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SEQUENTIAL"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "ncit:C48369", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:90", "type": "TherapeuticDescriptor", "label": "Multikinase Inhibitor AEE788", "xrefs": ["ncit:C48369"], "alternate_labels": ["AEE 788", "AEE-788", "AEE788"], "therapeutic": "ncit:C48369"}]}}
{"id": "civic.eid:6376", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony formation (P = 0.0004) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment was rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, siRNA facilitated depletion of ABL1 expression resulted in significantly increased cytotoxicity (P < 0.004) with no significant change in H2126 or Beas-2B lines for 2/3 siRNAs supporting ABL1 as the primary drug target. Significant tumor reduction was observed in murine NSCLC xenografts of the H1915 cell line treated with imatinib compared to vehicle treatment (P = 0.0016). No change in tumor growth was observed in xenografts of the H650 cell line containing a wildtype ABL1 locus. In both in vitro and in vivo experiments, doxycycline-inducible expression of drug-resistant ABL1-T315I rescued imatinib-mediated inhibitory effects supporting the specificity of drug responses.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-07-11T16:25:28.378Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-11-05T23:11:34.663Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-05T23:11:49.190Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-05T23:10:28.792Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2128", "type": "Document", "label": "Testoni et al., 2016, EMBO Mol Med", "xrefs": ["pmc:PMC4734836", "pmid:26758680"], "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7ZHTu2Xx9UckWuMC1MScQl1IYpJ1IRKn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KUWRWYBQPf83j33qhkDlkVqzIutJWdfu", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1656", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:7416", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary imatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Imatinib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = >10000 nM) showed resistance towards Imatinib compared to Ba/F3 cells with del 557-558 alone (IC50 = 27 +- 8 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (IC50 > 5000 nM) did show resistance towards Imatinib compared to GIST-T1 cells with 560-578 deletion (IC50 = 30 nM). Del 557-558/T670I cells were implanted into mice and treated with Imatinib. Imatinib was not effective in treating the del 557-558/T670I cells in mice as tumor volume progressively increased. In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Imatinib. In Imatinib incubated cells, T670I mutations were seen in approximately 80% of the resistant cell populations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-22T22:40:45.627Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-22T22:48:28.511Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T22:48:48.251Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T22:48:51.084Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JDcfHBvflIH4S_Pj1ZEfO1ViJiZTLwol", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:7417", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary ponatinib and sunitinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Ponatinib and Sunitinib resistances. Ba/F3 cells with del 557-558/T670I mutations (Ponatinib IC50 = 15 +/- 1 nM, Sunitinib IC50 = 12 +/- 2 nM) did not show resistance towards Ponatinib and Sunitinib compared to Ba/F3 cells with del 557-558 alone (Ponatinib IC50 = 3 +/- 0, Sunitinib IC50 = 7  +/- 2 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (Ponatinib IC50 = 8 nM, Sunitinib IC50 = 15 nM) showed no resistance towards Ponatinib and Sunitinib compared to GIST-T1 cells with 560-578 deletion (Ponatinib IC50 = 5 nM, Sunitinib IC50 = 48 nM). Additionally, del 557-558/T670I cells was implanted into mice and treated with Ponatinib or Sunitinib. Ponatinib or Sunitinib were shown to be effective in treating the Ba/F3 mutant cells as tumor volume progressively decreased to zero at around 14 days.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-22T23:03:52.059Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-22T23:19:04.139Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T23:19:11.407Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T23:19:14.146Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lrau5mLVYzdYIaCKS1ZxQJT8KEk5tFgj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:f0IOBQHIv94-aVcb5dMKA9rkPpDFY0jD", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:7907", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 S103T in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed S103T cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. S103T cells produce increased intracellular concentrations of hypoxanthine and IMP.  Also, after 6-MP exposure, S103T cells display reduced levels of DNA damage response and apoptosis protein markers. \n\nS103T results in the activation of the de novo purine synthesis pathway by reducing feedback inhibition, allowing the cell to continue to create nucleotides even when concentrations are elevated. This overactivation creates increased hypoxanthine levels, which likely competitively inhibit thiopurine conversion. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:06:11.159Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:18:47.872Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-02-25T23:37:46.787Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T09:02:48.158Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-4DhZi-Te2Jw2ejtIlP8tzVds3nwL043", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.kpxAsgdLxoYy3CJzjViN0HPWYG6Ry_Sv", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2927", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7909", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 A190T in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed A190T cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. A190T cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, A190T cells display reduced levels of DNA damage response and apoptosis protein markers. \n\nA190T results in the activation of the de novo purine synthesis pathway by reducing feedback inhibition, allowing the cell to continue to create nucleotides even when concentrations are elevated. This overactivation creates increased hypoxanthine levels, which likely competitively inhibits the conversion of the thiopurines to their active form.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:06:33.964Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T22:56:57.185Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-18T10:41:25.039Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T09:09:57.578Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:XBltlaoiRx9UPcxsW1F1gRplZohcyPAe", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.llKj9xXVUkAVc1SsVH7Bl7lzjb_tXzhI", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2929", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:43", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.736Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.736Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:80", "type": "Document", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22745105"], "title": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:xvqQ2h_y6LWqlwE-OrXOXyZsJVKQaCJ4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ZzfAyg7ZoPXj-XTF4aU5W9qP6XFMqEZx", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C64639", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:98", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}}
{"id": "civic.eid:44", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.785Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.785Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:80", "type": "Document", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22745105"], "title": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:zTPzX49SdbUDVx8bppaKiZzuzzZYBeap", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C64639", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}}
{"id": "civic.eid:45", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.833Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.833Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:80", "type": "Document", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22745105"], "title": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8Zp8d0oWLEBKCE75TxuqlqARHMVZE4np", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.XOA4u4E6Su3AFee6y-RDHne2rutg8MCm", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C64639", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:100", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}}
{"id": "civic.eid:47", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.906Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-16T16:00:20.079Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-18T18:22:03.161Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.906Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:80", "type": "Document", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22745105"], "title": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hPi2qREtq708oJsZRk7yHIYmERR7FvYF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4EgbHQhOHcn-fneuIkfUenDSiczwyZHy", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C64639", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:102", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}}
{"id": "civic.eid:136", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:44.277Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-09-27T17:36:06.943Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:44.277Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:123", "type": "Document", "label": "De Roock et al., 2010, JAMA", "xrefs": ["pmid:20978259"], "title": "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Mbn5sm4UhaBWJ4Btlb5mp7j_hP_fjlsP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:142", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:44.513Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:44.513Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:79", "type": "Document", "label": "George et al., 2008, Nature", "xrefs": ["pmc:PMC2587486", "pmid:18923525"], "title": "Activating mutations in ALK provide a therapeutic target in neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:fwWzHgcKDGWDHQvLYceNOjVX3Jcyq_eB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C171615", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:18", "type": "TherapeuticDescriptor", "label": "TAE684", "therapeutic": "ncit:C171615"}}
{"id": "civic.eid:145", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:44.692Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:44.692Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:123", "type": "Document", "label": "De Roock et al., 2010, JAMA", "xrefs": ["pmid:20978259"], "title": "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:jGbiXvIkc-azo7u4bW6UTarjSaC2lAkw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:266", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.388Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-03-25T00:07:09.991Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.388Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:179", "type": "Document", "label": "Hammerman et al., 2011, Cancer Discov", "xrefs": ["pmc:PMC3274752", "pmid:22328973"], "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:zNbxSP7hleCeWYEGd-SmTnijpy-6yr8m", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.USMUpm3KJn7b0WGKeWm1b63xvUP9irv2", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:141", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:267", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.417Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.417Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:179", "type": "Document", "label": "Hammerman et al., 2011, Cancer Discov", "xrefs": ["pmc:PMC3274752", "pmid:22328973"], "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:wGR3Oq-SkrOhYWITSySM35snfhCQw4HN", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TJMufZCyiaK5VWPMXW4TnlKhNZCx-Jkh", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:142", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:268", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.444Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.444Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:179", "type": "Document", "label": "Hammerman et al., 2011, Cancer Discov", "xrefs": ["pmc:PMC3274752", "pmid:22328973"], "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FctGvQF0TSi3aBijEXwbX0JN7OFvfWU2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yNZT3comT6vnycsDevOj1QhoEmunT85v", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:144", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:269", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.475Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.475Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:179", "type": "Document", "label": "Hammerman et al., 2011, Cancer Discov", "xrefs": ["pmc:PMC3274752", "pmid:22328973"], "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1LyECLHCPEzKh-PyG6Y44qmiMD2xCZ0s", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SwawUdQhdGwY6AF-h7M6tGRhOO7xINqx", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:143", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:270", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.507Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.507Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:179", "type": "Document", "label": "Hammerman et al., 2011, Cancer Discov", "xrefs": ["pmc:PMC3274752", "pmid:22328973"], "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-kVPX5dHL_EuX2Nl1Ieovv47atwiVrV3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Q0--Sk_lt9OV_ioEYRYiqgTSitLhW7i5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:140", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:271", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.546Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.546Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:179", "type": "Document", "label": "Hammerman et al., 2011, Cancer Discov", "xrefs": ["pmc:PMC3274752", "pmid:22328973"], "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:GKwGmiwd-y-nEE_zDWAWNChgvch76MMD", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.63g55q3_wl21Vpdd6kMEe6mdvt5x-JYo", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:139", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:274", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.704Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.704Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:181", "type": "Document", "label": "Paez et al., 2004, Science", "xrefs": ["pmid:15118125"], "title": "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9-DTeTKcrO7L3ckyaFCgLEY71FpPTT38", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3PO39DSennfsuKhGmlGEImSRA0C1WDjN", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:134", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:276", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.768Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.768Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:181", "type": "Document", "label": "Paez et al., 2004, Science", "xrefs": ["pmid:15118125"], "title": "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:c4WdqL5-kPyKfrnmThAqr8vTcxjz5Bal", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:279", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.869Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-09-13T07:16:05.899Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-10-21T23:12:01.649Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.869Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:yuDox8CRzRc8W8AtWd6ysGnCvdy7bgP5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Pe2t8daPO86int4itC1643JgSj33bcWc", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:35", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:bf_BuyNMwaqXScLEAS5F0_LZZf1t1H2f", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}]}}
{"id": "civic.eid:280", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.919Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.919Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:170", "type": "Document", "label": "Bose et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3570596", "pmid:23220880"], "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:g6VtmJnNNgVM3cvYur2o7CTnigsuI84s", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UkHzO1hLU6XGibjGtTAZ6sjIY2ujLwgh", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:36", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:305", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.855Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T23:59:57.690Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T23:57:42.205Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.855Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:193", "type": "Document", "label": "Engelman et al., 2008, Nat. Med.", "xrefs": ["pmc:PMC2683415", "pmid:19029981"], "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:J0kcdso6rmq3soE5l2t4taFTn59zJP_I", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:310", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:51.050Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:51.050Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:195", "type": "Document", "label": "Tanaka et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21558396"], "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1mAFXQ2VbkX_j5IbENUEEoLV51Vbqwu6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C158603", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:66", "type": "TherapeuticDescriptor", "label": "PI3K-alpha Inhibitor MEN1611", "xrefs": ["ncit:C158603"], "alternate_labels": ["5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine", "Alpha-selective PI3K Inhibitor MEN1611", "CH 5132799", "CH-5132799", "CH5132799", "MEN 1611", "MEN-1611", "MEN1611", "PA 799", "PA-799", "PA799", "PI3Kalpha Inhibitor MEN1611"], "therapeutic": "ncit:C158603"}}
{"id": "civic.eid:314", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:51.190Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-07-31T16:22:39.484Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:51.190Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:195", "type": "Document", "label": "Tanaka et al., 2011, Clin. Cancer Res.", "xrefs": ["pmid:21558396"], "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ntg-Yz5G7-LhW404U4WBK2M5Jlq7j8ZM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C158603", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:66", "type": "TherapeuticDescriptor", "label": "PI3K-alpha Inhibitor MEN1611", "xrefs": ["ncit:C158603"], "alternate_labels": ["5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine", "Alpha-selective PI3K Inhibitor MEN1611", "CH 5132799", "CH-5132799", "CH5132799", "MEN 1611", "MEN-1611", "MEN1611", "PA 799", "PA-799", "PA799", "PI3Kalpha Inhibitor MEN1611"], "therapeutic": "ncit:C158603"}}
{"id": "civic.eid:317", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:51.281Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:51.281Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:198", "type": "Document", "label": "Courtney et al., 2010, J. Clin. Oncol.", "xrefs": ["pmc:PMC2834432", "pmid:20085938"], "title": "The PI3K pathway as drug target in human cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FRbEutDHUWao5J8JMRYsUdJZwMeyByvm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ydOAUuYHUqnX4_fbCtv3brD2rGKkW21I", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C2201", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:110", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:67", "type": "TherapeuticDescriptor", "label": "MTOR Inhibitor", "xrefs": ["ncit:C2201"], "therapeutic": "ncit:C2201"}}
{"id": "civic.eid:439", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2015-08-05T18:46:30.804Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-08-05T18:46:30.804Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:261", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3893054", "pmid:24265152"], "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:w-TRxF-vzBMkYBkX0mtGfCnMKrt2yDXz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gI0FOE6Esplrs92wp0CJWOeriC8srpYN", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:169", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:447", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2015-08-05T18:46:36.906Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-06T20:47:04.038Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-20T18:30:22.747Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-08-05T18:46:36.906Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:265", "type": "Document", "label": "Joseph et al., 2013, Cancer Discov", "xrefs": ["pmid:23779130"], "title": "A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:I3SRJ78TflPlnxdnYEGjDcXrchRBFCYP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.olutIn7R2sm_1EoWJYBwEs082i4SWigh", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1307298", "type": "Therapeutic"}, {"id": "rxcui:1999574", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C7378", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:175", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:46", "type": "DiseaseDescriptor", "label": "Prostate Cancer", "xrefs": ["DOID:10283"], "disease": "ncit:C7378"}, "object_descriptor": {"id": "civic.tcd:WhfBuE9-X8HJ0XrZkBrvk5szSlPlh2lC", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1307298", "type": "Therapeutic"}, {"id": "rxcui:1999574", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:163", "type": "TherapeuticDescriptor", "label": "Enzalutamide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:658", "type": "DiseaseDescriptor", "label": "Prostate cancer", "disease": "ncit:C7378"}]}}], "xrefs": ["ncit:C71744"], "alternate_labels": ["ASP9785", "Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-", "MDV3100", "Xtandi"], "therapeutic": "rxcui:1307298"}, {"id": "civic.tid:364", "type": "TherapeuticDescriptor", "label": "Apalutamide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:658", "type": "DiseaseDescriptor", "label": "Prostate cancer", "disease": "ncit:C7378"}]}}], "xrefs": ["ncit:C92574"], "alternate_labels": ["4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide", "ARN 509", "ARN-509", "ARN509", "Erleada", "JNJ 56021927", "JNJ-56021927"], "therapeutic": "rxcui:1999574"}]}}
{"id": "civic.eid:630", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-10-21T17:39:18.698Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-10-21T19:10:14.766Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-11-05T04:01:25.736Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-10-28T20:30:42.280Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:399", "type": "Document", "label": "Tzoneva et al., 2013, Nat. Med.", "xrefs": ["pmc:PMC3594483", "pmid:23377281"], "title": "Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:iPhGgpz64Nz8CeGl_TnmaRSlS5jnmDau", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3QL816E82t5euatEr_7eLqoMQzCfNrCC", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "mondo:0003540", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:238", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:227", "type": "DiseaseDescriptor", "label": "T-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:5603"], "disease": "mondo:0003540"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:631", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-10-21T19:07:01.832Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2015-11-29T22:05:46.030Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-02T18:05:45.757Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-10-28T20:30:28.951Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:399", "type": "Document", "label": "Tzoneva et al., 2013, Nat. Med.", "xrefs": ["pmc:PMC3594483", "pmid:23377281"], "title": "Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FAhpqJRsPsTf6ZvP_0hicinE28chs3VR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Ij3MNtiDjVvgUUsbv8h7X7yO_A9J1mfh", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "mondo:0003540", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:239", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:227", "type": "DiseaseDescriptor", "label": "T-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:5603"], "disease": "mondo:0003540"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:632", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype protein.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-10-21T19:09:42.629Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-10-28T20:30:18.995Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:399", "type": "Document", "label": "Tzoneva et al., 2013, Nat. Med.", "xrefs": ["pmc:PMC3594483", "pmid:23377281"], "title": "Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:fgS7Xcn8XFVncyqwVnrUq6lajh_NxP9D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._2KqV3A6g-0liZvew_kHHrjlchS1DRM8", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "mondo:0003540", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:240", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:227", "type": "DiseaseDescriptor", "label": "T-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:5603"], "disease": "mondo:0003540"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:786", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-07T12:56:53.497Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-19T20:28:54.118Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-21T16:18:46.399Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-07T03:12:12.049Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:523", "type": "Document", "label": "Cho et al., 2014, Mol. Cancer", "xrefs": ["pmc:PMC4072491", "pmid:24894453"], "title": "Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:AmnDAgKxrBH-0kjMo3EplbJP9XnNbQb_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TAH5AY1a44R1vNlLbUYyNULHGUgomzG_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:317", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:787", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules. The same in-vitro results could be reproduced for the G719S mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-07T13:01:41.135Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-08T20:36:00.952Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-20T23:31:56.891Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-08T20:34:31.951Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:523", "type": "Document", "label": "Cho et al., 2014, Mol. Cancer", "xrefs": ["pmc:PMC4072491", "pmid:24894453"], "title": "Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qZGSYLkM3f5zPbRyyh0-p-ZIz1j5qJPW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3PO39DSennfsuKhGmlGEImSRA0C1WDjN", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:134", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:873", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-14T11:50:53.270Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-10T17:26:55.414Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-20T23:28:17.135Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-10T17:26:26.040Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:587", "type": "Document", "label": "Watson et al., 2014, Cancer Res.", "xrefs": ["pmc:PMC4167745", "pmid:25056119"], "title": "The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Ff9kw1rWX5efT1H1pnjM25MRKyYBrcdS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ApORZnY8ebSQ7jam_NW7Pf9mTBrIKNzL", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:367", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:7UdV-6r5BcGyVPqQkUITkTOl1vZRajMR", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1424911", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:22", "type": "TherapeuticDescriptor", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C82386"], "alternate_labels": ["BRAF Inhibitor GSK2118436", "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-", "GSK-2118436", "GSK-2118436A", "GSK2118436"], "therapeutic": "rxcui:1424911"}]}}
{"id": "civic.eid:979", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.  A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:27", "type": "Agent", "name": "Ethan Cerami"}, "date": "2016-02-06T02:08:26.240Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:27", "type": "Agent", "name": "Ethan Cerami"}, "date": "2016-02-07T14:57:00.109Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-07T23:35:57.531Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:27", "type": "Agent", "name": "Ethan Cerami"}, "date": "2016-02-07T14:59:38.602Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-06T22:43:51.465Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:678", "type": "Document", "label": "Rohle et al., 2013, Science", "xrefs": ["pmc:PMC3985613", "pmid:23558169"], "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:w3MNgbr4g5lZiY4Hu4fLH1meeRFNro8p", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cXxt95ehS1vnyR-ZKhMNpx2eKUX136uo", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:9240", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3288", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:420", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:241", "type": "DiseaseDescriptor", "label": "Oligodendroglioma", "xrefs": ["DOID:3181"], "disease": "ncit:C3288"}, "object_descriptor": {"id": "civic.tid:473", "type": "TherapeuticDescriptor", "label": "AGI-5198", "therapeutic": "iuphar.ligand:9240"}}
{"id": "civic.eid:1079", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-23T08:54:15.798Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:46:33.735Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:46:39.944Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:44:34.411Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:746", "type": "Document", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26888827"], "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qf_l2uo8wH1DDNz6us2CISLr5LRBp4ix", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VDg4To7ePAbIjjPfop3VmeFbcUpvgsf5", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C91381", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:453", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:DikLqTiUzvlAynTzqBw5f3Cj5Arf5sW1", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C91381", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:273", "type": "TherapeuticDescriptor", "label": "Futuximab/Modotuximab Mixture", "xrefs": ["ncit:C91381"], "alternate_labels": ["Anti-EGFR Monoclonal Antibody Mixture Sym004", "Futuximab/Modotuximab", "Futuximab/Zatuximab", "Sym004"], "therapeutic": "ncit:C91381"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:1080", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-23T08:54:57.600Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:47:55.398Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:48:00.584Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T19:48:04.740Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:746", "type": "Document", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26888827"], "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:If7Ryn_0-J-IXHcI7vcuv1sEnZ21XDOv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VDg4To7ePAbIjjPfop3VmeFbcUpvgsf5", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:453", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:1174", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:141", "type": "Agent", "name": "Ron Bose"}, "date": "2016-03-17T15:10:50.300Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-03-17T20:43:26.409Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-03-17T20:41:30.525Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:811", "type": "Document", "label": "Kavuri et al., 2015, Cancer Discov", "xrefs": ["pmc:PMC4527087", "pmid:26243863"], "title": "HER2 activating mutations are targets for colorectal cancer treatment."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:PujT4AyyB-RUCNsHc9xRE9a2sbRvU-tZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UODigU-kVH-oc3cGpEfL8RBPYzZuxbRJ", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:45", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:119", "type": "DiseaseDescriptor", "label": "Colon Cancer", "xrefs": ["DOID:219"], "disease": "ncit:C9242"}, "object_descriptor": {"id": "civic.tcd:fhoJlflGcyI7CoY-_bzWLsBwlsn7GwLN", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}]}}
{"id": "civic.eid:1176", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-03-17T20:45:16.079Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-03-17T22:21:46.583Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:811", "type": "Document", "label": "Kavuri et al., 2015, Cancer Discov", "xrefs": ["pmc:PMC4527087", "pmid:26243863"], "title": "HER2 activating mutations are targets for colorectal cancer treatment."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:WBlGAmOVC_wbsBb2aNH5lF5ZDaBeyHiO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Gb-3idkBuAo7OTK9h1VU76Re2uWRfCnk", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:39", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:119", "type": "DiseaseDescriptor", "label": "Colon Cancer", "xrefs": ["DOID:219"], "disease": "ncit:C9242"}, "object_descriptor": {"id": "civic.tcd:fhoJlflGcyI7CoY-_bzWLsBwlsn7GwLN", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}]}}
{"id": "civic.eid:1177", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-03-17T20:46:35.490Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-03-17T22:20:55.617Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:811", "type": "Document", "label": "Kavuri et al., 2015, Cancer Discov", "xrefs": ["pmc:PMC4527087", "pmid:26243863"], "title": "HER2 activating mutations are targets for colorectal cancer treatment."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:fZdtrsnXjJscw1o6ui0emy7-PfCTm4nz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4XK29Fat7-Qy7WpPdFMMCK15FaEC-O5O", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:44", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:119", "type": "DiseaseDescriptor", "label": "Colon Cancer", "xrefs": ["DOID:219"], "disease": "ncit:C9242"}, "object_descriptor": {"id": "civic.tcd:fhoJlflGcyI7CoY-_bzWLsBwlsn7GwLN", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}]}}
{"id": "civic.eid:1178", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-03-17T20:47:57.438Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-03-17T22:19:29.636Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:811", "type": "Document", "label": "Kavuri et al., 2015, Cancer Discov", "xrefs": ["pmc:PMC4527087", "pmid:26243863"], "title": "HER2 activating mutations are targets for colorectal cancer treatment."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DRefiXW4eTevul2lOHAEI9Ixn4rCOPfv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Cb62-L80eC4t34-oT4vXvOiKlJ5uh5ZB", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:496", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:119", "type": "DiseaseDescriptor", "label": "Colon Cancer", "xrefs": ["DOID:219"], "disease": "ncit:C9242"}, "object_descriptor": {"id": "civic.tcd:fhoJlflGcyI7CoY-_bzWLsBwlsn7GwLN", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1940643", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}]}}
{"id": "civic.eid:1329", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.  COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.  This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment. Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib. Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C). Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells. PF-06463922 was well tolerated in the in-vivo models.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-05-24T07:07:39.865Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T23:52:06.182Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-28T03:03:04.855Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-21T01:45:46.938Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:919", "type": "Document", "label": "Infarinato et al., 2016, Cancer Discov", "xrefs": ["pmc:PMC4707106", "pmid:26554404"], "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:6zZgyIeksUPGofN4DPTiKf1yQmU32R-o", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2103164", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:241", "type": "TherapeuticDescriptor", "label": "Lorlatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C113655"], "alternate_labels": ["2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-", "7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile", "Lorbrena", "PF-06463922"], "therapeutic": "rxcui:2103164"}}
{"id": "civic.eid:1331", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively. ALK wild-type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors. NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-05-24T07:29:57.980Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-13T16:58:56.682Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-28T00:29:20.589Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-13T16:57:27.019Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:919", "type": "Document", "label": "Infarinato et al., 2016, Cancer Discov", "xrefs": ["pmc:PMC4707106", "pmid:26554404"], "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8oJagv5SN_Wual4h3z0-AZXdz82gUj8Y", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eDIGsnE6r2Z4xJ1HLKHFZhShBjcUGpgJ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2103164", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:9", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:241", "type": "TherapeuticDescriptor", "label": "Lorlatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C113655"], "alternate_labels": ["2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-", "7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile", "Lorbrena", "PF-06463922"], "therapeutic": "rxcui:2103164"}}
{"id": "civic.eid:1543", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T08:42:14.207Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-28T19:01:46.339Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-11-02T19:44:15.863Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-28T19:01:48.299Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1025", "type": "Document", "label": "Rodrik-Outmezguine et al., 2016, Nature", "xrefs": ["pmc:PMC4902179", "pmid:27279227"], "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:a4rggeKnMZvvdvYVkd50VHibsIs6PhpS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mWN-AFixmkqHVuKjA0fLe3k2r13MWdhF", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:35302", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:470", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}}
{"id": "civic.eid:1544", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T08:48:18.760Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-28T18:21:55.647Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-11-02T19:44:46.402Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-28T18:21:58.862Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1025", "type": "Document", "label": "Rodrik-Outmezguine et al., 2016, Nature", "xrefs": ["pmc:PMC4902179", "pmid:27279227"], "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:NVSsPbTF7GWPLnRRjQc4VoVGuV3HMQF4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PngdxFdLfRjz--M1ZiXdtsq3D4ixwAFH", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C78856", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:609", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:124", "type": "TherapeuticDescriptor", "label": "MTOR Kinase Inhibitor AZD8055", "xrefs": ["ncit:C78856"], "alternate_labels": ["AZD-8055", "AZD8055"], "therapeutic": "ncit:C78856"}}
{"id": "civic.eid:1547", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T08:54:44.433Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-31T14:57:40.967Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-11-02T19:45:10.678Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-31T14:57:43.066Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1025", "type": "Document", "label": "Rodrik-Outmezguine et al., 2016, Nature", "xrefs": ["pmc:PMC4902179", "pmid:27279227"], "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:A0I3ii7GZQzWu6qD-drOUKEdGccZgAa0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KZBatARL-UIC5KRXOStcro4yQL1964Tq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:35302", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:610", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}}
{"id": "civic.eid:1548", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance to rapamycin but maintained sensistivity to AZD8055. A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro. AZD8055 also retained efficacy in these clones in xenograft.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T08:55:34.648Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-05T22:14:27.095Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-07T18:42:27.205Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-31T14:51:13.376Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1025", "type": "Document", "label": "Rodrik-Outmezguine et al., 2016, Nature", "xrefs": ["pmc:PMC4902179", "pmid:27279227"], "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0z24FpDH00vGJyuizgAk4m6ZCpNHKco0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KZBatARL-UIC5KRXOStcro4yQL1964Tq", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C78856", "type": "Therapeutic"}, {"id": "iuphar.ligand:9212", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:610", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:YPX4hWBVzOuHhIwr13nNgLhGznlVAIEa", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C78856", "type": "Therapeutic"}, {"id": "iuphar.ligand:9212", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:124", "type": "TherapeuticDescriptor", "label": "MTOR Kinase Inhibitor AZD8055", "xrefs": ["ncit:C78856"], "alternate_labels": ["AZD-8055", "AZD8055"], "therapeutic": "ncit:C78856"}, {"id": "civic.tid:376", "type": "TherapeuticDescriptor", "label": "RapaLink-1", "therapeutic": "iuphar.ligand:9212"}]}}
{"id": "civic.eid:1668", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:92", "type": "Agent", "name": "Nakul Shah"}, "date": "2016-09-16T01:42:38.667Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-03T10:00:55.211Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-11-03T18:57:57.751Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-03T10:00:58.975Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1129", "type": "Document", "label": "Wagenaar et al., 2014, Pigment Cell Melanoma Res", "xrefs": ["pmc:PMC4260813", "pmid:24112705"], "title": "Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:a2WBx7VottAegcHIRlfFZAWx8QZjtcgb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.X09E2r2MjKn-w1Ggsuy0XMWJ5_-lr-gd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:658", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1900", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX models bearing JAK1 S703I mutation and delays tumor progression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:341", "type": "Agent", "name": "Shruti Rao"}, "date": "2017-02-02T16:43:34.666Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-02-02T20:48:23.433Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-02-02T21:56:24.246Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-02-02T20:20:37.423Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1332", "type": "Document", "label": "Yang et al., 2016, Oncotarget", "xrefs": ["pmc:PMC4868698", "pmid:26701727"], "title": "Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JouWRH2f3ghScMU17o5J9ulWZi93Y0Um", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.F2XXgXt0oEWQSqg7CxTiyOEYsH6rLtHE", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1193326", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3099", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:822", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:196", "type": "DiseaseDescriptor", "label": "Hepatocellular Carcinoma", "xrefs": ["DOID:684"], "disease": "ncit:C3099"}, "object_descriptor": {"id": "civic.tid:386", "type": "TherapeuticDescriptor", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "DiseaseDescriptor", "label": "Graft versus host disease", "disease": "ncit:C3063"}, {"id": "hemonc:655", "type": "DiseaseDescriptor", "label": "Polycythemia vera", "disease": "ncit:C3336"}, {"id": "hemonc:635", "type": "DiseaseDescriptor", "label": "Myelofibrosis", "disease": "ncit:C3248"}]}}], "xrefs": ["ncit:C77888"], "alternate_labels": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"], "therapeutic": "rxcui:1193326"}}
{"id": "civic.eid:2041", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-231 is a basal-type breast cancer cell line which harbors KRAS G13D, and it had an ICD50 of 20uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice injected with MDA-MB-231 and treated with pictilisib saw no reduction in tumor volume compared to untreated control. There was no effect on G1 arrest in pictilisib treated cells; however, phosphorylated AKT (S473) was substantially reduced following pictilisib. Authors note that basal breast cancer cell lines were generally more resistant to pictilisib than luminal lines (p=0.02), and concluded that this cell line was resistant to pictilisib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:58:25.059Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-11T00:34:51.975Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-11T00:35:18.362Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-11T00:31:54.025Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-11T00:35:21.305Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:zf1UasnISiwqEF7dT71b_YcBFer3NU16", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2062", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-361 is a HER2 amplified breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.14uM. To asses the effect of pictilisib on cell cycle progression and apoptosis, fluorescence based cell cycle and flow cytometry were used to measure the proportion of cells in various phases and the relative presence of Annexin V, a marker of apoptosis. Untreated, 68% of cells were in G1 or sub-G1. Following treatment with 1.0uM pictilisib, the proportion of cells in G1 or sub-G1 rose to 78%, and the amount of Annexin V detected rose 3 fold. A substantial reduction in phosphorylated AKT (S473) was also noted. Authors concluded that pictilisib had a modest effect on cell cycle progression and encouraged apoptosis in this cell line, and that this cell line is sensitive to pictilisib. Authors further noted that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like breast cancer cell lines (p=0.002).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:58:45.783Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2021-03-03T20:02:35.015Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2021-03-03T20:16:37.969Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-12T18:32:52.051Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-12T18:32:43.200Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JSmlCvBvg3da7HmiJo5H4KLzL78AQHYc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2085", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.23uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice subsequently treated with 100mg/kg pictilisib experienced a 69% tumor reduction, and those treated with 150mg/kg experienced an 82% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:10.522Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-12T18:46:30.000Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-12T18:47:36.321Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-12T18:47:06.272Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-12T18:49:47.533Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9xtZwdghG6Crk0ofC39tECADwcGwgNr8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MwhPgqLyRggo95FGBET65hs3Dbmm0jW1", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1234", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2096", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL4 is a HER2 amplified breast cancer cell line harboring PIK3CA H1047R, and it had an IC50 of 0.28uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice, and allowed to grow. Subsequently, pictilisib was administered orally daily for 14 days. Mice treated with 100mg/kg experienced a 76% tumor reduction, and those treated with 150mg/kg experienced a 90% tumor reduction, with respect to untreated control. Phosphorylated AKT (S473) was substantially reduced with pictilisib administration. Three other HER2 amplified breast cancer cell lines harbored PIK3CA H1047R: UACC-893, HCC1954, MDA-MB-453, which had IC50s of 0.41uM, 0.49uM, and 0.64uM, suggesting that PIK3CA H1047R induces sensitivity to pictilisib in HER2 amplified breast cancer. Authors note that pictilisib was well tolerated in vivo and further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:36.246Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-16T19:56:22.614Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-16T19:56:48.743Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-15T03:59:31.323Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-16T19:56:54.166Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:smanZ6nIIlyebt2VzrZLjVW9D85cM77t", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2160", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:32.481Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:05:03.643Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T15:36:22.594Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:05:06.428Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1525", "type": "Document", "label": "Li et al., 2008, Oncogene", "xrefs": ["pmc:PMC2748240", "pmid:18408761"], "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Fo0nIHYyqvFpc9aVaxSbnQXoEApb3Li4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:480167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}}
{"id": "civic.eid:3012", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib (AC220), a second generation class II tyrosine kinase inhibitor (IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 888nM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:401", "type": "Agent", "name": "Emre KAR"}, "date": "2017-05-16T12:56:47.640Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:33:48.269Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2021-03-18T06:02:16.373Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:32:48.368Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1732", "type": "Document", "label": "Kampa-Schittenhelm et al., 2013, Mol. Cancer", "xrefs": ["pmc:PMC3637582", "pmid:23497317"], "title": "Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:COwUMGgmMVGvLH8k7bRKGz1qtP9bGaOt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C68936", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:505", "type": "TherapeuticDescriptor", "label": "Quizartinib", "xrefs": ["ncit:C68936"], "alternate_labels": ["(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide", "AC-220", "AC010220", "AC220", "N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"], "therapeutic": "ncit:C68936"}}
{"id": "civic.eid:3042", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248Q loss of function mutation is present in 5 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-05-26T17:57:28.085Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T04:37:30.676Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:55:17.366Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-05-27T18:14:26.393Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-15T15:37:34.061Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ndpbySy-bUU8OXBLIUFMLrO4xI2pWuCr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KGNX46jwzV5U7UlIgco_QUaTev8HzOw3", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:117", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:3989", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation. No G12R was detected in the parental line despite high-resolution evaluation. Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:33.026Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T17:03:40.445Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T17:06:21.274Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T17:03:44.782Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2008", "type": "Document", "label": "Misale et al., 2012, Nature", "xrefs": ["pmc:PMC3927413", "pmid:22722830"], "title": "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Bi1mjZlYKP-tBpvOySQtT8DFv_Yq5Ao6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._AIonI6Sp_E7tTUN81jJbNG3tERDCkVk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:530", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4489", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay. In addition, vemurafenib treatment strongly inhibited MEK and ERK phosphorylation in WM2664 cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:24.167Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-21T22:45:09.286Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-21T22:43:17.614Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-03-20T15:50:19.369Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:351", "type": "Document", "label": "Yang et al., 2010, Cancer Res.", "xrefs": ["pmid:20551065"], "title": "RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qDTjQOzTlZ9n7UlJhkmSZT4pTW_Mcr8N", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nstQWjDNJb8qwT0ZtyIGNK9El0LZGMn5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:11", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4510", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = 132 +- 25 nM) did show resistance towards  Regorafenib  compared to Ba/F3 cells with del 557-558 alone (IC50 = 30 +- 14 nM). In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Regorafenib. In Regorafenib incubated cells, T670I mutations were seen in approximately 10% of the resistant cell populations. The results suggest that T670I does induce regorafenib resistance in del 557-558/T670I cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:50.702Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-22T22:27:03.386Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T22:27:26.305Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T22:28:42.121Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:mIkVYpeIHQcL2MUMxM7d9_VeQiNBmccK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1267", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:4631", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Several preclinical studies were done in order to test the effects of various tyrosine kinase inhibitors (TKIs) on KIT-mutant cell lines derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and secondary mutation D816E. The cells were tested for Imatinib and Sunitinib resistances. GIST-T1/816 cells with 560-578 deletion and D816E mutations were resistant towards Imatinib and Sunitinib (Imatinib IC50: 604 nM and Sunitinib IC50: 3111 nM) compared to GIST-T1 cells with the 560-578 deletion mutation alone (Imatinib IC50: 30 nM and Sunitinib IC50: 15 nM). Imatinib inhibited phosphorylation in KIT and ERK at high concentrations. Sunitinib did not inhibit phosphorylation in KIT, ERK, or AKT at all. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. In Imatinib incubated cells, D816E mutations were seen in less than 5% of resistant Ba/F3 cell clones only in the lowest concentration. In Imatinib incubated cells, D816E mutations were seen in approximately 10% of resistant Ba/F3 cell clones.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:29.813Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-19T22:35:21.588Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:35:35.728Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:29:48.061Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:VHxWN_bGB2cgHn_H1rs4MOXY4U1g9GoG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SaoIXvys127Ns4mbkzg2MNe9BOHDzb1L", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1559", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:XfIozULZDMYsSPTJsoBBE_VUj4zzkscC", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:4787", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony formation (P < 0.001) and MTT assay, which tests for NADH activity (P = 1.09 x 10^5), with dasatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment could be rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, a significant increased in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.005) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:51.110Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-07-11T16:20:55.696Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-05T23:00:37.456Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-11-05T23:08:35.973Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2128", "type": "Document", "label": "Testoni et al., 2016, EMBO Mol Med", "xrefs": ["pmc:PMC4734836", "pmid:26758680"], "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:M0OXBh4nA0PDt3DKQHSTxIMgXAC8yzo7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KUWRWYBQPf83j33qhkDlkVqzIutJWdfu", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1656", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:4879", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248W loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T17:27:39.693Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T04:41:13.498Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:57:04.008Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-05-17T18:21:57.218Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:49:40.652Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:nF4eDhAfT8qpX0MkVmApgDeoKwzKH8ap", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.D4ygEfF35Dv0cNd8fIoOLhDPqxVSxpob", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:118", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4880", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R175H loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T17:32:34.310Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-07T00:40:05.345Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:54:53.477Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:431", "type": "Agent", "name": "D S"}, "date": "2018-05-14T18:32:15.842Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:46:48.251Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1Mq74SHjNixk7JBTpGqAKCxC2E4GgMhm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bpTmcx3yG0E4BahBLrCmkeqlsfNBeqHE", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:116", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4881", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273C loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T17:35:44.534Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T23:04:49.491Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:55:35.642Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:45:58.909Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:44:04.338Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:QeAR3v-hDrTGs4HRT2bgcamh8K1VruST", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.AXS1g9tgzIx75-Vv9T9DjEt4On7db0_k", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:121", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4882", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273H loss of function mutation is present in 7 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T17:40:35.788Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T04:39:14.641Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:55:51.902Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:43:25.952Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:43:26.930Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:_kWtSWT7euhMaK5xat6ES0xUPE4-E_dP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.GMSpJl-n2YHDTV8gGYODNruwMz3gjWEm", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:122", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4883", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 G245S loss of function mutation is present in 3 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T17:43:22.279Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T04:41:31.437Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:57:14.535Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:41:38.247Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:urHDmftcSIKlvXrx4I4T9nzLFnT7x8Aa", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rOFjD5FoaN3D0Uq4KtRsgnIfTmszXAiV", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:879", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4884", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 Y220C loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T18:02:05.937Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T04:40:11.627Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:56:21.013Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:41:00.994Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:mKGmrFoSbjYs16z3LUrwEXjUCsXZUkMd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.uI4nm8TgYWMXJIEl6R66zPRs7uJgguRF", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:922", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4887", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 V157F loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T20:08:01.633Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T19:09:42.115Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T19:05:45.577Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:56:09.459Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:GzjAOuSvR0hnnLzmFJJToE-yMHLxo796", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Afs5D-JAwDCg1ORV4VeoEhr3DKze6zti", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1092", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4888", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R249S loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T20:11:06.301Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T19:41:05.895Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T19:28:42.864Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:28:59.970Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0caeCFcI3TDEzD5dilVz-z8msHSPA-2g", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.XiQps_3vcKddUX5OQmrKWilNU58Yrkjo", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1696", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4889", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280K loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T20:13:04.344Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T19:42:47.940Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T19:41:27.574Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:28:26.923Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:gUTF2DuOHMpVh_meBYP2ZGZVA6sr-0uw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TbP1zhWcRgAo8pHzTVrK2yGVeMQJ0H6J", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1697", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4890", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280T loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T20:15:00.933Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T20:57:59.343Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T20:55:08.565Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:34:28.389Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:23:25.380Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:70VJb6isubZrgsl59EJgMx0cTbW5bv16", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.9Ztghq1JZwFk7WtS3dsbUxjlYKBdOQKy", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1698", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4891", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158L loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T20:18:00.259Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T21:55:40.232Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T21:01:27.687Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:431", "type": "Agent", "name": "D S"}, "date": "2018-05-14T17:49:40.577Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:16:00.716Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:t-MGYPFGelmRJP2GG5GTMFX0nvHbAwsK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bgCTkQnHs9ATnyLQOwskoDFAFJB8Xvuc", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1699", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:6204", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a preclinical study, efficacy of lapatinib and trastuzumab was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R. The study found that H1047R abrogated the growth inhibitory effects of lapatinib and trastuzumab, either in isolation or in combination, though somewhat increased cell death was observed with combination therapy relative to monotherapy. The authors concluded that the PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2-positive breast cancer cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-07T20:16:07.816Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-28T21:22:10.264Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:28:55.751Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:28:59.111Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2486", "type": "Document", "label": "Eichhorn et al., 2008, Cancer Res.", "xrefs": ["pmc:PMC2587064", "pmid:19010894"], "title": "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:fIX6o07MFV16wlinOVZP8dVWfI19quT2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tcd:Exy3-S7snfyhQHnOQ6ZbukSAmtGQaYfA", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}]}}
{"id": "civic.eid:6206", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of H1047R mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA H1047R expressing cells. Additionally, growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib. Authors concluded that PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2 positive breast cancer cells, but resistance can be reversed by dactolisib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-07T20:19:05.329Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:23:42.013Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-28T21:24:07.632Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:23:11.310Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2486", "type": "Document", "label": "Eichhorn et al., 2008, Cancer Res.", "xrefs": ["pmc:PMC2587064", "pmid:19010894"], "title": "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:C-DNBPj-C9Lu56DLdGvnCJrWBmDS3t0E", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C74072", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}}
{"id": "civic.eid:6380", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Demonstrates that activating mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that is sensitive to pharmacologic JAK inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2018-07-13T07:55:56.502Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-13T13:56:17.066Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2521", "type": "Document", "label": "Fleischman et al., 2013, Blood", "xrefs": ["pmc:PMC3837511", "pmid:24081659"], "title": "The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hNvXcmrcKYYSb_ZlIBQZIbSb1hXUrc91", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.febEL6t9p7599KYWol9A4wPFuh1cGDyd", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1193326", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3179", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2387", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2127", "type": "DiseaseDescriptor", "label": "Chronic Neutrophilic Leukemia", "xrefs": ["DOID:80187"], "disease": "ncit:C3179"}, "object_descriptor": {"id": "civic.tid:386", "type": "TherapeuticDescriptor", "label": "Ruxolitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:605", "type": "DiseaseDescriptor", "label": "Graft versus host disease", "disease": "ncit:C3063"}, {"id": "hemonc:655", "type": "DiseaseDescriptor", "label": "Polycythemia vera", "disease": "ncit:C3336"}, {"id": "hemonc:635", "type": "DiseaseDescriptor", "label": "Myelofibrosis", "disease": "ncit:C3248"}]}}], "xrefs": ["ncit:C77888"], "alternate_labels": ["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile", "INCB-18424", "INCB18424", "Jakafi", "Oral JAK Inhibitor INCB18424"], "therapeutic": "rxcui:1193326"}}
{"id": "civic.eid:7393", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In the patient-derived cell line GIST430 harboring KIT V560_L576del primary activating mutation implanted in mice, imatinib and ponatinib were shown to reduce KIT phosphorylation compared to the vehicle. In GIST430 cell lines, ponatinib and imatinib reduced phospho-AKT and phospho-ERK levels. A cell line derived from GIST430 patients expressing KIT V560_L576del primary mutation demonstrated sensitivity to imatinib (IC50: 61nmol/L) and ponatinib (IC50: 12nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >5000nmol/L and 2807nmol/L for these drugs respectively. IC50 was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-08T22:34:19.070Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T22:36:06.174Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:36:55.564Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:32:48.905Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hhAtRtoqNsA-DjrPSyIBuGP9pRL0fQgR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.8EdAufoZPtrrpbZTWFRym7CIluHpjO0D", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1550", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:Bp7LSZxv3sM5AUjPNf7nTRGI6VHQfjmY", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}]}}
{"id": "civic.eid:7401", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A preclinical study was done in order to test the effects of a tyrosine kinase inhibitor (TKI) on the ponatinib-sensitive KIT-mutant cell line GIST-T1 derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and additional secondary mutation D816E. The cells were tested for Ponatinib resistance. GIST-T1/816 cells containing del 560-578 and D816E mutations (IC50: 23 nM) did not show resistance towards Ponatinib compared to GIST-T1 cells with only del 560-578 mutation (IC50: 5 nM). Ponatinib reduced phosphorylation in KIT, AKT, and ERK at higher concentrations. According to the results, the authors suggest that Ponatinib remained highly active in GIST cell lines with secondary mutation D816E.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-11T21:26:25.215Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-19T22:42:30.106Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:43:30.982Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:43:39.221Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:sRDJjaBacJzMBrR4S_AbLVbWpg9Voufs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SaoIXvys127Ns4mbkzg2MNe9BOHDzb1L", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1364347", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1559", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}}
{"id": "civic.eid:7413", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ponatinib possesses potent activity against A829P KIT mutant cells in preclinical experiments. A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary ponatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and A829P mutations (IC50 for growth inhibition: 2 nM) did not show resistance towards Ponatinib compared to Ba/F3 cells with the del 557-558 mutation alone (IC50: 3 nM).  Ponatinib was shown to inhibit KIT phosphorylation in moderate concentrations. Similarly, GIST-T1/829 cells with 560-578 deletion/A829P mutations (IC50 = 16 nM) were not resistant to Ponatinib compared to GIST T1 cells with 560-578 deletion alone (IC50 = 5 nM). Ponatinib inhibited phosphorylation in KIT, ERK, and AKT at moderate to high concentrations in GIST-T1/829 cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2019-07-18T07:37:38.550Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-22T21:00:17.426Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T21:00:37.862Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T21:00:45.579Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:LpsdTOzFZSXut8kSohx_5rRzcNOvo1VO", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7y1CGe4PaanVm4XfIGmysXGuSn6tOG-6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1364347", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:990", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}}
{"id": "civic.eid:7414", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with primary TKI-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and N822K mutations (Sunitinib IC50 for growth inhibition: 225 +- 19 nM, Imatinib IC50: 483 +- 24 nM) did show resistance towards Sunitinib and Imatinib compared to Ba/F3 cells with the del 557-558 alone (Sunitinib IC50: 7 +- 2 nM, Imatinib IC50: 27 +- 8 nM).  Sunitinib and Imatinib did not completely inhibit KIT phosphorylation at 1000 nM, which was the highest concentration tested. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. From these results, N822K mutations were the most frequent KIT mutation observed in resistant Ba/F3 cell populations incubated in Sunitinib. In Imatinib incubated cells, N822K mutations were seen in approximately 10% of resistant Ba/F3 cell clones.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-19T21:56:29.472Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-19T22:12:14.393Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:12:36.399Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:12:43.582Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:NEHRu64KEkDCAZ5h_ULRHozBTv4pUcIl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:XfIozULZDMYsSPTJsoBBE_VUj4zzkscC", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:7415", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary sunitinib and imatinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and A829P mutations did show resistance towards Sunitinib and Imatinib (Sunitinib IC50 for growth inhibition: 319 +- 88 nM and Imatinib IC50: 179 +- 27 nM) compared to Ba/F3 cells with the del 557-558 mutation (Sunitinib IC50: 7 +- 2 nM and Imatinib IC50:  27 +- 8 nM). Imatinib and Sunitinib were shown to not reduce p-KIT at all in Ba/F3 cells with del 557-558/ A829P mutations.  Patient-derived GIST-T1/829 cells with 560-578 deletion/A829P mutations (Sunitinib IC50: 1168 nM and Imatinib IC50:1201 nM) did show resistance towards Sunitinib and Imatinib compared to GIST-T1 cells with 560-578 deletion alone (Sunitinib IC50: 15 nM and Imatinib IC50: 30 nM). Sunitinib and Imatinib did not inhibit p-KIT, p-ERK, and p-AKT in GIST-T1/829 cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-22T22:03:21.989Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-22T22:04:42.643Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Cy9HEu0uRPn1UaGUgvbfVW86IMx1wTx2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7y1CGe4PaanVm4XfIGmysXGuSn6tOG-6", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:990", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:XfIozULZDMYsSPTJsoBBE_VUj4zzkscC", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:7813", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of NT5C2 R238W in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R238W led to increased 5\u2019 nucleotidase activity.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-10T14:10:23.454Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-23T23:33:11.755Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-01-23T23:38:31.276Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-27T08:54:22.520Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3131", "type": "Document", "label": "Meyer et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3681285", "pmid:23377183"], "title": "Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:o4060SeWOweUzxa6MU4AXYIQYYKF4U-g", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.y5L30x-yI0w1U-KRCCBbHEKYKRr-VsXJ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3168", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2896", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2991", "type": "DiseaseDescriptor", "label": "Childhood Acute Lymphocytic Leukemia", "xrefs": ["DOID:80144"], "disease": "ncit:C3168"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7814", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of NT5C2 S445F in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis.  Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of S445F led to increased 5\u2019 nucleotidase activity.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-10T14:14:26.693Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-23T23:35:13.706Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-01-23T23:39:19.864Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-27T08:56:33.988Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3131", "type": "Document", "label": "Meyer et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3681285", "pmid:23377183"], "title": "Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:g_QXpU5w34xMaF2oscTObnYDExJ6Tfsh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eG6-xUpzeuyGT8_Gt7hjWGQbGQfvq2aV", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3168", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2897", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2991", "type": "DiseaseDescriptor", "label": "Childhood Acute Lymphocytic Leukemia", "xrefs": ["DOID:80144"], "disease": "ncit:C3168"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7815", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral mediated overexpression of NT5C2 R367Q in Reh cells resulted in no change in apoptosis after exposure to cytarabine, gemcitabine, doxorubicin, or prednisolone compared to wildtype NT5C2 overexpression and GFP control lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-10T14:55:51.577Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-24T22:01:08.926Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-01-30T20:23:17.103Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-24T00:13:50.909Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2020-02-14T16:20:22.385Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3131", "type": "Document", "label": "Meyer et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3681285", "pmid:23377183"], "title": "Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qyId4BzkNLfiC7nNI2FY2AhRjtqdWc7o", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3QL816E82t5euatEr_7eLqoMQzCfNrCC", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:8638", "type": "Therapeutic"}, {"id": "rxcui:142433", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3168", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:238", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2991", "type": "DiseaseDescriptor", "label": "Childhood Acute Lymphocytic Leukemia", "xrefs": ["DOID:80144"], "disease": "ncit:C3168"}, "object_descriptor": {"id": "civic.tcd:gVgGkpzxqiqLKaKyQVlfGYCzm6HVoRcE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:8638", "type": "Therapeutic"}, {"id": "rxcui:142433", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:85", "type": "TherapeuticDescriptor", "label": "Gemcitabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C66876"], "alternate_labels": ["1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose", "2'Deoxy-2',2'-Difluorocytidine", "DFdC", "DFdCyd", "Difluorodeoxycytidine"], "therapeutic": "rxcui:12574"}, {"id": "civic.tid:14194", "type": "TherapeuticDescriptor", "label": "Prednisolone", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C769"], "alternate_labels": ["(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione", ".delta.1-Hydrocortisone", "1,2-Dehydrohydrocortisone", "Adnisolone", "Aprednislon", "Capsoid", "Cortalone", "Cortisolone", "Dacortin H", "Decaprednil", "Decortin H", "Delta(1)Hydrocortisone", "Delta- Cortef", "Delta-Cortef", "Delta-Diona", "Delta-F", "Delta-Phoricol", "Delta1-dehydro-hydrocortisone", "Deltacortril", "Deltahydrocortisone", "Deltasolone", "Deltidrosol", "Dhasolone", "Di-Adreson-F", "Dontisolon D", "Estilsona", "Fisopred", "Frisolona", "Gupisone", "Hostacortin H", "Hydeltra", "Hydeltrasol", "Klismacort", "Kuhlprednon", "Lenisolone", "Lepi-Cortinolo", "Linola-H N", "Linola-H-Fett N", "Longiprednil", "Metacortandralone", "Meti Derm", "Meticortelone", "Opredsone", "Panafcortelone", "Precortisyl", "Pred-Clysma", "Predeltilone", "Predni-Coelin", "Predni-Helvacort", "Prednicortelone", "Prednisolonum", "Prelone", "Prenilone", "Sterane"], "therapeutic": "rxcui:8638"}, {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}]}}
{"id": "civic.eid:7816", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Overexpression of NT5C2 R238W in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-10T15:04:56.766Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-27T08:57:54.044Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3131", "type": "Document", "label": "Meyer et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3681285", "pmid:23377183"], "title": "Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8nGDt5Yowebajq1g-uq7IGWhdqqn-LMh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.y5L30x-yI0w1U-KRCCBbHEKYKRr-VsXJ", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:8638", "type": "Therapeutic"}, {"id": "rxcui:142433", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3168", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2896", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2991", "type": "DiseaseDescriptor", "label": "Childhood Acute Lymphocytic Leukemia", "xrefs": ["DOID:80144"], "disease": "ncit:C3168"}, "object_descriptor": {"id": "civic.tcd:gVgGkpzxqiqLKaKyQVlfGYCzm6HVoRcE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:8638", "type": "Therapeutic"}, {"id": "rxcui:142433", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:85", "type": "TherapeuticDescriptor", "label": "Gemcitabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C66876"], "alternate_labels": ["1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose", "2'Deoxy-2',2'-Difluorocytidine", "DFdC", "DFdCyd", "Difluorodeoxycytidine"], "therapeutic": "rxcui:12574"}, {"id": "civic.tid:14194", "type": "TherapeuticDescriptor", "label": "Prednisolone", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C769"], "alternate_labels": ["(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione", ".delta.1-Hydrocortisone", "1,2-Dehydrohydrocortisone", "Adnisolone", "Aprednislon", "Capsoid", "Cortalone", "Cortisolone", "Dacortin H", "Decaprednil", "Decortin H", "Delta(1)Hydrocortisone", "Delta- Cortef", "Delta-Cortef", "Delta-Diona", "Delta-F", "Delta-Phoricol", "Delta1-dehydro-hydrocortisone", "Deltacortril", "Deltahydrocortisone", "Deltasolone", "Deltidrosol", "Dhasolone", "Di-Adreson-F", "Dontisolon D", "Estilsona", "Fisopred", "Frisolona", "Gupisone", "Hostacortin H", "Hydeltra", "Hydeltrasol", "Klismacort", "Kuhlprednon", "Lenisolone", "Lepi-Cortinolo", "Linola-H N", "Linola-H-Fett N", "Longiprednil", "Metacortandralone", "Meti Derm", "Meticortelone", "Opredsone", "Panafcortelone", "Precortisyl", "Pred-Clysma", "Predeltilone", "Predni-Coelin", "Predni-Helvacort", "Prednicortelone", "Prednisolonum", "Prelone", "Prenilone", "Sterane"], "therapeutic": "rxcui:8638"}, {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}]}}
{"id": "civic.eid:7817", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Overexpression of NT5C2 S445F in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-10T15:43:04.885Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-27T08:58:14.208Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3131", "type": "Document", "label": "Meyer et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3681285", "pmid:23377183"], "title": "Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:G6wvwz7m1Jwgnf7sTRRcEKeEdfM0sAUI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eG6-xUpzeuyGT8_Gt7hjWGQbGQfvq2aV", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:8638", "type": "Therapeutic"}, {"id": "rxcui:142433", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3168", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2897", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2991", "type": "DiseaseDescriptor", "label": "Childhood Acute Lymphocytic Leukemia", "xrefs": ["DOID:80144"], "disease": "ncit:C3168"}, "object_descriptor": {"id": "civic.tcd:gVgGkpzxqiqLKaKyQVlfGYCzm6HVoRcE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:12574", "type": "Therapeutic"}, {"id": "rxcui:8638", "type": "Therapeutic"}, {"id": "rxcui:142433", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:85", "type": "TherapeuticDescriptor", "label": "Gemcitabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}, {"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C66876"], "alternate_labels": ["1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose", "2'Deoxy-2',2'-Difluorocytidine", "DFdC", "DFdCyd", "Difluorodeoxycytidine"], "therapeutic": "rxcui:12574"}, {"id": "civic.tid:14194", "type": "TherapeuticDescriptor", "label": "Prednisolone", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C769"], "alternate_labels": ["(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione", ".delta.1-Hydrocortisone", "1,2-Dehydrohydrocortisone", "Adnisolone", "Aprednislon", "Capsoid", "Cortalone", "Cortisolone", "Dacortin H", "Decaprednil", "Decortin H", "Delta(1)Hydrocortisone", "Delta- Cortef", "Delta-Cortef", "Delta-Diona", "Delta-F", "Delta-Phoricol", "Delta1-dehydro-hydrocortisone", "Deltacortril", "Deltahydrocortisone", "Deltasolone", "Deltidrosol", "Dhasolone", "Di-Adreson-F", "Dontisolon D", "Estilsona", "Fisopred", "Frisolona", "Gupisone", "Hostacortin H", "Hydeltra", "Hydeltrasol", "Klismacort", "Kuhlprednon", "Lenisolone", "Lepi-Cortinolo", "Linola-H N", "Linola-H-Fett N", "Longiprednil", "Metacortandralone", "Meti Derm", "Meticortelone", "Opredsone", "Panafcortelone", "Precortisyl", "Pred-Clysma", "Predeltilone", "Predni-Coelin", "Predni-Helvacort", "Prednicortelone", "Prednisolonum", "Prelone", "Prenilone", "Sterane"], "therapeutic": "rxcui:8638"}, {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}]}}
{"id": "civic.eid:7862", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of NT5C2 R367Q in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R367Q led to increased 5\u2019 nucleotidase activity.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-23T23:20:22.817Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-01-23T23:21:17.676Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3131", "type": "Document", "label": "Meyer et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3681285", "pmid:23377183"], "title": "Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Fnx09GkLk4-ccE9aEZZ-vlue-qXnODtg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3QL816E82t5euatEr_7eLqoMQzCfNrCC", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3168", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:238", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2991", "type": "DiseaseDescriptor", "label": "Childhood Acute Lymphocytic Leukemia", "xrefs": ["DOID:80144"], "disease": "ncit:C3168"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7898", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 T303S in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed T303S cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. T303S cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, T303S cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:03:53.872Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:25:43.296Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T19:59:46.016Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T10:05:22.537Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lO-cwgmMYQkyH8F1ErZLWK6cwkhyHEAQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JnuoBhFKSO1IYLvhodz0nk9eMItJ3FhY", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2918", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7899", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed L191F cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. L191F cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, L191F cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:04:11.102Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:15:26.786Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T20:00:19.172Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T10:06:47.999Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:2nddpZmdz0mkvZF26gJPOOP2yzqEFedX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mbGeepbjVfWRRfqDj7J_giIRlrT0Pzsl", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2919", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7900", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 D183E in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed D183E cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. D183E cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, D183E cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:04:27.602Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:10:45.505Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T20:00:39.328Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T10:08:42.704Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DGyyNl-xeRBNZ2TvgtYMqFCQFHrEz9dd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yTyEFFfv30-OhwXq82YzdefLxfq-zX0-", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2920", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7901", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 K176N in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed K176N cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. K176N cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, K176N cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:04:44.060Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:14:49.169Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T20:01:15.651Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T10:12:22.785Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:WpenhPgc4oBScR6n5Jz10SmeFQ1BQX7m", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.LGaiUgmB8wzfr0_X86xo3VZzbyNH90H8", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2921", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7903", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed N144S cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. N144S cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, N144S cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:05:10.076Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:16:57.971Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T20:04:19.238Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T10:16:32.062Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:kASy7YiGxZUJctPnWR2n4a4P9JZlLw6E", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Maq_xrhmRn5epsg2bAWeXhQJgIp7epBG", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2923", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7905", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 S103I in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). After 6-MP exposure, mass spectrometry revealed S103I cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. S103I cells produce increased intracellular concentrations of hypoxanthine and IMP. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:05:48.575Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:17:42.821Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T20:04:52.868Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T10:22:09.169Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:bfL6DyC4xAHSaqFIOtwcOkkX6qRYhJxs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nDbGOiUzjMenvo1OY-U2gZnbNKBk3jNC", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2925", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7906", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 S103N in Reh cells resulted in significant resistance against mercaptopurine (6-MP) and thioguanine (6-TG) as indicated by IC50 increases and reduced apoptosis compared to multiple controls (empty vector and overexpression of wildtype or known reduced-function PRPS1 mutants). 6-MP cytotoxicity results were confirmed using Jurkat cells. After 6-MP exposure, mass spectrometry revealed S103N cells possessed reduced concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. S103N cells produce increased intracellular concentrations of hypoxanthine and IMP. Also, after 6-MP exposure, S103N cells display reduced levels of DNA damage response and apoptosis protein markers. The enhanced production of hypoxanthine likely leads to reduced conversion of thiopurines to their active form due to competitive inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:05:59.421Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:18:07.949Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T20:05:20.432Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-03-26T23:59:55.953Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T10:23:14.095Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:CdyLSMkAG4-34IavjI3BHjCsiqF4FAKv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.daKnxmkFwXTSIAGtgfIpqHBNNdXlJtrn", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2926", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7919", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 A87T in Reh cells resulted in similar cytotoxic response (IC50 and apoptosis %) compared to controls (empty vector and wildtype PRPS1 overexpression) after treatment with mercaptopurine (6-MP) or thioguanine (6-TG).  After 6-MP exposure, mass spectrometry revealed A87T cells possessed similar concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. Intracellular concentrations of hypoxanthine and IMP were similar in A87T cells and controls. After 6-MP exposure, no difference in DNA damage response and apoptosis protein markers were observed between A87T cells and controls.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T23:12:45.424Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T21:06:27.690Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:YqI8FfHOFb_MVhT-01eXDZr9dpsUCvO-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.OSrv4pVmFb0yruYFvtS9tZfvau_K7Mks", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2939", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7920", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 M115T in Reh cells resulted in similar cytotoxic response (IC50 and apoptosis %) compared to controls (empty vector and wildtype PRPS1 overexpression) after treatment with mercaptopurine (6-MP) or thioguanine (6-TG).  After 6-MP exposure, mass spectrometry revealed M115T cells possessed similar concentrations of intracellular 6-MP metabolites (TIMP, TGMP, etc.) versus controls. Intracellular concentrations of hypoxanthine and IMP were similar in M115T cells and controls. After 6-MP exposure, no difference in DNA damage response and apoptosis protein markers were observed between M115T cells and controls.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T23:12:55.762Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-24T21:11:20.104Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:kkxS60ey8Eahb24XQeZCAiBMyXQOEArY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3J5YN3ZYdCz2Dof3BAJhD45m8St-tHtl", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2940", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:8106", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Gilteritinib inhibited the cell growth of Ba/F3 cells expressing D835Y (IC50 1.6 nM; 95% CI: 1.1\u20132.4 nM) compared to controls (IC50 420nM; 95% CI: 350\u2013500 nM). Additionally, immunoblots showed gliteritinib reduced phosphorylation of FLT3 and downstream targets in Ba/F3 D835Y cells in a dose dependent manner. Furthermore, in nude mice xenografted with Ba/F3 cells expressing D835Y, gilteritinib showed antitumor efficacy at 10 mg/kg and 30 mg/kg, and induced tumor regression at 30 mg/k. Computational modelling demonstrated that gilteritinib interacts with activated FLT3 at the ATP-binding site, which is distant from the D835 containing activation loop. This inhibitory mechanism allows for kinase inhibition to occur in the face of D835 mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:341", "type": "Agent", "name": "Shruti Rao"}, "date": "2020-04-15T02:26:20.143Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:341", "type": "Agent", "name": "Shruti Rao"}, "date": "2020-07-14T01:23:12.525Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-14T01:23:57.437Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-11T13:58:51.104Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-14T01:24:00.246Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3332", "type": "Document", "label": "Mori et al., 2017, Invest New Drugs", "xrefs": ["pmc:PMC5613053", "pmid:28516360"], "title": "Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:tK-16aPgpvUZ-YbY7IN1fCEXNh7j7cY3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Vti0p3hpaGkoQ8HvFtLXexpN29549Yo4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2105806", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3011", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:641", "type": "TherapeuticDescriptor", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C116722"], "alternate_labels": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"], "therapeutic": "rxcui:2105806"}}
{"id": "civic.eid:8337", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-10T20:16:13.685Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T05:31:53.701Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T15:10:09.438Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-13T05:07:33.795Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lmrrz5ItIN5JkycnYFEP4YL98ZDGJwn5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3070", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}}
{"id": "civic.eid:8339", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD Y842C treated with Lestaurtinib responded similarly to FLT3/ITD control cells (IC50: 2nM). Immunoblotting revealed Lestaurtinib inhibited FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD Y842C and control cells. These FLT3/ITD Y842C cells also responded to Lestaurtinib treatment in vivo after transplantation into Balb/c mice as measured by minimal bioluminescence and reduced spleen weight compared to vehicle and sorafenib treated mice.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-10T20:18:22.349Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T05:33:10.379Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-28T00:32:22.648Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-13T05:07:30.213Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:XLbrCc_7PJNsPTTNc0y3bvs9htzSafAJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C48402", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3070", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:260", "type": "TherapeuticDescriptor", "label": "Lestaurtinib", "xrefs": ["ncit:C48402"], "alternate_labels": ["9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-", "CEP-701", "KT-5555", "SPM-924"], "therapeutic": "ncit:C48402"}}
{"id": "civic.eid:12", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.308Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-13T00:12:07.136Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-08-19T18:23:15.868Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.308Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:58", "type": "Document", "label": "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC2777185", "pmid:19915144"], "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:V1azjfS4sclWqwy4mJLaiOaooifTpDIh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yzl9_KYeoW1CZXWr0VHb3_X0os3gHviA", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:82", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}}
{"id": "civic.eid:13", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.343Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-05T22:27:10.401Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-07T18:43:41.294Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.343Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:58", "type": "Document", "label": "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC2777185", "pmid:19915144"], "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1aPcU7TMa9lfeFBY_Mugg7ujbDGqtk56", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.irDnXyyR0inhcZ38LFSzr4sIb6e2Lx7s", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:83", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}}
{"id": "civic.eid:20", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:39.657Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:39.657Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:65", "type": "Document", "label": "Wernig et al., 2008, Cancer Cell", "xrefs": ["pmid:18394554"], "title": "Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:KB-gluXtAQxuxFh3sSKVeviBSbshmjpr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.V6Z7o5Im9ksiY2MojjqjLb86Xe4jjhlg", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2197490", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3336", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:64", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:9", "type": "DiseaseDescriptor", "label": "Polycythemia Vera", "xrefs": ["DOID:8997"], "disease": "ncit:C3336"}, "object_descriptor": {"id": "civic.tid:9", "type": "TherapeuticDescriptor", "label": "Fedratinib", "xrefs": ["ncit:C88293"], "alternate_labels": ["Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-", "SAR302503", "TG101348"], "therapeutic": "rxcui:2197490"}}
{"id": "civic.eid:32", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.181Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.181Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:73", "type": "Document", "label": "Sasaki et al., 2010, Cancer Res.", "xrefs": ["pmc:PMC3045808", "pmid:21030459"], "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:M9dno1HDQ-2RsR6uvyns84YT3KP6LCgX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C6481", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:12", "type": "DiseaseDescriptor", "label": "Inflammatory Myofibroblastic Tumor", "xrefs": ["DOID:50905"], "disease": "ncit:C6481"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:33", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.220Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.220Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:73", "type": "Document", "label": "Sasaki et al., 2010, Cancer Res.", "xrefs": ["pmc:PMC3045808", "pmid:21030459"], "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:g_ZgtAbpcAMZPQmTAIl0JwK489iAwS00", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:34", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.289Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-30T22:50:15.842Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-31T00:09:59.390Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.289Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:74", "type": "Document", "label": "Woodman et al., 2009, Mol. Cancer Ther.", "xrefs": ["pmc:PMC3346953", "pmid:19671763"], "title": "Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:SGccu1VQVHJhVPW35XNgHtTyN_wKlaP_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1i40nlLTUTxkw3VAG3tTQSuNjTWnMdy5", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:662281", "type": "Therapeutic"}, {"id": "rxcui:495881", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:72", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:XAeVSqTvUR0yOysNE_Ihbb9r0EdZ4Z1z", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:662281", "type": "Therapeutic"}, {"id": "rxcui:495881", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:13", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C48375"], "alternate_labels": ["4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide", "AMN 107 Base Form"], "therapeutic": "rxcui:662281"}, {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}]}}
{"id": "civic.eid:37", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "CH5424802 (Alectinib) is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.487Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-21T23:54:14.954Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-29T22:04:09.884Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.487Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:77", "type": "Document", "label": "Sakamoto et al., 2011, Cancer Cell", "xrefs": ["pmid:21575866"], "title": "CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:i9fqX2sgK5hy0O1qoKSUn-UM4LFwv2Ht", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1727455", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:17", "type": "TherapeuticDescriptor", "label": "Alectinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C101790"], "alternate_labels": ["5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-", "AF-802", "AF802", "ALK Inhibitor RO5424802", "Alecensa", "CH5424802", "RG7853", "RO5424802"], "therapeutic": "rxcui:1727455"}}
{"id": "civic.eid:38", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.528Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.528Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:78", "type": "Document", "label": "Heuckmann et al., 2011, Clin. Cancer Res.", "xrefs": ["pmc:PMC3382103", "pmid:21948233"], "title": "ALK mutations conferring differential resistance to structurally diverse ALK inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:RGryKRVVQcQD1m8cez8kilRKvNfCyV3-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:39", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.565Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.565Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:79", "type": "Document", "label": "George et al., 2008, Nature", "xrefs": ["pmc:PMC2587486", "pmid:18923525"], "title": "Activating mutations in ALK provide a therapeutic target in neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:_XkiJeHJuHpqxqjVzR-yeFGAZnYmJW82", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eDIGsnE6r2Z4xJ1HLKHFZhShBjcUGpgJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C171615", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:9", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:18", "type": "TherapeuticDescriptor", "label": "TAE684", "therapeutic": "ncit:C171615"}}
{"id": "civic.eid:40", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.603Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.603Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:6", "type": "Document", "label": "Imielinski et al., 2014, J. Clin. Invest.", "xrefs": ["pmc:PMC3973082", "pmid:24569458"], "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:3nZcSFZbxUrlPTshTQLLElZk0HUwESV2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NcfHbQ_k1M8S4zdJ9JAhe1qFBaBXQIil", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:10", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}}
{"id": "civic.eid:41", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.637Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.637Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:6", "type": "Document", "label": "Imielinski et al., 2014, J. Clin. Invest.", "xrefs": ["pmc:PMC3973082", "pmid:24569458"], "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5F02XIxo6r-LxOaVkCRlJ8jPT1RGsYaj", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NcfHbQ_k1M8S4zdJ9JAhe1qFBaBXQIil", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:10", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:42", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.683Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.683Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:74", "type": "Document", "label": "Woodman et al., 2009, Mol. Cancer Ther.", "xrefs": ["pmc:PMC3346953", "pmid:19671763"], "title": "Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:2DLlsFqgSTttdkc-rA8hNL51Iiqegwd4", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1i40nlLTUTxkw3VAG3tTQSuNjTWnMdy5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1546019", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:72", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}}
{"id": "civic.eid:46", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.871Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-07T05:18:37.387Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-04T16:27:48.516Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.871Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:80", "type": "Document", "label": "Heinrich et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22745105"], "title": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Y4jqtUT3_7v7K51-vWXGGbRMrpjKiNCq", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tUi_KlyJZO-wWdQd5JH1mvm2GCfwvZ1C", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C64639", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:101", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}}
{"id": "civic.eid:48", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:40.942Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:40.942Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:79", "type": "Document", "label": "George et al., 2008, Nature", "xrefs": ["pmc:PMC2587486", "pmid:18923525"], "title": "Activating mutations in ALK provide a therapeutic target in neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:X0uWkxoENOSMF-wAYd8xe6OYLkzV27_I", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eDIGsnE6r2Z4xJ1HLKHFZhShBjcUGpgJ", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171615", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:9", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:18", "type": "TherapeuticDescriptor", "label": "TAE684", "therapeutic": "ncit:C171615"}}
{"id": "civic.eid:75", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:41.986Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:41.986Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:90", "type": "Document", "label": "Coxon et al., 2012, J. Endocrinol. Invest.", "xrefs": ["pmid:21422803"], "title": "Anti-tumor activity of motesanib in a medullary thyroid cancer model."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Af4IH_Lrf7sJtdDfg2ZlR572ykh6BoIn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rSOkzbc0najG4N-uWpBWvJwF3Vk9cXt7", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C71896", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3879", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:112", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:15", "type": "DiseaseDescriptor", "label": "Thyroid Gland Medullary Carcinoma", "xrefs": ["DOID:3973"], "disease": "ncit:C3879"}, "object_descriptor": {"id": "civic.tid:23", "type": "TherapeuticDescriptor", "label": "Motesanib", "xrefs": ["ncit:C71896"], "therapeutic": "ncit:C71896"}}
{"id": "civic.eid:76", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.039Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.039Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:90", "type": "Document", "label": "Coxon et al., 2012, J. Endocrinol. Invest.", "xrefs": ["pmid:21422803"], "title": "Anti-tumor activity of motesanib in a medullary thyroid cancer model."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:uTrl0jL17Y2cm8r7g2TbuylknD3Lms1a", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ld4IL6kursGxjcAXopnYRTKKS-06pP8-", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C71896", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3879", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:113", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:15", "type": "DiseaseDescriptor", "label": "Thyroid Gland Medullary Carcinoma", "xrefs": ["DOID:3973"], "disease": "ncit:C3879"}, "object_descriptor": {"id": "civic.tid:23", "type": "TherapeuticDescriptor", "label": "Motesanib", "xrefs": ["ncit:C71896"], "therapeutic": "ncit:C71896"}}
{"id": "civic.eid:77", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.098Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.098Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:91", "type": "Document", "label": "Couto et al., 2012, PLoS ONE", "xrefs": ["pmc:PMC3462763", "pmid:23056499"], "title": "AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:aY4ZfYudGsQi3e4EbM__hWPIHi-kKQv9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ld4IL6kursGxjcAXopnYRTKKS-06pP8-", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C91394", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3879", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:113", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:15", "type": "DiseaseDescriptor", "label": "Thyroid Gland Medullary Carcinoma", "xrefs": ["DOID:3973"], "disease": "ncit:C3879"}, "object_descriptor": {"id": "civic.tid:24", "type": "TherapeuticDescriptor", "label": "JAK2 Inhibitor AZD1480", "xrefs": ["ncit:C91394"], "alternate_labels": ["AZD-1480", "AZD1480"], "therapeutic": "ncit:C91394"}}
{"id": "civic.eid:86", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.403Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-16T17:02:59.595Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-18T18:20:58.165Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.403Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:98", "type": "Document", "label": "Nissan et al., 2014, Cancer Res.", "xrefs": ["pmc:PMC4005042", "pmid:24576830"], "title": "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:NSnEjGkGK_WhNfMA-2wkHtnvvPygeZxS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "ncit:C52195", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:ngxhWeEUrfXP--l21wsFOlIfVCUCYTwb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "ncit:C52195", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:29", "type": "TherapeuticDescriptor", "label": "Mirdametinib", "xrefs": ["ncit:C52195"], "alternate_labels": ["MEK Inhibitor PD0325901", "PD 901", "PD-0325901", "PD0325901"], "therapeutic": "ncit:C52195"}]}}
{"id": "civic.eid:89", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.506Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-04-02T01:19:56.077Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-16T01:20:46.650Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-04-02T01:17:22.079Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.506Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:100", "type": "Document", "label": "Di Nicolantonio et al., 2008, J. Clin. Oncol.", "xrefs": ["pmid:19001320"], "title": "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:tkrHwhRHPvNK4MsgzpkivjMaMAfcDmY8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:Txylx4lLlleKme7VZW1QkEDa_a2KuP3v", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:90", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.551Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-19T20:23:55.048Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-02-21T00:50:13.373Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.551Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:98", "type": "Document", "label": "Nissan et al., 2014, Cancer Res.", "xrefs": ["pmc:PMC4005042", "pmid:24576830"], "title": "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:s7NV3ilRg_UayHTbSMBZvncuAlM3JJdG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:96", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.771Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-22T21:28:18.091Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-22T21:32:55.414Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.771Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:106", "type": "Document", "label": "Rad et al., 2013, Cancer Cell", "xrefs": ["pmc:PMC3706745", "pmid:23845441"], "title": "A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:UsRc0QOZo5MJcx1YqcnL_JKajqZ37CFd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "drugbank:DB06999", "type": "Therapeutic"}, {"id": "ncit:C82380", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:C9xIf4UNXDpcEhiDnKPFd6Gx6IIaT1E6", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "drugbank:DB06999", "type": "Therapeutic"}, {"id": "ncit:C82380", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:30", "type": "TherapeuticDescriptor", "label": "PLX4720", "therapeutic": "drugbank:DB06999"}, {"id": "civic.tid:477", "type": "TherapeuticDescriptor", "label": "Pictilisib Bismesylate", "xrefs": ["ncit:C82380"], "alternate_labels": ["2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- Ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine, Bimesylate Salt", "GDC-0941 Bismesylate", "GDC-0941 Dimesylate", "Pictilisib Dimesylate", "Thieno(3,2-d)pyrimidine, 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)-, Methanesulfonate (1:2)"], "therapeutic": "ncit:C82380"}]}}
{"id": "civic.eid:98", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Capecitabine, bevacizumab and vemurafenib combination therapy resulted in 100% tumor growth inhibition (TGI) and 190% increased lifespan (ILS) compared to vehicle treated controls. Seven mice experienced partial response and two experienced complete response. Triplet therapy resulted in better TGI and ILS compared to any agent in isolation or capecitabine + vemurafenib doublet therapy (p <0.05, p <0.0001, for all comparisons).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.876Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-09T21:22:02.823Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-07-09T21:26:14.516Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.876Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:108", "type": "Document", "label": "Yang et al., 2012, Cancer Res.", "xrefs": ["pmid:22180495"], "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:w0FUVW18ZPQMr3ppHb_AIkogMqkeXWaR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:194000", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:2046138", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:ga8GCopbz4xTHpmVbd_1oGREGpQbDTpo", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:194000", "type": "Therapeutic"}, {"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:2046138", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:32", "type": "TherapeuticDescriptor", "label": "Capecitabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}, {"id": "hemonc:585", "type": "DiseaseDescriptor", "label": "Colon cancer", "disease": "ncit:C9242"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C1794"], "alternate_labels": ["5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine", "Ro 09-1978/000", "Xeloda"], "therapeutic": "rxcui:194000"}, {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:33", "type": "TherapeuticDescriptor", "label": "Bevacizumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D003110", "type": "DiseaseDescriptor", "label": "Colonic Neoplasms", "disease": "ncit:C2953"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D002289", "type": "DiseaseDescriptor", "label": "Carcinoma, Non-Small-Cell Lung", "disease": "ncit:C2926"}, {"id": "mesh:D005909", "type": "DiseaseDescriptor", "label": "Glioblastoma", "disease": "ncit:C3058"}, {"id": "mesh:D002292", "type": "DiseaseDescriptor", "label": "Carcinoma, Renal Cell", "disease": "mondo:0005086"}, {"id": "mesh:D002583", "type": "DiseaseDescriptor", "label": "Uterine Cervical Neoplasms", "disease": "ncit:C9311"}]}}], "xrefs": ["ncit:C2039"], "alternate_labels": ["ABP 215", "Anti-VEGF", "Anti-VEGF Humanized Monoclonal Antibody", "Anti-VEGF RhuMAb", "Avastin", "BP102", "BP102 Biosimilar", "Bevacizumab Awwb", "Bevacizumab Biosimilar ABP 215", "Bevacizumab Biosimilar BEVZ92", "Bevacizumab Biosimilar BI 695502", "Bevacizumab Biosimilar CBT 124", "Bevacizumab Biosimilar CT-P16", "Bevacizumab Biosimilar FKB238", "Bevacizumab Biosimilar GB-222", "Bevacizumab Biosimilar HD204", "Bevacizumab Biosimilar HLX04", "Bevacizumab Biosimilar IBI305", "Bevacizumab Biosimilar LY01008", "Bevacizumab Biosimilar MIL60", "Bevacizumab Biosimilar MYL-1402O", "Bevacizumab Biosimilar Mvasi", "Bevacizumab Biosimilar QL 1101", "Bevacizumab Biosimilar RPH-001", "Bevacizumab Biosimilar SCT501", "Bevacizumab Biosimilar Zirabev", "Bevacizumab-awwb", "Bevacizumab-bvzr", "HD204", "Immunoglobulin G1 (Human-Mouse Monoclonal RhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal RhuMab-VEGF Light Chain, Dimer", "MYL-1402O", "Mvasi", "Recombinant Humanized Anti-VEGF Monoclonal Antibody", "RhuMab-VEGF", "SCT501", "Zirabev"], "therapeutic": "rxcui:2046138"}]}}
{"id": "civic.eid:125", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:43.885Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-10-19T15:56:28.760Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-10-19T15:58:24.988Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:43.885Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:119", "type": "Document", "label": "Bresler et al., 2011, Sci Transl Med", "xrefs": ["pmc:PMC3319004", "pmid:22072639"], "title": "Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:YDrJ4YMUrxxCClQr8ZYI9HBAWni2b-2i", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:143", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:44.546Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:44.546Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:119", "type": "Document", "label": "Bresler et al., 2011, Sci Transl Med", "xrefs": ["pmc:PMC3319004", "pmid:22072639"], "title": "Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:aZUVgjr8yzKbU9mjzD9sAwRLJ4rNMXco", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eDIGsnE6r2Z4xJ1HLKHFZhShBjcUGpgJ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1148495", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:9", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:12", "type": "TherapeuticDescriptor", "label": "Crizotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25958", "type": "DiseaseDescriptor", "label": "Anaplastic large cell lymphoma pediatric", "disease": null}]}}], "xrefs": ["ncit:C74061"], "alternate_labels": ["(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine", "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-", "MET Tyrosine Kinase Inhibitor PF-02341066", "PF-02341066", "PF-2341066", "Xalkori"], "therapeutic": "rxcui:1148495"}}
{"id": "civic.eid:231", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:47.993Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:47.993Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:163", "type": "Document", "label": "Beaver et al., 2013, Clin. Cancer Res.", "xrefs": ["pmc:PMC3805128", "pmid:23888070"], "title": "PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:BS53qrSTrWAZBGohni3JFTUQbtn6qA62", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._veAF5iFKxk_oSX9jnfNc4AHp8MvUCKO", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C90581", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:4", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:43", "type": "TherapeuticDescriptor", "label": "Akt Inhibitor MK2206", "xrefs": ["ncit:C90581"], "alternate_labels": ["1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-", "MK 2206", "MK-2206", "MK-2206 FREE BASE", "MK2206"], "therapeutic": "ncit:C90581"}}
{"id": "civic.eid:242", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.471Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2021-09-02T22:46:32.159Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.471Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:171", "type": "Document", "label": "Toy et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3903423", "pmid:24185512"], "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1pU_EXgGezEhDgb5H1TCpdv80H7JHl2C", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5ZOkJ_z4WY-prWoX_bz-OKTLxQAAhME0", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C147908", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:46", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:46", "type": "TherapeuticDescriptor", "label": "Hormone Therapy", "xrefs": ["ncit:C15445"], "alternate_labels": ["Chemotherapy-Hormones/Steroids", "Endocrine Therapy", "Hormonal Therapy", "Hormone Treatment", "Hormones"], "therapeutic": "ncit:C147908"}}
{"id": "civic.eid:243", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.526Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:388", "type": "Agent", "name": "liu liu"}, "date": "2017-04-13T03:32:18.317Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2017-04-13T16:33:01.829Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.526Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:171", "type": "Document", "label": "Toy et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3903423", "pmid:24185512"], "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:x4zZQ3PH0ulExWPLYttRcZznxutkb_Wp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VUrBmnIanxIELmkweHMA-oSus-zpdjyL", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C147908", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:47", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:46", "type": "TherapeuticDescriptor", "label": "Hormone Therapy", "xrefs": ["ncit:C15445"], "alternate_labels": ["Chemotherapy-Hormones/Steroids", "Endocrine Therapy", "Hormonal Therapy", "Hormone Treatment", "Hormones"], "therapeutic": "ncit:C147908"}}
{"id": "civic.eid:244", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.564Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.564Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:171", "type": "Document", "label": "Toy et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3903423", "pmid:24185512"], "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9RUgklx9XTgAGDgnluN3_2p3s85dCrMl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.FApHkwk1OD_nXJmrzBf7xUP9z0NtWl2q", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C147908", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:48", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:46", "type": "TherapeuticDescriptor", "label": "Hormone Therapy", "xrefs": ["ncit:C15445"], "alternate_labels": ["Chemotherapy-Hormones/Steroids", "Endocrine Therapy", "Hormonal Therapy", "Hormone Treatment", "Hormones"], "therapeutic": "ncit:C147908"}}
{"id": "civic.eid:245", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.601Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.601Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:171", "type": "Document", "label": "Toy et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3903423", "pmid:24185512"], "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:HU6lk5XR8SGRiQVrmFER_9M8vZzXVX8c", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.P0nisTOh1cxoPjsVBzFL8qpbkMitw2Qf", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C147908", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:49", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:46", "type": "TherapeuticDescriptor", "label": "Hormone Therapy", "xrefs": ["ncit:C15445"], "alternate_labels": ["Chemotherapy-Hormones/Steroids", "Endocrine Therapy", "Hormonal Therapy", "Hormone Treatment", "Hormones"], "therapeutic": "ncit:C147908"}}
{"id": "civic.eid:246", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.654Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:827", "type": "Agent", "name": "Wan-Hsin Lin"}, "date": "2019-09-10T22:09:03.820Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.654Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:171", "type": "Document", "label": "Toy et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3903423", "pmid:24185512"], "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:nGO5SG3-x2bBSHDa1gJaHfYxG2mEx1c9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PnJlRfBCZ6YxYPGMNHJQkxYTWrmTr0M4", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C147908", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:50", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:46", "type": "TherapeuticDescriptor", "label": "Hormone Therapy", "xrefs": ["ncit:C15445"], "alternate_labels": ["Chemotherapy-Hormones/Steroids", "Endocrine Therapy", "Hormonal Therapy", "Hormone Treatment", "Hormones"], "therapeutic": "ncit:C147908"}}
{"id": "civic.eid:249", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "KIT V654A results in imatinib resistance in GIST patient-derived cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:48.755Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:48.755Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:62", "type": "Document", "label": "Heinrich et al., 2006, J. Clin. Oncol.", "xrefs": ["pmid:16954519"], "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:aNGnO1hv3ZZMDa4YO7mx1cWA2_bYL5js", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CW1xXH97SiVFOHQp0rQ7-T5yYdwCE3ta", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:73", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:303", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ba/F3 cells harboring the KIT L576P mutation are sensitive to nilotinib, imatinib and lower concentrations of dasatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:50.769Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-30T23:48:57.363Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2019-02-25T19:15:40.919Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:50.769Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:191", "type": "Document", "label": "Antonescu et al., 2007, Int. J. Cancer", "xrefs": ["pmid:17372901"], "title": "L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:eduVEiRMzT33-DgNysH27cmtcaqpEM0U", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1i40nlLTUTxkw3VAG3tTQSuNjTWnMdy5", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1546019", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:662281", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:72", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:n4NuIj-lZJTjzG0Zb7E2v0XU0V35wlV6", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1546019", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:662281", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:13", "type": "TherapeuticDescriptor", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C48375"], "alternate_labels": ["4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide", "AMN 107 Base Form"], "therapeutic": "rxcui:662281"}]}}
{"id": "civic.eid:311", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Rapamycin inhibits transformation induced by mutation in PIK3CA.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:51.086Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:51.086Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:196", "type": "Document", "label": "Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC545580", "pmid:15647370"], "title": "Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:yHm4GJGsWZjDhjh52xviG2LGoMMRW3cd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:35302", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}}
{"id": "civic.eid:319", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:51.369Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-11T16:59:31.953Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2018-05-23T18:10:53.979Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-11T16:57:06.681Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:51.369Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:199", "type": "Document", "label": "Jackson et al., 2012, Cancer Cell", "xrefs": ["pmc:PMC3376352", "pmid:22698404"], "title": "p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ISSRi__W0lM0a5a0TOeL9trHZyvkcQhA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bpTmcx3yG0E4BahBLrCmkeqlsfNBeqHE", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:116", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:651", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-11-13T15:36:40.734Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-11-17T01:27:33.806Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:411", "type": "Document", "label": "Hirota et al., 2003, Gastroenterology", "xrefs": ["pmid:12949711"], "title": "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:652", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-11-13T15:43:03.092Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-11-17T01:27:44.478Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:411", "type": "Document", "label": "Hirota et al., 2003, Gastroenterology", "xrefs": ["pmid:12949711"], "title": "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:q1anFG9B1Yzw5MEVtFsIyIquet5TZZV6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.6uS7s0CfpTBvOBd3LDSibxYPdVE8un64", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:247", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:710", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-17T12:12:53.860Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-23T22:50:21.423Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-23T22:47:50.103Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:163", "type": "Document", "label": "Beaver et al., 2013, Clin. Cancer Res.", "xrefs": ["pmc:PMC3805128", "pmid:23888070"], "title": "PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Ul4FDkJ3JZD0cmGIuPIuyHRP8_xZyNZB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C90581", "type": "Therapeutic"}, {"id": "ncit:C165479", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:_4VF-9RhQ30VRa2AZYtxUNJ4lboZYB1X", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C90581", "type": "Therapeutic"}, {"id": "ncit:C165479", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:43", "type": "TherapeuticDescriptor", "label": "Akt Inhibitor MK2206", "xrefs": ["ncit:C90581"], "alternate_labels": ["1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-", "MK 2206", "MK-2206", "MK-2206 FREE BASE", "MK2206"], "therapeutic": "ncit:C90581"}, {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}]}}
{"id": "civic.eid:713", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-17T15:44:25.114Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-21T04:34:17.957Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-24T22:43:00.296Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-21T08:02:23.209Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-21T04:18:45.258Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:468", "type": "Document", "label": "Kong et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26490311"], "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:A8MGQyMmOdVnkfeBw6WzEvV-NUYXp5EM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.i7M-0wOkfZz-nhX-_GB9LkyM6Hqraihe", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C148229", "type": "Therapeutic"}, {"id": "ncit:C102564", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:283", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:MJtdjSZMt7R1cOWlhK2Kv7xnNUzVRmRQ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C148229", "type": "Therapeutic"}, {"id": "ncit:C102564", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:115", "type": "TherapeuticDescriptor", "label": "PI3K/BET Inhibitor LY294002", "xrefs": ["ncit:C148229"], "alternate_labels": ["2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one", "2-Morpholin-4-yl-8-phenylchromen-4-one", "4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-", "LY 294002", "LY-294002", "LY294002"], "therapeutic": "ncit:C148229"}, {"id": "civic.tid:112", "type": "TherapeuticDescriptor", "label": "Capivasertib", "xrefs": ["ncit:C102564"], "alternate_labels": ["AZD5363"], "therapeutic": "ncit:C102564"}]}}
{"id": "civic.eid:722", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-21T04:25:57.878Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-21T04:35:14.778Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-23T23:31:34.309Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:468", "type": "Document", "label": "Kong et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26490311"], "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Y2JRrPP7aRkYGCw3sKwaS0ADREGk93c_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5CnYcGdRZIj5q3XeHMVk1fs-piLuOgcH", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C148229", "type": "Therapeutic"}, {"id": "ncit:C102564", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:284", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:MJtdjSZMt7R1cOWlhK2Kv7xnNUzVRmRQ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C148229", "type": "Therapeutic"}, {"id": "ncit:C102564", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:115", "type": "TherapeuticDescriptor", "label": "PI3K/BET Inhibitor LY294002", "xrefs": ["ncit:C148229"], "alternate_labels": ["2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one", "2-Morpholin-4-yl-8-phenylchromen-4-one", "4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-", "LY 294002", "LY-294002", "LY294002"], "therapeutic": "ncit:C148229"}, {"id": "civic.tid:112", "type": "TherapeuticDescriptor", "label": "Capivasertib", "xrefs": ["ncit:C102564"], "alternate_labels": ["AZD5363"], "therapeutic": "ncit:C102564"}]}}
{"id": "civic.eid:755", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-12-30T09:31:30.068Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-02-03T23:06:50.144Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:493", "type": "Document", "label": "Atwood et al., 2015, Cancer Cell", "xrefs": ["pmc:PMC4357167", "pmid:25759020"], "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ySEGToTh2YCfdokGvKhwY1WMLZM9jNCV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hyt2pj4IH9Y-SEnEF-jNElPBrIIxBwwy", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1242987", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2921", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:299", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:314", "type": "DiseaseDescriptor", "label": "Basal Cell Carcinoma", "xrefs": ["DOID:2513"], "disease": "ncit:C2921"}, "object_descriptor": {"id": "civic.tid:190", "type": "TherapeuticDescriptor", "label": "Vismodegib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:587", "type": "DiseaseDescriptor", "label": "Cutaneous basal cell carcinoma", "disease": null}]}}], "xrefs": ["ncit:C74038"], "alternate_labels": ["2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide", "Erivedge", "GDC-0449", "Hedgehog Antagonist GDC-0449"], "therapeutic": "rxcui:1242987"}}
{"id": "civic.eid:762", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-01-02T03:23:34.295Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-02-03T23:26:51.894Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:505", "type": "Document", "label": "Walter et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC4048995", "pmid:24065731"], "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:UDP5UTYpeIjYWI3Cf3W4EflMGFKZ3L9J", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C99905", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:91", "type": "TherapeuticDescriptor", "label": "Rociletinib", "xrefs": ["ncit:C99905"], "alternate_labels": ["CO-1686", "N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide"], "therapeutic": "ncit:C99905"}}
{"id": "civic.eid:963", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-26T19:15:41.426Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-11T21:44:54.487Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-13T05:00:59.644Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-11T21:42:40.931Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:665", "type": "Document", "label": "Cross et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4315625", "pmid:24893891"], "title": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:NscnHk0pW34_5hMmk1-FmvCOlH71QsXE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:1002", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation). The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines. Single agent MEK inhibition (AZD6244/selumetinib, MEK162 or PD0325901) and single agent mTOR inhibition (Everolimus or AZD8055) also blocked cell growth in NRAS mutant cell lines, whereas single agent PI3K inhibitors or MEK Inhibitors in combination with PIK3CA/AKT inhibitors did not show synergistic effects.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-10T10:03:03.501Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-13T01:55:32.188Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-13T23:52:01.910Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-12T22:44:43.881Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:691", "type": "Document", "label": "Kiessling et al., 2016, PLoS ONE", "xrefs": ["pmc:PMC4731059", "pmid:26821351"], "title": "Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:sDfSOfuqjZekyUwVUk9eJ5s4RRpTKAoz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NHUtQ1IbZA9ZlH8wKbaMNF0W7esiwPKj", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:141704", "type": "Therapeutic"}, {"id": "rxcui:2049122", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:427", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tcd:SlRfPtAlZWrxQuj9zLGMRKRtxOV0-KKL", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:141704", "type": "Therapeutic"}, {"id": "rxcui:2049122", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:41", "type": "TherapeuticDescriptor", "label": "Everolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:45070", "type": "DiseaseDescriptor", "label": "Subependymal giant cell astrocytoma", "disease": "ncit:C3696"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:641", "type": "DiseaseDescriptor", "label": "Neuroendocrine tumor", "disease": "ncit:C3809"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C48387"], "alternate_labels": ["(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone", "42-O-(2-Hydroxy)ethyl Rapamycin", "Afinitor", "Certican", "RAD 001", "RAD001", "Votubia", "Zortress"], "therapeutic": "rxcui:141704"}, {"id": "civic.tid:485", "type": "TherapeuticDescriptor", "label": "Binimetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}]}}], "xrefs": ["ncit:C84865"], "alternate_labels": ["ARRY-162", "ARRY-438162", "MEK162", "Mektovi"], "therapeutic": "rxcui:2049122"}]}}
{"id": "civic.eid:1082", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-23T09:01:47.273Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-03-14T03:00:01.203Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-10-10T22:39:47.811Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:48:27.312Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:746", "type": "Document", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26888827"], "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1qmiQsTh5FH1_TcDsZ2aTvIcIvoSKnuI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.K55sYmiCjFDH_nWsWNp5z-lq4Dhqrh2o", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C91381", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:455", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:DikLqTiUzvlAynTzqBw5f3Cj5Arf5sW1", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C91381", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:273", "type": "TherapeuticDescriptor", "label": "Futuximab/Modotuximab Mixture", "xrefs": ["ncit:C91381"], "alternate_labels": ["Anti-EGFR Monoclonal Antibody Mixture Sym004", "Futuximab/Modotuximab", "Futuximab/Zatuximab", "Sym004"], "therapeutic": "ncit:C91381"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:1083", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-23T09:02:23.422Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-03-14T02:58:09.088Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-10-10T22:40:26.637Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:47:25.445Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:746", "type": "Document", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26888827"], "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:YJMKjnmCTpC0m98m5IN_jioB4jRu4hjc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.K55sYmiCjFDH_nWsWNp5z-lq4Dhqrh2o", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:455", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:1099", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:130", "type": "Agent", "name": "Robert Lesurf"}, "date": "2016-02-24T16:34:58.777Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-24T21:37:31.247Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:758", "type": "Document", "label": "Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC3356655", "pmid:22550175"], "title": "Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:LBV07qvavkwdpF4Z1IxChPnXkcuV2YWw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hyt2pj4IH9Y-SEnEF-jNElPBrIIxBwwy", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C80063", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3222", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:299", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:361", "type": "DiseaseDescriptor", "label": "Medulloblastoma", "xrefs": ["DOID:50902"], "disease": "ncit:C3222"}, "object_descriptor": {"id": "civic.tid:274", "type": "TherapeuticDescriptor", "label": "Patidegib", "xrefs": ["ncit:C80063"], "alternate_labels": ["FIN-5", "IP9 Free Base", "IPI-926", "IPI-926 Free Base", "Saridegib", "Smoothened Antagonist IPI-926"], "therapeutic": "ncit:C80063"}}
{"id": "civic.eid:1106", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or A1065T-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:130", "type": "Agent", "name": "Robert Lesurf"}, "date": "2016-02-24T22:54:14.019Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:38:12.723Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:38:24.587Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:38:17.801Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:764", "type": "Document", "label": "Antonescu et al., 2009, Cancer Res.", "xrefs": ["pmc:PMC2763376", "pmid:19723655"], "title": "KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:QJyshq_YOinDe7JaJlHgRzsd3H6Kr5NP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rlg-ioz6LkNwu8nUE_fVLR0HJWaMBNfT", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3088", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:467", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:330", "type": "DiseaseDescriptor", "label": "Angiosarcoma", "xrefs": ["DOID:1816"], "disease": "ncit:C3088"}, "object_descriptor": {"id": "civic.tcd:wsLrVLsW3tlJpvelphvNfi7j0WAQrFVD", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:1107", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or D717V-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:130", "type": "Agent", "name": "Robert Lesurf"}, "date": "2016-02-24T22:56:26.013Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:38:45.695Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:38:50.618Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-25T19:38:35.338Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:764", "type": "Document", "label": "Antonescu et al., 2009, Cancer Res.", "xrefs": ["pmc:PMC2763376", "pmid:19723655"], "title": "KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:dL4b2AXHyCFXU5kxs0KSP_T3_hBQJVSw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.P-cW-j5JPCXVL6Nv1Q85Z6Zk9M2EC1Wk", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3088", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:468", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:330", "type": "DiseaseDescriptor", "label": "Angiosarcoma", "xrefs": ["DOID:1816"], "disease": "ncit:C3088"}, "object_descriptor": {"id": "civic.tcd:wsLrVLsW3tlJpvelphvNfi7j0WAQrFVD", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:1141", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-29T11:59:57.692Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-01T20:50:47.286Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-06-29T21:04:10.231Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-01T20:50:50.480Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:790", "type": "Document", "label": "Hatzivassiliou et al., 2013, Nature", "xrefs": ["pmid:23934108"], "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:OCyf94GMKfOdEB48Yd0f54f-glyWaskS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1722365", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:342", "type": "TherapeuticDescriptor", "label": "Cobimetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C68923"], "alternate_labels": ["Cotellic", "GDC-0973", "MEK Inhibitor GDC-0973", "XL518"], "therapeutic": "rxcui:1722365"}}
{"id": "civic.eid:1322", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2016-05-14T05:40:45.496Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-26T19:58:34.486Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-06-29T20:23:46.667Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-26T19:58:40.046Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:952", "type": "Document", "label": "Byron et al., 2008, Cancer Res.", "xrefs": ["pmid:18757403"], "title": "Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:EZruHfhyRqeaUMCNWjYNIoaonr2xmrsx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4VmOKXSH9dALV7g9PhqHpNJ858mXZL3s", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:5037", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C27815", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:545", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:108", "type": "DiseaseDescriptor", "label": "Endometrial Cancer", "xrefs": ["DOID:1380"], "disease": "ncit:C27815"}, "object_descriptor": {"id": "civic.tid:36", "type": "TherapeuticDescriptor", "label": "PD173074", "therapeutic": "iuphar.ligand:5037"}}
{"id": "civic.eid:1327", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neuroblastoma cell lines containing wild-type ALK. Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment. AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways. Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-05-21T07:33:55.128Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-01T18:47:13.576Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-02T15:53:32.791Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-01T18:46:03.205Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:917", "type": "Document", "label": "Wang et al., 2016, Sci Rep", "xrefs": ["pmc:PMC4726162", "pmid:26786851"], "title": "Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:RP1lLkBvuj0V1tbD_CybrB6HM1ewtbdl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:7706", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:8", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:319", "type": "TherapeuticDescriptor", "label": "AZD3463", "therapeutic": "iuphar.ligand:7706"}}
{"id": "civic.eid:1330", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.  In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.  PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.  PF-06463922 was well tolerated in the animal models.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-05-24T07:16:24.422Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:56:42.982Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T19:58:24.035Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:56:06.856Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:919", "type": "Document", "label": "Infarinato et al., 2016, Cancer Discov", "xrefs": ["pmc:PMC4707106", "pmid:26554404"], "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:kBSzb-0VBrxP9eFlxh1zOMoWUgfR-y2O", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.vCqbachGaFmgPnncXcegGSNZIU9BaO8E", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2103164", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3270", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:549", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:13", "type": "DiseaseDescriptor", "label": "Neuroblastoma", "xrefs": ["DOID:769"], "disease": "ncit:C3270"}, "object_descriptor": {"id": "civic.tid:241", "type": "TherapeuticDescriptor", "label": "Lorlatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C113655"], "alternate_labels": ["2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-", "7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile", "Lorbrena", "PF-06463922"], "therapeutic": "rxcui:2103164"}}
{"id": "civic.eid:1408", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-27T08:22:28.935Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T23:33:41.797Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-06-29T20:22:51.992Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:25:44.978Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:344", "type": "Document", "label": "Prahallad et al., 2012, Nature", "xrefs": ["pmid:22281684"], "title": "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1wXTOKOmCtdpPDGMo2RnWqUcguyQRM2x", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:wV3Rrz2FQm2499F4G_2mMEekgKValyx3", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}]}}
{"id": "civic.eid:1428", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-29T02:32:47.562Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-08T18:00:38.361Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:967", "type": "Document", "label": "Coffee et al., 2013, Clin. Cancer Res.", "xrefs": ["pmc:PMC3815598", "pmid:23549875"], "title": "Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:LbZu-H5AN9g4sYjWA-2FbYgSNduMGyMN", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C74072", "type": "Therapeutic"}, {"id": "iuphar.ligand:5681", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:wSyKTzr1BRXrney-dvXpG5oeafYxe5rS", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C74072", "type": "Therapeutic"}, {"id": "iuphar.ligand:5681", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}, {"id": "civic.tid:344", "type": "TherapeuticDescriptor", "label": "GDC-0879", "therapeutic": "iuphar.ligand:5681"}]}}
{"id": "civic.eid:1447", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation. Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-30T01:27:43.860Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-08-04T05:15:43.589Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T23:21:27.894Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-18T07:52:29.119Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:193", "type": "Document", "label": "Engelman et al., 2008, Nat. Med.", "xrefs": ["pmc:PMC2683415", "pmid:19029981"], "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-Zsse0CnNGZSknki_mNiQFjmcOAvH1uh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C74072", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}}
{"id": "civic.eid:1462", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant\u2013expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:47:29.718Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-20T04:03:45.667Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:338", "type": "Document", "label": "Dahlman et al., 2012, Cancer Discov", "xrefs": ["pmc:PMC3449158", "pmid:22798288"], "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JWzx1Q50jSqU5LrAvii9CHxVt7_xzxzJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.OcUWoQ2D7_fkgr1dJw4mF2dJcy8Q3tu_", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:584", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:tWJleGyed3g0Eqv1ASxYxVix6lJUtxhw", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}]}}
{"id": "civic.eid:1505", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatment with trastuzumab and AZD5363 monotherapy induced moderate growth inhibition which was significant for AZD5363, but co-treatment with trastuzumab and AZD5363 induced significant tumor regression and enhanced growth delay upon removal of treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-07-06T10:40:07.690Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-06T19:35:33.401Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1005", "type": "Document", "label": "Davies et al., 2012, Mol. Cancer Ther.", "xrefs": ["pmid:22294718"], "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:2ZPAHRe72_HOMafL8x-j5EP2zpDsh6TS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C102564", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tcd:3yTLBT7LVjztI3zPC4FWN2nJQIyFTsx2", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C102564", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:112", "type": "TherapeuticDescriptor", "label": "Capivasertib", "xrefs": ["ncit:C102564"], "alternate_labels": ["AZD5363"], "therapeutic": "ncit:C102564"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}]}}
{"id": "civic.eid:1506", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD5363 or lapatinib alone induced growth inhibition (37%, not significant; 65%, P = 0.004), but treatment with AZD5363 and lapatinib together induced significant tumor regression (109%, P < 0.0001) as well as delayed tumor regrowth after removal of therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-07-06T10:44:56.171Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-21T15:37:47.092Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T23:21:50.128Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-21T15:37:52.515Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1005", "type": "Document", "label": "Davies et al., 2012, Mol. Cancer Ther.", "xrefs": ["pmid:22294718"], "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:pXIe0rGhQmFyw7tGDLBjRq_P_fbYZJTc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C102564", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tcd:rCQ3ME-7NyYYWvp6hnY7uiZVkQckf9-K", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C102564", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:112", "type": "TherapeuticDescriptor", "label": "Capivasertib", "xrefs": ["ncit:C102564"], "alternate_labels": ["AZD5363"], "therapeutic": "ncit:C102564"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}]}}
{"id": "civic.eid:1537", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-12T16:12:27.582Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-04T16:22:12.613Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-04T16:22:14.805Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1021", "type": "Document", "label": "Turajlic et al., 2014, Ann. Oncol.", "xrefs": ["pmc:PMC3999800", "pmid:24504448"], "title": "Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:RfqvEz928rCop3V80wsH6H7E46A096cu", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QYkNQvhUn7ivhb5plpyq7Hb9EpKTXT91", "predicate": "predicts_resistance_to", "object": {"id": "drugbank:DB06999", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:604", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:30", "type": "TherapeuticDescriptor", "label": "PLX4720", "therapeutic": "drugbank:DB06999"}}
{"id": "civic.eid:1545", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained sensitive to rapamycin and RapaLink-1 in vitro and in mouse xenografts. Expression of the mutation in MDA-MB-468 cells led to AZD8055 resistance and these cells were also rapamycin and RapaLink-1 sensitive.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-15T08:50:36.120Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-04T19:42:13.089Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-11-05T21:55:17.401Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-28T18:57:52.567Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1025", "type": "Document", "label": "Rodrik-Outmezguine et al., 2016, Nature", "xrefs": ["pmc:PMC4902179", "pmid:27279227"], "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:PTA5p7SIRofXtp3yQk93cu0Tk-naDrBc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PngdxFdLfRjz--M1ZiXdtsq3D4ixwAFH", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "iuphar.ligand:9212", "type": "Therapeutic"}, {"id": "rxcui:35302", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:609", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tcd:6f8Y3lvR4NV9ytfANIpnRCICPpmWkjSR", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "iuphar.ligand:9212", "type": "Therapeutic"}, {"id": "rxcui:35302", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:376", "type": "TherapeuticDescriptor", "label": "RapaLink-1", "therapeutic": "iuphar.ligand:9212"}, {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}]}}
{"id": "civic.eid:1625", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway.\nAmong the alterations, One cell line harbored a PIK3CA H1047R mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector. Perifosine treatment also increased apoptosis of a thyroid tumor xenograft with PIK3CA H1047R mutation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-31T08:48:10.903Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T23:23:54.542Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1076", "type": "Document", "label": "Liu et al., 2009, Cancer Res.", "xrefs": ["pmc:PMC2756336", "pmid:19706758"], "title": "Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:nbFibqjZffgozzIRlleoDyBbjkAiLqnx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C1727", "type": "Therapeutic"}, {"id": "rxcui:657797", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C7510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:16", "type": "DiseaseDescriptor", "label": "Thyroid Gland Cancer", "xrefs": ["DOID:1781"], "disease": "ncit:C7510"}, "object_descriptor": {"id": "civic.tcd:D46xUyn1b10HAjpKd6R9Pk2F5e_Dhj3C", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C1727", "type": "Therapeutic"}, {"id": "rxcui:657797", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:389", "type": "TherapeuticDescriptor", "label": "Perifosine", "xrefs": ["ncit:C1727"], "alternate_labels": ["4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt", "D21266", "Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate", "Octadecylphosphopiperidine"], "therapeutic": "ncit:C1727"}, {"id": "civic.tid:83", "type": "TherapeuticDescriptor", "label": "Temsirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002292", "type": "DiseaseDescriptor", "label": "Carcinoma, Renal Cell", "disease": "mondo:0005086"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1844"], "alternate_labels": ["42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin", "CCI-779", "CCI-779 Rapamycin Analog", "Cell Cycle Inhibitor 779", "Rapamycin Analog", "Rapamycin Analog CCI-779", "Torisel"], "therapeutic": "rxcui:657797"}]}}
{"id": "civic.eid:1626", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA E542K mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-31T08:49:41.449Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-11-05T23:25:45.191Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1076", "type": "Document", "label": "Liu et al., 2009, Cancer Res.", "xrefs": ["pmc:PMC2756336", "pmid:19706758"], "title": "Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:bpd7ax3Cr8IA26ZA5F963FoSK0MY9BJQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C1727", "type": "Therapeutic"}, {"id": "rxcui:657797", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C7510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:16", "type": "DiseaseDescriptor", "label": "Thyroid Gland Cancer", "xrefs": ["DOID:1781"], "disease": "ncit:C7510"}, "object_descriptor": {"id": "civic.tcd:D46xUyn1b10HAjpKd6R9Pk2F5e_Dhj3C", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C1727", "type": "Therapeutic"}, {"id": "rxcui:657797", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:389", "type": "TherapeuticDescriptor", "label": "Perifosine", "xrefs": ["ncit:C1727"], "alternate_labels": ["4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt", "D21266", "Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate", "Octadecylphosphopiperidine"], "therapeutic": "ncit:C1727"}, {"id": "civic.tid:83", "type": "TherapeuticDescriptor", "label": "Temsirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002292", "type": "DiseaseDescriptor", "label": "Carcinoma, Renal Cell", "disease": "mondo:0005086"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1844"], "alternate_labels": ["42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin", "CCI-779", "CCI-779 Rapamycin Analog", "Cell Cycle Inhibitor 779", "Rapamycin Analog", "Rapamycin Analog CCI-779", "Torisel"], "therapeutic": "rxcui:657797"}]}}
{"id": "civic.eid:1974", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D)  resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the  imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-16T09:57:28.582Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-10-06T20:44:08.800Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-10-05T23:03:48.365Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-03-16T10:12:47.325Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1389", "type": "Document", "label": "Dai et al., 2013, Clin. Cancer Res.", "xrefs": ["pmid:24132921"], "title": "Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7JPTJz_4qca_Es-Gr8J61OIPbpxlIuZ-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.C0rgzUpwcFdjMBg0zi_w5YtRubYanTeH", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:862", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:b5WTtG7LRkGXmkK9gDSA00gJ_AiZvgnj", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}]}}
{"id": "civic.eid:1975", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4.6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). PDGFRA R841K was detected in one sample of mucosal melanoma. In vitro, PDGFRA R841K expressed in IL-3 dependent Ba/F3 cells resulted in strong auto-phosphorylation and cell growth of PDGFRA independent of the presence of IL-3, suggesting oncogenicity. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA and cell proliferation. The authors concluded that PDGFRA R841K is sensitive to imatinib and crenolanib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-16T10:00:42.620Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-10-05T22:57:56.167Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-10-05T22:58:47.709Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-03-16T10:11:40.253Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1389", "type": "Document", "label": "Dai et al., 2013, Clin. Cancer Res.", "xrefs": ["pmid:24132921"], "title": "Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:YwF3BcyUG5iO1W3BV-sKj9uhzilyNJp5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.GyXeyLXX3qVI_4QEDws03Aby3FGdnwk0", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:863", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:b5WTtG7LRkGXmkK9gDSA00gJ_AiZvgnj", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}]}}
{"id": "civic.eid:1976", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-16T10:01:32.633Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-10-06T20:48:03.796Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-10-05T23:04:15.493Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-03-16T10:09:53.660Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-03-16T10:03:30.767Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1389", "type": "Document", "label": "Dai et al., 2013, Clin. Cancer Res.", "xrefs": ["pmid:24132921"], "title": "Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ItEvgmW75aGWPphZtYqqMrdhHjXW6VL6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NZKR5UoPECvb6hk08csNmFFBQQSS5KYr", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:864", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:b5WTtG7LRkGXmkK9gDSA00gJ_AiZvgnj", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}]}}
{"id": "civic.eid:1977", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-16T10:02:54.795Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-10-06T21:01:13.998Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-10-05T23:04:34.559Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-03-16T10:11:01.936Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1389", "type": "Document", "label": "Dai et al., 2013, Clin. Cancer Res.", "xrefs": ["pmid:24132921"], "title": "Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DqZPbquW5NXQJnjoqQoRu9rvdSoDyXDB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.H7ikP3HF5Mbc-sRURU9syl2u80gSmM51", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:865", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:b5WTtG7LRkGXmkK9gDSA00gJ_AiZvgnj", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C64639", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:21", "type": "TherapeuticDescriptor", "label": "Crenolanib", "xrefs": ["ncit:C64639"], "alternate_labels": ["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-", "CP-868,596", "CP-868596", "PDGFR Inhibitor CP-868596", "[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"], "therapeutic": "ncit:C64639"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}]}}
{"id": "civic.eid:1986", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 \u00b5M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-24T09:37:55.674Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-09-01T23:25:07.349Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-15T19:35:31.864Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1396", "type": "Document", "label": "Kancha et al., 2011, PLoS ONE", "xrefs": ["pmc:PMC3203921", "pmid:22046346"], "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9-Iz8gyjt3HaG5Xm9_S9NE_9jC0FFuaK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NjhhXseBQbnqoZe1jfZxCDklWnCYZ3lB", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:480167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4911", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:871", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:1322", "type": "DiseaseDescriptor", "label": "Stomach Carcinoma", "xrefs": ["DOID:5517"], "disease": "ncit:C4911"}, "object_descriptor": {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}}
{"id": "civic.eid:2001", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF, or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 8 G12V mutations (3 with PIK3CA mutations) where progressive disease occurred in only 1 tumor upon doublet treatment but 6 tumors in monotherapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:25.301Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T23:36:35.342Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-07-21T02:09:21.905Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T15:56:41.254Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1406", "type": "Document", "label": "Migliardi et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22392911"], "title": "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:KlXNVZER2DpftVQWmzsKmD69_nDUevfS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:2036", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations >0.01 ug/mL in both cell lines. Conversely, the cell line harboring PIK3CA E545K was resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on nude mice xenografted with PIK3CA E545K-harboring cells resulted in inhibition of tumor growth. A single dose of T-DM1 >3mg/kg was sufficient to induce tumor suppression lasting >20 days after administration.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:58:15.599Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-27T01:49:27.385Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-07-27T01:50:05.614Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-11-01T11:29:55.507Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T16:54:27.543Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:UhE4fIss0Z0leTHNspRbMbL-6axUAQU5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1371041", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:457", "type": "TherapeuticDescriptor", "label": "Trastuzumab Emtansine", "xrefs": ["ncit:C82492"], "alternate_labels": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"], "therapeutic": "rxcui:1371041"}}
{"id": "civic.eid:2078", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several HER2 amplified breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Two HER2 amplified breast cancer cell lines harboring PIK3CA C420R were tested for sensitivity to pictilisib. EFM-192A had an IC50 of 0.32uM and JIMT-1 had an IC50 of 0.86uM. Authors note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:06.048Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-12T18:37:31.397Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-12T18:37:52.056Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-12T18:35:51.210Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-12T18:38:10.820Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:cchGUIHkEifEsQIT6ofL9Gph4K131V2V", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:931", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2089", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1 umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal type breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.09uM, suggesting sensitivity. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=.02)", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:16.745Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-16T19:37:06.643Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-16T19:54:27.986Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-16T19:37:21.053Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-16T19:54:39.396Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:af8iX9hZkRMEkg4qC4lmHYCrKiV_w4iL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mCpnGyjIgv27feD0L-LFc95zm7d6RmDt", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1151", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2103", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in all three cell lines. Conversely, the cell lines harboring PIK3CA H1047R were resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on SCID mice xenografted with KPL-4 (PIK3CA H1047R cells) resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:44.915Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-27T01:55:06.295Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-07-27T01:55:21.310Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-11-01T11:29:26.399Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T19:38:55.786Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:RJQ1tYuqX5vViijw1HblZXgUPiCv7aXb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1371041", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:457", "type": "TherapeuticDescriptor", "label": "Trastuzumab Emtansine", "xrefs": ["ncit:C82492"], "alternate_labels": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"], "therapeutic": "rxcui:1371041"}}
{"id": "civic.eid:2161", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 \u03bcmol/L for all three cell lines).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:34.423Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-18T23:41:46.840Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-30T18:09:35.283Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:11:29.408Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1515", "type": "Document", "label": "Engelman et al., 2007, Cancer Res.", "xrefs": ["pmid:18089823"], "title": "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ubTJYnn22Ciocr3vBLnRKKB_sWeLggyt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2058848", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:44", "type": "TherapeuticDescriptor", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C53398"], "alternate_labels": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"], "therapeutic": "rxcui:2058848"}}
{"id": "civic.eid:2192", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring mutations in KRAS, NRAS, BRAF, or PIK3CA and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. NRAS mutations were in 4/40 tumors (three Q61K, one G12D).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:52.656Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T16:40:37.088Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:30:32.408Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:30:34.963Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1406", "type": "Document", "label": "Migliardi et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22392911"], "title": "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:APMUaTFcrCBylNtzzQiHZvaTpb0wllpT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NHUtQ1IbZA9ZlH8wKbaMNF0W7esiwPKj", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:427", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:2206", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 A146T tumors (1 also harboring PIK3CA E545K) which both showed disease stabilization during doublet therapy but progression on either single agent.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:55.382Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T19:01:10.825Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:32:50.606Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:32:46.552Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1406", "type": "Document", "label": "Migliardi et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22392911"], "title": "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DScBAq_A58ZrbkwVcvG9m0IOAVKXxH4l", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3uCfDUOYdVAjM2BG0xyWDioC6fPY1yn4", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:906", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:2209", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring NRAS, KRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 tumors with A146V mutations which achieved stable disease with combined therapy but progressive disease in either monotherapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:57.907Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T19:38:56.956Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:31:49.804Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:31:53.353Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1406", "type": "Document", "label": "Migliardi et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22392911"], "title": "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:EEXZJeULO_kFGlyHV8fSVMxEkxdM31Kd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.G-Fn2qLS-0ud98S5NNSSWeuiZ15OaYQo", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:322", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:2218", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors studied had KRAS mutations with 9 G12D (2 with PIK3CA H1047R) and 13 other G12 mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:00.894Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-20T18:44:39.708Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-20T22:35:26.292Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-20T22:35:22.133Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1406", "type": "Document", "label": "Migliardi et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22392911"], "title": "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:yFRszjGsSWdZs-TLr94MYxTH6ccOU5C-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:2221", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. Cells were treated with doxorubicin to induce double-strand (DSB) and p21 induction was monitored by qPCR. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the T2666A variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:07.517Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:01:59.644Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:02:13.171Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:02:16.171Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:VZ1RStELV9VVB6vC9Aarex37hjjdEk6g", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Q2S35WrvyuYDN2dEQAdqNoykhqqOPJHP", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:901", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2223", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the R3008C variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. In a patient sample with the R3008C variant of ATM in trans with a wild-type allele, confirmed by sanger sequencing, western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance. The authors propose that this variant has a dominant-negative effect.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:08.812Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:07:19.903Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:07:51.732Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:08:43.927Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5Blwf-ZNUaIUX8kNFEoxL4aT2Fsiz0Mf", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.To8S93QbZgfmwzt9nUu-BiWFs2Os_TPf", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:903", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2346", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; substantially reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA C420R experienced a smaller reduction in cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:58.435Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-27T02:01:15.654Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-07-27T02:02:05.267Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-07-27T02:02:07.781Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:c4jWmXgjxoGrbI07i9MRLJbkx7aSxIah", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1371041", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:931", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:457", "type": "TherapeuticDescriptor", "label": "Trastuzumab Emtansine", "xrefs": ["ncit:C82492"], "alternate_labels": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"], "therapeutic": "rxcui:1371041"}}
{"id": "civic.eid:2626", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:35.142Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-08T00:12:05.380Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T20:20:17.449Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:45:39.260Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1525", "type": "Document", "label": "Li et al., 2008, Oncogene", "xrefs": ["pmc:PMC2748240", "pmid:18408761"], "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:RpycfRKqeut5mo1giuMltdkonwOflqQt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:480167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}}
{"id": "civic.eid:2627", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:36.586Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-09-05T19:43:50.318Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-09-05T19:42:20.410Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:45:42.615Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1515", "type": "Document", "label": "Engelman et al., 2007, Cancer Res.", "xrefs": ["pmid:18089823"], "title": "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:p7sVbOSDxfEcJfJzPqC8Kxl7rO37GPxZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2058848", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:44", "type": "TherapeuticDescriptor", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C53398"], "alternate_labels": ["(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide", "EGFR Inhibitor PF-00299804", "PF-00299804", "PF-00299804-03", "PF-299804", "Vizimpro"], "therapeutic": "rxcui:2058848"}}
{"id": "civic.eid:2628", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated sensitivity to neratinib (IC50: 0.0049 \u03bcmol/L) compared to EGFRwt A549 cells (IC50 > 1 \u03bcmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:37.891Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-23T21:13:35.273Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-23T21:07:21.166Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:45:46.058Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1526", "type": "Document", "label": "Shimamura et al., 2006, Cancer Res.", "xrefs": ["pmid:16818618"], "title": "Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:PlkNc0J-N3ApugX4M9XmvsatgGLSXtGc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:2631", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:42.172Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-08T00:14:06.138Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T20:15:10.218Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:45:50.596Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1525", "type": "Document", "label": "Li et al., 2008, Oncogene", "xrefs": ["pmc:PMC2748240", "pmid:18408761"], "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:VY4QbYRZmRe069lQMr99X-TX2g2BMlO1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C77588", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:465", "type": "TherapeuticDescriptor", "label": "Canertinib", "xrefs": ["ncit:C77588"], "alternate_labels": ["2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-", "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide"], "therapeutic": "ncit:C77588"}}
{"id": "civic.eid:2832", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K293* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K293* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 92% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:32.098Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:12:36.713Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:13:57.851Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:14:25.444Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:WRpZz3qgcFPdu1NCOA1RzkSkzWtanHiK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SnNHiwjxElDYSwi_3-tFVQ9UqFshM3Pd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1155", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2835", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F1025L variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F1025L variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:32.483Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:15:28.408Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:16:12.369Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:16:14.179Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:gy8hW4dxynWadsCnL-mM1kBn8kq3-UoH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.DsNqZZtkjmBwWYy9SCQPY7PoEb6yrTRk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1158", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2839", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the E2187* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the E2187* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 96% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:33.005Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:16:33.989Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:16:53.893Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:17:36.042Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7D4A2WPWZuGyCbsZenfR0-udUlheRD3Z", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Xy0pE6GL2go3zYEteqG2O4RcIRGnRF84", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1162", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2840", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the L2427P variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the L2427P variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 94% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:33.156Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:20:56.464Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:21:14.102Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:22:43.638Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:e3Xi6bjhOveF7nk7QJE1VyZketcJcTIW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.-_I6gBvaWqmpoQiy7JOPcnb8W_1Qg2qt", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1163", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2841", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F2732V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F2732V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 98% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:33.250Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:23:02.433Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:23:36.192Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:24:36.726Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:dH0Gfr691SaSZlmMroj6AbFk8I25fp3V", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.vhBZUX844n7cC8W0Sx71rTBMSiW_BvQ3", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1164", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2845", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1682H variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1682H variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:33.754Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:28:39.305Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:29:21.586Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:29:23.955Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qL5Bj4bPc_0c0BPm5ovVAr44VftRlJk5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.R5WWfv7CUYjx7LyTJVkrCQR7gjEWGcnU", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1168", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2846", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the A2062V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the A2062V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 87% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:33.881Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:27:29.189Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:29:58.992Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:33:21.639Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:30:45.455Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:O3HfL85BIqonVo6c_LPE0Dk2H0Y7OHiH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.ylGgZvYUv6RQT8ODt_vMdmHz7Hk_qySB", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1169", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2849", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the C2488Y variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the C2488Y variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 90% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:34.236Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T03:31:09.909Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:41:40.472Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T03:43:13.446Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:OdoIzvtqD0vTJwVdNdhkAcHz1SVo9x4a", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.zRieVFQoxthGnTV-n5M7mbnxDXMoULBH", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1172", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2866", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA K111N experienced a smaller reduction in cell viability. Further, treatment with T-DM1 on SCID mice xenografted with PIK3CA K111N cells resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:26.705Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-14T20:31:11.072Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:32:01.917Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:32:04.020Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:SoGfcMqPfbkxZcBrcnPV37RfdDiuE8Ag", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MwhPgqLyRggo95FGBET65hs3Dbmm0jW1", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1371041", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1234", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:457", "type": "TherapeuticDescriptor", "label": "Trastuzumab Emtansine", "xrefs": ["ncit:C82492"], "alternate_labels": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"], "therapeutic": "rxcui:1371041"}}
{"id": "civic.eid:2867", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. When treated with trastuzumab, the cell line harboring PIK3CA I391M experienced similar reduction in cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:09:26.809Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-14T20:46:54.179Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:47:21.467Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:48:09.660Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:4kYFluiWAcz4s14H4QP9g6sqwppE1Bxx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.85QZR4K49RijmSG0hPIy9BQRNQBKuFgj", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1371041", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1235", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:457", "type": "TherapeuticDescriptor", "label": "Trastuzumab Emtansine", "xrefs": ["ncit:C82492"], "alternate_labels": ["ADO-TRASTUZUMAB EMTANSINE", "Ado Trastuzumab Emtansine", "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine", "Kadcyla", "PRO132365", "RO5304020", "T-DM1", "Trastuzumab-DM1", "Trastuzumab-MCC-DM1", "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate", "Trastuzumab-MCC-DM1 Immunoconjugate"], "therapeutic": "rxcui:1371041"}}
{"id": "civic.eid:2943", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-12T10:33:19.154Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-04-19T23:36:32.790Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:33:13.846Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-04-19T23:33:44.388Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1632", "type": "Document", "label": "Janakiraman et al., 2010, Cancer Res.", "xrefs": ["pmc:PMC2943514", "pmid:20570890"], "title": "Genomic and biological characterization of exon 4 KRAS mutations in human cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:RDjRbb67fdvGyULrd0ygmwcjxdgUi3Av", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.3uCfDUOYdVAjM2BG0xyWDioC6fPY1yn4", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:906", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:2984", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "CaSki cells that are heterozygous for the PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA-E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941/Pictilisib. In addition, GDC-0941 restored sensitivity of E545K mutant cell lines to cisplatin as combination treatment had a larger impact on cell survival than either drug alone.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-20T19:51:31.621Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-05T00:54:41.869Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-05T00:33:46.565Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-04-21T00:04:43.605Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1708", "type": "Document", "label": "Arjumand et al., 2016, Oncotarget", "xrefs": ["pmc:PMC5347702", "pmid:27489350"], "title": "Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:TjeIUxgqZ3Gh7q1tSG84DK_W68f6rFDn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C165479", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9039", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:125", "type": "DiseaseDescriptor", "label": "Cervix Carcinoma", "xrefs": ["DOID:2893"], "disease": "ncit:C9039"}, "object_descriptor": {"id": "civic.tcd:lKzFO2wvX0aR43_nXTZ19I1vjsXGQ6R8", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C165479", "type": "Therapeutic"}, {"id": "rxcui:2555", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}, {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}]}}
{"id": "civic.eid:2985", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutation were significantly more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941 (pictilisib).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-04-20T19:52:18.616Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-05T00:59:32.319Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T00:52:21.573Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-04-21T00:02:02.037Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1708", "type": "Document", "label": "Arjumand et al., 2016, Oncotarget", "xrefs": ["pmc:PMC5347702", "pmid:27489350"], "title": "Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5bojufpOoUGtRGfz0eIocSetw-fvXiou", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2555", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9311", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:159", "type": "DiseaseDescriptor", "label": "Cervical Cancer", "xrefs": ["DOID:4362"], "disease": "ncit:C9311"}, "object_descriptor": {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}}
{"id": "civic.eid:3007", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518 (Tandutinib). Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:401", "type": "Agent", "name": "Emre KAR"}, "date": "2017-05-15T20:53:15.626Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-22T07:15:29.886Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-08-29T21:46:53.477Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:21:50.540Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:367", "type": "Document", "label": "Clark et al., 2004, Blood", "xrefs": ["pmid:15256420"], "title": "Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qUxiJb1zm8BL7k9P8q1DFRA8G02WM01u", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C48404", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:503", "type": "TherapeuticDescriptor", "label": "Tandutinib", "xrefs": ["ncit:C48404"], "alternate_labels": ["1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-", "CT53518", "MLN 518", "MLN518"], "therapeutic": "ncit:C48404"}}
{"id": "civic.eid:3008", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248 (Sunitinib) with dose required to inhibit proliferation of cells to 50% of untreated controls ED50 = 110nM.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:401", "type": "Agent", "name": "Emre KAR"}, "date": "2017-05-16T06:47:26.394Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-21T23:35:48.335Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2019-09-05T19:37:44.146Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:26:21.288Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1731", "type": "Document", "label": "Yee et al., 2004, Blood", "xrefs": ["pmid:15304385"], "title": "Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:cNXnum0iMP9Mfx2sV-QCaVDJRb08KwAU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:3733", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a RKO cell line expressing BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R co-mutation demonstrated reduced sensitivity to vemurafenib treatment. Resistance was determined by assessing cellular proliferation and AKT phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:36.803Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-06-18T22:19:43.347Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T22:17:59.249Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T22:20:16.772Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:108", "type": "Document", "label": "Yang et al., 2012, Cancer Res.", "xrefs": ["pmid:22180495"], "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7DUBSsCEnDwTV2Kh1QnykNS5U_FyDOps", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3810", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated resistance to gefitinib and erlotinib and the tool construct AEE788. These cells had very high IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib>2000, Erlotinib>2000, AEE788>2000), indicating resitance to all three inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:35:51.633Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-09-02T00:44:38.050Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-02T06:58:29.966Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-14T22:43:32.682Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8kUPFGnofn6XbRF9_H67NbdqWI_bFLrN", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:337525", "type": "Therapeutic"}, {"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "ncit:C48369", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tcd:KuD9fVxtGEzkO9TjmpGN0Xt5x68Qm7S-", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:337525", "type": "Therapeutic"}, {"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "ncit:C48369", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}, {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:90", "type": "TherapeuticDescriptor", "label": "Multikinase Inhibitor AEE788", "xrefs": ["ncit:C48369"], "alternate_labels": ["AEE 788", "AEE-788", "AEE788"], "therapeutic": "ncit:C48369"}]}}
{"id": "civic.eid:3811", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:35:52.248Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-14T22:27:01.437Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-16T05:18:52.171Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-07T22:45:32.641Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-16T05:19:04.059Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qQ9X_ptQ_PabxAT-fo-9h8HNiMemhBdr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:337525", "type": "Therapeutic"}, {"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "ncit:C48369", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tcd:KuD9fVxtGEzkO9TjmpGN0Xt5x68Qm7S-", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:337525", "type": "Therapeutic"}, {"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "ncit:C48369", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}, {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:90", "type": "TherapeuticDescriptor", "label": "Multikinase Inhibitor AEE788", "xrefs": ["ncit:C48369"], "alternate_labels": ["AEE 788", "AEE-788", "AEE788"], "therapeutic": "ncit:C48369"}]}}
{"id": "civic.eid:3958", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Resistance was determined by assessing cell growth. Further, in an in vivo experiment, KRAS G12D expressing MCAS xenografts in nude mice had reduced response to cetuximab, as compared to KRAS wild-type expressing RMUG-L xenografts. Resistance was determined by assessing tumor growth.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:10.145Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-19T23:26:23.675Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-20T14:48:23.133Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T21:24:12.449Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2024", "type": "Document", "label": "Sato et al., 2012, Oncol. Rep.", "xrefs": ["pmid:22246397"], "title": "Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hxDm3RcJ-VZI7TPEWeKKrVmMsZmWK5Gi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7431", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:20", "type": "DiseaseDescriptor", "label": "Ovarian Cancer", "xrefs": ["DOID:2394"], "disease": "ncit:C7431"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4084", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to imatinib (IC50: 27nmol/L) and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability. In mice treated in vivo with Ba/F3 cells expressing KIT W557_K558 mutation, tumor volume was significantly reduced in response to both ponatinib and imatinib treatments.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:53.693Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-08T22:29:26.360Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:24:16.750Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:24:20.938Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:7gn1J87ek9USj_qcfHuL-ZMA1IIIEkDF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2gBgJAKNHo14J6N0g8ZYsewGjZK1O2tQ", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:961", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:Bp7LSZxv3sM5AUjPNf7nTRGI6VHQfjmY", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}]}}
{"id": "civic.eid:4127", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to imatinib (IC50: 3nmol/L), sunitinib (IC50: 2nmol/L), regorafenib (IC50: 3nmol/L), and ponatinib (IC50: 2nmol/L) treatments. IC50 was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:30.784Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T22:10:19.371Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:10:31.051Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:09:30.408Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:un-3Zx5nTn_TQgbO4AWlow71e9tx_DPB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wkbbLzMJDVWkn-GLG_Q3IhYQ261bvMFN", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:971", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:EFgr37MY89Im6stpaZjt2xyMOX1et0He", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:4167", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and N822K mutations did not show resistance towards Ponatinib (IC50 for growth inhibition: 3 nM) compared to Ba/F3 cells with del 557-558  alone (IC50: 3 nM). Ponatinib inhibited KIT phosphorylation at moderate concentrations. The results suggest that N822K does not induce Ponatinib resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:41:06.683Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-19T22:06:05.131Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:07:24.776Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T22:07:46.638Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:AAWMc-hrRb7s1ZVE5wsMVGb5hueiM6u8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1364347", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}}
{"id": "civic.eid:4169", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A preclinical study tested the effects of tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558 and N822K mutations did show resistance towards Regorafenib (IC50 for growth inhibition: 131 +- 9 nM) compared to Ba/F3 cells with the del 557-558 mutation (IC50 for growth inhibition: 30 +- 14 nM). Regorafenib inhibited KIT phosphorylation only at high concentrations. The results suggest that N822K does induce Regorafenib resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:41:08.726Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-19T21:58:53.358Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T21:59:27.739Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-19T21:34:17.719Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9zZr_91zEe56FU7LcA9uBqXHfSVrqNWq", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:4186", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:41:47.849Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-23T04:19:24.085Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-28T05:34:57.238Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-06-15T22:41:11.164Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1608", "type": "Document", "label": "Lee et al., 2006, PLoS Med.", "xrefs": ["pmc:PMC1702556", "pmid:17177598"], "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:pNatPrltMQFq9uWKHMf1yg3Wz5gSGIou", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.exS9Oqdo0Vl3EiX5wm82bgZCGHwUg4DV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4822", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:994", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:695", "type": "DiseaseDescriptor", "label": "High Grade Glioma", "xrefs": ["DOID:3070"], "disease": "ncit:C4822"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4187", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:41:48.551Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-23T04:22:19.689Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-28T05:43:54.556Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-06-15T22:39:45.847Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1608", "type": "Document", "label": "Lee et al., 2006, PLoS Med.", "xrefs": ["pmc:PMC1702556", "pmid:17177598"], "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:xpVLDxvphv3OHxd1BgEkN_O5Gqv16aOM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.eE_nlz1ZmG5PFWTIRhdALAWP1k8GuLuQ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4822", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:995", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:695", "type": "DiseaseDescriptor", "label": "High Grade Glioma", "xrefs": ["DOID:3070"], "disease": "ncit:C4822"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4188", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:41:49.632Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-06-15T14:54:52.815Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-08-25T01:11:47.890Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-06-15T14:55:03.457Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1608", "type": "Document", "label": "Lee et al., 2006, PLoS Med.", "xrefs": ["pmc:PMC1702556", "pmid:17177598"], "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lIjY8s_TXgyNP6PNghQ1ojV2Uf52d10m", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5NyvG1Whx8hMOkm0RuFVrglFMs5lH_WL", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4822", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:996", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:695", "type": "DiseaseDescriptor", "label": "High Grade Glioma", "xrefs": ["DOID:3070"], "disease": "ncit:C4822"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4265", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:46:57.685Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-08-25T00:46:21.464Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-08T20:56:59.230Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-08-25T01:02:47.255Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-09-08T20:57:09.108Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1991", "type": "Document", "label": "de Gunst et al., 2007, Mol. Cancer", "xrefs": ["pmc:PMC2064929", "pmid:17877814"], "title": "Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:SiixlQPIiMUTcOOHiEHlMp9LXEJSztAd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4274", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR S768I and EGFR L858R expressing cells were 250 nmol/L and 6 nmol/L, respectively. Gefitinib was similarly tested and IC50 of 315 nanomolar was obtained, indicating non-response and potential resistance", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:47:36.627Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-09-05T19:08:15.119Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-13T17:11:54.638Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:31:01.401Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FRRNThJZOU2ERufzg8OO9-NRoYZxihtr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2TmSETRJQzrU-OXco267vKiGgGY4qCLK", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:562", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:4286", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006 and 0.068 \u00b5M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:20.998Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T23:46:06.050Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T23:40:53.123Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:02.653Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:teH1xxIK6r4jpsaY8NccNewpkJ0YcjYX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4292", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:42.324Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-23T19:36:45.551Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-23T19:32:07.230Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:10.822Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2086", "type": "Document", "label": "Konduri et al., 2016, Cancer Discov", "xrefs": ["pmc:PMC4893907", "pmid:27102076"], "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:55kxkZvjr09aIUCKjw6jOHkKH-ezzi_O", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:318341", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}}
{"id": "civic.eid:4295", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:44.850Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-23T04:25:00.983Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-28T05:37:45.872Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-06-15T22:25:11.878Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1608", "type": "Document", "label": "Lee et al., 2006, PLoS Med.", "xrefs": ["pmc:PMC1702556", "pmid:17177598"], "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:WS0_pm2W5ANc_Q7Hg0Z40xc3rVjM74AE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4822", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:695", "type": "DiseaseDescriptor", "label": "High Grade Glioma", "xrefs": ["DOID:3070"], "disease": "ncit:C4822"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4299", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:51.699Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-23T04:26:12.810Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-28T05:36:55.511Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-06-15T22:23:33.674Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1608", "type": "Document", "label": "Lee et al., 2006, PLoS Med.", "xrefs": ["pmc:PMC1702556", "pmid:17177598"], "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:IPxAGIPuTU7jHVU7Ilxr-AVaEQms-SiH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U5KCINj8e9QhYAbBlFUiQWa5oWvL1uXs", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4822", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1020", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:695", "type": "DiseaseDescriptor", "label": "High Grade Glioma", "xrefs": ["DOID:3070"], "disease": "ncit:C4822"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4488", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, WM2664, a BRAF V600D expressing cell line, demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (WM2664, GI50: 1.5uM; vs. BRAF expressing cells (n=9) GI50: 10-41uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:23.542Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-19T22:49:24.235Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-20T14:49:36.331Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-07-06T14:04:17.693Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1952", "type": "Document", "label": "Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A.", "xrefs": ["pmc:PMC2268581", "pmid:18287029"], "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qDTjQOzTlZ9n7UlJhkmSZT4pTW_Mcr8N", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nstQWjDNJb8qwT0ZtyIGNK9El0LZGMn5", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:11", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4521", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:52:04.573Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-18T18:37:46.087Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:05:31.971Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-28T18:17:09.879Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:06:20.557Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hw8jVmn0Yy5cFet1qIhOFpMQCM8u0p3x", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.dDEqcxz4HCtU5NFIDMd5GIfcyWqL5HN4", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1227", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4630", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT A502_Y503insAY primary activating mutation demonstrated insensitivity to regorafenib (IC50: 138nmol/L), imatinib (IC50: 143nmol/L), and ponatinib (IC50: 56nmol/L) treatments. In comparison, sensitizing KIT mutation del550-557 showed IC50 22, 13 and 3 nmol/L for these drugs respectively. IC50 was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:29.059Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-08T22:18:32.742Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:03:35.707Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:06:35.134Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:9lXWnuR46QWPPhJpvssjJ_SLNMFFngZi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wz6wMfy1414Bg53uDpoW0GtkipcMyumU", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1558", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:pRXLOTUcGy266tKwrptqo3E3XUUSTYZh", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}]}}
{"id": "civic.eid:4655", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR W731L demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:46.922Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-19T00:34:54.869Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2022-03-23T20:04:51.626Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-18T23:33:33.322Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2081", "type": "Document", "label": "Foster et al., 2010, World J Surg Oncol", "xrefs": ["pmc:PMC2970593", "pmid:20942962"], "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:moKXRi9KTHRlbL9HJEDcLSZVyztOQMPm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.czYeeWu-jzRt2JmYkEb291gwoat-dscQ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1571", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4659", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR Y801H demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:53:49.867Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-19T00:30:11.546Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2022-03-23T19:09:13.908Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-01-18T23:31:47.118Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2081", "type": "Document", "label": "Foster et al., 2010, World J Surg Oncol", "xrefs": ["pmc:PMC2970593", "pmid:20942962"], "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:V0d06cxy6hs8nkxB44TjzZfjtP2HpC1W", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JaLuiStGZvFtZu1fvFG0KueiCc8sDd1Y", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1575", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4783", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3R2 N561D were significantly more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with an empty vector (40% vs 0% survival at the highest concentration, p < .0001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:48.278Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T20:30:53.419Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:31:09.266Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-27T21:43:11.382Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:31:18.942Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Q7_0_9nwv2bKvEwgCsZ1YLzipsq5m1uM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VqK773vLUUqBwBpE3ER4-XSXVh349TMB", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1652", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4788", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this in vitro study, the H2110 non-small cell lung cancer cell line (heterozygous for a G340L mutation) was shown to be susceptible to imatinib and dasatinib monotherapies. This line showed a significant reduction in colony formation (P = 0.0001) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. A significant reduction in colony formation (P < 0.001) with dasatinib treatment vs vehicle was also observed. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Moreover, a significant increase in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.001) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:51.798Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2018-07-11T16:17:53.340Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-23T21:37:56.706Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-23T21:38:00.735Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2128", "type": "Document", "label": "Testoni et al., 2016, EMBO Mol Med", "xrefs": ["pmc:PMC4734836", "pmid:26758680"], "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:i6l0pLn8SVg5bc4YnPmRAYUZQPUlZVDP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.a2AQi4f2PGXrCYgoe9MX9a4zGUVPJ8JZ", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1546019", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1657", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:dGeFezSlKdWXf9xk5Kn9yUW_wRthhsRt", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1546019", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}, {"id": "civic.tid:537", "type": "TherapeuticDescriptor", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C1687"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"], "therapeutic": "rxcui:282388"}]}}
{"id": "civic.eid:4885", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 M237I loss of function mutation is present in 1 cell line (T98G, glioblastoma) and it is insensitive to MDM2 Inhibitor AMGMDS3 (IC50: 49.97uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T19:52:49.302Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T04:41:46.106Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T18:57:30.380Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:29:19.303Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1356rlb1Hxjeni6fGny4K4eepyLNKgNi", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.oIP_Wv6LX8o9-TpPmpT_4mBK7JBtgYg2", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3058", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1066", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:19", "type": "DiseaseDescriptor", "label": "Glioblastoma", "xrefs": ["DOID:3068"], "disease": "ncit:C3058"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:4886", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158H loss of function mutation is present in 1 cell line (SW954) and it is insensitive to MDM2 Inhibitor AMGMDS3.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:430", "type": "Agent", "name": "Dmitriy Sonkin"}, "date": "2017-06-16T20:02:24.564Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-06T19:05:26.688Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2022-04-06T09:28:56.263Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-08-13T14:04:11.295Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-30T23:56:54.597Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1696", "type": "Document", "label": "Saiki et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4480710", "pmid:25730903"], "title": "Identifying the determinants of response to MDM2 inhibition."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ObSfbnkawn5_DRdYYMngwLfSFR_wEPmD", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.J34fq_QemA86Fe5wU6IlVdCp7WPLgAw6", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C171616", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4052", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1695", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:117", "type": "DiseaseDescriptor", "label": "Vulva Squamous Cell Carcinoma", "xrefs": ["DOID:2101"], "disease": "ncit:C4052"}, "object_descriptor": {"id": "civic.tid:20623", "type": "TherapeuticDescriptor", "label": "MDM2 Inhibitor AMGMDS3", "xrefs": ["ncit:C171616"], "alternate_labels": ["2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid", "AMGMDS3", "Q59770979"], "therapeutic": "ncit:C171616"}}
{"id": "civic.eid:5947", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ba/F3 cells transduced with EGFR D770_N771insNPG were IL3 growth independent, suggesting a driver mutation.\n\nGefitinib growth inhibition IC50 in D770_N771insNPG transduced Ba/F3 cells was 3.356 micro molar, which was higher than cells transduced with resistance mutation T790M (IC50=2.752). Similarly, afatinib growth inhibition IC50 was 0.0724 micro molar, which was higher than cells transduced with resistance mutation T790M (IC50=0.0629).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-02-11T10:23:16.652Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-03-27T01:35:01.088Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-03-27T01:35:10.802Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1230", "type": "Document", "label": "Yasuda et al., 2013, Sci Transl Med", "xrefs": ["pmc:PMC3954775", "pmid:24353160"], "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8kBcXm1FLeZkxdHMOmmNIrEnNwfAq4CV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.kjNBWIlntXr1owTK1p2HSUvbV39RQLeJ", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:1430438", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1569", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:mnS64Wd7Idu3tHEYX3g8MGHOl43L8wuU", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:1430438", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}]}}
{"id": "civic.eid:6001", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T12:52:54.941Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-24T15:33:17.413Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:337", "type": "Document", "label": "Smalley et al., 2009, Oncogene", "xrefs": ["pmc:PMC2898184", "pmid:18794803"], "title": "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:GaFp5ewnAymilBbH1gFh0FCaTPSmJioo", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:611", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}}
{"id": "civic.eid:6002", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T12:54:15.675Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-10-05T23:50:38.784Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-10-06T06:51:30.940Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-24T15:35:19.655Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:337", "type": "Document", "label": "Smalley et al., 2009, Oncogene", "xrefs": ["pmc:PMC2898184", "pmid:18794803"], "title": "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0uK1jvl5h0EwHwPvEz302aN89SyR4Amy", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX", "predicate": "predicts_resistance_to", "object": {"id": "iuphar.ligand:5282", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:611", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:568", "type": "TherapeuticDescriptor", "label": "U0126", "therapeutic": "iuphar.ligand:5282"}}
{"id": "civic.eid:6003", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T13:00:26.525Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-24T15:33:47.009Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:337", "type": "Document", "label": "Smalley et al., 2009, Oncogene", "xrefs": ["pmc:PMC2898184", "pmid:18794803"], "title": "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:L62GI700h3mI1rV46yUvAVPO-_BZ4VKP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qhJpha5rN0z-Rg2lOjtAhH1UhB9CaRJ-", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:495881", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:993", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}}
{"id": "civic.eid:6004", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis after shRNA-mediated CRAF knowdown or treatment with the pan-RAF inhibitor sorafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2018-02-16T13:01:33.900Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:212", "type": "Agent", "name": "Gabe Rudy"}, "date": "2020-02-26T23:22:24.584Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2020-09-24T18:56:19.862Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-07-24T15:34:47.904Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:337", "type": "Document", "label": "Smalley et al., 2009, Oncogene", "xrefs": ["pmc:PMC2898184", "pmid:18794803"], "title": "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:LFdjqFhNARKN8acHrPV2cD8UBgqKIne8", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qhJpha5rN0z-Rg2lOjtAhH1UhB9CaRJ-", "predicate": "predicts_resistance_to", "object": {"id": "iuphar.ligand:5282", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:993", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:568", "type": "TherapeuticDescriptor", "label": "U0126", "therapeutic": "iuphar.ligand:5282"}}
{"id": "civic.eid:6174", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Efficacy of osimertinib and its metabolite, AZ5104, at reducing phosphorylation of key proteins was evaluated by western blot. Osimertinib failed to induce substantial reductions in phosphorylated ERBB2 in NR6 mouse fibroblast cells transduced to co-express ERBB2 L869R and T798I or ERBB2 wt. AZ5104 blocked phosphorylation to a greater extent in the mutant and wildtype cells. MCF10A cells transduced with ERBB2 wt, ERBB2 T798I alone or ERBB2 L869R and T798I co-expressed did not show substantial reductions in phosphorylated ERBB2, AKT, ERK or S6. AZ5104 induced greater reductions. Authors note that AZ5104 is not being developed independently of osimertinib and only 10% of osimertinib is metabolized into AZ5104 in humans. Authors concluded that ERBB2 T798I is not sensitive to osimertinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:688", "type": "Agent", "name": "Fernanda Martins Rodrigues"}, "date": "2018-05-08T20:13:10.727Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-08T20:04:30.292Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2020-12-10T20:19:56.970Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-10T20:21:58.666Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2397", "type": "Document", "label": "Hanker et al., 2017, Cancer Discov", "xrefs": ["pmc:PMC5457707", "pmid:28274957"], "title": "An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:AxJbLAksaIqNnIfMQNF6mXdu1QiBoEzm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.-lzdusNSv3OOMumPo2ISeMRzbsnQABSZ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2331", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:6211", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a preclinical study, efficacy of lapatinib and trastuzumab was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E45K. The study found that E545K abrogated the growth inhibitory effects of lapatinib and trastuzumab, either in isolation or in combination, though increased cell death was observed with combination therapy relative to monotherapy. The authors concluded that the PIK3CA E545K induces resistance to lapatinib and trastuzumab in HER2-positive breast cancer cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-07T20:26:49.730Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-28T21:18:06.329Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:19:02.286Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:19:07.778Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2486", "type": "Document", "label": "Eichhorn et al., 2008, Cancer Res.", "xrefs": ["pmc:PMC2587064", "pmid:19010894"], "title": "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DJFMNiXHqpVY4ds-icvizE2LoUSTy3B5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tcd:Exy3-S7snfyhQHnOQ6ZbukSAmtGQaYfA", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:480167", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}]}}
{"id": "civic.eid:6213", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E545K to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of E545K mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA E545K expressing cells. Growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-07T20:29:18.386Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-28T21:08:23.404Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:11:37.308Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-20T23:46:58.641Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2486", "type": "Document", "label": "Eichhorn et al., 2008, Cancer Res.", "xrefs": ["pmc:PMC2587064", "pmid:19010894"], "title": "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:8H_mqH07KUfL_Q9w_q7AXuWIgQXTzcVr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C74072", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}}
{"id": "civic.eid:7370", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a preclinical trial, the AML cell line Kasumi-1 with the KIT mutation N822K was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the KIT mutation (IC50=8 nmol/L) compared to sorafenib (IC50=59 nmol/L) and sunitinib (IC50=56 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-06-21T22:14:14.910Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-06-21T22:58:34.985Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-06-21T23:23:53.354Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-06-21T23:00:28.233Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2913", "type": "Document", "label": "Gozgit et al., 2011, Mol. Cancer Ther.", "xrefs": ["pmc:PMC3236248", "pmid:21482694"], "title": "Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:wHSS44MtS1W_a7YrMMutdjVasgWSo2Ez", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tcd:wsLrVLsW3tlJpvelphvNfi7j0WAQrFVD", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:7395", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro kinase study, a KIT V560G primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 38nmol/L vs. 640nmol/L), regorafenib (IC50: 27nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.3nmol/L vs. 6nmol/L) treatments compared to the wildtype KIT. IC50 was determined by assessing kinase activity.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T15:19:02.764Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T23:16:35.556Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T23:17:49.099Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T23:18:43.901Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:UwMdXaSa6knQnohCfFTgqCWnyPVN6qip", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jD9f-R_toWrduybrjbm68lsaOpntmZAa", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:972", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:pRXLOTUcGy266tKwrptqo3E3XUUSTYZh", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}]}}
{"id": "civic.eid:7397", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The GIST882 patient derived cell line expressing KIT K642E mutation demonstrated sensitivity to ponatinib (IC50: 31nmol/L) and sunitinib (IC50: 54nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >2807nmol/L and >5000nmol/L for these drugs respectively. IC50 was determined by assessing cell viability. The GIST882 cell line only showed reduced levels of phospho-KIT and phospho-ERK at high concentrations for ponatinib and sunitinib, while phospho-AKT levels were reduced at all concentrations for ponatinib and sunitinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T15:23:58.923Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T23:29:07.181Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T23:29:46.250Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T23:29:48.904Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:W6wQ-L0ivRA1VzLt9ofbzIPMqhm0A_uv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qqyXsR4-bT1oCgmCJM4qHholRwDQ602L", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:978", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:f0IOBQHIv94-aVcb5dMKA9rkPpDFY0jD", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:7430", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Several preclinical studies were testing drug resistance mechanisms of TP53-R273H variant. Saos-2 cells were transfected with TP53-R273H mutation and these cells were used in the study. Using a western blot, Saos-2/TP53-R273H cells were shown to have a 0.6-fold down-regulation (compared to the Control) for Procaspase-3 protein expression. In addition, Saos-2/TP53-R273H cells were shown to be more resistant to methotrexate and doxorubicin. Reduced levels of drug-induced apoptosis were seen in Saos-2/TP53-R273H cells treated with doxorubicin (0.05 uM and 0.10 uM) and methotrexate (25 nM and 50 nM) in DNA fragmentation assays. According to the results, TP53-R273H induces drug resistance when procaspase-3 is down-regulated.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-07-29T18:02:47.961Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-03-23T20:04:55.370Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2932", "type": "Document", "label": "Wong et al., 2007, Mol. Cancer Ther.", "xrefs": ["pmid:17363498"], "title": "p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:10AmGrOMSyDeHjaSlOd8JoXaDPXOlseh", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.GMSpJl-n2YHDTV8gGYODNruwMz3gjWEm", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:142433", "type": "Therapeutic"}, {"id": "rxcui:6851", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9145", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:122", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:134", "type": "DiseaseDescriptor", "label": "Osteosarcoma", "xrefs": ["DOID:3347"], "disease": "ncit:C9145"}, "object_descriptor": {"id": "civic.tcd:R22Zf5CPlJKGeo-aqhjXFczWKERAMSbp", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:142433", "type": "Therapeutic"}, {"id": "rxcui:6851", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}, {"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}]}}
{"id": "civic.eid:7552", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-09-14T13:36:11.658Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T16:19:52.802Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3005", "type": "Document", "label": "Yao et al., 2017, Nature", "xrefs": ["pmc:PMC5648058", "pmid:28783719"], "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1b-V2-4BLRTfza6EdfaPorO-DPfUjmTy", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7eSQ_SJENIh9RJqKFIC_MtjExNqzuQdL", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2222", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:vz_W7U3qrxseu_SVPiT9P9WorfLg9cvg", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:7553", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-09-14T13:37:25.629Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T16:19:49.399Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3005", "type": "Document", "label": "Yao et al., 2017, Nature", "xrefs": ["pmc:PMC5648058", "pmid:28783719"], "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hwIb8SGY4l2pLSZVmZWPM8euJF6kO78H", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7eSQ_SJENIh9RJqKFIC_MtjExNqzuQdL", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2222", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:7554", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E,  D594G, D594N, and G596R).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-09-14T13:41:11.742Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T16:19:12.911Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3005", "type": "Document", "label": "Yao et al., 2017, Nature", "xrefs": ["pmc:PMC5648058", "pmid:28783719"], "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:4bI4RsKn9-8Yhi9-UET0pCFzoR6hkIcr", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7eSQ_SJENIh9RJqKFIC_MtjExNqzuQdL", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C8101", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2222", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2627", "type": "DiseaseDescriptor", "label": "Solid Tumor", "disease": "ncit:C8101"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:7556", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:394", "type": "Agent", "name": "Hideaki Takahashi"}, "date": "2019-09-14T13:42:49.725Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-02-10T00:56:17.743Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-04-09T20:07:18.445Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T15:39:58.243Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3005", "type": "Document", "label": "Yao et al., 2017, Nature", "xrefs": ["pmc:PMC5648058", "pmid:28783719"], "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:wGwEKkOsOKGbsjAkyls9JRZUv3bmygTZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:611", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:7913", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Treatment with the GART inhibitor, Lometrexol (de novo purine synthesis inhibitor), sensitized Reh cells overexpressing PRPS1 A190T to mercaptopurine (6-MP) as evidenced by significant reduction of the cell line's 6-MP IC50 and the significant increase of intracellular levels of TIMP. TIMP is one of the first metabolites 6-MP is converted to during activation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:36:08.066Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-04T23:33:25.571Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-23T20:06:22.801Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-02-04T23:14:38.450Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:eyebm0V3fnzDhYssDbMzFTmragCAXuse", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.llKj9xXVUkAVc1SsVH7Bl7lzjb_tXzhI", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C979", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2929", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:gfytNdjDYwoQXo5CF4jOdAg4wrcu2AFh", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "ncit:C979", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19112", "type": "TherapeuticDescriptor", "label": "Lometrexol", "xrefs": ["ncit:C979"], "alternate_labels": ["(6R)-DDATHF", "6R-5,10-Dideazatetrahydrofolate", "L-Glutamic Acid, N-(4-(2-((6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-", "L-Glutamic Acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-, (R)-", "Pyrido[2,3-d]pyrimidine, L-glutamic Acid Derivative (9CI)"], "therapeutic": "ncit:C979"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7915", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 D139G in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, D139G is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T21:37:50.649Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:27:55.665Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-6dCrOrDzK0iTLPw0nx9r3PsZr7qglNd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.KXhtNJngAwzANqqVnOCKL_bKwpwBHseF", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2935", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7916", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 C77S in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, C77S is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T21:38:07.231Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:28:48.709Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ltP5zRtWuAoYAa28HI7j1g3jw1oLBorY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.uGovS28zE1V9iTi5XT9h2-kT2zHncTeL", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2936", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7917", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 I72V in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, I72V is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T21:38:21.133Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:29:31.436Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:MhBs6cLfQqlVNFXhtgZe_XKOD_S8AnCP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cvGLxbElFalsVA9uJwr8k3mutCAt0ccN", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2937", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7918", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 V53A in Reh cells resulted in similar cytotoxic response to controls (empty vector and overexpression of known reduced-function PRPS1 mutants) after exposure to mercaptopurine or thioguanine. Based on the crystal structure of PRPS1, V53A is not in or near the allosteric site or dimer interface, which likely impedes the ability of the variant to impact thiopurine processing.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T21:38:28.437Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:30:23.123Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:bwVw0IHgOpaK8V_mKQCuQ99OlqAJOcph", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.zYYw2HThFTz8YIqofq9wtBFepl7H2R-1", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2938", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:IMgxRLc3XTtFhF3LrdtkdhJqiCh-_3dE", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:10485", "type": "Therapeutic"}, {"id": "rxcui:103", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:87", "type": "TherapeuticDescriptor", "label": "Thioguanine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C876"], "alternate_labels": ["2-Amino 6MP", "2-Amino-1,7-dihydro-6H-purine-6-thione", "2-Amino-6-mercaptopurine", "2-Amino-6-purinethiol", "2-Aminopurin-6-thiol", "2-Aminopurine-6(1H)-thione", "2-Aminopurine-6-thiol", "2-Aminopurine-6-thiol Hemihydrate", "2-Mercapto-6-aminopurine", "6 Mercaptoguanine", "6 Thioguanine", "6-Amino-2-mercaptopurine", "6-Mercapto-2-aminopurine", "6-Mercaptoguanine", "6-TG", "6-Thioguanine", "6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)", "BW 5071", "Lanvis", "Tabloid", "Thioguanine Hemihydrate", "Thioguanine Hydrate", "Tioguanin", "Tioguanine", "WR-1141", "Wellcome U3B", "X 27"], "therapeutic": "rxcui:10485"}, {"id": "civic.tid:86", "type": "TherapeuticDescriptor", "label": "Mercaptopurine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C195"], "alternate_labels": ["1,7-Dihydro-6H-purine-6-thione", "1,7-Dihydro-6H-purine-6-thione Monohydrate", "3H-Purine-6-thiol", "6 MP", "6 Thiohypoxanthine", "6 Thiopurine", "6-MP", "6-Mercaptopurine", "6-Mercaptopurine Monohydrate", "6-Purinethiol", "6-Thiopurine", "6-Thioxopurine", "6H-Purine-6-thione, 1,7-dihydro- (9CI)", "7-Mercapto-1,3,4,6-tetrazaindene", "Alti-Mercaptopurine", "Azathiopurine", "BW 57-323H", "Flocofil", "Ismipur", "Leukerin", "Leupurin", "Mercaleukim", "Mercaleukin", "Mercaptina", "Mercapto-6-purine", "Mercaptopurinum", "Mercapurin", "Mern", "NCI-C04886", "Puri-Nethol", "Purimethol", "Purine, 6-mercapto-", "Purine-6-thiol (8CI)", "Purine-6-thiol Monohydrate", "Purine-6-thiol, Monohydrate", "Purinethiol", "Purinethol", "U-4748", "WR-2785"], "therapeutic": "rxcui:103"}]}}
{"id": "civic.eid:7923", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:09:48.380Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-04-01T05:49:58.729Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:44:51.765Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:nIcdpxmiaE9qS5ZZ2SWu5xUFNsf66bnA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mbGeepbjVfWRRfqDj7J_giIRlrT0Pzsl", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2919", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:sRHtqV0Bx8glrh6cOUCk7nrpqP0Eeqrn", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:7924", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 S103T in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:09:51.472Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-04-01T05:49:17.940Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:48:09.741Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:d8u6X9EbPOmujl1JdolEUFPoiApRrozs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.kpxAsgdLxoYy3CJzjViN0HPWYG6Ry_Sv", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2927", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:R8MiNUEpMs_dHqM95yJGpkvXevdk6azb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:7925", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 S103N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:09:53.293Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-04-01T05:43:39.856Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:49:02.116Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:QQlK_6M-J6ZpiYdDh2QB4KXzhUVTba1X", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.daKnxmkFwXTSIAGtgfIpqHBNNdXlJtrn", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2926", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:R8MiNUEpMs_dHqM95yJGpkvXevdk6azb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:7926", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 K176N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:09:56.246Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-04-01T05:46:56.553Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:49:32.165Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Pth21qIT14EKD57mZ5MzgC1602um1G2D", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.LGaiUgmB8wzfr0_X86xo3VZzbyNH90H8", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2921", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:R8MiNUEpMs_dHqM95yJGpkvXevdk6azb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:7927", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 D183E in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:09:57.934Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-04-01T05:48:08.448Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:50:00.050Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:3TB1SI4rGB-n2HZwP3eVIDutUQbSo8GQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.yTyEFFfv30-OhwXq82YzdefLxfq-zX0-", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2920", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:R8MiNUEpMs_dHqM95yJGpkvXevdk6azb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:7928", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 A190T in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:09:59.850Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:50:29.376Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5MdN6E4v3DDg3glOcq5Sy33OakMWOHBp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.llKj9xXVUkAVc1SsVH7Bl7lzjb_tXzhI", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2929", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:R8MiNUEpMs_dHqM95yJGpkvXevdk6azb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:7929", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 T303S in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:10:02.500Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:50:47.066Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Gg2x7G_DULIH2qZVDhjr9qPPOzZ0rEZY", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.JnuoBhFKSO1IYLvhodz0nk9eMItJ3FhY", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2918", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:R8MiNUEpMs_dHqM95yJGpkvXevdk6azb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:7930", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpression controls as indicated similar cytotoxicity curves and IC50s.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-02-03T21:10:05.883Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:51:03.766Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:eZRF5HP20QmD54jSsCcJZkNIGRw627GK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Maq_xrhmRn5epsg2bAWeXhQJgIp7epBG", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:2923", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tcd:sRHtqV0Bx8glrh6cOUCk7nrpqP0Eeqrn", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:6851", "type": "Therapeutic"}, {"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:1156", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:422", "type": "TherapeuticDescriptor", "label": "Methotrexate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C642"], "alternate_labels": ["4-Amino-10-methylfolic Acid", "4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid", "Abitrexate", "Alpha-Methopterin", "Amethopterin", "Brimexate", "CL 14377", "CL-14377", "Emtexate", "Emthexat", "Emthexate", "Farmitrexat", "Fauldexato", "Folex", "Folex PFS", "Lantarel", "Ledertrexate", "Lumexon", "MTX", "Maxtrex", "Medsatrexate", "Metex", "Methoblastin", "Methotrexate LPF", "Methotrexate Methylaminopterin", "Methotrexatum", "Metotrexato", "Metrotex", "Mexate", "Mexate-AQ", "N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic Acid", "Novatrex", "Rheumatrex", "Texate", "Tremetex", "Trexeron", "Trixilem", "WR-19039"], "therapeutic": "rxcui:6851"}, {"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:258", "type": "TherapeuticDescriptor", "label": "Asparaginase", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D054198", "type": "DiseaseDescriptor", "label": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "disease": "ncit:C3167"}]}}], "xrefs": ["ncit:C286"], "alternate_labels": ["ASP-1", "Asparaginase II", "Asparaginase-E.Coli", "Colaspase", "Elspar", "Kidrolase", "L-ASP", "L-Asnase", "L-Asparaginase", "L-Asparagine Amidohydrolase", "Laspar", "Lcf-ASP", "Leucogen", "Leunase", "MK-965", "Paronal", "Re-82-TAD-15", "Serasa", "Spectrila"], "therapeutic": "rxcui:1156"}]}}
{"id": "civic.eid:8336", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-10T20:14:48.027Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T05:30:43.344Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-13T05:07:50.103Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:t7-fACbkhNPLFqH02luFN_HJYTWYTcqQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C116858", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3070", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:1629", "type": "TherapeuticDescriptor", "label": "FLT3/ABL/Aurora Kinase Inhibitor KW-2449", "xrefs": ["ncit:C116858"], "alternate_labels": ["KW-2449"], "therapeutic": "ncit:C116858"}}
{"id": "civic.eid:8338", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-10T20:17:08.044Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T05:30:00.024Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-13T05:07:45.422Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FUduXl_oEvlDg8k46HKQAKnvBtAFuxyE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3070", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:8340", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD Y842C treated with Midostaurin responded similarly to FLT3/ITD control cells (IC50: 4nM). Like in FLT3/ITD control cells, immunoblotting showed Midostaurin inhibited FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD Y842C cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-10T20:19:08.711Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T05:30:18.883Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-28T00:15:26.324Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-13T05:07:39.049Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:yQKd6iMZ_k7-lJ9nCz067gGjuWSGei-o", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1919083", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3070", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:323", "type": "TherapeuticDescriptor", "label": "Midostaurin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C1872"], "alternate_labels": ["CGP 41251", "CGP41251", "N-Benzoyl-Staurosporine", "N-Benzoylstaurosporine", "PKC-412", "PKC412", "Rydapt"], "therapeutic": "rxcui:1919083"}}
{"id": "civic.eid:8341", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified F691L. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD F691L conferred moderate resistance to lestaurtinib (IC50: 8nM) compared to FLT3/ITD control cells (IC50: 2nM). Immunoblotting showed lestaurtinib was able to partially inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD F691L cells. Structural modeling revealed F691 to be located in the ATP binding cleft. The authors hypothesize this amino acid change weakens inhibitor affinity as this residue likely makes direct contact with FLT3 TKIs.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-10T20:41:11.132Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T04:43:58.187Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-28T00:05:46.178Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:341", "type": "Agent", "name": "Shruti Rao"}, "date": "2021-03-12T14:30:14.438Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T04:44:01.895Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:P6mceecwqjZz8aoVFju55S6SOLDhdzSW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.alBmNUrND2Qcobv2zz7socu-8G727NX9", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C48402", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3071", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:260", "type": "TherapeuticDescriptor", "label": "Lestaurtinib", "xrefs": ["ncit:C48402"], "alternate_labels": ["9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-", "CEP-701", "KT-5555", "SPM-924"], "therapeutic": "ncit:C48402"}}
{"id": "civic.eid:8342", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in the FLT3 TKI midostaurin identified F691L in 1 of 400 clones. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD F691L conferred moderate resistance to midostaurin (IC50: 18nM) compared to FLT3/ITD control cells (IC50: 4nM). Immunoblotting showed midostaurin was able to partially inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD F691L cells. Structural modeling revealed F691 to be located in the ATP binding cleft. The authors hypothesize this amino acid change weakens inhibitor affinity as this residue likely makes direct contact with FLT3 TKIs.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-10T20:41:59.958Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T04:44:40.500Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-23T22:24:54.599Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T04:44:42.197Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:KO5ByVBzJFTbP2pkyk2ODwQdgfK4IhBo", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.alBmNUrND2Qcobv2zz7socu-8G727NX9", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1919083", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3071", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:323", "type": "TherapeuticDescriptor", "label": "Midostaurin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C1872"], "alternate_labels": ["CGP 41251", "CGP41251", "N-Benzoyl-Staurosporine", "N-Benzoylstaurosporine", "PKC-412", "PKC412", "Rydapt"], "therapeutic": "rxcui:1919083"}}
{"id": "civic.eid:8364", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Resistance of RKO cells, which harbor BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R, to vemurafenib monotherapy was abrogated by the addition of pan-AKT inhibitor MK-2206 in vitro and in vivo. In vitro, vemurafenib and MK-2206 combination treatment of RKO cells resulted in substantially greater proliferation inhibition than either agent in isolation or untreated control cells (combination index score = 0.691 at EC50). Synergistic effects of vemurafenib and MK-2206 on RKO cells was confirmed in vivo via xenografts on an athymic mouse model, where mice treated with vemurafenib monotherapy experienced minimal tumor growth inhibition (25%), mice treated with MK-2206 monotherapy experienced modest tumor growth inhibition (37%), and mice treated with both achieved 87% tumor growth inhibition compared to vehicle treated control mice (P <0.001).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-06-18T22:07:18.802Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-06-18T22:20:22.469Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T22:21:06.786Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T22:23:05.774Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:108", "type": "Document", "label": "Yang et al., 2012, Cancer Res.", "xrefs": ["pmid:22180495"], "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:d9KzTQguHAQ3gzrRNLBzhh4MDHJMrG_Q", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "ncit:C90581", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:CtWln7v8hgJLNPZj6vZ7dcTMZMT2ZYdx", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "ncit:C90581", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:43", "type": "TherapeuticDescriptor", "label": "Akt Inhibitor MK2206", "xrefs": ["ncit:C90581"], "alternate_labels": ["1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-", "MK 2206", "MK-2206", "MK-2206 FREE BASE", "MK2206"], "therapeutic": "ncit:C90581"}]}}
{"id": "civic.eid:8376", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell titer glo measured cytotoxicity assays. Plasmon resonance protein binding assays demonstrated marked impairment (300 fold) of venetoclax binding to F104I (Ki=5.9 nM) veresus WT (Ki=.018nM). The authors pointed out reduction in binding was a similar magnitude as that observed previously with the BCL2 G101V and F104L.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-06-26T18:59:18.308Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T00:07:38.251Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-15T20:53:24.538Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T00:07:40.871Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3502", "type": "Document", "label": "Blombery et al., 2019, Br. J. Haematol.", "xrefs": ["pmid:31234236"], "title": "Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:b-ICx3_0XquQYSfb0KiMLHPo_W7H6wlC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._ZzqdXiiqCOs9iTFtw5ac6N6_lT9vbfe", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1747556", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3209", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3082", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:51", "type": "DiseaseDescriptor", "label": "Follicular Lymphoma", "xrefs": ["DOID:50873"], "disease": "ncit:C3209"}, "object_descriptor": {"id": "civic.tid:574", "type": "TherapeuticDescriptor", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:581", "type": "DiseaseDescriptor", "label": "Chronic lymphocytic leukemia", "disease": "ncit:C3163"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C103147"], "alternate_labels": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"], "therapeutic": "rxcui:1747556"}}
{"id": "civic.eid:8506", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Irinotecan, cetuximab and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 250% increased lifespan (ILS) compared to vehicle treated controls. Of the ten treated mice, nine experienced partial response and one experienced a complete response. Compared to all doublet and single agent combinations of vemurafenib, irinotecan, and cetuximab, triplet therapy produced the best TGI and ILS (p<0.05, p <0.0001 for all comparisons).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-09T21:28:45.046Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-07-09T21:30:05.178Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:108", "type": "Document", "label": "Yang et al., 2012, Cancer Res.", "xrefs": ["pmid:22180495"], "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:CnbyyaBQJE0R0f3Llv7kLotEZkLkOxnl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:rF1JcnGq_-VTc0yiCsNIORfNqXQCC3yM", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:153329", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:101", "type": "TherapeuticDescriptor", "label": "Irinotecan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:46096", "type": "DiseaseDescriptor", "label": "Colorectal cancer", "disease": "ncit:C4978"}]}}], "xrefs": ["ncit:C62040"], "alternate_labels": ["(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione", "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate", "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin", "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"], "therapeutic": "rxcui:153329"}]}}
{"id": "civic.eid:8507", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Erlotinib and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 142% increased lifespan (ILS) compared to vehicle treated controls. Of ten treated mice, 9 experienced partial response. Doublet therapy produced a greater increase in TGI and ILS than either agent in isolation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-09T21:30:33.453Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-07-09T21:32:43.682Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:108", "type": "Document", "label": "Yang et al., 2012, Cancer Res.", "xrefs": ["pmid:22180495"], "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:qAseY4astMCiNv3V5VQnsrmyMKN4d8TH", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:lBPXvLJKdE1POtYbxr_yzUz79LYLApYN", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:8642", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Bladder cancer cell line 97-7 expressing endogenous FGFR3 S249C (IC50 44.6ug/ml) was resistant to cisplatin compared to two FGFR3 wild-type cell lines, 5637 (IC50 2.07ug/ml) and T24 (IC50 1.58ug/ml) as shown by a CCK-8 colorimetric cytotoxicity. Western blot revealed the ratio of phosphorylated-Akt/total Akt was higher in the 97-7 cells than in the wild-type cells, which was reversed by siRNA knockdown of FGFR3. Inhibition of Akt signaling by treatment with GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 cells (IC50 4.17ug/ml & 8.91ug/ml respectively).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1219", "type": "Agent", "name": "Tracy Lively"}, "date": "2020-08-06T14:28:11.312Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-19T06:44:25.244Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-24T21:28:39.241Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-19T15:09:22.941Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-19T06:44:29.911Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3631", "type": "Document", "label": "Xie et al., 2019, Exp Ther Med", "xrefs": ["pmc:PMC6601368", "pmid:31316618"], "title": "FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Kqo7c0OyeQrMG82Rm9rkSg6WiwKGEXXw", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.FNHAUxkAFnYKIjkp3qxbDsoN31F2i-wp", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2555", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2930", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:628", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:642", "type": "DiseaseDescriptor", "label": "Transitional Cell Carcinoma", "xrefs": ["DOID:2671"], "disease": "ncit:C2930"}, "object_descriptor": {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}}
{"id": "civic.eid:8654", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD Y842C conferred high-level resistance to Quizartinib (AC220) (IC50: 20nM) compared to FLT3/ITD control cells (IC50: 1nM). Unlike in FLT3/ITD control cells, immunoblotting showed Quizartinib was unable to inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD Y842C cells. Structural modeling revealed Y842 to be located in the activation loop. The authors hypothesize altered conformation interferes with drug interaction.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T05:36:47.869Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-28T00:39:52.762Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3472", "type": "Document", "label": "Williams et al., 2013, Leukemia", "xrefs": ["pmc:PMC3822911", "pmid:22858906"], "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:BOWjG8-rKYAlB4oIuIF5T9VAm0TZca5Z", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C68936", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3070", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:505", "type": "TherapeuticDescriptor", "label": "Quizartinib", "xrefs": ["ncit:C68936"], "alternate_labels": ["(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide", "AC-220", "AC010220", "AC220", "N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"], "therapeutic": "ncit:C68936"}}
{"id": "civic.eid:8841", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This study described the similar crystal structures of BCL-2 wild-type and G101V when bound to venetoclax. Steady state competition surface plasmon resonance experiments demonstrated a ~177 fold decrease in venetoclax affinity for G101V (Ki=3.2nM) versus WT (Ki=.018nM). Resistance is acquired by a knock-on effect in the P2 pocket of V101 on an adjacent residue, E152 as affinity for venetoclax was restored in BCL2 G101V through the introduction of an E152A mutation (Ki =.002nM). Additionally, BCL2 G101V maintains similar affinity for apoptotic BH3 peptides, which assists in the prevention of apoptosis.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:993", "type": "Agent", "name": "Xinjie Xu"}, "date": "2020-09-02T22:17:58.281Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T18:54:10.927Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-14T23:52:07.836Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-09-03T18:54:12.396Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3500", "type": "Document", "label": "Birkinshaw et al., 2019, Nat Commun", "xrefs": ["pmc:PMC6547681", "pmid:31160589"], "title": "Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1Y0dZ0HwuKmn2eZJUxillHwOpe4g16dx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.W2DykRCbXOXmqZLLiZeELFbtnqJvuqOW", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1747556", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2960", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:574", "type": "TherapeuticDescriptor", "label": "Venetoclax", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:581", "type": "DiseaseDescriptor", "label": "Chronic lymphocytic leukemia", "disease": "ncit:C3163"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}]}}], "xrefs": ["ncit:C103147"], "alternate_labels": ["4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide", "ABT-0199", "ABT-199", "ABT199", "GDC-0199", "RG7601", "Venclexta", "Venclyxto"], "therapeutic": "rxcui:1747556"}}
{"id": "civic.eid:9945", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:353", "type": "Agent", "name": ""}, "date": "2021-12-10T19:06:49.670Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-10T23:38:42.019Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-10T23:58:08.870Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:4212", "type": "Document", "label": "Kuo et al., 2016, Am J Cancer Res", "xrefs": ["pmc:PMC5126268", "pmid:27904766"], "title": "The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ZgSHkSkUA8ZCltvlaXuLYTKNdsqF_j8h", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.aP0xMmanUEUlDokkHAiLYfvmo_PNEjbF", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1442981", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C36081", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3643", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3090", "type": "DiseaseDescriptor", "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type", "xrefs": ["DOID:80996"], "disease": "ncit:C36081"}, "object_descriptor": {"id": "civic.tid:227", "type": "TherapeuticDescriptor", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015451", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphocytic, Chronic, B-Cell", "disease": "ncit:C3163"}, {"id": "mesh:D020522", "type": "DiseaseDescriptor", "label": "Lymphoma, Mantle-Cell", "disease": "ncit:C4337"}, {"id": "mesh:D008258", "type": "DiseaseDescriptor", "label": "Waldenstrom Macroglobulinemia", "disease": "ncit:C80307"}]}}], "xrefs": ["ncit:C81934"], "alternate_labels": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"], "therapeutic": "rxcui:1442981"}}
{"id": "civic.eid:9946", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:353", "type": "Agent", "name": ""}, "date": "2021-12-10T19:08:30.361Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-10T23:57:55.304Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-10T23:57:02.445Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-10T23:57:06.866Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:4212", "type": "Document", "label": "Kuo et al., 2016, Am J Cancer Res", "xrefs": ["pmc:PMC5126268", "pmid:27904766"], "title": "The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FAKEAkWWgHAz8lCYg7NovFaBjhM7u0l3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.s00v7sgfPv7r71Cj-ps1MYobW16SE8mb", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1442981", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C36081", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3644", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3090", "type": "DiseaseDescriptor", "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type", "xrefs": ["DOID:80996"], "disease": "ncit:C36081"}, "object_descriptor": {"id": "civic.tid:227", "type": "TherapeuticDescriptor", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015451", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphocytic, Chronic, B-Cell", "disease": "ncit:C3163"}, {"id": "mesh:D020522", "type": "DiseaseDescriptor", "label": "Lymphoma, Mantle-Cell", "disease": "ncit:C4337"}, {"id": "mesh:D008258", "type": "DiseaseDescriptor", "label": "Waldenstrom Macroglobulinemia", "disease": "ncit:C80307"}]}}], "xrefs": ["ncit:C81934"], "alternate_labels": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"], "therapeutic": "rxcui:1442981"}}
{"id": "civic.eid:9947", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines (TMD8) studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:353", "type": "Agent", "name": ""}, "date": "2021-12-10T19:09:35.634Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:353", "type": "Agent", "name": ""}, "date": "2021-12-10T23:53:27.889Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-10T23:56:35.463Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-12-10T23:56:51.352Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:4212", "type": "Document", "label": "Kuo et al., 2016, Am J Cancer Res", "xrefs": ["pmc:PMC5126268", "pmid:27904766"], "title": "The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:jNNEAP2eUZwL1HG2kWhMTDKFyoXBpVoB", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.WqqnpAZ7EK10TsO8oxNzzByf0B19r1R0", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1442981", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C36081", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3645", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3090", "type": "DiseaseDescriptor", "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type", "xrefs": ["DOID:80996"], "disease": "ncit:C36081"}, "object_descriptor": {"id": "civic.tid:227", "type": "TherapeuticDescriptor", "label": "Ibrutinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015451", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphocytic, Chronic, B-Cell", "disease": "ncit:C3163"}, {"id": "mesh:D020522", "type": "DiseaseDescriptor", "label": "Lymphoma, Mantle-Cell", "disease": "ncit:C4337"}, {"id": "mesh:D008258", "type": "DiseaseDescriptor", "label": "Waldenstrom Macroglobulinemia", "disease": "ncit:C80307"}]}}], "xrefs": ["ncit:C81934"], "alternate_labels": ["2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-", "BTK Inhibitor PCI-32765", "CRA-032765", "Imbruvica", "PCI-32765"], "therapeutic": "rxcui:1442981"}}
{"id": "civic.eid:10066", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR G598V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-01-06T22:48:40.846Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1443", "type": "Agent", "name": "Cara Reisle"}, "date": "2022-03-24T23:42:04.044Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-03-24T23:43:00.702Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-03-24T23:48:39.200Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1608", "type": "Document", "label": "Lee et al., 2006, PLoS Med.", "xrefs": ["pmc:PMC1702556", "pmid:17177598"], "title": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:iDbnNX3h8kOJdGjCoruK8JqXzFJ_6yip", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Ws_6b8tvM_N-6lCmuQ6vsIYylBC6OS3e", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:997", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:10139", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The cancer-associated SF3B1-K700E mutation compromises homologous recombination repair and increases the sensitivity to ionising radiation and DNA damaging agents, such as etoposide or small molecule inhibitors including olaparib in isogenic K562 cell line. The SF3B1-WT and SF3B1-K700E cell lines were also engrafted subcutaneously into immunocompromised mice, and the mice were treated with etoposide, olaparib or a vehicle control and monitored tumour growth for 28 days. Treatment with either etoposide or olaparib significantly reduced the volume of the SF3B1-K700E mutant tumours, but had little effect on the volume of SF3B1-WT tumours.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1260", "type": "Agent", "name": "Veronika Csizm\u00f3k"}, "date": "2022-01-26T23:56:58.026Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-27T18:35:31.608Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-27T18:20:35.390Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:4228", "type": "Document", "label": "Lappin et al., 2022, Cancer Res", "xrefs": ["pmc:PMC7612475", "pmid:35027467"], "title": "Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JVULcPXhuUXqvRjdEjmnC1vry12nQeYZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Ge-C1IvZCDIFpbNRTG4-lcalHsY3uu0T", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1597582", "type": "Therapeutic"}, {"id": "rxcui:4179", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3161", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:565", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:106", "type": "DiseaseDescriptor", "label": "Leukemia", "xrefs": ["DOID:1240"], "disease": "ncit:C3161"}, "object_descriptor": {"id": "civic.tcd:P-VDb1w-05LwHZRP9cAKSnie8IcKor1c", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1597582", "type": "Therapeutic"}, {"id": "rxcui:4179", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:42", "type": "TherapeuticDescriptor", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D010051", "type": "DiseaseDescriptor", "label": "Ovarian Neoplasms", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C71721"], "alternate_labels": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"], "therapeutic": "rxcui:1597582"}, {"id": "civic.tid:500", "type": "TherapeuticDescriptor", "label": "Etoposide", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}]}}], "xrefs": ["ncit:C491"], "alternate_labels": ["4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]", "9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one", "Demethyl Epipodophyllotoxin Ethylidine Glucoside", "EPEG", "Lastet", "Toposar", "VP 16", "VP 16-213", "VP-16", "VP-16-213", "VP16", "Vepesid"], "therapeutic": "rxcui:4179"}]}}
{"id": "civic.eid:10144", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "IDH1 R132C mutation confers a switch of function mutation where the mutated protein produces 2-hydroxyglutarate (2HG), rather than \u03b1-ketoglutarate (\u03b1KG). The novel metabolite induces a homologous recombination (HR) defect that sensitizes the tumor cells to poly (ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitor sensititivity was tested in vivo in HeLa cells where the R132C mutation was create with CRISPR, the HCT116 colon cancer cell line where R132C mutation was created with recombinant adeno-associated virus (rAAV), and the HT1080 human sarcoma cell line which already has R132C. The results were then duplicated in non-commercial glioma cell lines: 6 IDH1 R132 mutant; 4 IDH1 wt.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1329", "type": "Agent", "name": "Gregory Taylor"}, "date": "2022-01-27T01:59:29.913Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1329", "type": "Agent", "name": "Gregory Taylor"}, "date": "2022-01-28T01:13:41.770Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-28T01:58:11.082Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2022-01-28T02:03:17.298Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1683", "type": "Document", "label": "Sulkowski et al., 2017, Sci Transl Med", "xrefs": ["pmid:28148839"], "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FRgIDoKiTfCghzTpryg1td7CYHt6KM7T", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1597582", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:59", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:42", "type": "TherapeuticDescriptor", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D010051", "type": "DiseaseDescriptor", "label": "Ovarian Neoplasms", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C71721"], "alternate_labels": ["AZD 2281", "AZD-2281", "AZD2281", "KU-0059436", "Lynparza", "PARP Inhibitor AZD2281"], "therapeutic": "rxcui:1597582"}}
{"id": "civic.eid:97", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.825Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-30T21:45:43.991Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-31T00:11:36.456Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.825Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:107", "type": "Document", "label": "Ji et al., 2013, Clin. Cancer Res.", "xrefs": ["pmc:PMC3777641", "pmid:23812671"], "title": "Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5QbvMr9u-4vASieU4U6Mj4qf2QkEEjJX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "drugbank:DB06999", "type": "Therapeutic"}, {"id": "chembl:CHEMBL191334", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:Rad3lcAGeG99UmhaaJEnYIfVq2TB5gyS", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "drugbank:DB06999", "type": "Therapeutic"}, {"id": "chembl:CHEMBL191334", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:30", "type": "TherapeuticDescriptor", "label": "PLX4720", "therapeutic": "drugbank:DB06999"}, {"id": "civic.tid:31", "type": "TherapeuticDescriptor", "label": "Nutlin-3", "therapeutic": "chembl:CHEMBL191334"}]}}
{"id": "civic.eid:99", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in mouse xenograft experiments. Of the cell lines tested, six harbored BRAF V600E (and WT KRAS) and three harbored BRAF WT (but mutant KRAS). Of the six BRAF V600E expressing cell lines, four were sensitive to vemurafenib (IC50 ranging between 0.025 and 0.35 uM; HT29, Colo205, Colo741, LS411N). Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation (none of the three BRAF wt cell lines had IC50s less than 10uM). Authors note that one of the vemurafenib-resistant cell lines harboring BRAF V600E (RKO) harbored a concurrent activating PIK3CA H1047R mutation. Nude, athymic mice with HT29 xenografts treated with vemurafenib experienced substantial tumor inhibition and increased lifespan at every dose tested, though authors found 75 mg/kg twice daily to be optimal (95% tumor growth inhibition, 90% increased lifespan compared to vehicle treated controls).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:42.931Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-06-18T21:52:27.299Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T21:56:48.149Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:42.931Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:108", "type": "Document", "label": "Yang et al., 2012, Cancer Res.", "xrefs": ["pmid:22180495"], "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:GyTl-Ef5EFPmxguxr6_ZwPSdAx4bKvgg", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:707", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2015-12-17T11:44:25.061Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2015-12-23T20:01:18.374Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:465", "type": "Document", "label": "Lassen et al., 2014, Mol. Cancer", "xrefs": ["pmc:PMC4021505", "pmid:24735930"], "title": "Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:eAytuYEEJ6kqi2lwlhGJYXa3rInEBVrI", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._veAF5iFKxk_oSX9jnfNc4AHp8MvUCKO", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C84870", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:4", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:111", "type": "TherapeuticDescriptor", "label": "Uprosertib", "xrefs": ["ncit:C84870"], "alternate_labels": ["2-Furancarboxamide, N-((1S)-2-Amino-1-((3,4-difluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-", "GSK2141795", "Oral Akt Inhibitor GSK2141795"], "therapeutic": "ncit:C84870"}}
{"id": "civic.eid:941", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for C609T (only 3 were T/T, and the rest were C/C or C/T). Cell lines with the T/T genotype had lower expression of NQ01 and greater response to amrubicinol.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-19T09:52:10.509Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-11T23:28:58.028Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-22T02:52:19.241Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-11T23:20:21.046Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:643", "type": "Document", "label": "Takakuwa et al., 2011, J Thorac Oncol", "xrefs": ["pmid:21964527"], "title": "C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:VO2Yjm_T9aCcB68UnucduL3wKm9tOKzD", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Uegve5C58fBTuKbHL4iXazo6zMGk4w66", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C80089", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7377", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:402", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:23", "type": "DiseaseDescriptor", "label": "Lung Cancer", "xrefs": ["DOID:1324"], "disease": "ncit:C7377"}, "object_descriptor": {"id": "civic.tid:181", "type": "TherapeuticDescriptor", "label": "Amrubicin", "xrefs": ["ncit:C80089"], "alternate_labels": ["(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione"], "therapeutic": "ncit:C80089"}}
{"id": "civic.eid:967", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-26T20:24:26.283Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-11T21:56:10.255Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:669", "type": "Document", "label": "Hirano et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4770737", "pmid:26515464"], "title": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:TM31LnM2-EEPKHgZT3UNQlK1m4tAhATo", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1721560", "type": "Therapeutic"}, {"id": "ncit:C99905", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:WmGNUyuWQ9_7GPOtU24JRzOc2eee7RUA", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1721560", "type": "Therapeutic"}, {"id": "ncit:C99905", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}, {"id": "civic.tid:91", "type": "TherapeuticDescriptor", "label": "Rociletinib", "xrefs": ["ncit:C99905"], "alternate_labels": ["CO-1686", "N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide"], "therapeutic": "ncit:C99905"}]}}
{"id": "civic.eid:968", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-01-26T20:24:28.878Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-02-11T20:53:57.796Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:669", "type": "Document", "label": "Hirano et al., 2015, Oncotarget", "xrefs": ["pmc:PMC4770737", "pmid:26515464"], "title": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:AEC2fbyX0a0Y3wtOYoALtu06a2AJbVtm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:1005", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (AZD6244 [selumetinib]) and PI3K/mTOR (BEZ235 [dactolisib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720 (progenitor of vemurafenib)-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-10T13:00:28.779Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:827", "type": "Agent", "name": "Wan-Hsin Lin"}, "date": "2019-09-21T03:39:28.824Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-10-01T05:41:11.264Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-12T22:46:57.134Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:694", "type": "Document", "label": "Penna et al., 2016, Oncotarget", "xrefs": ["pmc:PMC4826182", "pmid:26678033"], "title": "Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lXXb1tycPJSto6StEH3b31HqeU28SW1a", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:12", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:1081", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetuximab and panitumumab treatment and inhibition of EGFR phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-02-23T08:59:55.934Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:39:53.025Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:40:03.399Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-02-23T18:43:15.244Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:746", "type": "Document", "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26888827"], "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:y1GLCyjSJDsh3lNrEsbAJBD8nHCLgZ_Y", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.dbAkU0qOMC4rMrZM1ehqjURpZawBRDpZ", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "ncit:C91381", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:454", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:v5lZVPkpFbPb9D0fGEzDQe6YBU5CmLdA", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}, {"id": "ncit:C91381", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}, {"id": "civic.tid:273", "type": "TherapeuticDescriptor", "label": "Futuximab/Modotuximab Mixture", "xrefs": ["ncit:C91381"], "alternate_labels": ["Anti-EGFR Monoclonal Antibody Mixture Sym004", "Futuximab/Modotuximab", "Futuximab/Zatuximab", "Sym004"], "therapeutic": "ncit:C91381"}]}}
{"id": "civic.eid:1171", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "HCC827 cell lines harboring activated PI3K (HCC827 p110\u03b1 E545K cells) were more resistant to gefitinib in vitro (IC50, 1 \u03bcM) compared with those harboring GFP alone (IC50, 0.01 \u03bcM). The presence of p110\u03b1 E545K also protected HCC827 cells from gefitinib-mediated apoptosis.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-03-10T23:47:24.342Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-03-14T03:13:23.251Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:808", "type": "Document", "label": "Engelman et al., 2006, J. Clin. Invest.", "xrefs": ["pmc:PMC1570180", "pmid:16906227"], "title": "Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:BQa0f6KC7aYH0B99bNVLit2Vgyub29xq", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:1309", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "15/127 patients with KIT-WT metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations. 6 GISTs harbored PDGFRA mutations. 1 patient had a deletion of I843. CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA. 2/3 patients with a mutation determined to be sensitive in vitro achieved partial response on imatinib treatment. It is not noted whether the patient whose GISTs harbored I843del had partial response or progressive disease.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-05-07T05:33:13.348Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T02:07:50.359Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T02:08:02.713Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-01T18:40:06.876Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:_nmvnUfFPeipK9oXJv8t_p9QYTcgP-y7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tUi_KlyJZO-wWdQd5JH1mvm2GCfwvZ1C", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:101", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:1319", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2016-05-14T05:26:59.434Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-24T21:03:09.495Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-06-29T20:24:38.249Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-24T20:39:33.799Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:911", "type": "Document", "label": "Grabiner et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4012430", "pmid:24631838"], "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:l8kJnQl6yvK6IdSc-czFdt4hhK6_eYxu", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.-JZf9GXqg_O07WNMgCWEkiOphNDQFuvw", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:35302", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C7359", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:542", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:666", "type": "DiseaseDescriptor", "label": "Endometrial Adenocarcinoma", "xrefs": ["DOID:2870"], "disease": "ncit:C7359"}, "object_descriptor": {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}}
{"id": "civic.eid:1320", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2016-05-14T05:30:34.451Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-24T20:51:31.662Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-06-24T20:56:26.785Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-24T20:47:47.927Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:911", "type": "Document", "label": "Grabiner et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4012430", "pmid:24631838"], "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:27S3TpHA0dU_vOkPypWzWeIHGBBuSPzk", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cUcMkB9IV2k-9CRi-9wyCxrH-VMr2Sy4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:35302", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "mondo:0003540", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:543", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:227", "type": "DiseaseDescriptor", "label": "T-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:5603"], "disease": "mondo:0003540"}, "object_descriptor": {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}}
{"id": "civic.eid:1321", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:57", "type": "Agent", "name": "Martin Jones"}, "date": "2016-05-14T05:32:08.579Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-24T21:09:34.257Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T15:24:35.197Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-21T20:02:24.753Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:911", "type": "Document", "label": "Grabiner et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4012430", "pmid:24631838"], "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:P146Hgr_YiVxmqpCxofxT4ZtnAbFqAen", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.UjNKRQlgBxxpKwqfniYSiUF7eQY2Bo9b", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:35302", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4033", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:544", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:48", "type": "DiseaseDescriptor", "label": "Clear Cell Renal Cell Carcinoma", "xrefs": ["DOID:4467"], "disease": "ncit:C4033"}, "object_descriptor": {"id": "civic.tid:469", "type": "TherapeuticDescriptor", "label": "Sirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:37829", "type": "DiseaseDescriptor", "label": "PEComa", "disease": "ncit:C38150"}]}}], "xrefs": ["ncit:C1212"], "alternate_labels": ["9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2", "AY 22989", "RAPA", "RAPAMYCIN", "Rapamune", "SILA 9268A", "WY-090217"], "therapeutic": "rxcui:35302"}}
{"id": "civic.eid:1362", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro. One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo. PIK3CA (H1047R) mutation positive cell lines used were \"CAL-33\" and \"Detroit 562\". Wild type cell lines used here were \"SCC-9\" and \"PE/CA-PJ34(clone C12)\".", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-01T13:03:59.323Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-08T22:03:08.259Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-06-22T19:27:09.971Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-08T21:54:23.207Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-08T21:55:18.368Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:927", "type": "Document", "label": "Lui et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3710532", "pmid:23619167"], "title": "Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:J9evO5P1EpX3l-r-2BtEahEa7DFN-mrN", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C74072", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4013", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:453", "type": "DiseaseDescriptor", "label": "Head And Neck Cancer", "xrefs": ["DOID:11934"], "disease": "ncit:C4013"}, "object_descriptor": {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}}
{"id": "civic.eid:1363", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-01T13:05:58.670Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-07T23:41:59.363Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-08T21:29:01.810Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-07T23:42:00.867Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:927", "type": "Document", "label": "Lui et al., 2013, Cancer Discov", "xrefs": ["pmc:PMC3710532", "pmid:23619167"], "title": "Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:3RetauRKuCbpO3Fm0g3i5Vsop61S6hQW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4013", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:453", "type": "DiseaseDescriptor", "label": "Head And Neck Cancer", "xrefs": ["DOID:11934"], "disease": "ncit:C4013"}, "object_descriptor": {"id": "civic.tcd:BdRk9XEXwBZytGoulOf00oeavewtOvFC", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:1453", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-07-01T06:37:52.705Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-21T17:22:19.889Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-21T17:21:42.336Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:981", "type": "Document", "label": "Serra et al., 2008, Cancer Res.", "xrefs": ["pmid:18829560"], "title": "NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:desKNJAFooL9t1omnjR5wXtKTxuyJz6d", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2103478", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}}
{"id": "civic.eid:1458", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant\u2013expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:40:35.779Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-20T04:02:20.965Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:338", "type": "Document", "label": "Dahlman et al., 2012, Cancer Discov", "xrefs": ["pmc:PMC3449158", "pmid:22798288"], "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:cNwU4yn_WM-Uf5FmH3kojlz72NqWyinM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2UeGMRTqHbmtgmiJbqa7vyXvVAv0ZW_m", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:288", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:tWJleGyed3g0Eqv1ASxYxVix6lJUtxhw", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}]}}
{"id": "civic.eid:1459", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant\u2013expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:41:51.941Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-18T15:24:58.058Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:338", "type": "Document", "label": "Dahlman et al., 2012, Cancer Discov", "xrefs": ["pmc:PMC3449158", "pmid:22798288"], "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FgvCwm9CqJAlSRKZ0qsOqWAoVT7F2zwP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.aSpuln9wE4lEOFN7gLZVnfLkjD77G9CK", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:582", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:tWJleGyed3g0Eqv1ASxYxVix6lJUtxhw", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}]}}
{"id": "civic.eid:1461", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant\u2013expressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:46:35.183Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-10-20T04:03:12.280Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:338", "type": "Document", "label": "Dahlman et al., 2012, Cancer Discov", "xrefs": ["pmc:PMC3449158", "pmid:22798288"], "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:PJJBABt7dhlPzmn-TY5V920K7wE4x3Hy", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.bTQroAvfd2NBts79PH2faeuM74FJxj6F", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:583", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:tWJleGyed3g0Eqv1ASxYxVix6lJUtxhw", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1147220", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}, {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}]}}
{"id": "civic.eid:1465", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker. Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild-type PI3K or PTEN mutant cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-07-01T09:13:25.274Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-21T20:54:23.799Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:984", "type": "Document", "label": "Zumsteg et al., 2016, Clin. Cancer Res.", "xrefs": ["pmc:PMC4870591", "pmid:26589432"], "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:4f28JCQnYheo2XV0J-_WqTXPKSKXdqVf", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C116876", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C34447", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:37", "type": "DiseaseDescriptor", "label": "Head And Neck Squamous Cell Carcinoma", "xrefs": ["DOID:5520"], "disease": "ncit:C34447"}, "object_descriptor": {"id": "civic.tid:660", "type": "TherapeuticDescriptor", "label": "Taselisib", "xrefs": ["ncit:C116876"], "alternate_labels": ["GDC-0032", "RO5537381"], "therapeutic": "ncit:C116876"}}
{"id": "civic.eid:1474", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T11:42:24.007Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-12T23:58:09.043Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-13T23:49:16.674Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-14T00:06:19.727Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-14T00:05:48.790Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:988", "type": "Document", "label": "Atefi et al., 2011, PLoS ONE", "xrefs": ["pmc:PMC3237573", "pmid:22194965"], "title": "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:3N0v7K1aHgekLJ1o87o2H8_YR9yo4hhc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NHUtQ1IbZA9ZlH8wKbaMNF0W7esiwPKj", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:427", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:1475", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T11:43:32.691Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-12T23:57:05.190Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-13T23:51:46.796Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-14T00:06:40.202Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-07-14T00:05:46.222Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:988", "type": "Document", "label": "Atefi et al., 2011, PLoS ONE", "xrefs": ["pmc:PMC3237573", "pmid:22194965"], "title": "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Nd0Pkdnh3sdMDhl7IzZWgerMIASqaG1C", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NHUtQ1IbZA9ZlH8wKbaMNF0W7esiwPKj", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:427", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}}
{"id": "civic.eid:1627", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, one cell line harbored a PTEN allele deletion and R130* mutation. This cell line harbored the lowest IC50 values to both perifosine and temsirolimus and also showed increased apoptosis with perifosine in a xenograft model.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-08-31T08:53:50.759Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-11T19:39:13.159Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-11T19:40:29.992Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1076", "type": "Document", "label": "Liu et al., 2009, Cancer Res.", "xrefs": ["pmc:PMC2756336", "pmid:19706758"], "title": "Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:iwM1b8H-x1BlDJ2UyhzBztODVsK7SBW5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7tCulWPsDO5qBKyC19gjEEdhD_TUYqEZ", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C1727", "type": "Therapeutic"}, {"id": "rxcui:657797", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C7510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:636", "neoplasm_type_descriptor": {"id": "civic.did:16", "type": "DiseaseDescriptor", "label": "Thyroid Gland Cancer", "xrefs": ["DOID:1781"], "disease": "ncit:C7510"}, "object_descriptor": {"id": "civic.tcd:D46xUyn1b10HAjpKd6R9Pk2F5e_Dhj3C", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C1727", "type": "Therapeutic"}, {"id": "rxcui:657797", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:389", "type": "TherapeuticDescriptor", "label": "Perifosine", "xrefs": ["ncit:C1727"], "alternate_labels": ["4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium, Inner Salt", "D21266", "Octadecyl-(N,N-dimethylpiperidino-4-yl)phosphate", "Octadecylphosphopiperidine"], "therapeutic": "ncit:C1727"}, {"id": "civic.tid:83", "type": "TherapeuticDescriptor", "label": "Temsirolimus", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002292", "type": "DiseaseDescriptor", "label": "Carcinoma, Renal Cell", "disease": "mondo:0005086"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1844"], "alternate_labels": ["42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin", "CCI-779", "CCI-779 Rapamycin Analog", "Cell Cycle Inhibitor 779", "Rapamycin Analog", "Rapamycin Analog CCI-779", "Torisel"], "therapeutic": "rxcui:657797"}]}}
{"id": "civic.eid:1727", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ER\u03b1 and appeared to possess estrogen-independent activity.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:233", "type": "Agent", "name": "Sarat Chandarlapaty"}, "date": "2016-10-27T20:37:16.085Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-08T22:36:52.911Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:3", "type": "Agent", "name": "Obi Griffith"}, "date": "2016-11-12T14:53:20.616Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-08T22:27:28.151Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-08T22:29:32.437Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:171", "type": "Document", "label": "Toy et al., 2013, Nat. Genet.", "xrefs": ["pmc:PMC3903423", "pmid:24185512"], "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:tRLO2sHCwZoEMnW9IOzLR95_sYwMy8UW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.sY73k3V_TN0fv2d2TyZ7pIkRVNpmqqzH", "predicate": "predicts_resistance_to", "object": {"id": "ncit:C1740", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "mondo:0006512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:692", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:28", "type": "DiseaseDescriptor", "label": "Estrogen-receptor Positive Breast Cancer", "xrefs": ["DOID:60075"], "disease": "mondo:0006512"}, "object_descriptor": {"id": "civic.tid:407", "type": "TherapeuticDescriptor", "label": "Aromatase Inhibitor", "xrefs": ["ncit:C1740"], "therapeutic": "ncit:C1740"}}
{"id": "civic.eid:1845", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Protein alignments indicated this mutation was analogous to EGFR-L858R and BRAF-L597V. Co-expression of wildtype HER2 and HER3-V855A in Ba/F3 cells led to sensitivity to afatinib and pertuzumab.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:254", "type": "Agent", "name": "RAJENDRA BAHADUR SHAHI"}, "date": "2016-12-02T13:29:56.843Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-02-04T22:23:19.368Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-02-06T22:37:17.221Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2017-02-06T22:37:14.571Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1267", "type": "Document", "label": "Umelo et al., 2016, Oncotarget", "xrefs": ["pmc:PMC4823091", "pmid:26689995"], "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:CsRmAOy0dRs7rncLwRR6OwUguLsvw2A3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.o8Po5gTJ5tbkHufY5bCq-E66q5sSzgLL", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1430438", "type": "Therapeutic"}, {"id": "rxcui:1298944", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:781", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:BxGzt07o7RtpY--kqGrD-2I03DB5WiMa", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1430438", "type": "Therapeutic"}, {"id": "rxcui:1298944", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}, {"id": "civic.tid:247", "type": "TherapeuticDescriptor", "label": "Pertuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C38692"], "alternate_labels": ["2C4", "2C4 Antibody", "HS627", "Immunoglobulin G1, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide With Human-Mouse Monoclonal 2C4 Kappa-Chain, Dimer", "MoAb 2C4", "Monoclonal Antibody 2C4", "Omnitarg", "Perjeta", "Pertuzumab Biosimilar HS627", "RO4368451", "RhuMAb2C4"], "therapeutic": "rxcui:1298944"}]}}
{"id": "civic.eid:2012", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:28.031Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:06:23.522Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:22:53.859Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:06:12.520Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1420", "type": "Document", "label": "Rowley et al., 2000, Blood", "xrefs": ["pmid:11050000"], "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2013", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:28.139Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:18:25.498Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:25:21.397Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:18:01.357Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1421", "type": "Document", "label": "Rowley et al., 2002, Oncogene", "xrefs": ["pmid:12483530"], "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2014", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:28.227Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:17:23.921Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:25:12.706Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:17:08.371Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1422", "type": "Document", "label": "Hoang et al., 2006, Blood", "xrefs": ["pmc:PMC1895799", "pmid:16497971"], "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2022", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 positive, ER/PR negative breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.80uM. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:37.042Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-11T00:24:06.203Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-11T00:24:20.573Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-11T00:25:22.873Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-11T00:24:36.104Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:2FxuTz2MU8hmSP4i4SYrIK9S7VxzNOSk", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2026", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), which is a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL-1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.72uM. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.02).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:57:52.510Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-11T00:27:24.167Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-11T00:27:35.504Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-15T03:55:53.078Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-11T00:27:56.996Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:dUmmeoP_J79n4Qnsfq_QCuavJCCvBbt7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2034", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal type breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.34uM. To evaluate in vivo efficacy, MCF7 cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice treated with 100mg/kg pictilisib experienced a 62% tumor reduction, and those treated with 150mg/kg experienced a 70% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=0.02).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:58:12.013Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-11T00:29:57.410Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-02-11T00:30:10.150Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-15T03:43:32.829Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T17:18:06.218Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:anRsHdPVb0nCBfSYfSEzu77iBLk37J1Z", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2102", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Three cell lines harbored PIK3CA H1047R. T-47D is a luminal type breast cancer cell line, and it had an IC50 of 0.22uM. Treatment with GDC-0941 resulted in a substantial reduction of phosphorylated AKT. BT-20 is a basal breast cancer cell line which had an ICD50 of 0.62uM. MFM-223 is basal cell line that had an ICD50 of 2.10uM, and experienced some reduction in pAKT. Authors note that luminal-like cell lines were generally more sensitive to GDC-0941 than basal-like (p=0.02).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:59:42.158Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-04-09T23:14:03.829Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-04-09T23:14:13.561Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-15T03:44:07.969Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T22:37:53.940Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:BbVQi1uo233h-eYgKLuh6jw53MlucZWv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C165479", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:141", "type": "TherapeuticDescriptor", "label": "Pictilisib", "therapeutic": "ncit:C165479"}}
{"id": "civic.eid:2162", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 \u03bcmol/L).\nIn an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:36.123Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:17:45.752Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T15:38:13.360Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:17:50.848Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1526", "type": "Document", "label": "Shimamura et al., 2006, Cancer Res.", "xrefs": ["pmid:16818618"], "title": "Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:yPOGFMpEIrh8iHgb84a6Y4d5ZUrd_5Qn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1940643", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:52", "type": "TherapeuticDescriptor", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C49094"], "alternate_labels": ["(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide", "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-", "HKI 272", "HKI-272", "PB 272", "PB-272"], "therapeutic": "rxcui:1940643"}}
{"id": "civic.eid:2163", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:38.007Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:22:24.008Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T15:37:43.685Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:22:26.600Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1525", "type": "Document", "label": "Li et al., 2008, Oncogene", "xrefs": ["pmc:PMC2748240", "pmid:18408761"], "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0tqk3Y4n75EQKdSTas44ZvWe4edDbMQT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:2164", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:38.362Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:26:11.762Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T15:37:55.060Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:26:15.162Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1527", "type": "Document", "label": "Cha et al., 2012, Int. J. Cancer", "xrefs": ["pmid:21732342"], "title": "Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0tqk3Y4n75EQKdSTas44ZvWe4edDbMQT", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:2165", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:42.180Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:29:55.841Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-27T15:36:56.020Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2017-04-12T09:29:58.249Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1525", "type": "Document", "label": "Li et al., 2008, Oncogene", "xrefs": ["pmc:PMC2748240", "pmid:18408761"], "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:V-z3F2Xt13dmI8nbV6z3437MQvEdOwb6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C77588", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:465", "type": "TherapeuticDescriptor", "label": "Canertinib", "xrefs": ["ncit:C77588"], "alternate_labels": ["2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-", "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide"], "therapeutic": "ncit:C77588"}}
{"id": "civic.eid:2183", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 mice harbored KRAS mutations including 5 G13D mutations where disease stabilization was achieved in 2/5 mice treated with AZD6244 or combination therapy and 0/5 mice treated with BEZ235 alone.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:50.690Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T15:55:04.102Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:29:30.132Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:29:44.924Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1406", "type": "Document", "label": "Migliardi et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22392911"], "title": "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-F3Sgayl_hHeftSVlVub1Kge6YOcRIOp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:2212", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring BRAF, KRAS, NRAS or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 4 G12C mutations where disease stabilization occurred in 3/4 treated with BEZ235 or doublet therapy and 2/4 treated with AZD6244 only.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:00:58.929Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T15:46:36.728Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:30:56.029Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T16:31:16.382Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1406", "type": "Document", "label": "Migliardi et al., 2012, Clin. Cancer Res.", "xrefs": ["pmid:22392911"], "title": "Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:xJ2rg0ajFyUpTfnDYa3wGJmRCm1WyIkl", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:23p9szOW83imwzdNpS6omDSCucd7VZPf", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:2289380", "type": "Therapeutic"}, {"id": "ncit:C74072", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}, {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}]}}
{"id": "civic.eid:2250", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:18.987Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:04:57.706Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:23:10.873Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:04:39.528Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1420", "type": "Document", "label": "Rowley et al., 2000, Blood", "xrefs": ["pmid:11050000"], "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2252", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:19.163Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:31:40.609Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:24:48.417Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:31:29.377Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1422", "type": "Document", "label": "Hoang et al., 2006, Blood", "xrefs": ["pmc:PMC1895799", "pmid:16497971"], "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2261", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:20.039Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:03:15.166Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:23:23.582Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:02:34.672Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1420", "type": "Document", "label": "Rowley et al., 2000, Blood", "xrefs": ["pmid:11050000"], "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2263", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:20.217Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:30:45.253Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:24:59.328Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:30:32.528Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1422", "type": "Document", "label": "Hoang et al., 2006, Blood", "xrefs": ["pmc:PMC1895799", "pmid:16497971"], "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2277", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:21.316Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:04:07.030Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:23:36.121Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:02:28.199Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1420", "type": "Document", "label": "Rowley et al., 2000, Blood", "xrefs": ["pmid:11050000"], "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2278", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:21.379Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:33:09.262Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:24:16.939Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:25:44.535Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1421", "type": "Document", "label": "Rowley et al., 2002, Oncogene", "xrefs": ["pmid:12483530"], "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2279", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:21.441Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T02:29:32.263Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-21T11:24:29.014Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T01:58:46.699Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1422", "type": "Document", "label": "Hoang et al., 2006, Blood", "xrefs": ["pmc:PMC1895799", "pmid:16497971"], "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:6718", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3242", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:41", "type": "DiseaseDescriptor", "label": "Multiple Myeloma", "xrefs": ["DOID:9538"], "disease": "ncit:C3242"}, "object_descriptor": {"id": "civic.tid:328", "type": "TherapeuticDescriptor", "label": "Melphalan", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:633", "type": "DiseaseDescriptor", "label": "Multiple myeloma", "disease": "ncit:C3242"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C633"], "alternate_labels": ["4-[bis(2-chloroethyl)amino]-L-phenylalanine", "Alanine Nitrogen Mustard", "CB-3025", "L-PAM", "L-Phenylalanine Mustard", "L-Sarcolysin", "L-Sarcolysin Phenylalanine Mustard", "L-Sarcolysine", "Melphalanum", "P-di(chloroethyl)amino-L-phenylalanine", "Phenylalanine Mustard", "Phenylalanine Nitrogen Mustard", "Sarcoclorin", "Sarkolysin", "WR-19813"], "therapeutic": "rxcui:6718"}}
{"id": "civic.eid:2329", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild-type IDH1. Sensitivity was determined by assessing cell growth.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:01:43.202Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T03:35:19.521Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-10T21:43:33.801Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2017-03-31T03:35:22.032Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:678", "type": "Document", "label": "Rohle et al., 2013, Science", "xrefs": ["pmc:PMC3985613", "pmid:23558169"], "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:L27liwS5SFdLj28F8q-fwUzAknFBz72e", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rNhxmp_gYSRocQWOzkt83kNujGnV-BVj", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:9240", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4822", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:59", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:695", "type": "DiseaseDescriptor", "label": "High Grade Glioma", "xrefs": ["DOID:3070"], "disease": "ncit:C4822"}, "object_descriptor": {"id": "civic.tid:473", "type": "TherapeuticDescriptor", "label": "AGI-5198", "therapeutic": "iuphar.ligand:9240"}}
{"id": "civic.eid:2445", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, KIT N822H was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822H were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:08.745Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T01:35:38.195Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:36:43.227Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:36:46.601Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:VZY9ZJ_NpqE1M-jD9pUZZDaIDhacKBQW", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1hiFwlYqyUZp6seEX9tIvVsOwS351O3U", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:987", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2448", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, KIT N822K was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822K were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:10.251Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T01:36:49.342Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:37:51.869Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:38:05.098Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ZxmOE-Tfyaz9d8IiIFwmUH4iPQpVJY-N", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2451", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, KIT D816V was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT D816V were resistant to imatinib up to 10 umol/L.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:12.411Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T01:38:31.838Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:39:40.956Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:40:08.445Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:OBcn0zF1MPc2s0JljTGL_6gsWYCaBj9Y", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nMt7siwiRwJd_T_l46fg_fFaPZ7-H4sN", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:65", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2454", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, PDGFRA V561D was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA V561D were as sensitive to imatinib as ligand activated wildtype PDGFRA (IC50: 100-200 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:14.203Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T01:46:46.440Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:47:59.636Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:48:17.688Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-xN_xeEUq0fac4KIaVJ3IN0SC4hNUHeR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PmR2KGO2d96zDOFtI79sijmIhGO2v-a0", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:941", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2463", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:31.040Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T02:12:27.673Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T02:18:03.085Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T02:23:08.231Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:4wAwz4JpInBDLo3whjYGXvXng0zm5369", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2469", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, KIT V560G was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for the presence of phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT V560G were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:34.429Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T01:19:33.673Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:20:27.012Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:17:44.283Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ZnyIormPEPZ-XjdFQAIs4Ae-T8XKoPzQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jD9f-R_toWrduybrjbm68lsaOpntmZAa", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:972", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2472", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, KIT K642E was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT K642E were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:45.722Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T01:32:31.438Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:32:54.336Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:34:11.164Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FRKx3lIwShOkc1Oo8nqmaPEVZJ1LIfc5", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.qqyXsR4-bT1oCgmCJM4qHholRwDQ602L", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:978", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2481", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, KIT W557_K558del was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT W557_K558del were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:50.684Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T02:24:53.858Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T02:25:21.181Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:24:36.304Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:VoPNvhNVKfg3xdR3v36DGQhB5l_Wr-G7", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2gBgJAKNHo14J6N0g8ZYsewGjZK1O2tQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:961", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2484", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study of imatinib sensitivity, KIT Y503_F504insAY was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT Y503_F504insAY were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:03:52.757Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-02-23T01:29:56.904Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:30:42.004Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-23T01:32:04.952Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:412", "type": "Document", "label": "Heinrich et al., 2003, J. Clin. Oncol.", "xrefs": ["pmid:14645423"], "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:hnaDX4UkS75ZznY5Fr6YVn-gnLWaEw2u", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nNvZsJYuz0nRzWuLxxZN9AXKkux3fCEN", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:946", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:2625", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:31.591Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T23:15:14.268Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-02-28T18:57:20.056Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T23:16:48.815Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:45:36.051Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:665", "type": "Document", "label": "Cross et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4315625", "pmid:24893891"], "title": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:TkqfFX9HbLhBIipEifDTfhLgd3GyueqQ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4_z-sPp1Hb0OeQhs_-VlATlyJ_lQbDjT", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:328134", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1002", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}}
{"id": "civic.eid:2629", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:07:39.204Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2018-04-18T20:56:19.882Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2018-04-18T20:58:35.556Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:45:48.159Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1525", "type": "Document", "label": "Li et al., 2008, Oncogene", "xrefs": ["pmc:PMC2748240", "pmid:18408761"], "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:AEC2fbyX0a0Y3wtOYoALtu06a2AJbVtm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1430438", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:146", "type": "TherapeuticDescriptor", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:25316", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer squamous", "disease": null}]}}], "xrefs": ["ncit:C66940"], "alternate_labels": ["(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide", "BIBW 2992", "BIBW2992"], "therapeutic": "rxcui:1430438"}}
{"id": "civic.eid:2837", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1930V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1930V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 88% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T22:08:32.753Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:706", "type": "Agent", "name": "Shahil Pema"}, "date": "2020-05-11T05:14:39.924Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T05:17:00.813Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-05-11T05:17:57.248Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1541", "type": "Document", "label": "Navrkalova et al., 2013, Haematologica", "xrefs": ["pmc:PMC3696617", "pmid:23585524"], "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:WQ34ZBqeP1n0ieEUlOA3Q5GIMl1I3cKf", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.It5QO3hhuuPpeF1AKVeSiQ1bxVmtW_EI", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:142433", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3163", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1160", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:52", "type": "DiseaseDescriptor", "label": "Chronic Lymphocytic Leukemia", "xrefs": ["DOID:1040"], "disease": "ncit:C3163"}, "object_descriptor": {"id": "civic.tid:68", "type": "TherapeuticDescriptor", "label": "Doxorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:666", "type": "DiseaseDescriptor", "label": "Small cell lung cancer", "disease": "ncit:C4917"}, {"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:614", "type": "DiseaseDescriptor", "label": "Hodgkin lymphoma", "disease": "ncit:C9357"}, {"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}, {"id": "hemonc:601", "type": "DiseaseDescriptor", "label": "Gastric cancer", "disease": "ncit:C9331"}, {"id": "hemonc:675", "type": "DiseaseDescriptor", "label": "Thyroid cancer", "disease": "ncit:C7510"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C456"], "alternate_labels": ["(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione", "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione", "14-Hydroxydaunomycin", "Adriablastin", "Hydroxydaunomycin", "Hydroxyl Daunorubicin", "Hydroxyldaunorubicin"], "therapeutic": "rxcui:142433"}}
{"id": "civic.eid:2888", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "28 acral or mucosal melanomas were examined for KIT expression and mutations (exons 11, 13, 17, and 18). Two of 19 melanomas examined harbored KIT mutations, with one subject harboring a D820Y mutation. Western blotting showed KIT phosphorylation (Y219) in this case and the SM3 cell line harboring the D820Y mutation. The SM3 cell line showed significant growth inhibition with sunitinib exposures of 1uM and 10uM while imatinib showed no activity. The authors comment that this indicates a potential role for sunitinib in growth inhibition of acral melanomas.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:122", "type": "Agent", "name": "Deb Irene"}, "date": "2017-03-31T00:43:26.145Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:212", "type": "Agent", "name": "Gabe Rudy"}, "date": "2020-02-26T23:00:48.451Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-31T23:18:40.141Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-11T15:01:29.043Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1648", "type": "Document", "label": "Ashida et al., 2009, Int. J. Cancer", "xrefs": ["pmid:19035443"], "title": "Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:41bDOH-EwwQsX5BIhatUGJULYC1J6UYo", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.k2xXiu-T1lSzrMEKj4oJo8vrUM0mG7A4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:986", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:2907", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, two Q61R, and three Q61K mutations) and 5/6 were sensitive to MEK inhibitors selumetinib and trametinib. One Q61K line was not sensitive to these inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-04-04T12:00:08.271Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-05-30T18:43:05.799Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-05-30T19:32:15.429Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T16:22:09.458Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1670", "type": "Document", "label": "Ohashi et al., 2013, Clin. Cancer Res.", "xrefs": ["pmc:PMC3643999", "pmid:23515407"], "title": "Characteristics of lung cancers harboring NRAS mutations."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:x1EEg96JbfXK4DaYuvo5QXQ26AOUK_c9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NHUtQ1IbZA9ZlH8wKbaMNF0W7esiwPKj", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:2289380", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:427", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tcd:7-vqdmeFPTHxXVuEkILH1hUqi8pUpKHI", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1425098", "type": "Therapeutic"}, {"id": "rxcui:2289380", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}, {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}]}}
{"id": "civic.eid:2936", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Mutational profiling of 207 lung adenocarcinomas identified in 2 of with activating mutation in exon 2 of MEK1 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF). Expression of mutant, but not wild-type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells. A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:418", "type": "Agent", "name": "Paul Roepman"}, "date": "2017-04-11T10:02:27.464Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-08T21:32:34.329Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-08T21:01:44.534Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-18T20:06:51.117Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1685", "type": "Document", "label": "Marks et al., 2008, Cancer Res.", "xrefs": ["pmc:PMC2586155", "pmid:18632602"], "title": "Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:HzfmXiWD-8Rgy07zUh53FJ4Q-s9Pyxrq", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.R6gvvb2EUEawmeshcvUxLcNatKmnaKiX", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2289380", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1272", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:63", "type": "TherapeuticDescriptor", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "xrefs": ["ncit:C66939"], "alternate_labels": ["ARRY-142886", "AZD6244", "MEK Inhibitor AZD6244"], "therapeutic": "rxcui:2289380"}}
{"id": "civic.eid:3009", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "SU11248 + Cytarabin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation (Combination Index = 0.59 for ED50, Combination Index = 0.71 for ED75, Combination Index = 0.82 for ED90)", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:401", "type": "Agent", "name": "Emre KAR"}, "date": "2017-05-16T07:34:19.305Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:401", "type": "Agent", "name": "Emre KAR"}, "date": "2017-05-16T07:42:49.317Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:31:16.994Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:31:03.943Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1731", "type": "Document", "label": "Yee et al., 2004, Blood", "xrefs": ["pmid:15304385"], "title": "Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:oJcnYEbabgZ1MjRjEVkQpu4msztN7Lp-", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tcd:EtvnZkfmUnX9dgYyiWoe5VRjtk66aANb", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:3041", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:3010", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "SU11248 + Daunorubicin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation. (Combination Index = 0.82 for ED50, Combination Index = 0.72 for ED75, Combination Index = 0.64 for ED90)", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:401", "type": "Agent", "name": "Emre KAR"}, "date": "2017-05-16T07:39:52.318Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:401", "type": "Agent", "name": "Emre KAR"}, "date": "2017-05-16T07:41:09.303Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:28:27.939Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-16T15:28:07.804Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1731", "type": "Document", "label": "Yee et al., 2004, Blood", "xrefs": ["pmid:15304385"], "title": "Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:nL44PCYKVcW8qvTMLg_sOu9xg4bHXhhs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tcd:kq_IlYPnxZshE98tdVEBg09-xj3EdRy6", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "COMBINATION"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:3109", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:2", "type": "TherapeuticDescriptor", "label": "Daunorubicin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D007945", "type": "DiseaseDescriptor", "label": "Leukemia, Lymphoid", "disease": "ncit:C7539"}, {"id": "mesh:D015470", "type": "DiseaseDescriptor", "label": "Leukemia, Myeloid, Acute", "disease": "ncit:C3171"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C62091"], "alternate_labels": ["(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione", "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-", "DAUNOMYCIN", "DNR", "Daunorrubicina", "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-", "Leukaemomycin C", "RUBOMYCIN C", "Rubidomycin"], "therapeutic": "rxcui:3109"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:3710", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, reported errantly as 3301.13nM in the source) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12A was more strongly resistant to regorafenib than KRAS wt and other KRAS G12/G13 mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:17.246Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-30T20:17:40.288Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-30T20:42:40.249Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T22:18:30.578Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T19:22:24.134Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1935", "type": "Document", "label": "Camaj et al., 2015, Future Oncol", "xrefs": ["pmid:26161928"], "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:QTBIX5Qbpy32hab7psJQJ2edqIzeEKog", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:148", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:3722", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for testing resistance to BRAF inhibition by vemurafenib. M229 cells virally transduced with PIK3CA E545K were significantly more resistant to vemurafenib-mediated growth suppression than cells transduced with empty vectors (50% vs 20% survival at the highest concentration, p <.0001). Furthermore, E545K appears to confer more resistance to vemurafenib than PIK3CA D350G and similar levels of resistance as E545G. Resistance was determined by assessing cell survival.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:26.842Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-18T19:07:11.501Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:24:57.082Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-28T17:41:05.419Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:25:43.300Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:om23Bqg2hisE2j8mNEAByuIjZMEkklrt", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3724", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA E545G were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with an empty vector (50% vs 20% survival at the highest concentration, p < .0001). Though statistics were not provided, E545G appears to confer similar levels of resistance to vemurafenib as the positive control variant, PIK3CA E545K.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:34:28.292Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-18T19:05:50.710Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:23:30.935Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-28T17:55:14.430Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:24:19.497Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:SL_Fy43hFX6hzEsBkdEu0sxG8gOpJUsM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.7NSMwTRR_yBpn8GqpL2Ux_8OD5PbOqjC", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:883", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3924", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wildtype. Resistance was determined by assessing cell viability. Regorafenib significantly reduced BRAF, Erk1/2 and Elk phosphorylation compared to wildtype, as assessed by western blot. Authors concluded that KRAS G12A was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:37:43.649Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T22:19:23.640Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-24T22:25:40.236Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T19:18:18.236Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1935", "type": "Document", "label": "Camaj et al., 2015, Future Oncol", "xrefs": ["pmid:26161928"], "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:BVX6D_q-DEbyuCe8nmss8i2EOG2k_mY1", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:3957", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express KRAS4a G12D or KRAS4b G12D  were more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with empty vectors (90% vs 10% survival).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:09.393Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-19T20:19:13.814Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:19:22.850Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-02T21:46:26.688Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:19:34.245Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Ywzi4619qFuSv6iLQlizo3fDCE_ZKMiA", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:3973", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. In vivo, KRAS G12C expressing SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth. Mice injected with KRAS wt cells did not significantly respond to regorafenib, although a trend was seen toward better response. IHC analysis of mouse tissue revealed no significant change in markers of proliferation (Ki67), angiogenesis (CD31) and apoptosis (TUNEL) in KRAS G12C expressing mice treated with regorafenib compared to KRAS wt expressing mice whose tumors displayed more pronounced changes. Authors concluded that G12C was more resistant to regorafenib than KRAS wt and other common KRAS G12/G13 mutants.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:21.111Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T22:20:05.552Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-24T22:25:57.348Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T19:12:43.771Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1935", "type": "Document", "label": "Camaj et al., 2015, Future Oncol", "xrefs": ["pmid:26161928"], "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:5rEhcKlm6SQAEZ5mzuo8V2snmslek5Z6", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:78", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:4012", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12S was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:49.817Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T22:21:09.669Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-24T22:26:08.179Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T19:00:47.381Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1935", "type": "Document", "label": "Camaj et al., 2015, Future Oncol", "xrefs": ["pmid:26161928"], "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:slJIDGiDqamg7FyaNaZd-RHTdbFdaaXJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:913", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:4056", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to sunitinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:27.885Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-04-26T19:10:30.221Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:13:59.419Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:10:03.470Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:2O1AVZOC5jsj8037pM-_fJw7EVte9aew", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PmR2KGO2d96zDOFtI79sijmIhGO2v-a0", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:941", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4060", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:30.867Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-04-26T18:25:58.930Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T18:51:24.896Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-20T15:12:28.712Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:iIUD9SPwZOOp5xlj4OSrGxihgQb0F5HS", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4061", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A GIST430 patient derived cell line expressing KIT V560_L576del primary activating mutation demonstrated insensitivity to regorafenib (IC50: 191nmol/L) treatment. IC50 was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:31.696Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T22:45:09.600Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:45:29.476Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:45:43.418Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:V0M8G5S7SshEZYSGAS7OObuW6pypjQHf", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.8EdAufoZPtrrpbZTWFRym7CIluHpjO0D", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1550", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:4077", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT V560D demonstrated comparable sensitivity to sunitinib treatment compared to cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:47.411Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-04-26T19:12:56.512Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:23:49.154Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:23:51.611Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:3Vj4gE4_RXwW9V2VAUSIROiX38FYUAPp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wkbbLzMJDVWkn-GLG_Q3IhYQ261bvMFN", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:971", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4087", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to sunitinib (IC50: 7 +/-  2nmol/L) and regorafenib (IC50: 30 +/- 14nmol/L) treatments. IC50 was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:56.647Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T22:21:29.291Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T23:06:12.226Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:20:20.301Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:u9IM22E-2N82CoBh0JuP4Y6A98hUuF18", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2gBgJAKNHo14J6N0g8ZYsewGjZK1O2tQ", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:961", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:bYViGyioquX85upNxP_jx2bCYehx3bhD", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:4100", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable sensitivity to sunitinib treatment compared to CHO cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:08.384Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-04-26T19:47:24.390Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:52:36.106Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:52:40.055Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-47Bm0nFB8M5aw4NKmB6dPjzuZ9pZxm2", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wz6wMfy1414Bg53uDpoW0GtkipcMyumU", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1558", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:4141", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, COS-7 cells expressing KIT L576P activating mutation demonstrated sensitivity to imatinib and dasatinib treatments. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:40:44.653Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-08-05T23:04:26.513Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-05T23:05:06.981Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-05T23:05:09.753Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2054", "type": "Document", "label": "Vita et al., 2014, JAMA Dermatol", "xrefs": ["pmid:25317746"], "title": "Characterization of S628N: a novel KIT mutation found in a metastatic melanoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:0OvARVTQxuHz-6QEMYSok9EuV0bgnkIn", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.1i40nlLTUTxkw3VAG3tTQSuNjTWnMdy5", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1546019", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:72", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tcd:jKuLlWRt_pXwz9R2lQrLzMdihFWFZMMK", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SEQUENTIAL"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1546019", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}]}}
{"id": "civic.eid:4280", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively. Similarly, gefitinib was tested and 187 nanomolar IC50 was seen, suggesting lack of sensitivity and potential resistance.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:47:58.218Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:25:49.363Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2022-03-10T03:19:29.892Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2017-09-16T11:05:55.526Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1528", "type": "Document", "label": "Kancha et al., 2009, Clin. Cancer Res.", "xrefs": ["pmid:19147750"], "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:dly7mIBbpvFvCkPu7B97Pse4n1LH99si", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.QCVth-Ixxzx5gG-eO5MGb5KPOkv_CPtD", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1018", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tcd:MHwrYYGaDMmdgFLNboI18QBl-zDj5Wso", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:328134", "type": "Therapeutic"}, {"id": "rxcui:337525", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:14", "type": "TherapeuticDescriptor", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C1855"], "alternate_labels": ["4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline", "Iressa", "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine", "ZD 1839", "ZD1839"], "therapeutic": "rxcui:328134"}, {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}]}}
{"id": "civic.eid:4284", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:17.898Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-07T02:06:07.325Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-08-10T20:18:02.330Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:45:57.800Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1525", "type": "Document", "label": "Li et al., 2008, Oncogene", "xrefs": ["pmc:PMC2748240", "pmid:18408761"], "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:teH1xxIK6r4jpsaY8NccNewpkJ0YcjYX", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4285", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:20.288Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-08-13T19:15:45.830Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-30T00:04:28.134Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:00.802Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1993", "type": "Document", "label": "Harada et al., 2011, Oncogene", "xrefs": ["pmid:21132006"], "title": "Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:SiixlQPIiMUTcOOHiEHlMp9LXEJSztAd", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4291", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9 \u00b1 12.4). Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:40.328Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-11-23T20:40:51.807Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2020-10-30T00:03:38.472Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:08.659Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2086", "type": "Document", "label": "Konduri et al., 2016, Cancer Discov", "xrefs": ["pmc:PMC4893907", "pmid:27102076"], "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:64rhaTRjJsCQ8ITpsF__1TSOOypqTk-P", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3512", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:30", "type": "DiseaseDescriptor", "label": "Lung Adenocarcinoma", "xrefs": ["DOID:3910"], "disease": "ncit:C3512"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4293", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8 and 11 nM) compared to EGFRwt NCI-H2073 cells (IC50: 108 nM; 95%CI 52-223 nM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:43.020Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2020-07-16T04:46:30.046Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T22:56:52.972Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:14.892Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:665", "type": "Document", "label": "Cross et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4315625", "pmid:24893891"], "title": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:SgYMBNbVCqr1tJu-HrnI_AKmraMyqz8R", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:337525", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4917", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:174", "type": "DiseaseDescriptor", "label": "Lung Small Cell Carcinoma", "xrefs": ["DOID:5409"], "disease": "ncit:C4917"}, "object_descriptor": {"id": "civic.tid:15", "type": "TherapeuticDescriptor", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}, {"id": "hemonc:648", "type": "DiseaseDescriptor", "label": "Pancreatic cancer", "disease": "ncit:C43298"}]}}], "xrefs": ["ncit:C65530"], "therapeutic": "rxcui:337525"}}
{"id": "civic.eid:4294", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to AZD9291 (IC50: 60 and 49 nM) compared to EGFRwt NCI-H2073 cells (IC50: 1865 nM; 95%CI 872-3988 nM). In vivo experiments with NCI-H3255 xenograft models showed drastic tumour volume reduction upon treatment with 5mg/kg/day AZD9291.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:48:43.977Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T23:08:50.359Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-02-03T23:04:06.687Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2018-02-13T19:46:18.104Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:665", "type": "Document", "label": "Cross et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC4315625", "pmid:24893891"], "title": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:btf_YXh-Xokf9PrBB-GipkFRbcngQGZZ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1721560", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:33", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:187", "type": "TherapeuticDescriptor", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "DiseaseDescriptor", "label": "Non-small cell lung cancer", "disease": "ncit:C2926"}]}}], "xrefs": ["ncit:C116377"], "alternate_labels": ["2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-", "AZD-9291", "AZD9291", "Mereletinib", "Tagrisso"], "therapeutic": "rxcui:1721560"}}
{"id": "civic.eid:4459", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro kinase study, a KIT V559D primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 36nmol/L vs. 640nmol/L), regorafenib (IC50: 57nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.8nmol/L vs. 6nmol/L) treatments compared to the wild-type KIT. IC50 was determined by assessing kinase activity.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:00.526Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T22:59:18.843Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:59:29.229Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:59:36.323Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ClcppE0QFdRvqnoipKn9zmuy1dH-ThU_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wkbbLzMJDVWkn-GLG_Q3IhYQ261bvMFN", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:968", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:pRXLOTUcGy266tKwrptqo3E3XUUSTYZh", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}]}}
{"id": "civic.eid:4498", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:51:33.376Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-25T16:46:53.891Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-12T18:57:05.940Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-07-25T16:46:55.202Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:w-TRxF-vzBMkYBkX0mtGfCnMKrt2yDXz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gI0FOE6Esplrs92wp0CJWOeriC8srpYN", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:169", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4583", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT K550_W557del primary activating mutation demonstrated sensitivity to imatinib (IC50: 13nmol/L), sunitinib (IC50: 5nmol/L), regorafenib (IC50: 22nmol/L), and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:52:52.496Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T22:41:08.705Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-12T19:08:05.649Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:39:42.000Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:VuFlUKZngW0td0ef7NFF2QoDXtewPSx0", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2merS66xoRF3fdt-iSbkXYZ7hyd58Y6L", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:948", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tcd:EFgr37MY89Im6stpaZjt2xyMOX1et0He", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1312397", "type": "Therapeutic"}, {"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1364347", "type": "Therapeutic"}, {"id": "rxcui:357977", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}, {"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}, {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}]}}
{"id": "civic.eid:4784", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA D350G were significantly more resistant to BRAF inhibition by vemurafenib  than cells transduced with empty vectors (40% vs 20% survival at the highest concentration, p=.0148). Though statistics were not provided, D350G appears to confer less resistance to vemurafenib than the positive control variant, PIK3CA E545K.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:48.965Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-07-18T18:47:39.207Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:22:10.797Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2018-06-28T17:56:15.446Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2018-07-19T20:22:57.638Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:HfaPSsJEoYLotl2Phf-Kr8HDZ6ltVgjG", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.78e11s6zb_99DWGCz8hfSLSqWxS5tCF9", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1653", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4791", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, COS-7 cells expressing KIT S628N activating mutation demonstrated sensitivity to imatinib and dasatinib treatments when compared to the KIT L576P, which was used as an imatinib-sensitive control. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:55:55.832Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-08-05T23:11:35.585Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-05T23:11:46.453Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-08-05T23:10:32.397Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2054", "type": "Document", "label": "Vita et al., 2014, JAMA Dermatol", "xrefs": ["pmid:25317746"], "title": "Characterization of S628N: a novel KIT mutation found in a metastatic melanoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ZPSvgEdl92TqTkhEO6gmCiYyl_pNWDna", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.nk4PdRd1ft2MmNl1CPXEHh47vBckdGBG", "predicate": "predicts_sensitivity_to", "object": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1546019", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1659", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tcd:jKuLlWRt_pXwz9R2lQrLzMdihFWFZMMK", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SEQUENTIAL"}], "therapeutic_collection": {"type": "CombinationTherapeutics", "members": [{"id": "rxcui:282388", "type": "Therapeutic"}, {"id": "rxcui:1546019", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:5", "type": "TherapeuticDescriptor", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C62035"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"], "therapeutic": "rxcui:282388"}, {"id": "civic.tid:20", "type": "TherapeuticDescriptor", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C38713"], "alternate_labels": ["5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate", "BMS-354825", "Dasatinib Hydrate", "Dasatinib Monohydrate", "Sprycel"], "therapeutic": "rxcui:1546019"}]}}
{"id": "civic.eid:5346", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-20T15:21:12.331Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-04-26T18:53:24.627Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T18:54:04.778Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:08:00.622Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:4wAwz4JpInBDLo3whjYGXvXng0zm5369", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:99", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:537", "type": "TherapeuticDescriptor", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C1687"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:5347", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to imatinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-20T15:41:48.781Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-04-26T18:55:39.653Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T18:56:04.707Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:09:12.770Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-xN_xeEUq0fac4KIaVJ3IN0SC4hNUHeR", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.PmR2KGO2d96zDOFtI79sijmIhGO2v-a0", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:941", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:537", "type": "TherapeuticDescriptor", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C1687"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:5348", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT V560D mutation demonstrated sensitivity to imatinib treatment (IC50 = 100 vs IC50 = 1000) when compared to Chinese hamster ovary cells expressing ligand-activated wild-type KIT. Sensitivity was determined by assessing KIT auto-phosphorylation.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:7", "type": "Agent", "name": "Alex Handler Wagner, PhD"}, "date": "2017-07-20T15:58:15.425Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2019-04-26T19:16:20.289Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:17:04.271Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-04-26T19:21:22.674Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:965", "type": "Document", "label": "Heinrich et al., 2008, J. Clin. Oncol.", "xrefs": ["pmc:PMC2651076", "pmid:18955458"], "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Uw6_5645-sHWjylIVVQxFwGmRI2r_KMV", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wkbbLzMJDVWkn-GLG_Q3IhYQ261bvMFN", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:282388", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:971", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:537", "type": "TherapeuticDescriptor", "label": "Imatinib Mesylate", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:667", "type": "DiseaseDescriptor", "label": "Soft tissue sarcoma", "disease": "ncit:C9306"}, {"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:616", "type": "DiseaseDescriptor", "label": "Hypereosinophilic syndrome", "disease": "ncit:C27038"}, {"id": "hemonc:33893", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia pediatric", "disease": null}, {"id": "hemonc:634", "type": "DiseaseDescriptor", "label": "Myelodysplastic syndrome", "disease": "ncit:C3247"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}, {"id": "hemonc:669", "type": "DiseaseDescriptor", "label": "Systemic mastocytosis", "disease": "ncit:C9235"}]}}], "xrefs": ["ncit:C1687"], "alternate_labels": ["4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate", "CGP 57148", "CGP57148B", "Gleevec", "Glivec", "STI 571", "STI-571", "STI571"], "therapeutic": "rxcui:282388"}}
{"id": "civic.eid:7379", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at IC50 values 20 nmol/L and 8 nmol/L respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-06-21T22:39:55.316Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:955", "type": "Agent", "name": "Justin Guerra"}, "date": "2019-06-21T22:47:03.195Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-06-21T22:48:19.792Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-06-21T22:48:26.986Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2913", "type": "Document", "label": "Gozgit et al., 2011, Mol. Cancer Ther.", "xrefs": ["pmc:PMC3236248", "pmid:21482694"], "title": "Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:IyXHnM9wXTO1vkBYHyz58rn2I6rXU0K_", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1364347", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1263", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}}
{"id": "civic.eid:7392", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, an IL3 independant Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to sunitinib treatment (IC50: 5nmol/L). IC50 was determined by assessing cell viability.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-08T22:20:58.315Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:954", "type": "Agent", "name": "Brian Li"}, "date": "2019-07-09T22:05:20.144Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:05:30.173Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2019-07-09T22:04:52.110Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2042", "type": "Document", "label": "Garner et al., 2014, Clin. Cancer Res.", "xrefs": ["pmc:PMC4233175", "pmid:25239608"], "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:X--rk5KYF8More-tcFGLU2GU-3wS87MC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.wz6wMfy1414Bg53uDpoW0GtkipcMyumU", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:357977", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3868", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1558", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2", "type": "DiseaseDescriptor", "label": "Gastrointestinal Stromal Tumor", "xrefs": ["DOID:9253"], "disease": "ncit:C3868"}, "object_descriptor": {"id": "civic.tid:157", "type": "TherapeuticDescriptor", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:602", "type": "DiseaseDescriptor", "label": "Gastrointestinal stromal tumor", "disease": "ncit:C3868"}, {"id": "hemonc:647", "type": "DiseaseDescriptor", "label": "Pancreatic NET", "disease": "ncit:C27720"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C71622"], "alternate_labels": ["1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"], "therapeutic": "rxcui:357977"}}
{"id": "civic.eid:7760", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a BRAF-mutation inducible model in the NIH3T3 cell line, class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R) were resistant to vemurafenib but sensitive to MEK-inhibitor trametinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2019-11-22T15:46:53.976Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2019-11-26T21:52:44.042Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3005", "type": "Document", "label": "Yao et al., 2017, Nature", "xrefs": ["pmc:PMC5648058", "pmid:28783719"], "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:GKz4jGK-6cuGPYPWCmWhR_Wpld0c3vUK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1425098", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:611", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}}
{"id": "civic.eid:7910", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted in sensitivity to cytarabine (Ara-C) treatment as indicated by reduced cell viability and IC50 compared to empty vector and wildtype PRPS1 overexpression controls.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:23:10.525Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-03-25T01:51:34.528Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:QHrBplIaoqXePtoWIlcz8wfVoG-yfdct", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Maq_xrhmRn5epsg2bAWeXhQJgIp7epBG", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:3041", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2923", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}}
{"id": "civic.eid:7911", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted in sensitivity to cytarabine (Ara-C) treatment as indicated by reduced cell viability and IC50 compared to empty vector and wildtype PRPS1 overexpression controls.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-01-31T19:23:31.857Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-02-04T23:20:07.873Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3161", "type": "Document", "label": "Li et al., 2015, Nat. Med.", "xrefs": ["pmc:PMC4670083", "pmid:25962120"], "title": "Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:pycvLc0U_85jyTOrJfSEzmz8w7j_9rJ9", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mbGeepbjVfWRRfqDj7J_giIRlrT0Pzsl", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:3041", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9140", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2919", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:2953", "type": "DiseaseDescriptor", "label": "Childhood B-cell Acute Lymphoblastic Leukemia", "xrefs": ["DOID:80146"], "disease": "ncit:C9140"}, "object_descriptor": {"id": "civic.tid:173", "type": "TherapeuticDescriptor", "label": "Cytarabine", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:575", "type": "DiseaseDescriptor", "label": "CNS leukemia", "disease": "ncit:C5440"}, {"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:552", "type": "DiseaseDescriptor", "label": "Acute myeloid leukemia", "disease": "ncit:C3171"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C408"], "alternate_labels": [".beta.-Cytosine Arabinoside", "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-.beta.-D-Arabinofuranosylcytosine", "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone", "1-Beta-D-arabinofuranosylcytosine", "1.beta.-D-Arabinofuranosylcytosine", "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-", "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-", "4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone", "ARA-cell", "Alexan", "Ara-C", "Arabine", "Arabinofuranosylcytosine", "Arabinosylcytosine", "Aracytidine", "Aracytin", "Aracytine", "Beta-Cytosine Arabinoside", "CHX-3311", "Cytarabinum", "Cytarbel", "Cytosar", "Cytosar-U", "Cytosine Arabinoside", "Cytosine-.beta.-arabinoside", "Cytosine-beta-arabinoside", "Erpalfa", "Starasid", "Tarabine PFS", "U 19920", "U-19920", "Udicil", "WR-28453"], "therapeutic": "rxcui:3041"}}
{"id": "civic.eid:8108", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 35 year-old male patient (AML4) presented with a FLT3-ITD mutation at diagnosis and was refractory to induction and salvage chemotherapy. He then received quizartinib and underwent allogenic transplant, but relapsed after 6 months. He then responded to sorafenib, but had disease progression with a FLT3-D835Y mutation. The patient derived relapse sample containing ITD and D835Y mutations was sensitive to gilteritinib based on cytotoxicity assays using MTT. Additionally, immunoblot demonstrated gilteritinib reduced FLT3 phosphorylation in Ba/F3 cells expressing only D835Y with an IC50 of 1.4 nM.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:341", "type": "Agent", "name": "Shruti Rao"}, "date": "2020-04-15T16:52:47.819Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-15T01:56:53.037Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-03T18:41:17.039Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-15T02:02:54.738Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-17T05:25:12.758Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3336", "type": "Document", "label": "Lee et al., 2017, Blood", "xrefs": ["pmc:PMC5234222", "pmid:27908881"], "title": "Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:tvJCe9XAOsqR9pc1rM79DidUe63IS7tP", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.Vti0p3hpaGkoQ8HvFtLXexpN29549Yo4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2105806", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3011", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:641", "type": "TherapeuticDescriptor", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C116722"], "alternate_labels": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"], "therapeutic": "rxcui:2105806"}}
{"id": "civic.eid:8183", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The BT-474 HER2 positive human breast cancer cell line, which is heterozygous for the PIK3CA K111N mutation, demonstrated strongly reduced colony formation when treated with lapatinib, trastuzumab or dactolisib alone or in combination, suggesting that K111N does not induce resistance to these drugs.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-04-30T20:02:52.990Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-28T21:27:04.756Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:30:34.075Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-01-28T21:27:23.300Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-01-28T21:30:42.474Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2486", "type": "Document", "label": "Eichhorn et al., 2008, Cancer Res.", "xrefs": ["pmc:PMC2587064", "pmid:19010894"], "title": "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:aS9zFMZ-KAkyX5gvQG3USIFyRPmVoRYF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MwhPgqLyRggo95FGBET65hs3Dbmm0jW1", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C74072", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1234", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tcd:KpOIbC8KoMmAJMv0VhZEeNN81aMernIK", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "ncit:C74072", "type": "Therapeutic"}, {"id": "rxcui:2103478", "type": "Therapeutic"}, {"id": "rxcui:480167", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}, {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}, {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}]}}
{"id": "civic.eid:8351", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "A 62-year-old female patient (AML5) was refractory to conventional chemotherapy and developed disease progression to quizartinib due to a D835I mutation. Using MTT to measure cytotoxicity, gilteritinib inhibited this patient\u2019s relapse sample. Additionally, immunoblot demonstrated gilteritinib inhibited FLT3 phosphoryaltion at a concentration of 20 nM in the patient dereivd relapse cells.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:341", "type": "Agent", "name": "Shruti Rao"}, "date": "2020-06-17T02:13:04.328Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-15T01:54:51.911Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:341", "type": "Agent", "name": "Shruti Rao"}, "date": "2020-07-15T18:39:51.929Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-15T18:41:06.948Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3336", "type": "Document", "label": "Lee et al., 2017, Blood", "xrefs": ["pmc:PMC5234222", "pmid:27908881"], "title": "Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:BsrpEv3uvOObt8coJ3u0jRVbsgblZslp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TVh5VT2LZdZ-rJdxlk71Vjj7Jk7Fyaul", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2105806", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3075", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:641", "type": "TherapeuticDescriptor", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C116722"], "alternate_labels": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"], "therapeutic": "rxcui:2105806"}}
{"id": "civic.eid:8517", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 2nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-15T07:01:57.188Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-03T19:24:19.657Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-08T02:01:39.136Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-03T19:19:21.052Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3336", "type": "Document", "label": "Lee et al., 2017, Blood", "xrefs": ["pmc:PMC5234222", "pmid:27908881"], "title": "Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:l9B-1LCy1aID28aDRnMPKXkh_gkPog8T", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MswFBbwawqmZ-OcumYQ5lb69AVzAq2GV", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2105806", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:612", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:641", "type": "TherapeuticDescriptor", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C116722"], "alternate_labels": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"], "therapeutic": "rxcui:2105806"}}
{"id": "civic.eid:8518", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 0.7nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:1053", "type": "Agent", "name": "Jason Saliba"}, "date": "2020-07-15T07:02:29.041Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-08T01:45:09.410Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-08T01:44:12.186Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-03T19:33:46.462Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-03T19:33:17.210Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:3336", "type": "Document", "label": "Lee et al., 2017, Blood", "xrefs": ["pmc:PMC5234222", "pmid:27908881"], "title": "Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:WU2ZYUH6o1F7CQH0bIWAzBTaFwA6kJoD", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2105806", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3171", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1302", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:3", "type": "DiseaseDescriptor", "label": "Acute Myeloid Leukemia", "xrefs": ["DOID:9119"], "disease": "ncit:C3171"}, "object_descriptor": {"id": "civic.tid:641", "type": "TherapeuticDescriptor", "label": "Gilteritinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C116722"], "alternate_labels": ["6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide", "ASP-2215", "ASP2215", "Xospata"], "therapeutic": "rxcui:2105806"}}
{"id": "civic.eid:8547", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-17T16:17:53.572Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-14T20:54:44.263Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:55:48.500Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:55:56.228Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:desKNJAFooL9t1omnjR5wXtKTxuyJz6d", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2103478", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}}
{"id": "civic.eid:8548", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-17T16:21:23.586Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-14T20:57:49.704Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:58:54.932Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T20:59:19.805Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:_GrAGad44C40DPxk2nbOP9tPhZQUKGve", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2103478", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}}
{"id": "civic.eid:8549", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-07-17T16:33:43.999Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-14T21:06:44.791Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T21:07:04.378Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T21:07:19.096Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Kl6s1I_CbVIhQQlkIS8URjfYMKlcgHXc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2103478", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:931", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}}
{"id": "civic.eid:8662", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to trastuzumab as PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-14T21:16:05.301Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T21:16:46.470Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ra3GmtMjZISXUhxnATIq8JK14R_DpRnM", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MwhPgqLyRggo95FGBET65hs3Dbmm0jW1", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2103478", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1234", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}}
{"id": "civic.eid:8663", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-08-14T21:18:49.577Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-14T21:19:33.714Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1468", "type": "Document", "label": "Baselga et al., 2016, Clin. Cancer Res.", "xrefs": ["pmid:26920887"], "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:1xWTPr--T7lrUpwHUtF2qZ8di5fsbSfz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.85QZR4K49RijmSG0hPIy9BQRNQBKuFgj", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2103478", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1235", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:84", "type": "TherapeuticDescriptor", "label": "Trastuzumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D001943", "type": "DiseaseDescriptor", "label": "Breast Neoplasms", "disease": "ncit:C2910"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C1647"], "alternate_labels": ["ABP 980", "ALT02", "Anti-ERB-2", "Anti-HER2/c-erbB2 Monoclonal Antibody", "Anti-c-ERB-2", "Anti-c-erbB2 Monoclonal Antibody", "Anti-erbB-2", "Anti-erbB2 Monoclonal Antibody", "Anti-p185-HER2", "C-erb-2 Monoclonal Antibody", "HER2 Monoclonal Antibody", "Herceptin", "Herceptin Biosimilar PF-05280014", "Herceptin Trastuzumab Biosimilar PF-05280014", "Herzuma", "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer", "Kanjinti", "MoAb HER2", "Monoclonal Antibody C-erb-2", "Monoclonal Antibody HER2", "Ogivri", "Ontruzant", "PF-05280014", "RO0452317", "RhuMAb HER2", "SB3", "Trastuzumab Biosimilar ABP 980", "Trastuzumab Biosimilar ALT02", "Trastuzumab Biosimilar EG12014", "Trastuzumab Biosimilar HLX02", "Trastuzumab Biosimilar PF-05280014", "Trastuzumab Biosimilar SB3", "Trastuzumab Biosimilar SIBP-01", "Trastuzumab-anns", "Trastuzumab-dkst", "Trastuzumab-dttb", "Trastuzumab-pkrb", "Trastuzumab-qyyp", "Trazimera"], "therapeutic": "rxcui:2103478"}}
{"id": "civic.eid:9339", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "R1032Q affects the gene's universal kinase catalytic motif. The authors found that injection of mice with COLO-320 cells that harbor this mutation resulted in tumor generation, indicating that this mutation could have oncogenic potential. In vitro kinase assays showed R1032Q reduced VEGFR2 kinase activity. Using proliferation studies with the COLO-320 cell-line, the authors observed sensitivity to 4 tyrosine kinase inhibitors. Treatment of the MDST8 colorectal cancer cell line carrying the R1032Q mutation with cabozantinib resulted in significant reduction in cell growth and increased ERK phosphorylation levels.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:66", "type": "Agent", "name": "Melika Bonakdar"}, "date": "2021-06-03T20:47:12.698Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:66", "type": "Agent", "name": "Melika Bonakdar"}, "date": "2021-06-03T22:24:48.927Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-03T22:28:31.990Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-06-03T22:29:08.687Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:4010", "type": "Document", "label": "Toledo et al., 2018, Clin Cancer Res", "xrefs": ["pmid:29588308"], "title": "Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:ztQrueYpiE_BMuHSHX3rGE8pmzk_opIs", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.zBAXdV1boKCig9MUMpy2aIamLOPvSdQ8", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1242999", "type": "Therapeutic"}, {"id": "rxcui:1363267", "type": "Therapeutic"}, {"id": "ncit:C76199", "type": "Therapeutic"}, {"id": "rxcui:1603296", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:3350", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:M_Sea-m2TfCKdX-BNxASF4JMdFU5Jnj9", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:1242999", "type": "Therapeutic"}, {"id": "rxcui:1363267", "type": "Therapeutic"}, {"id": "ncit:C76199", "type": "Therapeutic"}, {"id": "rxcui:1603296", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:519", "type": "TherapeuticDescriptor", "label": "Axitinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C38718"], "alternate_labels": ["AG-013736", "AG013736", "Inlyta", "N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide"], "therapeutic": "rxcui:1242999"}, {"id": "civic.tid:144", "type": "TherapeuticDescriptor", "label": "Cabozantinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:68942", "type": "DiseaseDescriptor", "label": "Thyroid cancer medullary", "disease": null}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}, {"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}]}}], "xrefs": ["ncit:C52200"], "alternate_labels": ["1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- Fluorophenyl)-", "N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- Dicarboxamide"], "therapeutic": "rxcui:1363267"}, {"id": "civic.tid:228", "type": "TherapeuticDescriptor", "label": "Dovitinib", "xrefs": ["ncit:C76199"], "therapeutic": "ncit:C76199"}, {"id": "civic.tid:527", "type": "TherapeuticDescriptor", "label": "Lenvatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:593", "type": "DiseaseDescriptor", "label": "Endometrial cancer", "disease": "ncit:C27815"}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}]}}], "xrefs": ["ncit:C95124"], "alternate_labels": ["6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-", "E7080", "ER-203492-00", "Multi-Kinase Inhibitor E7080"], "therapeutic": "rxcui:1603296"}]}}
{"id": "civic.eid:795", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-01-08T12:22:17.922Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-04T23:44:09.319Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-08T21:56:45.164Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-02-04T23:45:04.691Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-02-08T21:56:35.138Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:529", "type": "Document", "label": "Puyol et al., 2010, Cancer Cell", "xrefs": ["pmid:20609353"], "title": "A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:zc1Du468_mERjyUhuBSeyqcIMUbOUU10", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1601374", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:425", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:429", "type": "TherapeuticDescriptor", "label": "Palbociclib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C49176"], "alternate_labels": ["6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one", "Ibrance", "PD 0332991", "PD 332991", "PD 991", "PD-0332991", "Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-"], "therapeutic": "rxcui:1601374"}}
{"id": "civic.eid:1361", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-01T13:01:08.503Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-08T22:19:34.428Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:5", "type": "Agent", "name": "Ben Ainscough"}, "date": "2016-06-22T19:27:42.518Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-08T22:15:23.231Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:926", "type": "Document", "label": "Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg", "xrefs": ["pmc:PMC4474763", "pmid:25855885"], "title": "Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:J9evO5P1EpX3l-r-2BtEahEa7DFN-mrN", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C74072", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4013", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:453", "type": "DiseaseDescriptor", "label": "Head And Neck Cancer", "xrefs": ["DOID:11934"], "disease": "ncit:C4013"}, "object_descriptor": {"id": "civic.tid:343", "type": "TherapeuticDescriptor", "label": "Dactolisib", "xrefs": ["ncit:C74072"], "alternate_labels": ["BEZ235", "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-", "NVPBEZ235"], "therapeutic": "ncit:C74072"}}
{"id": "civic.eid:1376", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-06-10T09:56:04.899Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:34:22.344Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T21:10:46.601Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-06-27T18:34:24.023Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:932", "type": "Document", "label": "Young et al., 2014, Pigment Cell Melanoma Res", "xrefs": ["pmid:24495407"], "title": "Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:FcfoNnLQ0YOnCSzGEBvoH2f6rVBHUj1r", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.b6Pjz1-VHI2yuch9tj1eOxn0AHTqVxp7", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1601374", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:556", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tid:429", "type": "TherapeuticDescriptor", "label": "Palbociclib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C49176"], "alternate_labels": ["6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one", "Ibrance", "PD 0332991", "PD 332991", "PD 991", "PD-0332991", "Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-"], "therapeutic": "rxcui:1601374"}}
{"id": "civic.eid:1401", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 \u03bcM; SNU-1041, 20.65 \u03bcM; FaDu, 19.67 \u03bcM; SCC25, 49.30 \u03bcM). In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2016-06-25T18:17:25.206Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-28T02:24:51.423Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-28T22:10:38.690Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-06-27T16:53:18.439Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:949", "type": "Document", "label": "Keam et al., 2015, Anticancer Res.", "xrefs": ["pmid:25550549"], "title": "In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:6g8UgmDwPzp0X3OVQis2MZ0yuLLCNMjz", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:2169285", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4013", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:107", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:453", "type": "DiseaseDescriptor", "label": "Head And Neck Cancer", "xrefs": ["DOID:11934"], "disease": "ncit:C4013"}, "object_descriptor": {"id": "civic.tid:570", "type": "TherapeuticDescriptor", "label": "Alpelisib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C94214"], "alternate_labels": ["BYL719", "Phosphoinositide 3-kinase Inhibitor BYL719", "Piqray"], "therapeutic": "rxcui:2169285"}}
{"id": "civic.eid:1987", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The IC90 of ERBB2-V773A cell lines was approximately 0.5 \u00b5M and was considered as lapatinib-sensitive. Since levels of up to 1 \u00b5M of lapatinib may be achieved in patients, ERBB2-T773A might respond to higher doses of lapatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-24T09:40:19.632Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-09-01T23:29:35.904Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-09-01T23:26:45.838Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-15T19:18:42.481Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1396", "type": "Document", "label": "Kancha et al., 2011, PLoS ONE", "xrefs": ["pmc:PMC3203921", "pmid:22046346"], "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:S-3daEWCkxFwTTAsRkEp0Z__6BelEcwL", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tKVltEg8vfdk5nJiVpZcmu1P3R7n8n7X", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:480167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:872", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}}
{"id": "civic.eid:1988", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The IC90 of ERBB2-N857S cell lines was approximately 0.5 \u00b5M and was considered as lapatinib-sensitive. Since levels of up to 1 \u00b5M of lapatinib may be achieved in patients, ERBB2-N857S might respond to higher doses of lapatinib.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-24T09:41:51.778Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-30T20:22:51.427Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-30T20:19:37.361Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-15T19:30:43.363Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1396", "type": "Document", "label": "Kancha et al., 2011, PLoS ONE", "xrefs": ["pmc:PMC3203921", "pmid:22046346"], "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:tC8efjak4r4fgZnIcnVSoGsNnCR1kGls", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.cMA3w7fj-gdDgt54AYgeRWum1R3DmtU6", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:480167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:873", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}}
{"id": "civic.eid:1989", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Cell proliferation analysis of ERBB2 mutant expressing cell lines showed that the ERBB2-H878Y mutant, which is observed in 11% of hepatocellular carcinoma patients, had the highest sensitivity against lapatinib among all mutations tested (IC50<30nM).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2017-03-24T09:43:22.789Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-30T19:52:48.697Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-08-30T19:25:41.225Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-05-15T19:24:27.517Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1396", "type": "Document", "label": "Kancha et al., 2011, PLoS ONE", "xrefs": ["pmc:PMC3203921", "pmid:22046346"], "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:G7g7YGIgUhw6F6KiQQIF722m_dTrVEpC", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2hV5axyNx24UD0gckBg9IwuI7i2d1Xqv", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:480167", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3099", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:874", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:196", "type": "DiseaseDescriptor", "label": "Hepatocellular Carcinoma", "xrefs": ["DOID:684"], "disease": "ncit:C3099"}, "object_descriptor": {"id": "civic.tid:45", "type": "TherapeuticDescriptor", "label": "Lapatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "DiseaseDescriptor", "label": "Breast cancer", "disease": "ncit:C9335"}]}}], "xrefs": ["ncit:C26653"], "alternate_labels": ["GSK572016", "GW 2016", "GW2016", "GW572016"], "therapeutic": "rxcui:480167"}}
{"id": "civic.eid:2058", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a preclinical study, the efficacy of PI-103 (a dual inhibitor of MTOR and Class IA PI3Ks) was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.43uM.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-03-30T21:58:39.336Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-04-09T22:38:12.190Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2021-04-09T22:38:57.562Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-04-09T22:29:10.593Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2021-04-09T22:38:43.678Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:xfoGes6gczPckTlF_rbrs6p6U27o4fau", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:5701", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:19830", "type": "TherapeuticDescriptor", "label": "PI-103", "therapeutic": "iuphar.ligand:5701"}}
{"id": "civic.eid:3889", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G13D is more resistant to regorafenib than KRAS wt, but more sensitive than common KRAS G12 mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:37:18.164Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T22:22:00.651Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-24T22:26:30.574Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-08-30T21:01:19.423Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1935", "type": "Document", "label": "Camaj et al., 2015, Future Oncol", "xrefs": ["pmid:26161928"], "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:bAtc-Af-8-sIJGDG8bqAIin1qHgH9Hz3", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:81", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:3946", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12D was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:01.043Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T22:22:36.658Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-24T22:26:57.418Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T19:17:49.116Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1935", "type": "Document", "label": "Camaj et al., 2015, Future Oncol", "xrefs": ["pmid:26161928"], "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:Fm54Yy1dy2lIrS3uLR19W_4RGrDj83pv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:79", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:3991", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12R was resistant to regorafenib compared to wildtype but was less resistant than other common KRAS G12/G13 mutations.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:38:34.633Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-09-24T22:25:38.977Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-09-24T22:27:16.996Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2017-07-21T19:11:37.827Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1935", "type": "Document", "label": "Camaj et al., 2015, Future Oncol", "xrefs": ["pmid:26161928"], "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:KSJXjaqja0P4isoTPx4vOztsuMbCjy9w", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._AIonI6Sp_E7tTUN81jJbNG3tERDCkVk", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1312397", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:530", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:27", "type": "TherapeuticDescriptor", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C78204"], "alternate_labels": ["4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide", "BAY 73-4506", "REGORAFENIB ANHYDROUS", "Stivarga"], "therapeutic": "rxcui:1312397"}}
{"id": "civic.eid:4029", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:39:04.157Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-09T19:13:58.835Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:968", "type": "Agent", "name": "Cam Grisdale"}, "date": "2021-11-12T18:53:34.856Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:179", "type": "Agent", "name": "Erica Barnell"}, "date": "2017-06-09T19:14:00.201Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1941", "type": "Document", "label": "Shi et al., 2014, Cancer Discov", "xrefs": ["pmc:PMC3936420", "pmid:24265155"], "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:lTXrhZex53tbhd1MXL0-JAzqXKZtEmRK", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA._veAF5iFKxk_oSX9jnfNc4AHp8MvUCKO", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C3224", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:4", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:7", "type": "DiseaseDescriptor", "label": "Melanoma", "xrefs": ["DOID:1909"], "disease": "ncit:C3224"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:4729", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing mutation; IC50 9.89 uM vs 0.025-0.35uM for BRAF V600E expressing cell lines). Note that NCI-H508 also expresses PIK3CA E545K.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:48", "type": "Agent", "name": "Illumina Biomedical Informatics"}, "date": "2017-06-02T04:54:47.185Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-06-18T22:33:19.558Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T22:33:46.576Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T22:36:32.168Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2020-06-18T22:37:29.813Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:108", "type": "Document", "label": "Yang et al., 2012, Cancer Res.", "xrefs": ["pmid:22180495"], "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:-t53mrhsSgW8zTLjeoNkQ6FblBbwMnFm", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.83yWphFc1Hfr3VygXn2NWL6Rr2CzlkP3", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1147220", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "opposes", "subject_descriptor": "civic.vid:1627", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tid:4", "type": "TherapeuticDescriptor", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "DiseaseDescriptor", "label": "Melanoma", "disease": "ncit:C3224"}, {"id": "hemonc:594", "type": "DiseaseDescriptor", "label": "Erdheim-Chester disease", "disease": "ncit:C53972"}]}}], "xrefs": ["ncit:C64768"], "alternate_labels": ["1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-", "BRAF (V600E) Kinase Inhibitor RO5185426", "BRAF(V600E) Kinase Inhibitor RO5185426", "PLX-4032", "PLX4032", "RG 7204", "RG7204", "RO 5185426", "Zelboraf"], "therapeutic": "rxcui:1147220"}}
{"id": "civic.eid:8007", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 7.62uM.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-20T18:31:06.315Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2022-01-26T00:13:05.315Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:vaY8Fjm5kdr7FBGZIxtIZBzAVYOeeM9C", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD", "predicate": "predicts_resistance_to", "object": {"id": "iuphar.ligand:5701", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:103", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:19830", "type": "TherapeuticDescriptor", "label": "PI-103", "therapeutic": "iuphar.ligand:5701"}}
{"id": "civic.eid:8008", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal-like breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 1.53uM.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-20T18:33:04.466Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2022-01-26T00:13:49.345Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:DgKaqxFMw3e61DMW-0tQJkHD4bw7iRzv", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8", "predicate": "predicts_resistance_to", "object": {"id": "iuphar.ligand:5701", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:104", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:19830", "type": "TherapeuticDescriptor", "label": "PI-103", "therapeutic": "iuphar.ligand:5701"}}
{"id": "civic.eid:8009", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal-like breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.16uM.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-20T18:34:26.269Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2022-01-26T00:14:34.583Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:iwsxC_IMirTr3PsjveemQpSnc6bCCMGp", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.mCpnGyjIgv27feD0L-LFc95zm7d6RmDt", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:5701", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9335", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1151", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:22", "type": "DiseaseDescriptor", "label": "Breast Cancer", "xrefs": ["DOID:1612"], "disease": "ncit:C9335"}, "object_descriptor": {"id": "civic.tid:19830", "type": "TherapeuticDescriptor", "label": "PI-103", "therapeutic": "iuphar.ligand:5701"}}
{"id": "civic.eid:8011", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.60uM.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-03-20T18:38:34.737Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:110", "type": "Agent", "name": "Arpad Danos"}, "date": "2022-01-26T00:18:12.985Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:1435", "type": "Document", "label": "O'Brien et al., 2010, Clin. Cancer Res.", "xrefs": ["pmid:20453058"], "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."}], "evidence_level": {"id": "vicc:e00009", "type": "Coding", "label": "preclinical evidence"}, "target_proposition": {"id": "proposition:WAl38rPkHCKwjuMikad8BrXaHoCsA8oJ", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.MwhPgqLyRggo95FGBET65hs3Dbmm0jW1", "predicate": "predicts_sensitivity_to", "object": {"id": "iuphar.ligand:5701", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C53556", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:1234", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:368", "type": "DiseaseDescriptor", "label": "Her2-receptor Positive Breast Cancer", "xrefs": ["DOID:60079"], "disease": "ncit:C53556"}, "object_descriptor": {"id": "civic.tid:19830", "type": "TherapeuticDescriptor", "label": "PI-103", "therapeutic": "iuphar.ligand:5701"}}
{"id": "civic.eid:1454", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:09:29.000Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-10T03:02:26.380Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-09-12T10:41:05.898Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:198", "type": "Agent", "name": "Amber Wollam"}, "date": "2016-08-31T15:11:36.171Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-08-02T20:55:30.144Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:982", "type": "Document", "label": "Heidorn et al., 2010, Cell", "xrefs": ["pmc:PMC2872605", "pmid:20141835"], "title": "Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF."}], "evidence_level": {"id": "vicc:e00010", "type": "Coding", "label": "inferential evidence"}, "target_proposition": {"id": "proposition:JhG1i7APT0bpDcYNYqYyYpDi0GklRXLE", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.laN0XcugeJNPAY6sCPqY520k40hMU_Z7", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:579", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:cI8a1KqlKHGJhEYJvUfvA11fkiIQd--H", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}, {"id": "civic.tid:110", "type": "TherapeuticDescriptor", "label": "Mitogen-Activated Protein Kinase Kinase Inhibitor", "xrefs": ["ncit:C69145"], "therapeutic": "ncit:C69145"}]}}
{"id": "civic.eid:1456", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors could instead block ERK pathway hyperactivation in RAS mutated cancers.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:10:43.738Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-10T02:59:23.905Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2016-11-07T22:42:59.691Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-01T22:57:46.964Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:982", "type": "Document", "label": "Heidorn et al., 2010, Cell", "xrefs": ["pmc:PMC2872605", "pmid:20141835"], "title": "Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF."}], "evidence_level": {"id": "vicc:e00010", "type": "Coding", "label": "inferential evidence"}, "target_proposition": {"id": "proposition:AznDOxLdDa6p7mCklxTtW58cQYNtbfgc", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.NsyJAjYL_nfsm4iZB1pU0902jR5uEuVp", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:580", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:DfnGfZruKv7WdSpFN0MrdQY7MH9LeePi", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "rxcui:1425098", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}, {"id": "civic.tid:19", "type": "TherapeuticDescriptor", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}]}}], "xrefs": ["ncit:C77908"], "alternate_labels": ["GSK1120212", "JTP-74057", "MEK Inhibitor GSK1120212", "Mekinist", "N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide"], "therapeutic": "rxcui:1425098"}]}}
{"id": "civic.eid:1457", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-07-01T08:11:48.881Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-10T02:55:05.064Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-09-12T10:41:34.298Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-10T02:51:15.116Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-09-01T23:01:36.960Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:982", "type": "Document", "label": "Heidorn et al., 2010, Cell", "xrefs": ["pmc:PMC2872605", "pmid:20141835"], "title": "Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF."}], "evidence_level": {"id": "vicc:e00010", "type": "Coding", "label": "inferential evidence"}, "target_proposition": {"id": "proposition:Y7a8o7Nani1i7CPIOkdepJOiQnnJxApb", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.2mY9ONFhH8qPlEXXLagd40cUTHKuJj-l", "predicate": "predicts_sensitivity_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C3510", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:581", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:206", "type": "DiseaseDescriptor", "label": "Skin Melanoma", "xrefs": ["DOID:8923"], "disease": "ncit:C3510"}, "object_descriptor": {"id": "civic.tcd:cI8a1KqlKHGJhEYJvUfvA11fkiIQd--H", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:495881", "type": "Therapeutic"}, {"id": "ncit:C69145", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:6", "type": "TherapeuticDescriptor", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:612", "type": "DiseaseDescriptor", "label": "Hepatocellular carcinoma", "disease": "ncit:C3099"}, {"id": "hemonc:65823", "type": "DiseaseDescriptor", "label": "Thyroid cancer differentiated", "disease": null}, {"id": "hemonc:660", "type": "DiseaseDescriptor", "label": "Renal cell carcinoma", "disease": "ncit:C9385"}]}}], "xrefs": ["ncit:C61948"], "alternate_labels": ["BA4 43 9006", "BAY 43-9006", "Bay-439006"], "therapeutic": "rxcui:495881"}, {"id": "civic.tid:110", "type": "TherapeuticDescriptor", "label": "Mitogen-Activated Protein Kinase Kinase Inhibitor", "xrefs": ["ncit:C69145"], "therapeutic": "ncit:C69145"}]}}
{"id": "civic.eid:1209", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports functional studies of this variant. Mouse models with this variant show an increase in spontaneous tumor formation. 16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age. Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other\ntumor types. In S47/wild-type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found. Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild-type cells (apoptosis and viability).", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-04-04T08:31:40.511Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-04-04T08:38:07.092Z", "activity": {"type": "Coding", "label": "last_commented_on"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-06-09T03:45:44.476Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:834", "type": "Document", "label": "Jennis et al., 2016, Genes Dev.", "xrefs": ["pmc:PMC4840298", "pmid:27034505"], "title": "An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model."}], "evidence_level": {"id": "vicc:e00010", "type": "Coding", "label": "inferential evidence"}, "target_proposition": {"id": "proposition:OZMdO9Wzd6Z74Ce_9XymPApaFyIGzrdq", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.77LTqg70IhQdX3kzFa3LZE_E0tQTdG-0", "predicate": "predicts_resistance_to", "object": {"id": "rxcui:2555", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C9305", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:504", "variation_origin": "germline", "neoplasm_type_descriptor": {"id": "civic.did:216", "type": "DiseaseDescriptor", "label": "Cancer", "xrefs": ["DOID:162"], "disease": "ncit:C9305"}, "object_descriptor": {"id": "civic.tid:326", "type": "TherapeuticDescriptor", "label": "Cisplatin", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "DiseaseDescriptor", "label": "Bladder cancer", "disease": "ncit:C9334"}, {"id": "hemonc:671", "type": "DiseaseDescriptor", "label": "Testicular cancer", "disease": "ncit:C7251"}, {"id": "hemonc:645", "type": "DiseaseDescriptor", "label": "Ovarian cancer", "disease": "ncit:C7431"}]}}], "xrefs": ["ncit:C376"], "alternate_labels": ["(SP-4-2)-Diamminedichloroplatinum", "Abiplatin", "Blastolem", "Briplatin", "CDDP", "Cis-diammine-dichloroplatinum", "Cis-diamminedichloridoplatinum", "Cis-diamminedichloro Platinum (II)", "Cis-diamminedichloroplatinum", "Cis-dichloroammine Platinum (II)", "Cis-platinous Diamine Dichloride", "Cis-platinum", "Cis-platinum II", "Cis-platinum II Diamine Dichloride", "Cismaplat", "Cisplatina", "Cisplatinum", "Cisplatyl", "Citoplatino", "Citosin", "Cysplatyna", "DDP", "Lederplatin", "Metaplatin", "Neoplatin", "Peyrone's Chloride", "Peyrone's Salt", "Placis", "Plastistil", "Platamine", "Platiblastin", "Platiblastin-S", "Platinex", "Platinol", "Platinol- AQ", "Platinol-AQ", "Platinol-AQ VHA Plus", "Platinoxan", "Platinum", "Platinum Diamminodichloride", "Platinum, Diaminedichloro-, Cis- (8CI)", "Platiran", "Platistin", "Platosin"], "therapeutic": "rxcui:2555"}}
{"id": "civic.eid:1246", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:100", "type": "Agent", "name": "Damian Rieke"}, "date": "2016-04-12T08:11:16.283Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-01T18:15:20.916Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2016-07-02T15:36:54.450Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2016-07-01T18:14:45.120Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:446", "type": "Document", "label": "Agelopoulos et al., 2015, Clin. Cancer Res.", "xrefs": ["pmid:26179511"], "title": "Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma."}], "evidence_level": {"id": "vicc:e00010", "type": "Coding", "label": "inferential evidence"}, "target_proposition": {"id": "proposition:tRUibEoB4snELaZfA32niUhto9O87wpU", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.4OW2WDKXQ4JxiQz6RWz5YQM3XQyxcLeb", "predicate": "predicts_sensitivity_to", "object": {"id": "rxcui:1364347", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C4835", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:515", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:135", "type": "DiseaseDescriptor", "label": "Ewing Sarcoma Of Bone", "xrefs": ["DOID:3368"], "disease": "ncit:C4835"}, "object_descriptor": {"id": "civic.tid:55", "type": "TherapeuticDescriptor", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:24309", "type": "DiseaseDescriptor", "label": "Acute lymphoblastic leukemia", "disease": "ncit:C3167"}, {"id": "hemonc:582", "type": "DiseaseDescriptor", "label": "Chronic myelogenous leukemia", "disease": "ncit:C3174"}]}}], "xrefs": ["ncit:C95777"], "alternate_labels": ["AP-24534", "AP24534", "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"], "therapeutic": "rxcui:1364347"}}
{"id": "civic.eid:7096", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "Next-generation sequencing data of cfDNA from 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD). EGFR V441G/D/F mutations were found in 19% (n=8) of patients with EGFR ECD domain III (location of cetuximab and panitumumab binding epitope) mutations. V441D and V441G were more common than V441F. Resistance of V441G to cetuximab was modeled in silico, and authors predicted that it destroys a critical hydrophobic node. In vitro, V441G/D transduced NIH3T3 cells had significantly reduced binding to panitumumab and cetuximab compared to EGFR wt NH3T3 cells (p<0.01 for all comparisons to wt). Authors inferred that EGFR domain III (ECD) mutations, including V441F, may be responsible for secondary resistance to EGFR blockade.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:208", "type": "Agent", "name": "Peter Horak"}, "date": "2019-02-08T15:40:33.066Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-04T01:39:18.166Z", "activity": {"type": "Coding", "label": "last_modified"}}, {"type": "Contribution", "contributor": {"id": "civic.user:15", "type": "Agent", "name": "Malachi Griffith"}, "date": "2020-12-04T18:56:26.092Z", "activity": {"type": "Coding", "label": "last_reviewed"}}, {"type": "Contribution", "contributor": {"id": "civic.user:709", "type": "Agent", "name": "Lana Sheta"}, "date": "2020-12-07T17:59:04.340Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:2672", "type": "Document", "label": "Strickler et al., 2018, Cancer Discov", "xrefs": ["pmc:PMC5809260", "pmid:29196463"], "title": "Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer."}], "evidence_level": {"id": "vicc:e00010", "type": "Coding", "label": "inferential evidence"}, "target_proposition": {"id": "proposition:04pmVieuERL8QtgMhaeYPGFla43WfiAF", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.5U0NWYeCO_TbhjpYlRi505zukJD3Tytr", "predicate": "predicts_resistance_to", "object": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "neoplasm_type_qualifier": {"id": "ncit:C4978", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:2613", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:11", "type": "DiseaseDescriptor", "label": "Colorectal Cancer", "xrefs": ["DOID:9256"], "disease": "ncit:C4978"}, "object_descriptor": {"id": "civic.tcd:7IxyhCwID0QYyVCP2xuIyYvwwu-S_HrZ", "type": "TherapeuticsCollectionDescriptor", "extensions": [{"type": "Extension", "name": "civic_drug_interaction_type", "value": "SUBSTITUTES"}], "therapeutic_collection": {"type": "SubstituteTherapeutics", "members": [{"id": "rxcui:318341", "type": "Therapeutic"}, {"id": "rxcui:263034", "type": "Therapeutic"}]}, "member_descriptors": [{"id": "civic.tid:16", "type": "TherapeuticDescriptor", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D002294", "type": "DiseaseDescriptor", "label": "Carcinoma, Squamous Cell", "disease": "ncit:C2929"}, {"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}, {"id": "mesh:D006258", "type": "DiseaseDescriptor", "label": "Head and Neck Neoplasms", "disease": "ncit:C4013"}]}}], "xrefs": ["ncit:C1723"], "alternate_labels": ["Cetuximab Biosimilar CDP-1", "Cetuximab Biosimilar CMAB009", "Cetuximab Biosimilar KL 140", "Chimeric Anti-EGFR Monoclonal Antibody", "Chimeric MoAb C225", "Chimeric Monoclonal Antibody C225", "Erbitux", "IMC-C225"], "therapeutic": "rxcui:318341"}, {"id": "civic.tid:28", "type": "TherapeuticDescriptor", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "DiseaseDescriptor", "label": "Neoplasms", "disease": "ncit:C3262"}, {"id": "mesh:D015179", "type": "DiseaseDescriptor", "label": "Colorectal Neoplasms", "disease": "ncit:C2956"}]}}], "xrefs": ["ncit:C1857"], "alternate_labels": ["ABX-EGF", "ABX-EGF Monoclonal Antibody", "ABX-EGF, Clone E7.6.3", "E7.6.3", "Human IgG2K Monoclonal Antibody", "MoAb ABX-EGF", "MoAb E7.6.3", "Monoclonal Antibody ABX-EGF", "Monoclonal Antibody E7.6.3", "Vectibix"], "therapeutic": "rxcui:263034"}]}}
{"id": "civic.eid:278", "type": "VariationNeoplasmTherapeuticResponseStatement", "description": "In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.", "specified_by": "metakb.method:1", "contributions": [{"type": "Contribution", "contributor": {"id": "civic.user:41", "type": "Agent", "name": "Nick Spies"}, "date": "2015-06-21T16:49:49.834Z", "activity": {"type": "Coding", "label": "submitted"}}, {"type": "Contribution", "contributor": {"id": "civic.user:6", "type": "Agent", "name": "Kilannin Krysiak"}, "date": "2015-06-21T16:49:49.834Z", "activity": {"type": "Coding", "label": "accepted"}}], "is_reported_in": [{"id": "civic.source:184", "type": "Document", "label": "Ai et al., 2014, Amino Acids", "xrefs": ["pmid:24658966"], "title": "A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity."}], "evidence_level": {"id": "vicc:e00010", "type": "Coding", "label": "inferential evidence"}, "target_proposition": {"id": "proposition:TBkz3cWPrplJo3oy2YLDlhvpan9KsdFq", "type": "VariationNeoplasmTherapeuticResponseProposition", "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV", "predicate": "predicts_sensitivity_to", "object": {"id": "ncit:C1237", "type": "Therapeutic"}, "neoplasm_type_qualifier": {"id": "ncit:C2926", "type": "Disease"}}, "direction": "supports", "subject_descriptor": "civic.vid:34", "variation_origin": "somatic", "neoplasm_type_descriptor": {"id": "civic.did:8", "type": "DiseaseDescriptor", "label": "Lung Non-small Cell Carcinoma", "xrefs": ["DOID:3908"], "disease": "ncit:C2926"}, "object_descriptor": {"id": "civic.tid:51", "type": "TherapeuticDescriptor", "label": "Staurosporine", "xrefs": ["ncit:C1237"], "alternate_labels": ["(9alpha,10beta,11beta,13alpha)-(+)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H-9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one", "8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-", "AM-2282", "Antibiotic 230", "Antibiotic AM 2282", "CGP-39360"], "therapeutic": "ncit:C1237"}}